Tablets O O
, O O
Injection O O
, O O
and O O
Oral O O
Solution O O
One O O
study O O
in O O
six O O
subjects O O
demonstrated O O
that O O
the O O
combination O O
of O O
furosemide B-drug B-drug
and O O
acetylsalicylic B-drug B-drug
acid I-drug I-drug
temporarily O O
reduced O O
creatinine O O
clearance O O
in O O
patients O O
with O O
chronic O O
renal O O
insufficiency O O
. O O

Because O O
the O O
potential O O
interaction O O
of O O
efavirenz B-drug B-drug
with O O
oral O O
contraceptives B-group B-group
has O O
not O O
been O O
fully O O
characterized O O
, O O
a O O
reliable O O
method O O
of O O
barrier O O
contraception O O
should O O
be O O
used O O
in O O
addition O O
to O O
oral O O
contraceptives B-group B-group
. O O

and O O
exert O O
direct O O
effects O O
on O O
the O O
mechanisms O O
of O O
insulin O B-drug
resistance O O
. O O

Furthermore O O
, O O
whenever O O
one O O
of O O
these O O
drugs O O
is O O
withdrawn O O
from O O
co-therapy O O
, O O
an O O
increased O O
dose O O
of O O
tricyclic B-group B-group
antidepressant I-group I-group
agent I-group I-group
may O O
be O O
required O O
. O O

use O O
of O O
a O O
nonhormonal B-group B-group
contraceptive I-group I-group
product I-group I-group
is O O
recommended O O
. O O

Transfer O O
from O O
the O O
intestinal O O
lumen O O
to O O
the O O
mucosal O O
cells O O
at O O
low O O
As B-drug_n B-drug_n
( I-drug_n I-drug_n
V I-drug_n I-drug_n
) I-drug_n I-drug_n
concentration O O
( O O
0.1 O O
mM O O
) O O
is O O
rapid O O
, O O
while O O
transfer O O
from O O
the O O
mucosal O O
cells O O
to O O
the O O
body O O
occurs O O
more O O
slowly O O
. O O

Increased O O
metoprolol B-drug B-drug
plasma O O
levels O O
have O O
been O O
associated O O
with O O
decreased O O
cardioselectivity O O
. O O

Bacteriostatic B-group B-group
Antibiotics I-group I-group
: O O
Chloramphenicol B-drug B-drug
, O O
erythromycins B-drug B-group
, O O
sulfonamides B-group B-group
, O O
or O O
tetracyclines B-group B-group
may O O
interfere O O
with O O
the O O
bactericidal O O
effect O O
of O O
penicillins B-group B-group
. O O

It O O
is O O
possible O O
that O O
the O O
cardiovascular O O
action O O
of O O
other O O
calcium B-group B-group
channel I-group I-group
blockers I-group I-group
could O O
be O O
enhanced O O
by O O
the O O
addition O O
of O O
Nimotop B-brand B-brand
. O O

Free O O
T4 O O
and O O
T3 O O
concentrations O O
are O O
unaltered O O
. O O

uterine O B-group
fibroids O I-group
; O O

Co-administration O O
of O O
tacrolimus B-drug B-drug
and O O
bosentan B-drug B-drug
resulted O O
in O O
markedly O O
increased O O
plasma O O
concentrations O O
of O O
bosentan B-drug B-drug
in O O
animals O O
. O O

sucralfate B-drug B-drug
or O O
divalent O O
or O O
trivalent O O
cations O O
such O O
as O O
iron B-drug B-drug
; O O

Indocyanine B-drug_n O
green I-drug_n O
as O O
an O O
index O O
of O O
hepatic O O
drug O O
extraction O O
has O O
been O O
tested O O
and O O
no O O
significant O O
effects O O
have O O
been O O
found O O
. O O

Tumors O O
of O O
more O O
malignant O O
phenotype O O
were O O
demonstrated O O
only O O
in O O
genetically O O
predisposed O O
mice O O
( O O
C57BL/6N O O
X O O
C3H/HeN O O
F1 O O
) O O
that O O
received O O
one O O
dose O O
of O O
carcinogen O O
. O O

use O O
potassium B-drug B-drug
supplements O O
if O O
necessary O O
. O O

It O O
is O O
recommended O O
that O O
plasma O O
lithium B-drug B-drug
levels O O
be O O
monitored O O
when O O
ketoprofen B-drug B-drug
is O O
coadministered O O
with O O
lithium B-drug B-drug
. O O

Tagamet B-brand B-brand
, O O
apparently O O
through O O
an O O
effect O O
on O O
certain O O
microsomal O O
enzyme O O
systems O O
, O O
has O O
been O O
reported O O
to O O
reduce O O
the O O
hepatic O O
metabolism O O
of O O
warfarin-type B-group B-group
anticoagulants I-group I-group
, O O
phenytoin B-drug B-drug
, O O
propranolol B-drug B-drug
, O O
nifedipine B-drug B-drug
, O O
chlordiazepoxide B-drug B-drug
, O O
diazepam B-drug B-drug
, O O
certain O O
tricyclic B-group B-group
antidepressants I-group I-group
, O O
lidocaine B-drug B-drug
, O O
theophylline B-drug B-drug
and O O
metronidazole B-drug B-drug
, O O
thereby O O
delaying O O
elimination O O
and O O
increasing O O
blood O O
levels O O
of O O
these O O
drugs O O
. O O

Drug/Laboratory O O
Test O O
Interactions O O
A O O
false-positive O O
reaction O O
for O O
ketones O O
in O O
the O O
urine O O
may O O
occur O O
with O O
tests O O
using O O
nitroprusside B-drug B-drug
but O O
not O O
with O O
those O O
using O O
nitroferricyanide B-drug B-drug
. O O

Because O O
of O O
the O O
potential O O
for O O
adverse O O
reactions O O
from O O
the O O
drugs O O
in O O
nursing O O
infants O O
, O O
a O O
decision O O
must O O
be O O
made O O
whether O O
to O O
discontinue O O
nursing O O
or O O
discontinue O O
PEGASYS B-brand B-brand
and O O
COPEGUS B-brand B-brand
treatment O O
. O O

Several O O
classes O O
of O O
cardiovascular O O
drugs O O
are O O
also O O
discussed O O
in O O
relationship O O
to O O
their O O
differential O O
effects O O
on O O
the O O
management O O
and O O
progression O O
of O O
renal O O
disease O O
. O O

Exercise O O
that O O
produces O O
cardiopulmonary O O
stimulation O O
is O O
a O O
helpful O O
means O O
of O O
reducing O O
drug O O
hunger O O
and O O
anxiety O O
during O O
recovery O O
therapy O O
. O O

There O O
has O O
been O O
little O O
experience O O
with O O
the O O
coadministration O O
of O O
TAMBOCOR B-brand B-brand
and O O
either O O
disopyramide B-drug B-drug
or O O
verapamil B-drug B-drug
. O O

The O O
administration O O
of O O
cefdinir B-drug B-drug
may O O
result O O
in O O
a O O
false-positive O O
reaction O O
for O O
glucose O O
in O O
urine O O
using O O
Clinitest O O
, O O
Benedict O O
s O O
solution O O
, O O
or O O
Fehlings O O
solution O O
. O O

Anaesthesia O O
and O O
the O O
epileptic O O
pateint O O
. O O

. O O

therefore O O
, O O
nelfinavir B-drug B-drug
should O O
be O O
administered O O
( O O
with O O
food O O
) O O
one O O
hour O O
after O O
or O O
more O O
than O O
two O O
hours O O
before O O
didanosine B-drug B-drug
. O O

Dose O O
reduction O O
of O O
rifabutin B-drug B-drug
to O O
half O O
the O O
standard O O
dose O O
and O O
a O O
dose O O
increase O O
of O O
CRIXIVAN B-brand B-brand
to O O
1000 O O
mg O O
( O O
three O O
333-mg O O
capsules O O
) O O
every O O
8 O O
hours O O
are O O
recommended O O
when O O
rifabutin B-drug B-drug
and O O
CRIXIVAN B-brand B-brand
are O O
coadministered O O
. O O

Succinylcholine B-drug B-drug
may O O
cause O O
a O O
sudden O O
extrusion O O
of O O
potassium O O
from O O
muscle O O
cells O O
, O O
and O O
may O O
thereby O O
cause O O
arrhythmias O O
in O O
digitalized O O
patients O O
. O O

dextrothyroxine B-drug B-drug
; O O

Cardiac O O
effects O O
of O O
dopamine B-drug B-drug
are O O
antagonized O O
by O O
beta-adrenergic B-group B-group
blocking I-group I-group
agents I-group I-group
, O O
such O O
as O O
propranolol B-drug B-drug
and O O
metoprolol B-drug B-drug
. O O

The O O
principal O O
drugs O O
given O O
( O O
number O O
of O O
patients O O
in O O
parentheses O O
) O O
were O O
: O O
cardiac B-group B-group
glycosides I-group I-group
( O O
115 O O
) O O
, O O
sedatives B-group B-group
and O O
hypnotics B-group B-group
( O O
103 O O
) O O
, O O
coronary B-group B-group
vasodilators I-group I-group
( O O
52 O O
) O O
, O O
oral O O
hypoglycemics B-group B-group
( O O
45 O O
) O O
, O O
cough O O
and O O
cold O O
preparations O O
( O O
45 O O
) O O
, O O
NSAIDs B-group B-group
( O O
38 O O
) O O
, O O
antihyperlipidemics B-group B-group
( O O
29 O O
) O O
, O O
antigout B-group B-group
drugs I-group I-group
( O O
24 O O
) O O
, O O
oral O O
contraceptives B-group B-group
( O O
18 O O
) O O
, O O
bronchodilators B-group B-group
( O O
13 O O
) O O
, O O
insulin B-drug B-drug
( O O
10 O O
) O O
, O O
and O O
beta B-group B-group
blockers I-group I-group
( O O
10 O O
) O O
. O O

Phenobarbital B-drug B-drug
: O O
Estimates O O
of O O
steady-state O O
pharmacokinetic O O
parameters O O
for O O
phenobarbital B-drug B-drug
or O O
gabapentin B-drug B-drug
( O O
300 O O
mg O O
TID O O
; O O

It O O
is O O
concluded O O
that O O
chloral B-drug B-drug
hydrate I-drug I-drug
and O O
methaqualone B-drug B-drug
may O O
be O O
administered O O
safely O O
without O O
additional O O
caution O O
in O O
prothrombin O O
test O O
monitoring O O
during O O
oral O O
anticoagulant B-group B-group
therapy O O
. O O

Based O O
on O O
anecdotal O O
reports O O
, O O
there O O
may O O
be O O
an O O
interaction O O
between O O
buprenorphine B-drug B-drug
and O O
benzodiazepines B-group B-group
. O O

Unlike O O
nucleolin/C23 O O
, O O
down-regulation O O
of O O
nucleophosmin/B23 O O
was O O
thus O O
not O O
proliferation-dependent O O
but O O
caspase-3- O O
and O O
apoptosis-dependent O O
. O O

Buforin B-drug_n B-brand
II I-drug_n O
showed O O
moderate O O
activity O O
, O O
which O O
increased O O
with O O
increasing O O
concentration O O
to O O
55.7 O O
% O O
suppression O O
of O O
growth O O
at O O
20 O O
microM O O
. O O

To O O
avoid O O
this O O
interaction O O
, O O
delavirdine B-drug B-drug
or O O
indinavir B-drug B-drug
should O O
be O O
given O O
1 O O
hour O O
prior O O
to O O
dosing O O
with O O
VIDEX B-brand B-brand
. O O

Drug O O
interactions O O
with O O
clomiphene B-drug B-drug
citrate I-drug I-drug
tablets O O
USP O O
have O O
not O O
been O O
documented O O
. O O

Drug O O
Name O O

In O O
the O O
general O O
population O O
, O O
sildenafil B-drug B-drug
is O O
considered O O
to O O
have O O
an O O
acceptable O O
tolerability O O
profile O O
; O O

The O O
incidence O O
of O O
cancer O O
increases O O
progressively O O
with O O
age O O
. O O

Absorption O O
of O O
tetracycline B-drug B-drug
is O O
impaired O O
by O O
bismuth B-drug B-drug
subsalicylate I-drug I-drug
. O O

increased O O
factors O O
II O O
, O O
VII O O
antigen O O
, O O
VIII O O
antigen O O
, O O
VIII O O
coagulant O O
activity O O
, O O
IX O O
, O O
X O O
, O O
XII O O
, O O
VII-X O O
complex O O
, O O
II-VII-X O O
complex O O
, O O
and O O
beta-thromboglobulin O B-drug_n
; O O

If O O
labetalol B-drug B-drug
HCl I-drug I-drug
is O O
used O O
with O O
nitroglycerin B-drug B-drug
in O O
patients O O
with O O
angina O O
pectoris O O
, O O
additional O O
antihypertensive O O
effects O O
may O O
occur O O
. O O

Oxcarbazepine B-drug B-drug
can O O
inhibit O O
CYP2C19 O O
and O O
induce O O
CYP3A4/5 O O
with O O
potentially O O
important O O
effects O O
on O O
plasma O O
concentrations O O
of O O
other O O
drugs O O
. O O

Thus O O
, O O
results O O
of O O
the O O
DST O O
should O O
be O O
interpreted O O
with O O
caution O O
in O O
these O O
patients O O
. O O

Broad-Spectrum B-group B-group
Antibiotics-Broad-spectrum I-group I-group
antibiotics I-group I-group
may O O
sterilize O O
the O O
bowel O O
and O O
decrease O O
the O O
vitamin B-group B-group
K I-group I-group
contribution O O
to O O
the O O
body O O
by O O
the O O
intestinal O O
microflora O O
. O O

The O O
effect O O
of O O
TORADOL B-brand B-brand
on O O
methotrexate B-drug B-drug
clearance O O
has O O
not O O
been O O
studied O O
. O O

Exaggerated O O
hypertensive O O
responses O O
have O O
been O O
reported O O
from O O
the O O
combined O O
use O O
of O O
beta-adrenergic B-group B-group
antagonists I-group I-group
and O O
alpha-adrenergic B-group B-group
stimulants I-group I-group
, O O
including O O
those O O
contained O O
in O O
proprietary O O
cold O O
remedies O O
and O O
vasoconstrictive O O
nasal O O
drops O O
. O O

TAMBOCOR B-brand B-brand
has O O
been O O
administered O O
to O O
patients O O
receiving O O
digitalis B-group B-group
preparations I-group I-group
or O O
beta-adrenergic B-group B-group
blocking I-group I-group
agents I-group I-group
without O O
adverse O O
effects O O
. O O

Pharmacological O O
treatment O O
of O O
depression O O
: O O
the O O
role O O
of O O
paroxetine B-drug B-drug
. O O

Anticoagulant O O
inhibition O O
was O O
observed O O
during O O
the O O
administration O O
of O O
phenobarbital B-drug B-drug
, O O
secobarbital B-drug B-drug
and O O
glutethimide B-drug B-drug
; O O

Hypertensive O O
crises O O
have O O
resulted O O
when O O
sympathomimetic B-group B-group
amines I-group I-group
have O O
been O O
used O O
concomitantly O O
within14 O O
days O O
following O O
use O O
of O O
monoamine B-group B-group
oxidase I-group I-group
inhibitors I-group I-group
. O O

Systemic O O
exposure O O
is O O
limited O O
, O O
as O O
fluvastatin B-drug B-drug
is O O
subject O O
to O O
first-pass O O
metabolism O O
, O O
and O O
the O O
plasma O O
half-life O O
of O O
the O O
drug O O
is O O
approximately O O
30 O O
minutes O O
. O O

In O O
these O O
subjects O O
( O O
R= O O
B O O
) O O
, O O
the O O
clearance O O
of O O
diazepam B-drug B-drug
was O O
reduced O O
by O O
65 O O
% O O
and O O
that O O
of O O
N-desmethyldiazepam B-drug_n B-drug_n
to O O
a O O
level O O
that O O
was O O
too O O
low O O
to O O
measure O O
over O O
the O O
course O O
of O O
the O O
2 O O
week O O
long O O
study O O
. O O

an O O
interval O O
of O O
at O O
least O O
4 O O
hours O O
between O O
intake O O
of O O
these O O
agents O O
and O O
chloroquine B-drug B-drug
should O O
be O O
observed O O
. O O

Following O O
the O O
administration O O
of O O
INAPSINE B-brand B-brand
, O O
the O O
dose O O
of O O
other O O
CNS B-group B-group
depressant I-group I-group
drugs I-group I-group
should O O
be O O
reduced O O
. O O

PROLEUKIN B-brand B-brand
may O O
affect O O
central O O
nervous O O
function O O
. O O

In O O
another O O
study O O
with O O
intravenous O O
administration O O
of O O
midazolam B-drug B-drug
, O O
Aprepitant B-drug B-drug
was O O
given O O
as O O
125 O O
mg O O
on O O
Day O O
1 O O
and O O
80 O O
mg/day O O
on O O
Days O O
2 O O
and O O
3 O O
, O O
and O O
midazolam B-drug B-drug
2 O O
mg O O
IV O O
was O O
given O O
prior O O
to O O
the O O
administration O O
of O O
the O O
3-day O O
regimen O O
of O O
Aprepitant B-drug B-drug
and O O
on O O
Days O O
4 O O
, O O
8 O O
, O O
and O O
15 O O
. O O

The O O
impact O O
of O O
the O O
combined O O
chemotherapy O O
plus O O
HAART O O
treatment O O
on O O
patient O O
survival O O
needs O O
urgently O O
to O O
be O O
evaluated O O
in O O
prospective O O
studies O O
. O O

In O O
clinical O O
studies O O
, O O
caspofungin B-drug B-drug
did O O
not O O
induce O O
the O O
CYP3A4 O O
metabolism O O
of O O
other O O
drugs O O
. O O

Physostigmine B-drug B-drug
pretreatment O O
augmented O O
the O O
depressant O O
effect O O
of O O
alcohol B-drug B-drug
on O O
the O O
early O O
components O O
P1 O O
and O O
N1 O O
, O O
while O O
attenuating O O
alcohol B-drug B-drug
's O O
influence O O
on O O
components O O
P2 O O
and O O
P3 O O
. O O

Concomitant O O
use O O
with O O
iron B-group B-drug
supplements O O
may O O
result O O
in O O
the O O
reduced O O
absorption O O
of O O
iron B-drug B-drug
. O O

Skin O O
tests O O
: O O
Corticosteroids B-group B-group
may O O
suppress O O
reactions O O
to O O
skin O O
tests O O
. O O

If O O
digitalis B-drug B-group
treatment O O
is O O
continued O O
, O O
serum O O
levels O O
should O O
be O O
closely O O
monitored O O
and O O
patients O O
observed O O
for O O
clinical O O
evidence O O
of O O
toxicity O O
. O O

Dexamethasone B-drug B-drug
is O O
a O O
moderate O O
inducer O O
of O O
CYP O O
3A4 O O
. O O

Caution O O
should O O
be O O
exercised O O
when O O
the O O
following O O
drugs O O
are O O
administered O O
concomitantly O O
with O O
LODOSYN B-brand B-brand
( O O
Carbidopa B-drug B-drug
) O O
given O O
with O O
levodopa B-drug B-drug
or O O
carbidopa-levodopa B-drug B-drug
combination O O
products O O
. O O

In O O
patients O O
, O O
the O O
concomitant O O
administration O O
of O O
digoxin B-drug B-drug
with O O
dofetilide B-drug B-drug
was O O
associated O O
with O O
a O O
higher O O
occurrence O O
of O O
torsade O O
de O O
pointes O O
. O O

Chlorthalidone B-drug B-drug
and O O
related O O
drugs O O
may O O
decrease O O
arterial O O
responsiveness O O
to O O
norepinephrine B-drug B-drug
. O O

Anticholinergic B-group B-group
drugs I-group I-group
in O O
the O O
presence O O
of O O
increased O O
intraocular O O
pressure O O
may O O
be O O
hazardous O O
when O O
taken O O
concurrently O O
with O O
agents O O
such O O
as O O
corti O O
costeroids.. O O

Although O O
there O O
may O O
be O O
decreased O O
zalcitabine B-drug B-drug
activity O O
because O O
of O O
lessened O O
active O O
metabolite O O
formation O O
, O O
the O O
clinical O O
relevance O O
of O O
these O O
in O O
vitro O O
results O O
are O O
not O O
known O O
. O O

Phenytoin/Phenobarbital B-drug B-drug
: O O
The O O
coadministration O O
of O O
phenytoin B-drug B-drug
or O O
phenobarbital B-drug B-drug
will O O
not O O
affect O O
plasma O O
concentrations O O
of O O
vitamin B-group B-group
D I-group I-group
, O O
but O O
may O O
reduce O O
endogenous O O
plasma O O
levels O O
of O O
calcitriol/ergocalcitriol B-drug B-drug
by O O
accelerating O O
metabolism O O
. O O

Because O O
the O O
incidence O O
of O O
infections O O
and O O
certain O O
malignancies O O
is O O
higher O O
in O O
the O O
elderly O O
population O O
, O O
in O O
general O O
, O O
caution O O
should O O
be O O
used O O
in O O
treating O O
the O O
elderly O O
. O O

An O O
increase O O
of O O
63 O O
% O O
in O O
the O O
mean O O
AUC O O
and O O
increases O O
of O O
50 O O
% O O
and O O
4 O O
% O O
, O O
respectively O O
, O O
in O O
the O O
mean O O
T O O
max O O
and O O
mean O O
C O O
max O O
were O O
noted O O
in O O
1 O O
study O O
of O O
6 O O
individuals O O
. O O

- O O
Anticoagulants B-group B-group
( O O
blood B-group B-group
thinners O I-group
) O O
or O O

The O O
use O O
of O O
erythromycin B-drug B-drug
in O O
patients O O
concurrently O O
taking O O
drugs O O
metabolized O O
by O O
the O O
cytochrome O O
P450 O O
system O O
may O O
be O O
associated O O
with O O
elevations O O
in O O
serum O O
levels O O
of O O
these O O
other O O
drugs O O
. O O

Results O O
demonstrate O O
that O O
oxcarbazepine B-drug B-drug
and O O
its O O
pharmacologically O O
active O O
10-monohydroxy O O
metabolite O O
( O O
MHD B-drug_n B-drug_n
) O O
have O O
little O O
or O O
no O O
capacity O O
to O O
function O O
as O O
inhibitors O O
for O O
most O O
of O O
the O O
human O O
cytochrome O O
P450 O O
enzymes O O
evaluated O O
( O O
CYP1A2 O O
, O O
CYP2A6 O O
, O O
CYP2C9 O O
, O O
CYP2D6 O O
, O O
CYP2E1 O O
, O O
CYP4A9 O O
and O O
CYP4A11 O O
) O O
with O O
the O O
exception O O
of O O
CYP2C19 O O
and O O
CYP3A4/5 O O
. O O

The O O
use O O
of O O
codeine B-drug B-drug
may O O
result O O
in O O
additive O O
CNS O O
depressant O O
effects O O
when O O
coadministered O O
with O O
alcohol B-drug B-drug
, O O
antihistamines B-group B-group
, O O
psychotropics B-group B-group
or O O
other O O
drugs O O
that O O
produce O O
CNS O O
depression O O
. O O

Concomitant O O
administration O O
of O O
Targretin B-brand B-brand
capsules O O
and O O
gemfibrozil B-drug B-drug
resulted O O
in O O
substantial O O
increases O O
in O O
plasma O O
concentrations O O
of O O
bexarotene B-drug B-drug
, O O
probably O O
at O O
least O O
partially O O
related O O
to O O
cytochrome O O
P450 O O
3A4 O O
inhibition O O
by O O
gemfibrozil B-drug B-drug
. O O

It O O
is O O
recommended O O
that O O
GABA-positive O B-group
drugs O I-group
be O O
included O O
into O O
a O O
complex O O
of O O
treatment O O
measures O O
for O O
edema O O
. O O

The O O
effects O O
of O O
coadministered O O
drugs O O
and O O
ethanol B-drug B-drug
on O O
the O O
binding O O
of O O
therapeutic O O
drugs O O
to O O
human O O
serum O O
in O O
vitro O O
was O O
investigated O O
. O O

Oral O O
Contraceptives B-group B-group
: O O
May O O
be O O
less O O
effective O O
and O O
increased O O
breakthrough O O
bleeding O O
may O O
occur O O
. O O

rifampin B-drug B-drug
; O O

Specific O O
drug O O
interaction O O
studies O O
have O O
not O O
been O O
conducted O O
with O O
ENBREL B-brand B-brand
. O O

However O O
, O O
patients O O
on O O
digoxin B-drug B-drug
may O O
show O O
elevations O O
of O O
digoxin B-drug B-drug
concentrations O O
after O O
initiation O O
of O O
therapy O O
with O O
FLOLAN B-brand B-brand
, O O
which O O
may O O
be O O
clinically O O
significant O O
in O O
patients O O
prone O O
to O O
digoxin B-drug B-drug
toxicity O O
. O O

A O O
number O O
of O O
substances O O
affect O O
glucose O O
metabolism O O
and O O
may O O
require O O
insulin B-drug B-drug
dose O O
adjustment O O
and O O
particularly O O
close O O
monitoring O O
. O O

While O O
no O O
clinical O O
studies O O
have O O
been O O
conducted O O
to O O
evaluate O O
the O O
effect O O
of O O
grepafloxacin B-drug B-drug
on O O
the O O
metabolism O O
of O O
C.P.A O O
. O O

Alternatives O O
to O O
clarithromycin B-drug B-drug
, O O
such O O
as O O
azithromycin B-drug B-drug
, O O
should O O
be O O
considered O O
. O O

Drugs O O
that O O
raise O O
the O O
gastrointestinal O O
pH O O
may O O
lead O O
to O O
an O O
earlier O O
release O O
of O O
duloxetine B-drug B-drug
. O O

indinavir I-drug B-drug
concentration O O
rifabutin B-drug B-drug
concentration O O

Coumarin B-group B-group
Anticoagulants I-group I-group
Altered O O
coagulation O O
parameters O O
and/or O O
bleeding O O
have O O
been O O
reported O O
in O O
patients O O
taking O O
capecitabine B-drug B-drug
concomitantly O O
with O O
coumarin-derivative B-group B-group
anticoagulants I-group I-group
such O O
as O O
warfarin B-drug B-drug
and O O
phenprocoumon B-drug B-drug
. O O

Fluconazole B-drug B-drug
, O O
and O O
the O O
5-HT3 B-group B-group
antiemetics I-group I-group
ondansetron B-drug B-drug
( O O
Zofran B-brand B-brand
) O O
and O O
granisetron B-drug B-drug
( O O
Kytril B-brand B-brand
) O O
have O O
all O O
been O O
used O O
with O O
BUSULFEX B-brand B-brand
. O O

Though O O
individual O O
theophylline B-drug B-drug
levels O O
fluctuated O O
, O O
there O O
were O O
no O O
clinically O O
significant O O
symptoms O O
of O O
drug O O
inter-action O O
. O O

Furthermore O O
, O O
whenever O O
one O O
of O O
these O O
other O O
drugs O O
is O O
withdrawn O O
from O O
co-therapy O O
, O O
an O O
increased O O
dose O O
of O O
tricyclic B-group B-group
antidepressant I-group I-group
may O O
be O O
required O O
. O O

Serum O O
potassium O O
levels O O
should O O
be O O
monitored O O
and O O
deficiencies O O
corrected O O
. O O

These O O
effects O O
were O O
not O O
observed O O
when O O
Vardenafil B-drug B-drug
20 O O
mg O O
was O O
taken O O
24 O O
hours O O
before O O
the O O
NTG B-drug O
. O O

Caution O O
should O O
be O O
exercised O O
when O O
INDOCIN B-brand B-brand
and O O
anticoagulants B-group B-group
are O O
administered O O
concomitantly O O
. O O

Administration O O
of O O
quinolones B-group B-group
with O O
antacids B-group B-group
containing O O
aluminum B-drug B-drug
, O O
magnesium B-drug B-drug
, O O
or O O
calcium B-drug B-drug
, O O
with O O
sucralfate B-drug B-drug
, O O
with O O
metal O O
cations O O
such O O
as O O
iron B-drug B-drug
, O O
or O O
with O O
multivitamins B-group B-group
containing O O
iron B-drug B-drug
or O O
zinc B-drug B-drug
, O O
or O O
with O O
formulations O O
containing O O
divalent O O
and O O
trivalent O O
cations O O
such O O
as O O
VIDEX B-brand B-brand
( O O
didanosine B-drug B-drug
) O O
chewable/buffered O O
tablets O O
or O O
the O O
pediatric O O
powder O O
for O O
oral O O
solution O O
, O O
may O O
substantially O O
interfere O O
with O O
the O O
absorption O O
of O O
quinolones B-group B-group
, O O
resulting O O
in O O
systemic O O
concentrations O O
considerably O O
lower O O
than O O
desired O O
. O O

Steady-state O O
serum O O
concentrations O O
of O O
tricyclic B-group B-group
antidepressants I-group I-group
are O O
reported O O
to O O
fluctuate O O
significantly O O
when O O
cimetidine B-drug B-drug
is O O
either O O
added O O
or O O
deleted O O
from O O
the O O
drug O O
regimen O O
. O O

Concurrent O O
therapy O O
with O O
bumetanide B-drug B-drug
is O O
thus O O
not O O
recommended O O
. O O

Drug O O
Laboratory O O
Test O O
Interactions O O
: O O
Prolongation O O
of O O
the O O
template O O
bleeding O O
time O O
has O O
been O O
reported O O
during O O
continuous O O
intravenous O O
infusion O O
of O O
AMICAR B-brand B-brand
at O O
dosages O O
exceeding O O
24 O O
g/day O O
. O O

Diazepam B-drug B-drug
: O O
The O O
co-administration O O
of O O
Fluvoxamine B-drug B-drug
Tablets O O
and O O
diazepam B-drug B-drug
is O O
generally O O
not O O
advisable O O
. O O

Anti-HIV B-group B-group
Protease I-group I-group
Inhibitors I-group I-group

Although O O
verapamil B-drug B-drug
administered O O
at O O
either O O
dose O O
had O O
little O O
or O O
no O O
effect O O
on O O
the O O
enhancement O O
of O O
intestinal O O
carcinogenesis O O
by O O
bombesin B-drug_n B-drug_n
or O O
on O O
the O O
location O O
, O O
histologic O O
type O O
, O O
depth O O
of O O
involvement O O
, O O
labeling O O
index O O
, O O
apoptotic O O
index O O
or O O
tumor O O
vascularity O O
of O O
intestinal O O
cancers O O
, O O
it O O
significantly O O
decreased O O
the O O
incidence O O
of O O
cancer O O
metastasis O O
. O O

The O O
following O O
are O O
examples O O
of O O
drugs O O
known O O
to O O
inhibit O O
the O O
metabolism O O
of O O
other O O
related O O
benzodiazepines B-group B-group
, O O
presumably O O
through O O
inhibition O O
of O O
CYP3A O O
: O O
nefazodone B-drug B-drug
, O O
fluvoxamine B-drug B-drug
, O O
cimetidine B-drug B-drug
, O O
diltiazem B-drug B-drug
, O O
isoniazide B-drug B-drug
, O O
and O O
some O O
macrolide B-group B-group
antibiotics I-group I-group
. O O

There O O
have O O
been O O
no O O
formal O O
drug-interaction O O
studies O O
performed O O
with O O
Mylotarg B-brand B-brand
. O O

Vasoconstrictors B-group B-group
: O O
D.H.E B-brand B-brand
. I-brand O
45 I-brand B-brand
( O O
dihydroergotamine B-drug B-drug
mesylate I-drug I-drug
) O O
Injection O O
, O O
USP O O
should O O
not O O
be O O
used O O
with O O
peripheral B-group B-group
vasoconstrictors I-group I-group
because O O
the O O
combination O O
may O O
cause O O
synergistic O O
elevation O O
of O O
blood O O
pressure O O
. O O

Valproate B-drug B-drug
: O O
A O O
recent O O
case O O
study O O
has O O
shown O O
a O O
possible O O
increase O O
in O O
the O O
plasma O O
level O O
of O O
valproate B-drug B-drug
when O O
co O O
administered O O
with O O
isoniazid B-drug B-drug
. O O

This O O
did O O
not O O
result O O
in O O
any O O
statistically O O
or O O
clinically O O
relevant O O
changes O O
in O O
the O O
pharmacokinetic O O
parameters O O
of O O
either O O
caffeine B-drug B-drug
or O O
its O O
major O O
metabolite O O
, O O
paraxanthine B-drug_n B-drug
. O O

Leukopenia O O
was O O
similar O O
between O O
the O O
two O O
groups O O
, O O
but O O
colony O O
stimulating O O
factor O O
support O O
was O O
significantly O O
greater O O
in O O
the O O
CHOP-HAART O O
group O O
than O O
in O O
the O O
control O O
group O O
( O O
92 O O
% O O
vs. O O
66 O O
% O O
, O O
respectively O O
; O O
P O O
= O O
0.03 O O
) O O
. O O

The O O
possibility O O
of O O
hypotensive O O
effects O O
with O O
PRINIVIL B-brand B-brand
can O O
be O O
minimized O O
by O O
either O O
discontinuing O O
the O O
diuretic B-group B-group
or O O
increasing O O
the O O
salt O O
intake O O
prior O O
to O O
initiation O O
of O O
treatment O O
with O O
PRINIVIL B-brand B-brand
. O O

When O O
other O O
antiplatelet B-group B-group
agents I-group I-group
or O O
anticoagulants B-group B-group
are O O
used O O
concomitantly O O
, O O
there O O
is O O
the O O
potential O O
for O O
FLOLAN B-brand B-brand
to O O
increase O O
the O O
risk O O
of O O
bleeding O O
. O O

Taking O O
a O O
rauwolfia B-group B-drug
alkaloid I-group I-drug
while O O
you O O
are O O
taking O O
or O O
within O O
2 O O
weeks O O
of O O
taking O O
MAO B-group B-group
inhibitors I-group I-group
may O O
increase O O
the O O
risk O O
of O O
central O O
nervous O O
system O O
depression O O
or O O
may O O
cause O O
a O O
severe O O
high O O
blood O O
pressure O O
reaction O O
. O O

No O O
autoinduction O O
has O O
been O O
observed O O
with O O
Trileptal B-brand B-brand
. O O

Latent O O
diabetes O O
mellitus O O
may O O
become O O
manifest O O
during O O
chlorthalidone B-drug B-drug
administration O O
. O O

Repeated O O
oral O O
administration O O
of O O
coumaphos B-drug_n B-drug_n
in O O
sheep O O
: O O
interactions O O
of O O
coumaphos B-drug_n B-group
with O O
bishydroxycoumarin B-drug B-drug
, O O
trichlorfon B-drug_n B-drug
, O O
and O O
phenobarbital B-drug B-drug
sodium I-drug I-drug
. O O

surgery O O
; O O

In O O
another O O
drug O O
interaction O O
study O O
, O O
co-administration O O
of O O
orally O O
inhaled O O
ciclesonide B-drug B-drug
and O O
oral O O
ketoconazole B-drug B-drug
, O O
a O O
potent O O
inhibitor O O
of O O
cytochrome O O
P450 O O
3A4 O O
, O O
increased O O
the O O
exposure O O
( O O
AUC O O
) O O
of O O
des-ciclesonide B-drug B-drug
by O O
approximately O O
3.6-fold O O
at O O
steady O O
state O O
, O O
while O O
levels O O
of O O
ciclesonide B-drug B-drug
remained O O
unchanged O O
. O O

rifabutin I-drug B-drug
concentration O O

The O O
percentage O O
of O O
neurons O O
hyperpolarized O O
by O O
mu- B-group O
, O O
delta O O
( O O
1 O O
) O O
- O O
, O O
and O O
kappa-selective B-group O
opioids I-group B-group
was O O
significantly O O
reduced O O
when O O
1 O O
% O O
but O O
not O O
< O O

antacids B-group B-group
after O O
meals O O
. O O

Coadministration O O
of O O
rifampin B-drug B-drug
with O O
diltiazem B-drug B-drug
lowered O O
the O O
diltiazem B-drug B-drug
plasma O O
concentrations O O
to O O
undetectable O O
levels O O
. O O

Laboratory O O
Tests O O
: O O
The O O
combination O O
of O O
Amprenavir B-drug B-drug
and O O
low-dose O O
ritonavir B-drug B-drug
has O O
been O O
associated O O
with O O
elevations O O
of O O
cholesterol O O
and O O
triglycerides O O
, O O
SGOT O O
( O O
AST O O
) O O
, O O
and O O
SGPT O O
( O O
ALT O O
) O O
in O O
some O O
patients O O
. O O

The O O
elimination O O
half O O
life O O
of O O
midazolam B-drug B-drug
and O O
triazolam B-drug B-drug
also O O
increased O O
( O O
1.5-2.5 O O
fold O O
) O O
during O O
coadministration O O
with O O
diltiazem B-drug B-drug
. O O

These O O
effects O O
have O O
been O O
attributed O O
to O O
inhibition O O
of O O
renal O O
prostaglandin O O
synthesis O O
by O O
the O O
NSAID B-group B-group
. O O

If O O
possible O O
, O O
anticholinesterase B-group B-group
agents I-group I-group
should O O
be O O
withdrawn O O
at O O
least O O
24 O O
hours O O
before O O
initiating O O
corticosteroid B-group B-group
therapy O O
. O O

Potential O O
for O O
Interaction O O
with O O
Monoamine B-group B-group
Oxidase I-group I-group
Inhibitors I-group I-group

Therefore O O
, O O
the O O
combination O O
of O O
ketoprofen B-drug B-drug
and O O
probenecid B-drug B-drug
is O O
not O O
recommended O O
. O O

Eprosartan B-drug B-drug
doses O O
of O O
up O O
to O O
300 O O
mg O O
b.i.d O O
. O O
have O O
been O O
safely O O
used O O
concomitantly O O
with O O
sustained-release O B-group
calcium B-group I-group
channel I-group I-group
blockers I-group I-group
( O O
sustained-release O O
nifedipine B-drug B-drug
) O O
with O O
no O O
clinically O O
significant O O
adverse O O
interactions O O
. O O

there O O
was O O
no O O
effect O O
on O O
the O O
3 O O
major O O
metabolites O O
( O O
5-DFUR B-drug_n O
, O O
5-FU B-drug_n O
and O O
FBAL B-drug_n O
) O O
. O O

Concomitant O O
use O O
of O O
ELLENCE B-brand B-brand
with O O
other O O
cardioactive O B-group
compounds O I-group
that O O
could O O
cause O O
heart O O
failure O O
( O O
e.g. O O
, O O
calcium B-group B-group
channel I-group I-group
blockers I-group I-group
) O O
, O O
requires O O
close O O
monitoring O O
of O O
cardiac O O
function O O
throughout O O
treatment O O
. O O

Clearance O O
of O O
hydrodolasetron B-drug_n B-drug
decreased O O
by O O
about O O
27 O O
% O O
when O O
dolasetron B-drug B-drug
mesylate I-drug I-drug
was O O
administered O O
intravenously O O
concomitantly O O
with O O
atenolol B-drug B-drug
. O O

The O O
blockade O O
of O O
the O O
spinal O O
endorphinergic O O
system O O
by O O
intrathecal O O
naloxone B-drug B-drug
on O O
the O O
production O O
of O O
tail-flick O O
inhibition O O
induced O O
by O O
intraventricular O O
beta-endorphin B-drug_n B-drug_n
and O O
morphine B-drug B-drug
was O O
then O O
studied O O
. O O

The O O
time O O
to O O
onset O O
of O O
maximum O O
block O O
following O O
NIMBEX B-brand B-brand
is O O
approximately O O
2 O O
minutes O O
faster O O
with O O
prior O O
administration O O
of O O
succinylcholine B-drug B-drug
. O O

There O O
is O O
no O O
significant O O
change O O
in O O
platelet O O
count O O
, O O
prothrombin O O
time O O
, O O
partial O O
thromboplastin O O
time O O
, O O
or O O
thrombin O O
time O O
. O O

Serum O O
transaminase O O
levels O O
should O O
be O O
obtained O O
before O O
starting O O
treatment O O
with O O
Plenaxis B-brand B-brand
and O O
periodically O O
during O O
treatment O O
. O O

Benzthiazide B-drug B-drug
may O O
interact O O
with O O
alcohol B-drug B-drug
, O O
blood B-group B-group
thinners O I-group
, O O
decongestant B-group B-group
drugs I-group I-group
( O O
allergy O O
, O O
cold O O
, O O
and O O
sinus O O
medicines O O
) O O
, O O
diabetic O O
drugs O O
, O O
lithium B-drug B-drug
, O O
norepinephrine B-drug B-drug
, O O
NSAIDs B-group B-group
like O O
Aleve B-brand B-brand
or O O
Ibuprofen B-drug B-drug
, O O
and O O
high O O
blood O O
pressure O O
medications O O
. O O

Concomitant O O
use O O
of O O
prostaglandin O B-group
synthase O I-group
inhibiting O I-group
drugs O I-group
, O O
eg O O
, O O
indomethacin B-drug B-drug
, O O
may O O
decrease O O
the O O
hypotensive O O
effects O O
of O O
beta B-group B-group
blockers I-group I-group
. O O

Therefore O O
when O O
central B-group B-group
nervous I-group I-group
system I-group I-group
depressants I-group I-group
are O O
administered O O
concomitantly O O
with O O
hydroxyzine B-drug B-drug
their O O
dosage O O
should O O
be O O
reduced O O
. O O

- O O
The O O
persistence O O
of O O
clinical O O
and O O
laboratory O O
evidence O O
of O O
hypothyroidism O O
in O O
spite O O
of O O
adequate O O
dosage O O
replacement O O
indicates O O
either O O
poor O O
patient O O
compliance O O
, O O
poor O O
absorption O O
, O O
excessive O O
fecal O O
loss O O
, O O
or O O
inactivity O O
of O O
the O O
preparation O O
. O O

. O O

Diclofenac B-drug B-drug
: O O
Administration O O
of O O
morning O O
and O O
lunch O O
doses O O
of O O
Starlix B-brand B-brand
120 O O
mg O O
in O O
combination O O
with O O
a O O
single O O
75-mg O O
dose O O
of O O
diclofenac B-drug B-drug
in O O
healthy O O
volunteers O O
resulted O O
in O O
no O O
significant O O
changes O O
to O O
the O O
pharmacokinetics O O
of O O
either O O
agent O O
. O O

Loratadine B-drug B-drug
( O O
10 O O
mg O O
once O O
daily O O
) O O
has O O
been O O
coadministered O O
with O O
therapeutic O O
doses O O
of O O
erythromycin B-drug B-drug
, O O
cimetidine B-drug B-drug
, O O
and O O
ketoconazole B-drug B-drug
in O O
controlled O O
clinical O O
pharmacology O O
studies O O
in O O
adult O O
volunteers O O
. O O

No O O
data O O
on O O
the O O
level O O
of O O
circulating O O
catecholamines O O
after O O
ALPHAGAN B-brand B-brand
P I-brand O
administration O O
are O O
available O O
. O O

Amitriptyline B-drug B-drug
in O O
combination O O
with O O
clonidine B-drug B-drug
enhances O O
the O O
manifestation O O
of O O
corneal O O
lesions O O
in O O
rats O O
Epidural O O
Injection O O
Clonidine B-drug B-drug
may O O
potentiate O O
the O O
CNS-depressive O O
effect O O
of O O
alcohol B-drug B-drug
, O O
barbiturates B-group B-group
or O O
other O O
sedating B-group B-group
drugs I-group I-group
. O O

Other O O
substances O O
, O O
including O O
herbal O O
preparations O O
: O O
St. O O
John O O
s O O
Wort O O
( O O
Hypericum O O
perforatum O O
) O O
induces O O
CYP3A4 O O
. O O

In O O
normal O O
volunteers O O
receiving O O
indomethacin B-drug B-drug
, O O
the O O
administration O O
of O O
diflunisal B-drug B-drug
decreased O O
the O O
renal O O
clearance O O
and O O
significantly O O
increased O O
the O O
plasma O O
levels O O
of O O
indomethacin B-drug B-drug
. O O

Valproate B-drug B-drug
: O O
Felbatol B-brand B-brand
causes O O
an O O
increase O O
in O O
steady-state O O
valproate B-drug B-drug
concentrations O O
. O O

APRD00513_IN O O
, O O
txt O O

These O O
agents O O
should O O
not O O
be O O
taken O O
within O O
the O O
two O O
hour O O
period O O
before O O
or O O
within O O
the O O
two-hour O O
period O O
after O O
nalidixic B-drug B-drug
acid I-drug I-drug
administration O O
. O O

Intrathecal O O
injection O O
of O O
naloxone B-drug B-drug
at O O
doses O O
of O O
0.4 O O
to O O
40 O O
micrograms O O
caused O O
a O O
dose-related O O
blockade O O
of O O
the O O
inhibition O O
of O O
the O O
tail-flick O O
response O O
induced O O
by O O
intraventricular O O
injection O O
of O O
beta-endorphin B-drug_n B-drug_n
, O O
and O O
a O O
high O O
dose O O
of O O
naloxone B-drug B-drug
( O O
40 O O
micrograms O O
) O O
completely O O
blocked O O
the O O
tail-flick O O
inhibition O O
induced O O
by O O
intraventricular O O
beta-endorphin B-drug_n B-drug_n
( O O
16 O O
micrograms O O
) O O
. O O

In O O
one O O
survey O O
, O O
2.3 O O
% O O
of O O
patients O O
taking O O
labetalol B-drug B-drug
HCl I-drug I-drug
in O O
combination O O
with O O
tricyclic B-group B-group
antidepressants I-group I-group
experienced O O
tremor O O
, O O
as O O
compared O O
to O O
0.7 O O
% O O
reported O O
to O O
occur O O
with O O
labetalol B-drug B-drug
HCl I-drug I-drug
alone O O
. O O

When O O
sympathomimetic B-group B-group
drugs I-group I-group
are O O
given O O
to O O
patients O O
receiving O O
monoamine B-group B-group
oxidase I-group I-group
inhibitors I-group I-group
, O O
hypertensive O O
reactions O O
, O O
including O O
hypertensive O O
crises O O
, O O
may O O
occur O O
. O O

Resins B-group B-group
: O O
Since O O
bile B-group B-group
acid I-group I-group
sequestrants I-group I-group
may O O
bind O O
other O O
drugs O O
given O O
concurrently O O
, O O
patients O O
should O O
take O O
TRICOR B-brand B-brand
at O O
least O O
1 O O
hour O O
before O O
or O O
4-6 O O
hours O O
after O O
a O O
bile B-group B-group
acid I-group I-group
binding I-group I-group
resin I-group I-group
to O O
avoid O O
impeding O O
its O O
absorption O O
. O O

No O O
drug O O
interaction O O
studies O O
have O O
been O O
performed O O
. O O

In O O
common O O
with O O
other O O
broad-spectrum B-group B-group
antibiotics I-group I-group
, O O
AUGMENTIN B-brand B-brand
XR I-brand I-brand
may O O
reduce O O
the O O
efficacy O O
of O O
oral O O
contraceptives B-group B-group

Antimycobacterial B-group B-group
Agents I-group I-group

Valdecoxib B-drug B-drug
steady O O
state O O
plasma O O
concentrations O O
( O O
40 O O
mg O O
BID O O
) O O
were O O
not O O
affected O O
significantly O O
with O O
multiple O O
doses O O
of O O
omeprazole B-drug B-drug
( O O
40 O O
mg O O
QD O O
) O O
. O O

lopinavir I-drug B-drug
concentration O O

3 O O
. O O

Warfarin B-drug B-drug
and O O
Anticoagulants B-group B-group
: O O
Increased O O
prothrombin O O
time O O
, O O
with O O
or O O
without O O
clinical O O
bleeding O O
, O O
has O O
been O O
reported O O
when O O
cefixime B-drug B-drug
is O O
administered O O
concomitantly O O
. O O

Drugs O O
that O O
Lower O O
Seizure O O
Threshold O O
: O O
Concurrent O O
administration O O
of O O
WELLBUTRIN B-brand B-brand
and O O
agents O O
( O O
e.g. O O
, O O
antipsychotics B-group B-group
, O O
other O O
antidepressants B-group B-group
, O O
theophylline B-drug B-drug
, O O
systemic O B-group
steroids B-group I-group
, O O
etc O O
. O O
) O O
that O O
lower O O
seizure O O
threshold O O
should O O
be O O
undertaken O O
only O O
with O O
extreme O O
caution O O
. O O

Drug O O
Name O O

A O O
single O O
0.5 O O
mg O O
oral O O
dose O O
of O O
digoxin B-drug B-drug
elixir O O
was O O
administered O O
on O O
the O O
7th O O
day O O
of O O
each O O
11-day O O
period O O
. O O

HCTZ B-drug B-drug
50 O O
mg O O
QD O O
or O O
HCTZ/triamterene B-drug B-drug
50/100 O O
mg O O
QD O O
was O O
co-administered O O
with O O
TIKOSYN B-brand B-brand
( O O
500 O O
mcg O O
BID O O
) O O
for O O
5 O O
days O O
( O O
following O O
2 O O
days O O
of O O
diuretic B-group B-group
use O O
at O O
half O O
dose O O
) O O
. O O

Results O O
from O O
existing O O
clinical O O
trials O O
suggest O O
no O O
significant O O
interactions O O
between O O
COPAXONE B-brand B-brand
and O O
other O O
therapies O O
commonly O O
used O O
in O O
MS O O
patients O O
, O O
including O O
the O O
concurrent O O
use O O
of O O
corticosteroids B-group B-group
for O O
up O O
to O O
28 O O
days O O
. O O

Antacids B-group B-group
may O O
interfere O O
with O O
the O O
absorption O O
of O O
LEVSIN B-brand B-brand
. O O

The O O
zidovudine B-drug B-drug
study O O
dosed O O
subjects O O
with O O
1200 O O
mg/day O O
of O O
azithromycin B-drug B-drug
( O O
n O O
= O O
7 O O
) O O
( O O
later O O
changed O O
to O O
600 O O
mg/day O O
[ O O
n O O
= O O
5 O O
] O O
) O O
for O O
Days O O
8 O O
to O O
21 O O
of O O
a O O
21-day O O
course O O
of O O
100 O O
mg O O
, O O
five O O
times/day O O
of O O
zidovudine B-drug B-drug
. O O

Sulindac B-drug B-drug
: O O
The O O
concomitant O O
administration O O
of O O
diflunisal B-drug B-drug
and O O
sulindac B-drug B-drug
in O O
normal O O
volunteers O O
resulted O O
in O O
lowering O O
of O O
the O O
plasma O O
levels O O
of O O
the O O
active O O
sulindac O B-drug
sulfide O I-drug
metabolite O O
by O O
approximately O O
one-third O O
. O O

Thus O O
, O O
concomitant O O
administration O O
of O O
enoxacin B-drug B-drug
and O O
bismuth B-drug B-drug
subsalicylate I-drug I-drug
should O O
be O O
avoided O O
. O O

CRIXIVAN B-brand B-brand
may O O
not O O
be O O
effective O O
due O O
to O O
decreased O O
indinavir B-drug B-drug
concentrations O O
in O O
patients O O
taking O O
these O O
agents O O
concomitantly O O
. O O

Nifedipine B-drug B-drug
: O O
Vardenafil B-drug B-drug
20 O O
mg O O
, O O
when O O
co-administered O O
with O O
slow-release O O
nifedipine B-drug B-drug
30 O O
mg O O
or O O
60 O O
mg O O
once O O
daily O O
, O O
did O O
not O O
affect O O
the O O
relative O O
bioavailability O O
( O O
AUC O O
) O O
or O O
maximum O O
concentration O O
( O O
Cmax O O
) O O
of O O
nifedipine B-drug B-drug
, O O
a O O
drug O O
that O O
is O O
metabolized O O
via O O
CYP3A4 O O
. O O

Isoflurane B-drug B-drug
, O O
enflurane B-drug B-drug
, O O
and O O
halothane B-drug B-drug
decrease O O
the O O
ED50 O O
of O O
NUROMAX B-brand B-brand
by O O
30 O O
% O O
to O O
45 O O
% O O
. O O

Since O O
photic O O
evoked O O
potential O O
components O O
are O O
representations O O
of O O
neural O O
pathways O O
which O O
are O O
activated O O
during O O
photic O O
stimulation O O
, O O
study O O
of O O
the O O
effects O O
of O O
alcohol B-drug B-drug
on O O
these O O
components O O
may O O
help O O
to O O
trace O O
pathways O O
which O O
are O O
affected O O
by O O
alcohol B-drug B-drug
. O O

While O O
all O O
the O O
selective B-group B-group
serotonin I-group I-group
reuptake I-group I-group
inhibitors I-group I-group
( O O
SSRIs B-group B-group
) O O
, O O
e.g. O O
, O O
fluoxetine B-drug B-drug
, O O
seriraline O B-drug
, O O
and O O
paroxetine B-drug B-drug
, O O
inhibit O O
P450 O O
2D6 O O
, O O
they O O
may O O
vary O O
in O O
the O O
extent O O
of O O
inhibition O O
. O O

In O O
this O O
study O O
, O O
we O O
investigated O O
the O O
mechanism O O
( O O
s O O
) O O
of O O
resveratrol-induced B-drug_n B-drug_n
vasorelaxation O O
in O O
resistance O O
mesenteric O O
arteries O O
from O O
male O O
lean O O
and O O
dietary-induced O B-drug
obese O O
rats O O
. O O

Coadministration O O
of O O
VIDEX B-brand B-brand
with O O
drugs O O
that O O
are O O
known O O
to O O
cause O O
pancreatitis O O
may O O
increase O O
the O O
risk O O
of O O
this O O
toxicity O O
( O O
see O O
WARNINGS O O
) O O
and O O
should O O
be O O
done O O
with O O
extreme O O
caution O O
, O O
only O O
if O O
other O O
alternatives O O
are O O
not O O
available O O
, O O
and O O
only O O
if O O
clearly O O
indicated O O
. O O

When O O
such O O
drugs O O
are O O
withdrawn O O
from O O
a O O
patient O O
receiving O O
glipizide B-drug B-drug
, O O
the O O
patient O O
should O O
be O O
observed O O
closely O O
for O O
hypoglycemia O O
. O O

The O O
in O O
vitro O O
interaction O O
between O O
nevirapine B-drug B-drug
and O O
the O O
antithrombotic B-group B-group
agent I-group I-group
warfarin B-drug B-drug
is O O
complex O O
. O O

In O O
addition O O
, O O
neuromuscular O O
blocking O O
action O O
is O O
enhanced O O
by O O
general O O
anesthetics B-group B-group
, O O
local O O
anesthetics B-group B-group
like O O
lidocaine B-drug B-drug
, O O
procaine B-drug B-drug
, O O
beta-blockers B-group B-group
, O O
metaclopramide B-drug B-drug
, O O
lithium B-drug B-drug
carbonate I-drug I-drug
, O O
and O O
terbutaline B-drug B-drug
. O O

The O O
optimal O O
dose O O
of O O
indinavir B-drug B-drug
, O O
when O O
given O O
in O O
combination O O
with O O
efavirenz B-drug B-drug
, O O
is O O
not O O
known O O
. O O

Example O O
inducers O O
include O O
aminoglutethimide B-drug B-drug
, O O
carbamazepine B-drug B-drug
, O O
nafcillin B-drug B-drug
, O O
nevirapine B-drug B-drug
, O O
phenobarbital B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
and O O
rifamycins B-group B-group
. O O

Cobalt B-drug B-drug
excretion O O
was O O
enhanced O O
by O O
supplementary O O
cobalt B-drug B-drug
; O O

This O O
effect O O
is O O
small O O
with O O
occasional O O
doses O O
of O O
antacids B-group B-group
, O O
but O O
may O O
be O O
clinically O O
significant O O
when O O
antacids B-group B-group
are O O
used O O
on O O
a O O
continuous O O
schedule O O
. O O

Toxicologic O O
and O O
toxicokinetic O O
studies O O
in O O
rats O O
did O O
not O O
demonstrate O O
any O O
alterations O O
in O O
the O O
clearance O O
or O O
toxicologic O O
profile O O
of O O
either O O
methotrexate B-drug B-drug
or O O
Kineret B-brand B-brand
when O O
the O O
two O O
agents O O
were O O
administered O O
together O O
. O O

Whether O O
this O O
interaction O O
also O O
occurs O O
with O O
the O O
intravenous O O
, O O
topical O O
, O O
or O O
vaginal O O
preparations O O
of O O
miconazole B-drug B-drug
is O O
not O O
known O O
. O O

Concomitant O O
administration O O
of O O
Aprepitant B-drug B-drug
with O O
strong O O
CYP3A4 O O
inhibitors O O
should O O
be O O
approached O O
cautiously O O
. O O

Dosage O O
adjustment O O
may O O
be O O
warranted O O
when O O
levobupivacaine B-drug B-drug
is O O
concurrently O O
administered O O
with O O
CYP3A4 O O
inhibitors O O
and O O
CYP1A2 O O
inhibitors O O
as O O
systemic O O
levobupivacaine B-drug B-drug
levels O O
may O O
rise O O
resulting O O
in O O
toxicity O O
. O O

Microdosed O O
minipill O B-drug
progestin B-drug I-drug
preparations O O
are O O
not O O
recommended O O
for O O
use O O
with O O
Soriatane B-drug B-brand
. O O

An O O
in O O
vivo O O
interaction O O
study O O
in O O
humans O O
demonstrated O O
that O O
a O O
single O O
1mg O O
dose O O
of O O
anagrelide B-drug B-drug
administered O O
concomitantly O O
with O O
a O O
single O O
900 O O
mg O O
dose O O
of O O
aspirin B-brand B-brand
was O O
generally O O
well O O
tolerated O O
. O O

N=50 O O
) O O
Cmax O O
and O O
AUC O O
values O O
in O O
a O O
dose-dependent O O
manner O O
relative O O
to O O
administration O O
of O O
hydrocodone B-drug B-drug
alone O O
; O O

INDOCIN B-brand B-brand
can O O
reduce O O
the O O
antihypertensive O O
effects O O
of O O
captopril B-drug B-drug
and O O
losartan B-drug B-drug
. O O

The O O
general O O
public O O
feels O O
that O O
cocaine B-drug B-drug
is O O
not O O
particularly O O
dangerous O O
because O O
it O O
does O O
not O O
produce O O
a O O
well O O
defined O O
physical O O
dependency O O
and O O
abstinence O O
syndrome O O
. O O

It O O
should O O
also O O
be O O
avoided O O
in O O
patients O O
with O O
blood O O
, O O
liver O O
or O O
kidney O O
diseases O O
, O O
recent O O
radiation O O
treatment O O
, O O
or O O
uncontrolled O O
diabetes O O
. O O

A O O
decrease O O
of O O
the O O
dosage O O
may O O
be O O
necessary O O
when O O
patient O O
becomes O O
euthyroid O O
. O O

dihydropyridine B-group B-group
calcium I-group I-group
channel I-group I-group
blockers I-group I-group
concentration O O

The O O
clinical O O
relevance O O
of O O
the O O
potential O O
effect O O
of O O
grepafloxacin B-drug B-drug
on O O
the O O
metabolism O O
of O O
C.P.A O O
. O O
substrates O O
is O O
not O O
known O O
. O O

Acute O O
hydrocortisone B-drug B-drug
administration O O
does O O
not O O
affect O O
subjective O O
responses O O
to O O
d-amphetamine B-drug B-drug
in O O
humans O O
. O O

Acetaminophen B-drug B-drug
: O O
May O O
increase O O
plasma O O
concentration O O
of O O
synthetic B-group B-group
estrogens I-group I-group
, O O
possibly O O
by O O
inhibiting O O
conjugation O O
. O O

Concomitant O O
Crohn O O
s O O
disease O O
medications O O
were O O
antibiotics B-group B-group
, O O
antivirals B-group B-group
, O O
corticosteroids B-group B-group
, O O
6-MP/AZA B-drug O
and O O
aminosalicylates O B-group
. O O

Serum O O
concentrations O O
of O O
drugs O O
metabolized O O
by O O
the O O
cytochrome O O
P450 O O
system O O
should O O
be O O
monitored O O
closely O O
in O O
patients O O
concurrently O O
receiving O O
erythromycin B-drug B-drug
. O O

Interaction O O
between O O
oxytocin B-drug B-drug
and O O
antidiuretic O B-group
hormone O I-group
and O O
its O O
effect O O
on O O
the O O
milk O O
secretion O O
by O O
alveoli O O
of O O
the O O
mammary O O
gland O O
of O O
lactating O O
rats O O
. O O

The O O
following O O
eight O O
target O O
drug/added O O
drug O O
combinations O O
were O O
studied O O
: O O
acetaminophen/phenobarbital B-drug B-drug
. O O

The O O
antifungal B-group B-group
drug I-group I-group
, O O
miconazole B-drug B-drug
nitrate I-drug I-drug
, O O
inhibits O O
the O O
growth O O
of O O
several O O
species O O
of O O
Candida O O
. O O

No O O
dosage O O
adjustment O O
is O O
required O O
for O O
Fluvoxamine B-drug B-drug
Tablets O O
. O O

Fluoroquinolones B-drug B-group
, O O
macrolide B-drug B-group
antibiotics I-drug I-group
, O O
and O O
azoles O B-group
are O O
known O O
to O O
cause O O
QTc O O
prolongation O O
. O O

Concomitant O O
use O O
with O O
other O O
calcium-containing B-drug B-group
medicines O I-group
( O O
including O O
antacids B-group B-group
) O O
may O O
cause O O
too O O
much O O
calcium B-drug B-drug
in O O
the O O
blood O O
or O O
urine O O
, O O
which O O
may O O
increase O O
the O O
chance O O
of O O
side O O
effects O O
. O O

These O O
individuals O O
may O O
develop O O
higher O O
than O O
expected O O
plasma O O
concentrations O O
of O O
clozapine B-drug B-drug
when O O
given O O
usual O O
doses O O
. O O

Other O O
reported O O
interactions O O
with O O
amiodarone B-drug B-drug
: O O
Fentanyl B-drug B-drug
( O O
CYP3A4 B-drug O
substrate O O
) O O
in O O
combination O O
with O O
amiodarone B-drug B-drug
may O O
cause O O
hypotension O O
, O O
bradycardia O O
, O O
and O O
decreased O O
cardiac O O
output O O
. O O

Finally O O
, O O
it O O
is O O
notable O O
that O O
xanthine-derived O O
adenosine O O
antagonists O O
tested O O
here O O
commonly O O
showed O O
anxiogenic O O
effects O O
in O O
the O O
light/dark O O
test O O
in O O
mice O O
. O O

Theophylline B-drug B-drug
: O O
The O O
pharmacokinetics O O
of O O
theophylline B-drug B-drug
( O O
aminophylline B-drug B-drug
5.8 O O
mg/kg O O
infused O O
over O O
20 O O
minutes O O
) O O
were O O
unchanged O O
following O O
a O O
single O O
oral O O
dose O O
of O O
albendazole B-drug B-drug
( O O
400 O O
mg O O
) O O
in O O
6 O O
healthy O O
subjects O O
. O O

Drug/Laboratory O O
Tests O O
Interactions O O
Because O O
false O O
positive O O
readings O O
were O O
reported O O
with O O
the O O
Ames O O
N-Multistix O O
SG O O
dipstick O O
test O O
for O O
urinary O O
protein O O
when O O
gabapentin B-drug B-drug
was O O
added O O
to O O
other O O
antiepileptic B-group B-group
drugs I-group I-group
, O O
the O O
more O O
specific O O
sulfosalicylic O B-drug
acid O I-drug
precipitation O O
procedure O O
is O O
recommended O O
to O O
determine O O
the O O
presence O O
of O O
urine O O
protein O O

Thus O O
, O O
certain O O
factors O O
, O O
such O O
as O O
reinforcing O O
drug O O
effects O O
, O O
conditioning O O
processes O O
, O O
automatic O O
behavior O O
, O O
and O O
stress O O
, O O
may O O
influence O O
the O O
development O O
of O O
dependence O O
on O O
both O O
drugs O O
. O O

. O O

This O O
risk O O
is O O
present O O
whether O O
the O O
drugs O O
are O O
administered O O
as O O
oral O O
, O O
parenteral O O
, O O
or O O
topical O O
formulations O O
. O O

Successful O O
prophylaxis O O
of O O
manic-depressive O O
disorder O O
requires O O
more O O
than O O
the O O
prescription O O
of O O
lithium B-drug B-drug
carbonate I-drug I-drug
. O O

Dependent O O
measures O O
included O O
self-reported O O
mood O O
and O O
subjective O O
effects O O
( O O
Addiction O O
Research O O
Center O O
inventory O O
, O O
the O O
profile O O
of O O
mood O O
states O O
, O O
and O O
a O O
series O O
of O O
visual O O
analogue O O
scales O O
) O O
, O O
vital O O
signs O O
, O O
salivary O O
cortisol O O
, O O
and O O
psychomotor O O
performance O O
. O O

When O O
these O O
products O O
are O O
administered O O
concomitantly O O
, O O
prothrombin O O
or O O
other O O
suitable O O
coagulation O O
tests O O
should O O
be O O
monitored O O
closely O O
. O O

No O O
formal O O
drug O O
interaction O O
studies O O
have O O
been O O
conducted O O
with O O
Cyanokit B-brand B-brand
. O O

vitamin B-drug B-drug
C I-drug I-drug
; O O

Meclofenamate B-drug B-drug
sodium I-drug I-drug
does O O
not O O
affect O O
serum O O
salicylate B-group O
levels O O
. O O

The O O
use O O
of O O
NSAIDs B-group B-group
in O O
patients O O
who O O
are O O
receiving O O
ACE B-group B-group
inhibitors I-group I-group
may O O
potentiate O O
renal O O
disease O O
states O O
. O O

Therapeutic O O
drug O O
monitoring O O
can O O
avoid O O
iatrogenic O O
alterations O O
caused O O
by O O
99mTc-methylene B-drug B-drug
diphosphonate I-drug I-drug
( O O
MDP O B-drug
) O O
-gentamicin B-drug B-drug
interaction O O
. O O

Consequently O O
, O O
prothrombin O O
time O O
should O O
be O O
reassessed O O
periodically O O
in O O
patients O O
receiving O O
both O O
drugs O O
. O O

Rifampin B-drug B-drug
has O O
been O O
reported O O
to O O
increase O O
the O O
warfarin B-drug B-drug
requirements O O
in O O
human O O
subjects O O
ingesting O O
these O O
agents O O
simultaneously O O
. O O

This O O
appears O O
to O O
be O O
the O O
only O O
clinically O O
relevant O O
interaction O O
of O O
this O O
kind O O
with O O
Mefloquine B-drug B-drug
, O O
although O O
theoretically O O
, O O
coadministration O O
of O O
other O O
drugs O O
known O O
to O O
alter O O
cardiac O O
conduction O O
( O O
eg O O
, O O
anti-arrhythmic B-drug O
or O O
beta-adrenergic B-group B-group
blocking I-group I-group
agents I-group I-group
, O O
calcium B-group B-group
channel I-group I-group
blockers I-group I-group
, O O
antihistamines B-group B-group
or O O
H1-blocking B-group B-group
agents I-group I-group
, O O
tricyclic B-group B-group
antidepressants I-group I-group
and O O
phenothiazines B-group B-group
) O O
might O O
also O O
contribute O O
to O O
a O O
prolongation O O
of O O
the O O
QTc O O
interval O O
. O O

The O O
effect O O
was O O
present O O
for O O
at O O
least O O
7 O O
days O O
after O O
the O O
last O O
dose O O
of O O
bupropion B-drug B-drug
. O O

Barbiturates B-group B-group
, O O
carbamazepine B-drug B-drug
, O O
and O O
phenytoin B-drug B-drug
decrease O O
the O O
half-life O O
of O O
doxycycline B-drug B-drug
. O O

If O O
nifedipine B-drug B-drug
therapy O O
is O O
initiated O O
in O O
a O O
patient O O
currently O O
receiving O O
cimetidine B-drug B-drug
, O O
cautious O O
titration O O
is O O
advised O O
. O O

During O O
concomitant O O
therapy O O
of O O
Ponstel B-brand B-brand
with O O
furosemide B-drug B-drug
, O O
the O O
patient O O
should O O
be O O
observed O O
closely O O
for O O
signs O O
of O O
renal O O
failure O O
, O O
as O O
well O O
as O O
to O O
assure O O
diuretic O O
efficacy O O
. O O

However O O
, O O
appropriate O O
monitoring O O
of O O
blood O O
glucose O B-drug
should O O
be O O
performed O O
when O O
initiating O O
EXTRANEAL B-brand B-brand
in O O
diabetic O O
patients O O
and O O
insulin B-drug B-drug
dosage O O
should O O
be O O
adjusted O O
if O O
needed O O
. O O

Depending O O
on O O
the O O
fraction O O
of O O
drug O O
metabolized O O
by O O
P450 O O
2D6 O O
, O O
the O O
increase O O
in O O
plasma O O
concentration O O
may O O
be O O
small O O
, O O
or O O
quite O O
large O O
( O O
8-fold O O
increase O O
in O O
plasma O O
AUC O O
of O O
the O O
TCA B-group B-group
) O O
. O O

An O O
alternative O O
non-CYP3A4 O O
substrate O O
hypnotic B-group O
agent I-group O
may O O
be O O
considered O O
in O O
patients O O
taking O O
CYP3A4 O O
inducers O O
such O O
as O O
rifampin B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
carbamazepine B-drug B-drug
, O O
and O O
phenobarbital B-drug B-drug
. O O

Antidiabetic B-group B-group
Agents I-group I-group
: O O
Disturbances O O
of O O
blood O O
glucose O O
, O O
including O O
hyperglycemia O O
and O O
hypoglycemia O O
, O O
have O O
been O O
reported O O
in O O
patients O O
treated O O
concomitantly O O
with O O
quinolones B-group B-group
and O O
an O O
antidiabetic B-group B-group
agent I-group I-group
. O O

The O O
purpose O O
of O O
this O O
study O O
was O O
to O O
evaluate O O
the O O
effect O O
of O O
sodium B-drug_n B-drug
carboxymethylcellulose I-drug_n I-drug
( O O
NaCMC B-drug_n B-drug_n
) O O
and O O
carboxymethylcellulose-cysteine B-drug_n B-drug_n
( O O
CMC-Cys B-drug_n B-drug_n
) O O
conjugates O O
on O O
the O O
intestinal O O
permeation O O
of O O
sodium B-drug O
fluorescein I-drug O
( O O
NaFlu B-drug B-drug
) O O
and O O
model O O
peptide O O
drugs O O
, O O
bacitracin B-drug B-drug
and O O
insulin B-drug B-drug
. O O

Uricosuric B-group B-group
Agents I-group I-group
: O O
Aspirin B-brand B-brand
may O O
decrease O O
the O O
effects O O
of O O
probenecid B-drug B-drug
, O O
sulfinpyrazone B-drug B-drug
, O O
and O O
phenylbutazone B-drug B-drug
. O O

The O O
effects O O
of O O
fulvestrant B-drug B-drug
on O O
the O O
fertility O O
of O O
female O O
rats O O
appear O O
to O O
be O O
consistent O O
with O O
its O O
anti-estrogenic O O
activity O O
. O O

The O O
availability O O
of O O
potent O O
non-nucleoside B-group B-group
reverse I-group I-group
transcriptase I-group I-group
inhibitor I-group I-group
( O O
NNRTI B-group B-group
) O O
-based O O
regimens O O
for O O
antiretroviral B-group B-group
therapy O O
and O O
concerns O O
regarding O O
protease B-group B-group
inhibitor I-group I-group
( O O
PI B-group O
) O O
-related O O
metabolic O O
disturbances O O
have O O
led O O
to O O
significant O O
shifts O O
in O O
treatment O O
practices O O
in O O
HIV O O
infection O O
. O O

- O O
Antidiabetic B-group B-group
drugs I-group I-group
: O O
( O O
Oral O O
agents O O
and O O
insulin B-drug B-drug
) O O
Dosage O O
adjustment O O
of O O
the O O
antidiabetic B-group B-group
drug I-group I-group
may O O
be O O
required O O

Ketoconazole B-drug B-drug
: O O
Ketoconazole B-drug B-drug
has O O
been O O
reported O O
to O O
decrease O O
the O O
metabolism O O
of O O
certain O O
corticosteroids B-group B-group
by O O
up O O
to O O
60 O O
% O O
, O O
leading O O
to O O
increased O O
risk O O
of O O
corticosteroid B-group B-group
side O O
effects O O
. O O

a O O
See O O
Tables O O
1 O O
and O O
2 O O
. O O

NSAIDs B-group B-group
should O O
be O O
used O O
with O O
caution O O
in O O
patients O O
taking O O
cyclosporine B-drug B-drug
, O O
and O O
renal O O
function O O
should O O
be O O
carefully O O
monitored O O
. O O

Electrophilic O O
agents O O
-- O O
a O O
class O O
of O O
chemicals O O
that O O
includes O O
most O O
genotoxic O B-group
compounds O I-group
-- O O
can O O
be O O
inactivated O O
by O O
reaction O O
with O O
glutathione O B-drug
or O O
other O O
SH-bearing O O
molecules O O
. O O

Theophylline B-drug B-drug
: O O
In O O
three O O
pharmacokinetic O O
studies O O
including O O
46 O O
normal O O
, O O
healthy O O
subjects O O
, O O
theophylline B-drug B-drug
clearance O O
and O O
concentration O O
were O O
not O O
significantly O O
altered O O
by O O
the O O
addition O O
of O O
lomefloxacin B-drug B-drug
. O O

Concurrent O O
therapy O O
with O O
ORENCIA B-brand B-brand
and O O
TNF B-group B-group
antagonists I-group I-group
is O O
not O O
recommended O O
. O O

Cimetidine B-drug B-drug
: O O
Cimetidine B-drug B-drug
can O O
inhibit O O
the O O
metabolism O O
of O O
chloroquine B-drug B-drug
, O O
increasing O O
its O O
plasma O O
level O O
. O O

the O O
time O O
to O O
reach O O
maximum O O
concentration O O
was O O
delayed O O
approximately O O
30 O O
minutes O O
. O O

It O O
is O O
also O O
shown O O
that O O
after O O
14 O O
days O O
of O O
daily O O
administration O O
of O O
chlordiazepoxide B-drug B-drug
, O O
withdrawal O O
of O O
the O O
drug O O
not O O
only O O
re-results O O
in O O
almost O O
complete O O
loss O O
of O O
bar-press O O
response O O
in O O
the O O
E-strain O O
subjects O O
but O O
also O O
results O O
in O O
a O O
temporary O O
decrease O O
in O O
the O O
acquired O O
behavioral O O
response O O
of O O
the O O
stable O O
A-strain O O
subjects O O
. O O

This O O
interaction O O
should O O
be O O
given O O
consideration O O
in O O
patients O O
taking O O
CELEBREX B-brand B-brand
concomitantly O O
with O O
ACE-inhibitors B-group B-group
. O O

Lithium B-drug B-drug
: O O
Lithium B-drug B-drug
toxicity O O
has O O
been O O
reported O O
in O O
patients O O
receiving O O
lithium B-drug B-drug
concomitantly O O
with O O
drugs O O
which O O
cause O O
elimination O O
of O O
sodium O B-drug
, O O
including O O
ACE B-group B-group
inhibitors I-group I-group
. O O

Reciprocal O O
interactions O O
may O O
occur O O
with O O
concomitant O O
use O O
of O O
Antizol B-brand B-brand
and O O
drugs O O
that O O
increase O O
or O O
inhibit O O
the O O
cytochrome O O
P450 O O
system O O
( O O
e.g. O O
, O O
phenytoin B-drug B-drug
, O O
carbamazepine B-drug B-drug
, O O
cimetidine B-drug B-drug
, O O
ketoconazole B-drug B-drug
) O O
, O O
though O O
this O O
has O O
not O O
been O O
studied O O

Ranitidine B-drug B-drug
also O O
has O O
no O O
effect O O
on O O
eprosartan B-drug B-drug
pharmacokinetics O O
. O O

multivitamins B-group B-group
containing O O
zinc B-drug B-drug
; O O

The O O
benzodiazepines B-group B-group
are O O
a O O
family O O
of O O
anxiolytic B-group B-group
and O O
hypnotic B-group B-group
drugs I-group I-group
. O O

Warfarin B-drug B-drug
: O O
The O O
effects O O
of O O
aliskiren B-drug B-drug
on O O
warfarin B-drug B-drug
pharmacokinetics O O
have O O
not O O
been O O
evaluated O O
in O O
a O O
well-controlled O O
clinical O O
trial O O
. O O

Phenobarbital B-drug B-drug
: O O
It O O
appears O O
that O O
phenobarbital B-drug B-drug
may O O
reduce O O
plasma O O
felbamate B-drug B-drug
concentrations O O
. O O

False-negative O O
results O O
in O O
the O O
dexamethasone O O
suppression O O
test O O
( O O
DST O O
) O O
in O O
patients O O
being O O
treated O O
with O O
INDOCIN B-brand B-brand
have O O
been O O
reported O O
. O O

The O O
EC50 O O
values O O
for O O
isoproterenol B-drug B-drug
, O O
which O O
is O O
not O O
a O O
substrate O O
for O O
norepinephrine B-drug B-drug
uptake-1 O O
, O O
were O O
reduced O O
in O O
myocardium O O
in O O
functional O O
classes O O
II O O
to O O
III O O
and O O
IV O O
compared O O
with O O
those O O
in O O
nonfailing O O
myocardium O O
. O O

HIV B-group B-group
Protease I-group I-group
Inhibitors I-group I-group
: O O
The O O
effect O O
of O O
amprenavir B-drug B-drug
on O O
total O O
drug O O
concentrations O O
of O O
other O O
HIV B-group B-group
protease I-group I-group
inhibitors I-group I-group
in O O
subjects O O
receiving O O
both O O
agents O O
was O O
evaluated O O
using O O
comparisons O O
to O O
historical O O
data O O
. O O

A O O
false-positive O O
direct O O
Coombs O O
test O O
has O O
been O O
reported O O
during O O
treatment O O
with O O
other O O
cephalosporin B-group B-group
antibiotics I-group I-group
; O O

Another O O
study O O
showed O O
that O O
alosetron B-drug B-drug
had O O
no O O
clinically O O
significant O O
effect O O
on O O
plasma O O
concentrations O O
of O O
the O O
oral O O
contraceptive B-group B-group
agents I-group I-group
ethinyl B-drug B-drug
estradiol I-drug I-drug
and O O
levonorgestrel B-drug B-drug
( O O
CYP3A4 O O
substrates O O
) O O
. O O

Cytadren B-brand B-drug
accelerates O O
the O O
metabolism O O
of O O
dexamethasone B-drug B-drug
; O O

CONTRAINDICATED O O
due O O
to O O
potential O O
for O O
serious O O
and/or O O
life-threatening O O
reactions O O
such O O
as O O
acute O O
ergot O O
toxicity O O
characterized O O
by O O
peripheral O O
vasospasm O O
and O O
ischemia O O
of O O
the O O
extremities O O
and O O
other O O
tissues O O
. O O

Anticholinergics B-group B-group
: O O
Concurrent O O
administration O O
of O O
certain O O
anticholinergic B-group B-group
compounds I-group I-group
, O O
such O O
as O O
belladonna B-group B-group
alkaloids I-group I-group
and O O
dicyclomine B-drug B-drug
, O O
would O O
be O O
expected O O
to O O
compromise O O
the O O
beneficial O O
effects O O
of O O
cisapride B-drug B-drug
. O O

Use O O
of O O
a O O
nonhormonal B-group B-group
contraceptive I-group I-group
product I-group I-group
is O O
recommended O O
. O O

Phenytoin B-drug B-drug
: O O
Isoniazid B-drug B-drug
may O O
increase O O
serum O O
levels O O
of O O
phenytoin B-drug B-drug
. O O

Non-nucleoside B-group B-group
reverse I-group I-group
transcriptase I-group I-group
inhibitors I-group I-group
( O O
NNRTIs B-group B-group
) O O
: O O
Nevirapine B-drug B-drug
may O O
decrease O O
plasma O O
levels O O
of O O
combination B-group B-group
hormonal I-group I-group
contraceptives I-group I-group
; O O

PEGASYS B-brand B-brand
contains O O
benzyl B-drug_n B-drug
alcohol I-drug_n I-drug
. O O

because O O
of O O
this O O
, O O
the O O
dosage O O
of O O
flecainide B-drug B-drug
should O O
be O O
adjusted O O
when O O
these O O
drugs B-drug O
are O O
administered O O
concomitantly O O
. O O

The O O
possibility O O
of O O
hypotensive O O
effects O O
with O O
Lotensin B-brand B-brand
can O O
be O O
minimized O O
by O O
either O O
discontinuing O O
the O O
diuretic B-group B-group
or O O
increasing O O
the O O
salt O O
intake O O
prior O O
to O O
initiation O O
of O O
treatment O O
with O O
Lotensin B-brand B-brand
. O O

these O O
drugs O O
were O O
not O O
tested O O
to O O
determine O O
the O O
effect O O
of O O
administration O O
one O O
hour O O
before O O
colestipol B-drug B-drug
hydrochloride I-drug I-drug
. O O

Patients O O
receiving O O
beta-adrenergic B-group B-group
blocking I-group I-group
agents I-group I-group
along O O
with O O
either O O
oral O O
or O O
intravenous O O
calcium B-group B-group
antagonists I-group I-group
should O O
be O O
monitored O O
for O O
possible O O
atrioventricular O O
conduction O O
disturbances O O
, O O
left O O
ventricular O O
failure O O
and O O
hypotension O O
. O O

Nitrofurantoin B-drug B-drug
interferes O O
with O O
the O O
therapeutic O O
action O O
of O O
nalidixic B-drug B-drug
acid I-drug I-drug
. O O

In O O
vitro O O
, O O
at O O
total O O
drug O O
concentrations O O
27-fold O O
higher O O
than O O
peak O O
plasma O O
concentrations O O
observed O O
with O O
the O O
1-mg O O
dosage O O
, O O
alosetron B-drug B-drug
inhibited O O
CYP O O
enzymes O O
1A2 O O
( O O
60 O O
% O O
) O O
and O O
2E1 O O
( O O
50 O O
% O O
) O O
. O O

Activity O O
of O O
buforin B-drug_n B-drug_n
II I-drug_n I-drug_n
alone O O
and O O
in O O
combination O O
with O O
azithromycin B-drug B-drug
and O O
minocycline B-drug B-drug
against O O
Cryptosporidium O B-drug_n
parvum O O
in O O
cell O O
culture O O
. O O

In O O
patients O O
using O O
cardiac B-group B-group
glycosides I-group I-group
( O O
digoxin B-drug B-drug
and O O
others O O
) O O
, O O
plasma O O
levels O O
of O O
calcium O B-drug
, O O
potassium O B-drug
and O O
magnesium O B-drug
must O O
be O O
carefully O O
monitored O O
. O O

This O O
study O O
indicates O O
that O O
: O O
( O O
a O O
) O O
the O O
maximal O O
effects O O
of O O
resveratrol B-drug_n B-drug_n
on O O
resistance O O
arteries O O
from O O
lean O O
and O O
dietary-obese O O
rats O O
are O O
not O O
effected O O
by O O
endothelial O O
dysfunction O O
, O O
and O O
( O O
b O O
) O O
the O O
effects O O
of O O
resveratrol B-drug_n B-drug_n
in O O
lean O O
animals O O
( O O
where O O
endothelial O O
function O O
is O O
not O O
impaired O O
) O O
, O O
but O O
not O O
in O O
dietary-obese O O
rats O O
, O O
are O O
mediated O O
via O O
NO O O
. O O

In O O
period O O
B O O
, O O
the O O
volunteers O O
were O O
randomly O O
assigned O O
to O O
one O O
of O O
two O O
groups O O
. O O

However O O
, O O
there O O
are O O
several O O
instances O O
in O O
the O O
animal O O
literature O O
showing O O
that O O
hippocampal O O
lesions O O
actually O O
produced O O
enhanced O O
learning O O
and O O
memory O O
function O O
. O O

This O O
secretory O O
diarrhea O O
model O O
is O O
suitable O O
for O O
evaluating O O
the O O
antidiarrheal O O
activity O O
of O O
drugs O O
. O O

In O O
addition O O
, O O
there O O
have O O
been O O
cases O O
reported O O
in O O
which O O
concomitant O O
use O O
of O O
amphotericin B-drug B-drug
B I-drug I-drug
and O O
hydrocortisone B-drug B-drug
was O O
followed O O
by O O
cardiac O O
enlargement O O
and O O
congestive O O
heart O O
failure O O
. O O

Cyclosporine B-drug B-drug
: O O
Increased O O
activity O O
of O O
both O O
cyclosporine B-drug B-drug
and O O
corticosteroids B-group B-group
may O O
occur O O
when O O
the O O
two O O
are O O
used O O
concurrently O O
. O O

Phenytoin/Phenobarbital B-drug B-drug
: O O
The O O
coadministration O O
of O O
phenytoin B-drug B-drug
or O O
phenobarbital B-drug B-drug
will O O
not O O
affect O O
plasma O O
concentrations O O
of O O
vitamin B-group B-group
D I-group I-group
, O O
but O O
may O O
reduce O O
endogenous O O
plasma O O
levels O O
of O O
calcitriol/ergocalcitriol B-drug B-drug
by O O
accelerating O O
metabolism O O
. O O

Clinical O O
studies O O
in O O
healthy O O
volunteers O O
show O O
that O O
the O O
pharmacokinetics O O
of O O
CANCIDAS B-brand B-brand
are O O
not O O
altered O O
by O O
itraconazole B-drug B-drug
, O O
amphotericin B-drug B-drug
B I-drug I-drug
, O O
mycophenolate B-drug B-drug
, O O
nelfinavir B-drug B-drug
, O O
or O O
tacrolimus B-drug B-drug
. O O

The O O
implications O O
of O O
these O O
results O O
are O O
discussed O O
, O O
especially O O
with O O
respect O O
to O O
observations O O
which O O
indicate O O
that O O
homocysteine O O
may O O
be O O
a O O
precipitating O O
factor O O
in O O
the O O
development O O
of O O
thrombosis O O
. O O

Calcium B-drug B-drug
Supplements O O
: O O
Uncontrolled O O
intake O O
of O O
additional O O
calcium-containing B-drug B-drug
preparations O O
should O O
be O O
avoided O O
. O O

Available O O
data O O
are O O
neither O O
sufficient O O
to O O
rule O O
out O O
possible O O
increases O O
in O O
serum O O
digoxin B-drug B-drug
with O O
concomitant O O
treatment O O
in O O
some O O
patients O O
, O O
nor O O
other O O
possible O O
interactions O O
, O O
particularly O O
in O O
patients O O
with O O
cardiac O O
conduction O O
abnormalities O O
( O O
Also O O
see O O
WARNINGS O O
Congestive O O
Heart O O
Failure O O
) O O
. O O

6 O O
. O O

In O O
clinical O O
studies O O
propofol B-drug B-drug
had O O
no O O
effect O O
on O O
the O O
duration O O
of O O
action O O
or O O
dosing O O
requirements O O
for O O
NIMBEX B-brand B-brand
. O O

The O O
pharmacodynamic O O
consequences O O
of O O
concomitant O O
use O O
of O O
losartan B-drug B-drug
and O O
inhibitors O O
of O O
P450 O O
2C9 O O
have O O
not O O
been O O
examined O O
. O O

this O O
was O O
seen O O
in O O
studies O O
with O O
estazolam B-drug B-drug
. O O

In O O
some O O
cases O O
the O O
onset O O
of O O
the O O
injection O O
site O O
reaction O O
either O O
occurred O O
during O O
a O O
prolonged O O
infusion O O
or O O
was O O
delayed O O
by O O
a O O
week O O
to O O
ten O O
days O O
. O O

Free O O
T3 O O
resin O O
uptake O O
is O O
decreased O O
, O O
reflecting O O
the O O
elevated O O
TBG O O
; O O

Anticonvulsants B-group B-group
: O O
In O O
a O O
pharmacokinetic O O
study O O
, O O
maximum O O
plasma O O
concentrations O O
of O O
felodipine B-drug B-drug
were O O
considerably O O
lower O O
in O O
epileptic O O
patients O O
on O O
long-term O O
anticonvulsant B-group B-group
therapy O O
( O O
eg O O
, O O
phenytoin B-drug B-drug
, O O
carbamazepine B-drug B-drug
, O O
or O O
phenobarbital B-drug B-drug
) O O
than O O
in O O
healthy O O
volunteers O O
. O O

The O O
injection O O
should O O
be O O
made O O
immediately O O
after O O
mixing O O
. O O

Patients O O
using O O
cardiovascular O O
drugs O O
concurrently O O
with O O
IOPIDINE B-brand B-brand
0.5 O O
% O O
Ophthalmic O O
Solution O O
should O O
have O O
pulse O O
and O O
blood O O
pressures O O
frequently O O
monitored O O
. O O

Because O O
of O O
the O O
potential O O
for O O
ARAVA B-brand B-brand
levels O O
to O O
continue O O
to O O
increase O O
with O O
multiple O O
dosing O O
, O O
caution O O
should O O
be O O
used O O
if O O
patients O O
are O O
to O O
be O O
receiving O O
both O O
ARAVA B-brand B-brand
and O O
rifampin B-drug B-drug
. O O

Frequent O O
vital O O
sign O O
monitoring O O
, O O
particularly O O
during O O
the O O
first O O
hour O O
of O O
TAXOL B-brand B-brand
infusion O O
, O O
is O O
recommended O O
. O O

tricyclic B-group B-group
antidepressants I-group I-group
( O O
such O O
as O O
amitriptyline B-drug B-drug
) O O
; O O

Numerous O O
drug O O
interactions O O
are O O
possible O O
with O O
some O O
anticonvulsant B-group B-group
agents I-group I-group
, O O
such O O
as O O
phenobarbitone B-drug B-drug
and O O
phenytoin B-drug B-drug
, O O
which O O
affect O O
hepatic O O
microsomal O O
enzyme O O
systems O O
. O O

Therefore O O
, O O
cyclosporine B-drug B-drug
serum O O
levels O O
should O O
be O O
monitored O O
and O O
appropriate O O
cyclosporine B-drug B-drug
dosage O O
adjustments O O
made O O
when O O
these O O
drugs O O
are O O
used O O
concomitantly O O
. O O

Amprenavir B-drug B-drug
decreased O O
the O O
results O O
of O O
the O O
ERMBT O O
by O O
83 O O
% O O
. O O

There O O
was O O
no O O
effect O O
on O O
the O O
pharmacokinetics O O
of O O
representative O O
drugs O O
metabolized O O
by O O
CYP O O
2C9 O O
, O O
CYP O O
2C19 O O
, O O
CYP O O
2D6 O O
or O O
CYP O O
3A4 O O
. O O

Systemic B-group O
Corticosteroids I-group B-group
: O O
Systemic B-group O
corticosteroids I-group B-group
are O O
known O O
to O O
cause O O
osteoporosis O O
. O O

The O O
influence O O
of O O
midazolam B-drug B-drug
and O O
diazepam B-drug B-drug
on O O
antinociceptive O O
effect O O
of O O
morphine B-drug B-drug
( O O
10 O O
mg/kg O O
) O O
, O O
metamizol B-drug B-drug
( O O
500 O O
mg/kg O O
) O O
and O O
indomethacin B-drug B-drug
( O O
10 O O
mg/kg O O
) O O
was O O
investigated O O
in O O
a O O
mouse O O
model O O
using O O
the O O
tail-flick O O
and O O
hot-plate O O
tests O O
. O O

Drug/Laboratory O O
Test O O
Interactions O O
: O O
There O O
have O O
been O O
no O O
chemical O O
or O O
laboratory O O
test O O
interactions O O
with O O
ceftibuten B-drug B-drug
noted O O
to O O
date O O
. O O

incomplete O O
data O O
for O O
efavirenz B-drug B-drug
. O O

Preliminary O O
clinical O O
data O O
suggest O O
that O O
the O O
incidence O O
of O O
nephrolithiasis O O
is O O
higher O O
in O O
patients O O
receiving O O
indinavir B-drug B-drug
in O O
combination O O
with O O
ritonavir B-drug B-drug
than O O
those O O
receiving O O
CRIXIVAN B-brand B-brand
800 O O
mg O O
q8h O O
. O O

Propranolol B-drug B-drug
: O O
In O O
normal O O
volunteers O O
, O O
there O O
was O O
no O O
clinically O O
significant O O
pharmacokinetic O O
or O O
pharmacodynamic O O
interaction O O
with O O
concomitant O O
administration O O
of O O
single O O
doses O O
of O O
lovastatin B-drug B-drug
and O O
propranolol B-drug B-drug
. O O

cases O O
, O O
occurred O O
between O O
the O O
5th O O
and O O
the O O
11th O O
day O O
of O O
treatment O O
. O O

Arginine B-drug B-drug
, O O
in O O
the O O
presence O O
of O O
glucose B-drug B-drug
and O O
theophylline B-drug B-drug
, O O
caused O O
excessive O O
glucagon O O
release O O
but O O
nearly O O
normal O O
insulin O O
release O O
in O O
the O O
diabetics O O
. O O

A O O
routine O O
dosage O O
adjustment O O
of O O
zaleplon B-drug B-drug
is O O
not O O
considered O O
necessary O O
. O O

Sirolimus B-drug B-drug
: O O
mammalian O O
target O O
of O O
rapamycin B-drug B-drug
inhibitor O I-drug
to O O
prevent O O
kidney O O
rejection O O
. O O

Serum O O
theophylline B-drug B-drug
concentrations O O
increase O O
when O O
grepafloxacin B-drug B-drug
is O O
initiated O O
in O O
a O O
patient O O
maintained O O
on O O
theophylline B-drug B-drug
. O O

Amprenavir B-drug B-drug
is O O
an O O
inhibitor O O
of O O
cytochrome O O
P450 O O
C.P.A O O
. O O
metabolism O O
and O O
therefore O O
should O O
not O O
be O O
administered O O
concurrently O O
with O O
medications O O
with O O
narrow O O
therapeutic O O
windows O O
that O O
are O O
substrates O O
of O O
CYP3A4 O O
. O O

Colestipol B-drug B-drug
: O O
Plasma O O
concentrations O O
of O O
atorvastatin B-drug B-drug
decreased O O
approximately O O
25 O O
% O O
when O O
colestipol B-drug B-drug
and O O
atorvastatin B-drug B-drug
were O O
coadministered O O
. O O

Although O O
the O O
clinical O O
significance O O
is O O
not O O
known O O
, O O
it O O
is O O
not O O
recommended O O
that O O
cefditoren B-drug B-drug
pivoxil I-drug I-drug
be O O
taken O O
concomitantly O O
with O O
antacids B-group B-group
. O O

Maprotiline B-drug B-drug
: O O
Risk O O
of O O
cardiac O O
arrhythmias O O
may O O
increase O O
. O O

Effects O O
of O O
Aliskiren B-drug B-drug
on O O
Other O O
Drugs O O
Aliskiren B-drug B-drug
does O O
not O O
inhibit O O
the O O
CYP450 O O
isoenzymes O O
( O O
CYP1A2 O O
, O O
2C8 O O
, O O
2C9 O O
, O O
2C19 O O
, O O
2D6 O O
, O O
2E1 O O
, O O
and O O
CYP O O
3A O O
) O O
or O O
induce O O
CYP O O
3A4 O O
. O O

Clinical O O
interaction O O
studies O O
with O O
cimetidine B-drug B-drug
and O O
warfarin B-drug B-drug
indicated O O
that O O
the O O
coadministration O O
of O O
Femara B-brand B-brand
with O O
these O O
drugs O O
does O O
not O O
result O O
in O O
clinically- O O
significant O O
drug O O
interactions O O
. O O

This O O
may O O
lead O O
to O O
reduced O O
clearance O O
of O O
caffeine B-drug B-drug
and O O
a O O
prolongation O O
of O O
its O O
serum O O
half-life O O
. O O

Ganciclovir B-drug B-drug
: O O
The O O
pharmacokinetics O O
of O O
foscarnet B-drug B-drug
and O O
ganciclovir B-drug B-drug
were O O
not O O
altered O O
in O O
13 O O
patients O O
receiving O O
either O O
concomitant O O
therapy O O
or O O
daily O O
alternating O O
therapy O O
for O O
maintenance O O
of O O
CMV O O
disease O O
. O O

Drug/Laboratory O O
Tests O O
Interactions O O
No O O
clinically O O
relevant O O
changes O O
in O O
the O O
results O O
of O O
clinical O O
laboratory O O
tests O O
have O O
been O O
observed O O
. O O

Pretreatment O O
with O O
atropine B-drug B-drug
likewise O O
further O O
reduced O O
the O O
amplitudes O O
of O O
components O O
P1 O O
and O O
N1 O O
, O O
and O O
produced O O
a O O
similar O O
effect O O
on O O
component O O
N3 O O
. O O

naproxen B-drug B-drug
; O O

Pharmacodynamic-related O O
Interactions O O
: O O
The O O
mechanism O O
of O O
Clozapine B-drug B-drug
induced O O
agranulocytosis O O
is O O
unknown O O
; O O

Consequently O O
, O O
the O O
effect O O
of O O
iron B-drug B-drug
on O O
the O O
retention O O
of O O
cobalt B-drug B-drug
was O O
lower O O
than O O
on O O
absorption O O
. O O

Dextromethorphan B-drug B-drug
is O O
a O O
substrate O O
for O O
both O O
CYP2D6 B-drug O
and O O
CYP3A4 B-drug O
. O O

The O O
AUC O O
and O O
Cmax O O
of O O
metoprolol B-drug B-drug
, O O
however O O
, O O
were O O
increased O O
approximately O O
31 O O
and O O
38 O O
% O O
, O O
respectively O O
. O O

Patients O O
receiving O O
antihistamines B-group B-group
should O O
be O O
advised O O
against O O
the O O
concurrent O O
use O O
of O O
other O O
CNS B-group B-group
depressant I-group I-group
drugs I-group I-group
. O O

Fourteen O O
days O O
later O O
, O O
all O O
animals O O
were O O
challenged O O
with O O
a O O
single O O
hypnotic O O
dose O O
of O O
ethanol B-drug B-drug
( O O
3.5 O O
g/kg O O
IP O O
) O O
. O O

Quinidine B-drug B-drug
at O O
648 O O
mg O O
bid O O
decreased O O
the O O
bioavailability O O
( O O
AUC O O
) O O
of O O
nisoldipine B-drug B-drug
by O O
26 O O
% O O
, O O
but O O
not O O
the O O
peak O O
concentration O O
. O O

Dopamine B-group B-group
D2 I-group I-group
receptor I-group I-group
antagonists I-group I-group
( O O
e.g. O O
, O O
phenothiazines B-group B-group
, O O
butyrophenones B-group B-group
, O O
risperidone B-drug B-drug
) O O
and O O
isoniazid B-drug B-drug
may O O
reduce O O
the O O
therapeutic O O
effects O O
of O O
levodopa B-drug B-drug
. O O

or O O
=0.2 O O
% O O
biocytin O O
was O O
included O O
in O O
the O O
recording O O
pipette O O
, O O
compared O O
with O O
neurons O O
recorded O O
without O O
biocytin O O
. O O

Whenever O O
increased O O
thioether O O
excretion O O
is O O
observed O O
, O O
it O O
is O O
likely O O
to O O
be O O
due O O
to O O
exposure O O
to O O
one O O
or O O
more O O
suspect O O
compounds O O
. O O

Two O O
studies O O
were O O
conducted O O
in O O
HIV-infected O O
subjects O O
to O O
assess O O
the O O
potential O O
for O O
azithromycin B-drug B-drug
to O O
interact O O
with O O
zidovudine B-drug B-drug
and O O
dideoxyinosine B-drug B-drug
. O O

Comparative O O
analysis O O
of O O
the O O
effects O O
of O O
stimulation O O
and O O
inhibition O O
of O O
cholino- O B-drug_n
and O O
adrenoreceptors O B-drug_n
on O O
this O O
inhibitory O O
action O O
of O O
angiotensins B-drug_n B-group
suggested O O
the O O
mediation O O
of O O
angiotensin B-drug_n B-drug_n
influence O O
through O O
the O O
modulation O O
of O O
cholinergic O O
reactions O O
of O O
parietal O O
cells O O
in O O
the O O
stomach O O
. O O

Cimetidine B-drug B-drug
reduces O O
the O O
clearance O O
of O O
ALFENTA B-brand B-brand
. O O

Drugs O O
that O O
cause O O
significant O O
sustained O O
elevation O O
in O O
gastric O O
pH O O
( O O
histamine B-group B-group
H2-receptor I-group I-group
antagonists I-group I-group
such O O
as O O
ranitidine B-drug B-drug
or O O
cimetidine B-drug B-drug
) O O
may O O
reduce O O
plasma O O
concentrations O O
of O O
IRESSA B-brand B-brand
and O O
therefore O O
potentially O O
may O O
reduce O O
efficacy O O
. O O

Therefore O O
, O O
linezolid B-drug B-drug
has O O
the O O
potential O O
for O O
interaction O O
with O O
adrenergic B-group O
and O O
serotonergic B-group B-group
agents I-group I-group
. O O

Phencyclidine B-drug_n B-drug_n
( O O
PCP B-drug_n B-drug_n
) O O
produces O O
psychotomimetic O O
effects O O
in O O
humans O O
that O O
resemble O O
schizophrenia O O
symptoms O O
. O O

Simvastatin B-drug B-drug
and O O
Other O O
Statins B-group B-group
: O O
Co-administration O O
of O O
bosentan B-drug B-drug
decreased O O
the O O
plasma O O
concentrations O O
of O O
simvastatin B-drug B-drug
( O O
a O O
CYP3A4 O O
substrate O O
) O O
, O O
and O O
its O O
active O O
-hydroxy O O
acid O O
metabolite O O
, O O
by O O
approximately O O
50 O O
% O O
. O O

After O O
prolonged O O
administration O O
of O O
neuroleptics B-group B-group
the O O
displacing O O
effect O O
of O O
cerulein B-drug_n O
, O O
an O O
analog O O
of O O
cholecystokinin O O
octapeptide O O
, O O
was O O
replaced O O
by O O
the O O
stimulant O O
action O O
on O O
3H-spiroperidol B-drug_n B-drug_n
binding O O
. O O

therefore O O
, O O
administration O O
of O O
EQUETROTM B-brand B-brand
to O O
a O O
patient O O
taking O O
another O O
drug O O
that O O
is O O
highly O O
protein O O
bound O O
should O O
not O O
cause O O
increased O O
free O O
concentrations O O
of O O
the O O
other O O
drug O O
. O O

Medication O O
such O O
as O O
digitalis B-group B-group
may O O
also O O
influence O O
serum O O
electrolytes O O
. O O

Antidiabetic B-group B-group
drug I-group I-group
requirements O O
( O O
i.e. O O
, O O
insulin B-drug B-drug
) O O
may O O
be O O
altered O O
. O O

Drug/Laboratory O O
Test O O
Interactions O O
As O O
a O O
result O O
of O O
the O O
presence O O
of O O
nitrofurantoin B-drug B-drug
, O O
a O O
false-positive O O
reaction O O
for O O
glucose O O
in O O
the O O
urine O O
may O O
occur O O
. O O

Urinary B-group O
acidifying I-group O
agents I-group O
( O O
ammonium B-drug B-drug
chloride I-drug I-drug
, O O
sodium B-drug B-drug
acid I-drug I-drug
phosphate I-drug I-drug
, O O
etc O O
. O O
) O O
increase O O
the O O
concentration O O
of O O
the O O
ionized O O
species O O
of O O
the O O
amphetamine B-drug B-drug
molecule O O
, O O
thereby O O
increasing O O
urinary O O
excretion O O
. O O

Responses O O
to O O
arginine B-drug B-drug
of O O
the O O
perfused O O
pancreas O O
of O O
the O O
genetically O O
diabetic O O
Chinese O O
hamster O O
. O O

A O O
two-way O O
interaction O O
between O O
the O O
hydantoin B-group B-group
antiepileptic I-group I-group
, O O
phenytoin B-drug B-drug
, O O
and O O
the O O
coumarin B-group B-group
anticoagulants O I-group
has O O
been O O
suggested O O
. O O

Amprenavir B-drug B-drug
plus O O
rifampin B-drug B-drug
was O O
well O O
tolerated O O
. O O

Therefore O O
, O O
if O O
concomitant O O
use O O
of O O
these O O
agents O O
is O O
indicated O O
because O O
of O O
demonstrated O O
hypokalemia O O
, O O
they O O
should O O
be O O
used O O
with O O
caution O O
and O O
with O O
frequent O O
monitoring O O
of O O
serum O O
potassium O O
. O O

Lithium B-drug B-drug
: O O
Increased O O
serum O O
lithium B-drug B-drug
levels O O
and O O
symptoms O O
of O O
lithium B-drug B-drug
toxicity O O
have O O
been O O
reported O O
in O O
patients O O
receiving O O
concomitant O O
lithium B-drug B-drug
and O O
ACE B-group B-group
inhibitor I-group I-group
therapy O O
. O O

Patients O O
who O O
have O O
developed O O
severe O O
hypersensitivity O O
reactions O O
should O O
not O O
be O O
rechallenged O O
with O O
TAXOL B-brand B-brand
. O O

and O O
, O O
rarely O O
, O O
enuresis O O
, O O
urinary O O
retention O O
, O O
dysuria O O
, O O
impotence O O
, O O
inability O O
to O O
ejaculate O O
, O O
nocturia O O
, O O
hematuria O O
. O O

A O O
single O O
dose O O
of O O
liquid O O
antacid B-group B-group
did O O
not O O
affect O O
the O O
C O O
max O O
or O O
AUC O O
of O O
ceftibuten B-drug B-drug
; O O

An O O
evaluation O O
of O O
prothrombin O O
time O O
and O O
an O O
adjustment O O
of O O
anticoagulant B-group B-group
dosage O O
are O O
recommended O O

For O O
this O O
reason O O
, O O
the O O
dose O O
of O O
the O O
anticoagulant B-drug B-group
should O O
be O O
reduced O O
by O O
30 O O
- O O
50 O O
% O O
at O O
the O O
start O O
of O O
treatment O O
with O O
Bezalip B-brand B-brand
or O O
Bezalip B-brand B-brand
retard O I-brand
and O O
then O O
titrated O O
according O O
to O O
the O O
blood O O
clotting O O
parameters O O

ibuprofen B-drug B-drug
; O O

The O O
appropriate O O
dose O O
for O O
nelfinavir B-drug B-drug
incombination O O
with O O
nevirapine B-drug B-drug
, O O
with O O
respectto O O
safety O O
and O O
efficacy O O
, O O
has O O
not O O
been O O
established O O
. O O

Concomitant O O
administration O O
of O O
fenofibrate B-drug B-drug
( O O
equivalent O O
to O O
145mg O O
TRICOR B-brand B-brand
) O O
with O O
pravastatin B-drug B-drug
( O O
40 O O
mg O O
) O O
once O O
daily O O
for O O
10 O O
days O O
has O O
been O O
shown O O
to O O
increase O O
the O O
mean O O
Cmax O O
and O O
AUC O O
values O O
for O O
pravastatin B-drug B-drug
by O O
36 O O
% O O
( O O
range O O
from O O
69 O O
% O O
decrease O O
to O O
321 O O
% O O
increase O O
) O O
and O O
28 O O
% O O
( O O
range O O
from O O
54 O O
% O O
decrease O O
to O O
128 O O
% O O
increase O O
) O O
, O O
respectively O O
, O O
and O O
for O O
3 O O
-hydroxy-iso-pravastatin O O
by O O
55 O O
% O O
( O O
range O O
from O O
32 O O
% O O
decrease O O
to O O
314 O O
% O O
increase O O
) O O
and O O
39 O O
% O O
( O O
range O O
from O O
24 O O
% O O
decrease O O
to O O
261 O O
% O O
increase O O
) O O
, O O
respectively O O
in O O
23 O O
healthy O O
adults O O
. O O

Data O O
from O O
several O O
studies O O
, O O
ie O O
, O O
TIMI-II O O
, O O
ISIS-2 O O
, O O
currently O O
do O O
not O O
suggest O O
any O O
clinical O O
interaction O O
between O O
aspirin B-brand B-brand
and O O
beta B-group B-group
blockers I-group I-group
in O O
the O O
acute O O
myocardial O O
infarction O O
setting O O
. O O

chlordiazepoxide B-drug B-drug
; O O

Treatment O O
with O O
daily O O
doses O O
of O O
2 O O
mg O O
of O O
coumaphos/kg B-drug_n B-drug_n
for O O
6 O O
days O O
did O O
not O O
modify O O
the O O
anticholinesterase O O
effect O O
of O O
a O O
2nd O O
series O O
of O O
treatments O O
given O O
6 O O
weeks O O
later O O
. O O

Effects O O
of O O
Vardenafil B-drug B-drug
on O O
other O O
drugs O O

Doxorubicin B-drug B-drug
: O O
Doxorubicin B-drug B-drug
caused O O
a O O
decrease O O
in O O
zalcitabine B-drug B-drug
phosphorylation O O
( O O
50 O O
% O O
inhibition O O
of O O
total O O
phosphate O O
formation O O
) O O
in O O
U937/Molt O O
4 O O
cells O O
. O O

it O O
is O O
possible O O
that O O
larger O O
theophylline B-drug B-drug
doses O O
could O O
have O O
a O O
greater O O
effect O O
. O O

Progestin-only O B-group
oral O O
contraception O O
: O O
a O O
comprehensive O O
review O O
. O O

Although O O
the O O
magnitude O O
of O O
changes O O
in O O
diazepam B-drug B-drug
plasma O O
exposure O O
when O O
coadministered O O
with O O
valdecoxib B-drug B-drug
were O O
not O O
sufficient O O
to O O
warrant O O
dosage O O
adjustments O O
, O O
patients O O
may O O
experience O O
enhanced O O
sedative O B-group
side O O
effects O O
caused O O
by O O
increased O O
exposure O O
of O O
diazepam B-drug B-drug
under O O
this O O
circumstance O O
. O O

cardiovascular O O
effects O O
can O O
be O O
potentiated O O
. O O

However O O
, O O
interactions O O
may O O
be O O
expected O O
, O O
and O O
UROXATRAL B-brand B-brand
should O O
NOT O O
be O O
used O O
in O O
combination O O
with O O
other O O
alpha-blockers B-group B-group
. O O

The O O
addition O O
of O O
540 O O
mg/kg/day O O
of O O
cromolyn B-drug B-drug
sodium I-drug I-drug
( O O
approximately O O
340 O O
times O O
the O O
maximum O O
recommended O O
daily O O
inhalation O O
dose O O
in O O
adults O O
on O O
a O O
mg/m2 O O
basis O O
) O O
to O O
2.7 O O
mg/kg/day O O
of O O
isoproterenol B-drug B-drug
( O O
approximately O O
7 O O
times O O
the O O
maximum O O
recommended O O
daily O O
inhalation O O
dose O O
in O O
adults O O
on O O
a O O
mg/m2 O O
basis O O
) O O
appears O O
to O O
have O O
increased O O
the O O
incidence O O
of O O
both O O
resorptions O O
and O O
malformations O O
. O O

Agents O O
with O O
Decreased O O
Levels O O
in O O
the O O
Presence O O
of O O
Carbamazepine B-drug B-drug
due O O
to O O
Induction O O
of O O
Cytochrome O O
P450 O O
Enzymes O O
Carbamazepine B-drug B-drug
is O O
known O O
to O O
induce O O
CYP1A2 O O
and O O
CYP3A4 O O
. O O

Drug/Laboratory O O
Test O O
Interactions O O
As O O
with O O
other O O
penicillins B-drug B-group
, O O
the O O
administration O O
of O O
PIPRACIL B-brand B-brand
may O O
result O O
in O O
a O O
false-positive O O
reaction O O
for O O
glucose O O
in O O
the O O
urine O O
using O O
a O O
copper-reduction O O
method O O
. O O

The O O
total O O
drug O O
exposure O O
for O O
the O O
plasma O O
was O O
approximately O O
twofold O O
at O O
the O O
higher O O
cisplatin B-drug B-drug
dose O O
. O O

The O O
patient O O
should O O
be O O
informed O O
that O O
the O O
response O O
to O O
alcohol B-drug B-drug
may O O
be O O
exaggerated O O
. O O

Drug O O
Interaction O O
with O O
Fluoxetine B-drug B-drug
: O O
A O O
multiple-dose O O
study O O
was O O
conducted O O
to O O
assess O O
the O O
effect O O
of O O
fluoxetine B-drug B-drug
20 O O
mg O O
BID O O
on O O
the O O
pharmacokinetics O O
of O O
estazolam B-drug B-drug
2 O O
mg O O
QHS O O
after O O
seven O O
days O O
. O O

Reductions O O
in O O
serum O O
endogenous O O
vitamin O O
D O O
concentrations O O
have O O
been O O
observed O O
following O O
the O O
administration O O
of O O
300 O O
mg/day O O
to O O
1200 O O
mg/day O O
ketoconazole B-drug B-drug
for O O
a O O
week O O
to O O
healthy O O
men O O
. O O

+45 O O
% O O
+39 O O
% O O
+43 O O
% O O
+72 O O
% O O

Geocillin B-brand B-drug
( O O
carbenicillin B-drug B-drug
indanyl I-drug I-drug
sodium I-drug I-drug
) O O
blood O O
levels O O
may O O
be O O
increased O O
and O O
prolonged O O
by O O
concurrent O O
administration O O
of O O
probenecid B-drug B-drug
. O O

It O O
may O O
increase O O
excretion O O
of O O
barbiturates B-group B-group
, O O
lithium B-drug B-drug
, O O
and O O
ASA B-drug O
and O O
may O O
also O O
increase O O
the O O
toxicity O O
of O O
salicylates B-group B-group
. O O

Do O O
not O O
mix O O
TORADOL B-brand B-brand
and O O
morphine B-drug B-drug
in O O
the O O
same O O
syringe O O
. O O

The O O
steady-state O O
Cmin O O
increased O O
to O O
21 O O
5 O O
micrograms/mL O O
when O O
1200 O O
mg/day O O
of O O
felbamate B-drug B-drug
was O O
coadministered O O
. O O

Isoflurane B-drug B-drug
or O O
enflurane B-drug B-drug
administered O O
with O O
nitrous B-drug B-group
oxide/oxygen I-drug I-group
to O O
achieve O O
1.25 O O
MAC O O
[ O O
Minimum O O
Alveolar O O
Concentration O O
] O O
may O O
prolong O O
the O O
clinically O O
effective O O
duration O O
of O O
action O O
of O O
initial O O
and O O
maintenance O O
doses O O
of O O
NIMBEX B-brand B-brand
and O O
decrease O O
the O O
required O O
infusion O O
rate O O
of O O
NIMBEX B-brand B-brand
. O O

It O O
is O O
, O O
therefore O O
, O O
advisable O O
to O O
monitor O O
digoxin B-drug B-drug
concentrations O O
in O O
patients O O
receiving O O
ketoconazole B-drug B-drug
. O O

- O O
Vitamin B-group B-group
K I-group I-group
( O O
e.g. O O
, O O
AquaMEPHYTON B-brand B-brand
, O O
Synkayvite B-brand B-brand
) O O
Use O O
of O O
sulfapyridine B-drug B-drug
with O O
these O O
medicines O O
may O O
increase O O
the O O
chance O O
of O O
side O O
effects O O
affecting O O
the O O
blood O O

No O O
information O O
provided O O

Patients O O
receiving O O
the O O
two O O
drugs O O
concomitantly O O
should O O
be O O
carefully O O
monitored O O
. O O

Notably O O
, O O
systemic O O
exposure O O
( O O
AUC0-12 O O
) O O
of O O
dapsone B-drug_n B-drug
hydroxylamine I-drug_n I-drug
( O O
DHA B-drug_n O
) O O
was O O
more O O
than O O
doubled O O
in O O
the O O
presence O O
of O O
TMP/SMX B-drug B-drug
. O O

If O O
the O O
two O O
drugs O O
are O O
coadministered O O
, O O
the O O
beta B-group B-group
blocker I-group I-group
should O O
be O O
withdrawn O O
several O O
days O O
before O O
the O O
gradual O O
withdrawal O O
of O O
clonidine B-drug B-drug
. O O

Therefore O O
concomitant O O
administration O O
of O O
ketoconazole B-drug B-drug
tablets O O
with O O
cisapride B-drug B-drug
is O O
contraindicated O O
. O O

benign O O
breast O O
disease O O
; O O

Colchicine B-drug B-drug
is O O
inhibited O O
by O O
acidifying B-group B-group
agents I-group I-group
. O O

Co-administration O O
with O O
efavirenz B-drug B-drug
or O O
fluconazole B-drug B-drug
had O O
a O O
modest O O
effect O O
on O O
the O O
pharmacokinetics O O
of O O
azithromycin B-drug B-drug
. O O

Oral O O
Hypoglycemic B-group B-group
Agents I-group I-group
: O O
In O O
pharmacokinetic O O
studies O O
of O O
MEVACOR B-brand B-brand
in O O
hypercholesterolemic O O
noninsulin O O
dependent O O
diabetic O O
patients O O
, O O
there O O
was O O
no O O
drug O O
interaction O O
with O O
glipizide B-drug B-drug
or O O
with O O
chlorpropamide B-drug B-drug

Comparison O O
of O O
cisplatin B-drug B-drug
pharmacokinetics O O
in O O
patients O O
treated O O
with O O
202.5 O O
mg/m2 O O
plus O O
thiosulfate B-drug B-drug
to O O
those O O
in O O
patients O O
treated O O
with O O
100 O O
mg/m2 O O
without O O
thiosulfate B-drug B-drug
indicated O O
that O O
there O O
were O O
no O O
changes O O
in O O
the O O
elimination O O
rate O O
constant O O
, O O
volume O O
of O O
distribution O O
, O O
or O O
total O O
body O O
clearance O O
of O O
cisplatin B-drug B-drug
. O O

Dosage O O
adjustment O O
may O O
be O O
required O O
if O O
cyclosporine B-drug B-drug
, O O
tacrolimus B-drug B-drug
, O O
or O O
methylprednisolone B-drug B-drug
are O O
given O O
concomitantly O O
with O O
NIZORAL B-brand B-brand
Tablets O O
. O O

No O O
depressant O O
effect O O
on O O
blood O O
levels O O
in O O
humans O O
was O O
noted O O
when O O
colestipol B-drug B-drug
hydrochloride I-drug I-drug
was O O
administered O O
with O O
any O O
of O O
the O O
following O O
drugs O O
: O O
aspirin B-brand B-brand
, O O
clindamycin B-brand B-drug
, O O
clofibrate B-drug B-drug
, O O
methyldopa B-drug B-drug
, O O
nicotinic B-drug B-drug
acid I-drug I-drug
( O O
niacin B-drug B-drug
) O O
, O O
tolbutamide B-drug B-drug
, O O
phenytoin B-drug B-drug
or O O
warfarin B-drug B-drug
. O O

- O O
phenytoin B-drug B-drug
( O O
Dilantin B-brand B-brand
) O O
; O O

Withdrawal O O
from O O
cocaine B-drug B-drug
dependence O O
usually O O
involves O O
depression O O
, O O
anxiety O O
and O O
lethargy O O
. O O

Therapeutic O O
drug O O
monitoring O O
( O O
TDM O O
) O O
of O O
gentamicin B-drug B-drug
therapy O O
, O O
and O O
bone O O
scintigraphy O O
employing O O
99mTc-MDP B-drug B-drug
as O O
the O O
radiopharmaceutical B-group O
was O O
carried O O
out O O
in O O
22 O O
patients O O
. O O

Refer O O
to O O
the O O
package O O
insert O O
for O O
lithium B-drug B-drug
preparations O O
before O O
use O O
of O O
such O O
preparations O O
with O O
chlorothiazide B-drug B-drug

Drug O O
Interaction O O
with O O
Erythromycin B-drug B-drug
and O O
Ketoconazole B-drug B-drug
Fexofenadine I-drug I-drug
has O O
been O O
shown O O
to O O
exhibit O O
minimal O O
( O O
ca O O
. O O
5 O O
% O O
) O O
metabolism O O
. O O

Because O O
eprosartan B-drug B-drug
is O O
not O O
metabolized O O
by O O
the O O
cytochrome O O
P450 O O
system O O
, O O
inhibitors O O
of O O
CYP450 O O
enzyme O O
would O O
not O O
be O O
expected O O
to O O
affect O O
its O O
metabolism O O
, O O
and O O
ketoconazole B-drug B-drug
and O O
fluconazole B-drug B-drug
, O O
potent O O
inhibitors O O
of O O
CYP3A O O
and O O
2C9 O O
, O O
respectively O O
, O O
have O O
been O O
shown O O
to O O
have O O
no O O
effect O O
on O O
eprosartan B-drug B-drug
pharmacokinetics O O
. O O

The O O
concomitant O O
intake O O
of O O
alcohol B-drug B-drug
and O O
Acamprosate B-drug B-drug
does O O
not O O
affect O O
the O O
pharmacokinetics O O
of O O
either O O
alcohol B-drug B-drug
or O O
acamprosate B-drug B-drug
. O O

The O O
following O O
specific O O
interactions O O
have O O
been O O
reported O O
: O O
Itraconazole O B-drug
Co-administration O O
of O O
another O O
extended O O
release O O
formulation O O
of O O
felodipine B-drug B-drug
with O O
itraconazole B-drug B-drug
resulted O O
in O O
approximately O O
8-fold O O
increase O O
in O O
the O O
AUC O O
, O O
more O O
than O O
6- O O
fold O O
increase O O
in O O
the O O
Cmax O O
, O O
and O O
2-fold O O
prolongation O O
in O O
the O O
half- O O
life O O
of O O
felodipine B-drug B-drug
. O O

Erythromycin B-drug B-drug
has O O
been O O
reported O O
to O O
significantly O O
alter O O
the O O
metabolism O O
of O O
nonsedating O B-group
antihistamines B-group I-group
terfenadine B-drug B-drug
and O O
astemizole B-drug B-drug
when O O
taken O O
concomitantly O O
. O O

Mixtures O O
of O O
cadmium O O
and O O
zinc B-drug B-drug
had O O
a O O
synergistic O O
effect O O
compared O O
with O O
single O O
metal O O
toxicity O O
but O O
only O O
at O O
50000 O O
microg/l O O
. O O

ALLEGRA B-brand B-brand
should O O
not O O
be O O
taken O O
closely O O
in O O
time O O
with O O
aluminum B-drug B-drug
and O O
magnesium B-drug B-drug
containing O O
antacids B-group B-group
. O O

No O O
interaction O O
was O O
noted O O
with O O
the O O
MAO-B B-group B-group
inhibitor I-group I-group
selegiline B-drug B-drug
in O O
two O O
multiple-dose O O
interaction O O
studies O O
when O O
entacapone B-drug B-drug
was O O
coadministered O O
with O O
a O O
levodopa/dopa B-drug B-drug
decarboxylase B-group B-group
inhibitor I-group I-group
( O O
n=29 O O
) O O
. O O

There O O
is O O
the O O
risk O O
of O O
convulsions O O
occurring O O
in O O
susceptible O O
patients O O
following O O
the O O
use O O
of O O
the O O
new O O
anaesthetic B-group B-group
agents I-group I-group
which O O
are O O
capable O O
of O O
inducing O O
CNS O O
excitability O O
. O O

RESULTS O O
: O O
Hydrocortisone B-drug B-drug
elevated O O
salivary O O
cortisol O O
levels O O
, O O
produced O O
modest O O
dysphoria O O
, O O
and O O
reduced O O
subjects O O
' O O
reports O O
of O O
wanting O O
more O O
drug O O
. O O

Clarithromycin I-drug B-drug
14OH- O O
clarithromycin O B-drug

Caution O O
should O O
be O O
exercised O O
during O O
the O O
administration O O
of O O
adrenaline B-drug B-drug
to O O
patients O O
anaesthetised O O
with O O
FLUOTHANE B-brand B-brand
as O O
arrhythmias O O
may O O
be O O
precipitated O O
. O O

Probenecid B-drug B-drug
: O O
The O O
oral O O
combination O O
of O O
probenecid B-drug B-drug
before O O
intramuscular O O
injection O O
of O O
PIPRACIL B-brand B-brand
produces O O
an O O
increase O O
in O O
piperacillin B-drug B-drug
peak O O
serum O O
level O O
of O O
about O O
30 O O
% O O
. O O

A O O
review O O
. O O

The O O
effects O O
of O O
medicinal O O
products O O
with O O
similar O O
properties O O
such O O
as O O
inotropes O O
milrinone B-drug B-drug
, O O
enoximone B-drug B-drug
, O O
amrinone B-drug B-drug
, O O
olprinone B-drug_n B-drug
and O O
cilostazol B-drug B-drug
may O O
be O O
exacerbated O O
by O O
anagrelide B-drug B-drug
. O O

Our O O
data O O
suggest O O
that O O
TAM B-drug_n B-drug_n
significantly O O
potentiates O O
the O O
reduction O O
in O O
cell O O
number O O
induced O O
by O O
1,25 B-drug B-drug
( I-drug I-drug
OH I-drug I-drug
) I-drug I-drug
2D3 I-drug I-drug
alone O O
. O O

Determinants O O
downstream O O
of O O
cleavable O O
complex O O
formation O O
that O O
affect O O
the O O
sensitivity O O
of O O
tumor O O
versus O O
normal O O
cells O O
to O O
topo O O
drugs O O
in O O
particular O O
and O O
DNA-damaging O O
agents O O
in O O
general O O
are O O
little O O
known O O
. O O

ethchlorvynol B-drug B-drug
; O O

Injection O O
of O O
estradiol B-drug B-drug
5 O O
min O O
before O O
a O O
nonlethal O O
dose O O
of O O
endotoxin B-drug_n B-drug_n
changed O O
the O O
serum O O
sex O O
steroid O O
hormone O O
response O O
of O O
male O O
rats O O
to O O
endotoxin B-drug_n B-drug_n
. O O

Additive O O
depressant O O
effect O O
when O O
used O O
with O O
general O O
anesthetics B-group B-group
, O O
sedatives B-group B-group
, O O
antianxiety B-group B-group
drugs I-group I-group
, O O
hypnotics B-group B-group
, O O
alcohol B-drug B-drug
, O O
and O O
other O O
opiate B-group B-group
analgesics I-group I-group
. O O

Antagonism O O
has O O
been O O
demonstrated O O
between O O
clindamycin B-drug B-drug
and O O
erythromycin B-drug B-drug
in O O
vitro O O
. O O

It O O
may O O
also O O
interact O O
with O O
amantadine B-drug B-drug
or O O
other O O
anticholinergic B-group B-group
drugs I-group I-group
or O O
MAOIs B-group B-group
, O O
which O O
may O O
intensify O O
the O O
anticholinergic O O
action O O
. O O

Oral O O
Anticoagulants B-group B-group
: O O
In O O
some O O
normal O O
volunteers O O
, O O
the O O
concomitant O O
administration O O
of O O
diflunisal B-drug B-drug
and O O
warfarin B-drug B-drug
, O O
acenocoumarol B-drug B-drug
, O O
or O O
phenprocoumon B-drug B-drug
resulted O O
in O O
prolongation O O
of O O
prothrombin O O
time O O
. O O

Rifabutin I-drug B-drug
and O O
its O O
metabolite O O
concentrationswere O O
moderately O O
increased O O
. O O

The O O
concomitant O O
use O O
of O O
sodium B-drug B-drug
cephalothin I-drug I-drug
and O O
Coly-Mycin B-brand B-brand
M I-brand I-brand
Parenteral O O
should O O
be O O
avoided O O
. O O

for O O
some O O
strains O O
combinations O O
were O O
synergistic O O
. O O

The O O
absorption O O
of O O
tetracycline B-drug B-drug
, O O
furosemide B-drug B-drug
, O O
penicillin B-drug B-drug
G I-drug I-drug
, O O
hydrochlorothiazide B-drug B-drug
, O O
and O O
gemfibrozil B-drug B-drug
was O O
significantly O O
decreased O O
when O O
given O O
simultaneously O O
with O O
colestipol B-drug B-drug
hydrochloride I-drug I-drug
; O O

The O O
results O O
indicate O O
that O O
a O O
spinal O O
naloxone-sensitive B-drug O
endorphinergic O O
system O O
is O O
involved O O
in O O
the O O
production O O
of O O
beta-endorphin B-drug_n B-drug_n
but O O
not O O
morphine-induced B-drug B-drug
tail-flick O O
inhibition O O
, O O
and O O
suggest O O
that O O
intraventricular O O
beta-endorphin B-drug_n B-drug_n
and O O
morphine B-drug B-drug
elicit O O
their O O
pharmacological O O
actions O O
via O O
the O O
activation O O
of O O
different O O
descending O O
pain O O
inhibitory O O
systems O O
; O O

Effects O O
of O O
Other O O
Drugs O O
on O O
Aliskiren B-drug B-drug
Based O O
on O O
in-vitro O O
studies O O
, O O
aliskiren B-drug B-drug
is O O
metabolized O O
by O O
CYP O O
3A4 O O
. O O

Combined O O
treatment O O
with O O
1,25 B-drug B-drug
( I-drug I-drug
OH I-drug I-drug
) I-drug I-drug
2D3 I-drug I-drug
and O O
TAM B-drug_n B-drug
enhances O O
the O O
degree O O
of O O
apoptosis O O
assessed O O
using O O
morphological O O
markers O O
that O O
identify O O
chromatin O O
and O O
nuclear O O
matrix O O
protein O O
condensation O O
. O O

At O O
0.3 O O
mg/kg O O
, O O
the O O
diarrhea-inducing O O
effects O O
of O O
dmPGE2 B-drug_n B-drug_n
were O O
more O O
pronounced O O
in O O
cecectomized O O
than O O
in O O
control O O
rats O O
. O O

Tissue O O
culture O O
and O O
animal O O
studies O O
indicate O O
that O O
ELSPAR B-brand B-brand
can O O
diminish O O
or O O
abolish O O
the O O
effect O O
of O O
methotrexate B-drug B-drug
on O O
malignant O O
cells.14 O O
This O O
effect O O
on O O
methotrexate B-drug B-drug
activity O O
persists O O
as O O
long O O
as O O
plasma O O
asparagine O B-drug
levels O O
are O O
suppressed O O
. O O

Therefore O O
, O O
the O O
use O O
of O O
genetic O O
data O O
in O O
these O O
instances O O
has O O
to O O
be O O
regulated O O
. O O

- O O
Quinine B-drug B-drug
( O O
e.g. O O
, O O
Quinamm B-brand B-brand
) O O
or O O

Drug-drug O O
interactions O O
have O O
not O O
been O O
observed O O
between O O
Argatroban B-drug B-drug
and O O
digoxin B-drug B-drug
or O O
erythromycin B-drug B-drug
. O O

Probenecid B-drug B-drug
depresses O O
tubular O O
secretion O O
of O O
certain O O
weak O O
acids O O
such O O
as O O
PAH B-drug B-drug
. O O

Particular O O
caution O O
should O O
be O O
observed O O
with O O
digitalis B-group B-group
preparations I-group I-group
since O O
there O O
are O O
conflicting O O
results O O
for O O
the O O
effect O O
of O O
colestipol B-drug B-drug
hydrochloride I-drug I-drug
on O O
the O O
availability O O
of O O
digoxin B-drug B-drug
and O O
digitoxin B-drug B-drug
. O O

While O O
taking O O
beta B-group B-group
blockers I-group I-group
, O O
patients O O
with O O
a O O
history O O
of O O
severe O O
anaphylactic O O
reaction O O
to O O
a O O
variety O O
of O O
allergens O O
may O O
be O O
more O O
reactive O O
to O O
repeated O O
challenge O O
, O O
either O O
accidental O O
, O O
diagnostic O O
, O O
or O O
therapeutic O O
. O O

Rifampin B-drug B-drug
: O O
When O O
a O O
single O O
375-mg O O
dose O O
of O O
Aprepitant B-drug B-drug
was O O
administered O O
on O O
Day9 O O
of O O
a O O
14-day O O
regimen O O
of O O
600 O O
mg/day O O
of O O
rifampin B-drug B-drug
, O O
a O O
strong O O
CYP3A4 O O
inducer O O
, O O
the O O
AUC O O
of O O
aprepitant B-drug B-drug
decreased O O
approximately O O
11-fold O O
and O O
the O O
mean O O
terminal O O
half-life O O
decreased O O
approximately O O
3-fold O O
. O O

For O O
patients O O
receiving O O
monoamine B-group B-group
oxidase I-group I-group
inhibitors I-group I-group
, O O
see O O
CONTRAINDICATIONS O O
. O O

If O O
used O O
concomitantly O O
, O O
closely O O
monitor O O
serum O O
electrolytes O O
and O O
cardiac O O
function O O
. O O

Interactions O O
with O O
the O O
drugs O O
listed O O
below O O
have O O
not O O
been O O
reported O O
in O O
clinical O O
trials O O
with O O
azithromycin B-drug B-drug
; O O

Propranolol B-drug B-drug
attenuated O O
the O O
heart O O
rate O O
increase O O
following O O
administration O O
of O O
immediate O O
release O O
nisoldipine B-drug B-drug
. O O

Ethinyl B-drug B-drug
estradiol I-drug I-drug

ELLENCE B-brand B-brand
when O O
used O O
in O O
combination O O
with O O
other O O
cytotoxic O B-group
drugs O I-group
may O O
show O O
on-treatment O O
additive O O
toxicity O O
, O O
especially O O
hematologic O O
and O O
gastrointestinal O O
effects O O
. O O

poor O O
metabolizers O O
of O O
debrisoquin B-drug B-drug
: O O
Interactions O O
of O O
carvedilol B-drug B-drug
with O O
strong O O
inhibitors O O
of O O
CYP2D6 O O
( O O
such O O
as O O
quinidine B-drug B-drug
, O O
fluoxetine B-drug B-drug
, O O
paroxetine B-drug B-drug
, O O
and O O
propafenone B-drug B-drug
) O O
have O O
not O O
been O O
studied O O
, O O
but O O
these O O
drugs O O
would O O
be O O
expected O O
to O O
increase O O
blood O O
levels O O
of O O
the O O
R O O
( O O
+ O O
) O O
enantiomer O O
of O O
carvedilol B-drug B-drug
. O O

- O O
Indomethacin B-drug B-drug
: O O
Indomethacin B-drug B-drug
blunts O O
the O O
increases O O
in O O
urine O O
volume O O
and O O
sodium O O
excretion O O
seen O O
during O O
bumetanide B-drug B-drug
treatment O O
and O O
inhibits O O
the O O
bumetanide-induced B-drug B-drug
increase O O
in O O
plasma O O
renin O O
activity O O
. O O

anaphylaxis O O

It O O
has O O
been O O
reported O O
that O O
results O O
of O O
studies O O
in O O
animals O O
indicate O O
that O O
dopamine-induced B-drug B-drug
ventricular O O
arrhythmias O O
during O O
anesthesia O O
can O O
be O O
reversed O O
by O O
propranolol B-drug B-drug
. O O

Calcium B-group B-group
Channel I-group I-group
Blockers I-group I-group
: O O
Isolated O O
cases O O
of O O
conduction O O
disturbance O O
( O O
rarely O O
with O O
hemodynamic O O
compromise O O
) O O
have O O
been O O
observed O O
when O O
COREG B-brand B-brand
is O O
co-administered O O
with O O
diltiazem B-drug B-drug
. O O

Verapamil B-drug B-drug
: O O
Coadministration O O
of O O
almotriptan B-drug B-drug
and O O
verapamil B-drug B-drug
resulted O O
in O O
a O O
24 O O
% O O
increase O O
in O O
plasma O O
concentrations O O
of O O
almotriptan B-drug B-drug
. O O

The O O
elevated O O
plasma O O
alprazolam B-drug B-drug
concentrations O O
resulted O O
in O O
decreased O O
psychomotor O O
performance O O
and O O
memory O O
. O O

The O O
potential O O
for O O
binding O O
of O O
these O O
drugs O O
if O O
given O O
concomitantly O O
is O O
present O O
. O O

Intraventricular O O
injection O O
of O O
naloxone B-drug B-drug
at O O
doses O O
of O O
1.2 O O
to O O
12 O O
micrograms O O
equally O O
antagonized O O
in O O
a O O
dose-dependent O O
manner O O
the O O
tail-flick O O
inhibition O O
induced O O
by O O
intraventricular O O
beta-endorphin B-drug_n B-drug
and O O
morphine B-drug B-drug
. O O

Lamivudine B-drug B-drug
and O O
zalcitabine B-drug B-drug
may O O
inhibit O O
the O O
intracellular O O
phosphorylation O O
of O O
one O O
another O O
. O O

Coadministration O O
of O O
fluoxetine B-drug B-drug
significantly O O
decreased O O
cisapride B-drug B-drug
plasma O O
concentrations O O
. O O

decreased O O
levels O O
of O O
anti-factor O O
Xa O O
and O O
antithrombin O B-drug
III O I-drug
, O O
decreased O O
antithrombin O O
III O O
activity O O
; O O

Some O O
95 O O
% O O
of O O
a O O
single O O
dosage O O
of O O
fluvastatin B-drug B-drug
is O O
excreted O O
via O O
the O O
biliary O O
route O O
, O O
with O O
less O O
than O O
2 O O
% O O
of O O
this O O
being O O
the O O
parent O O
compound O O
. O O

. O O

higher O O
doses O O
decreased O O
FI O O
and O O
FR O O
responding O O
in O O
both O O
species O O
. O O

ERYTHROMYCIN B-drug B-drug
: O O
In O O
hypercholesterolemic O O
patients O O
, O O
steady-state O O
cerivastatin B-drug B-drug
AUC O O
and O O
Cmax O O
increased O O
approximately O O
50 O O
% O O
and O O
24 O O
% O O
respectively O O
after O O
10 O O
days O O
with O O
co-administration O O
of O O
erythromycin B-drug B-drug
, O O
a O O
known O O
inhibitor O O
of O O
cytochrome O O
P450 O O
3A4 O O
. O O

As O O
a O O
false-negative O O
result O O
may O O
occur O O
in O O
the O O
ferricyanide O O
test O O
, O O
it O O
is O O
recommended O O
that O O
either O O
the O O
glucose O O
oxidase O O
or O O
hexokinase O O
method O O
be O O
used O O
to O O
determine O O
blood O O
plasma O O
glucose O O
levels O O
in O O
patients O O
receiving O O
cefuroxime B-drug B-drug
. O O

Norpace B-brand B-brand
does O O
not O O
increase O O
serum O O
digoxin B-drug B-drug
levels O O
. O O

Although O O
the O O
interactions O O
observed O O
in O O
these O O
studies O O
do O O
not O O
appear O O
to O O
be O O
of O O
major O O
clinical O O
importance O O
, O O
BREVIBLOC B-brand B-brand
should O O
be O O
titrated O O
with O O
caution O O
in O O
patients O O
being O O
treated O O
concurrently O O
with O O
digoxin B-drug B-drug
, O O
morphine B-drug B-drug
, O O
succinylcholine B-drug B-drug
or O O
warfarin B-drug B-drug
. O O

Carcinogenesis O O
, O O
Mutagenesis O O
, O O
and O O
Fertility O O

[ O O
Dose-time O O
effects O O
of O O
competitive O O
displacement O O
of O O
radiopertechnetate B-drug B-drug
by O O
sodium B-drug_n B-drug
perchlorate I-drug_n I-drug
following O O
oral O O
and O O
intravenous O O
administration O O
] O O
The O O
effect O O
of O O
various O O
doses O O
of O O
sodium B-drug_n B-drug
perchlorate I-drug_n I-drug
in O O
several O O
dose O O
fractions O O
on O O
the O O
extent O O
and O O
the O O
time O O
scale O O
of O O
displacement O O
of O O
radiopertechnetate B-drug B-drug
, O O
in O O
dependence O O
on O O
application O O
mode O O
, O O
was O O
studied O O
. O O

oral O O
contraceptives B-group B-group
; O O

CONCLUSIONS O O
: O O
Single-dose O O
diltiazem B-drug B-drug
coadministration O O
leads O O
to O O
higher O O
sirolimus B-drug B-drug
exposure O O
, O O
presumably O O
by O O
inhibition O O
of O O
the O O
first-pass O O
metabolism O O
of O O
sirolimus B-drug B-drug
. O O

methylphenidate B-drug B-drug
; O O

Diuretic B-group B-group
: O O
Hydrochlorothiazide B-drug B-drug
, O O
given O O
concomitantly O O
with O O
ketoprofen B-drug B-drug
, O O
produces O O
a O O
reduction O O
in O O
urinary O O
potassium O O
and O O
chloride O B-drug
excretion O O
compared O O
to O O
hydrochlorothiazide B-drug B-drug
alone O O
. O O

Drugs O O
Metabolized O O
by O O
Cytochrome O O
P450 O O
Enzymes O O
The O O
drug O O
interaction O O
study O O
evaluating O O
the O O
effect O O
of O O
grepafloxacin B-drug B-drug
on O O
theophylline B-drug B-drug
indicates O O
that O O
grepafloxacin B-drug B-drug
inhibits O O
theophylline B-drug B-drug
metabolism O O
, O O
which O O
is O O
mediated O O
by O O
CYP1A2 O O
. O O

When O O
such O O
combined O O
therapy O O
is O O
contemplated O O
, O O
the O O
dose O O
of O O
one O O
or O O
both O O
agents O O
should O O
be O O
reduced O O
. O O

Serum O O
digitalis B-group B-group
levels O O
may O O
be O O
decreased O O
in O O
hyperthyroidism O O
or O O
when O O
a O O
hypothyroid O O
patient O O
becomes O O
euthyroid O O
. O O

Nafazodone B-drug B-drug
, O O
fluvoxamine B-drug B-drug
, O O
cimetidine B-drug B-drug
( O O
consider O O
Xanax B-brand B-brand
dose O O
reduction O O
) O O
. O O

When O O
the O O
CYP3A4 O O
inhibitor O O
is O O
withdrawn O O
from O O
the O O
combination O O
therapy O O
, O O
aripiprazole B-drug B-drug
dose O O
should O O
then O O
be O O
increased O O
. O O

Sildenafil B-drug B-drug
is O O
contraindicated O O
in O O
patients O O
using O O
long-acting B-group B-group
nitrates I-group I-group
or O O
who O O
may O O
need O O
to O O
use O O
short-acting B-group B-group
nitrates I-group I-group
, O O
because O O
the O O
combination O O
may O O
cause O O
a O O
sharp O O
fall O O
of O O
the O O
blood O O
pressure O O
. O O

In O O
patients O O
with O O
mild O O
to O O
moderate O O
hypertension O O
, O O
administration O O
of O O
25 O O
mg O O
daily O O
of O O
VIOXX B-brand B-brand
with O O
the O O
ACE B-group B-group
inhibitor I-group I-group
benazepril B-drug B-drug
, O O
10 O O
to O O
40 O O
mg O O
for O O
4 O O
weeks O O
, O O
was O O
associated O O
with O O
an O O
average O O
increase O O
in O O
mean O O
arterial O O
pressure O O
of O O
about O O
3 O O
mm O O
Hg O O
compared O O
to O O
ACE B-group B-group
inhibitor I-group I-group
alone O O
. O O

The O O
effects O O
seen O O
are O O
poorly O O
understood O O
and O O
depend O O
upon O O
a O O
variety O O
of O O
factors O O
such O O
as O O
dose O O
and O O
type O O
of O O
thyroid B-group O
preparations I-group O
and O O
endocrine O O
status O O
of O O
the O O
patient O O
. O O

Midazolam B-drug B-drug
Synergism O O

Moreover O O
, O O
the O O
acquisition O O
of O O
tasks O O
that O O
are O O
facilitated O O
by O O
hippocampal O O
lesions O O
( O O
or O O
dysfunction O O
) O O
is O O
nevertheless O O
associated O O
, O O
in O O
intact O O
subjects O O
, O O
with O O
specific O O
neurobiological O O
alterations O O
in O O
the O O
hippocampus O O
. O O

Tolazamide B-drug B-drug
: O O
A O O
case O O
of O O
severe O O
hypoglycemia O O
has O O
been O O
reported O O
in O O
a O O
type O O
II O O
diabetic O O
patient O O
maintained O O
on O O
tolazamide B-drug B-drug
( O O
1 O O
gm/day O O
) O O
11 O O
days O O
after O O
the O O
addition O O
of O O
doxepin B-drug B-drug
( O O
75 O O
mg/day O O
) O O
. O O

In O O
situations O O
when O O
concurrent O O
therapy O O
is O O
necessary O O
, O O
careful O O
patient O O
monitoring O O
is O O
essential O O
. O O

Oral O O
Anticoagulants B-group B-group
Interaction O O
studies O O
with O O
warfarin B-drug B-drug
and O O
acenocoumarol B-drug B-drug
failed O O
to O O
identify O O
any O O
clinically O O
important O O
effects O O
on O O
the O O
serum O O
concentrations O O
or O O
clinical O O
effects O O
of O O
these O O
anticoagulants B-group B-group
. O O

( O O
Cancer O O
Res. O O
, O O
38 O O
: O O
2003-2010 O O
, O O
1978 O O
) O O
have O O
reported O O
that O O
a O O
single O O
, O O
small O O
pulse O O
of O O
carcinogen O O
can O O
induce O O
early O O
and O O
numerous O O
liver O O
tumors O O
when O O
administered O O
neonatally O O
to O O
mice O O
with O O
a O O
genetic O O
predisposition O O
to O O
hepatotumorigenesis O O
. O O

As O O
with O O
most O O
psychoactive O B-group
medications O I-group
, O O
patients O O
should O O
be O O
advised O O
to O O
avoid O O
alcohol B-drug B-drug
while O O
taking O O
ABILIFY B-brand B-brand

This O O
decrease O O
in O O
absorption O O
results O O
in O O
a O O
36 O O
% O O
and O O
50 O O
% O O
lower O O
AUC O O
for O O
trovafloxacin B-drug B-drug
and O O
ciprofloxacin B-drug B-drug
, O O
respectively O O
, O O
which O O
could O O
cause O O
clinical O O
failures O O
. O O

A O O
pregnancy O O
test O O
must O O
be O O
repeated O O
each O O
month O O
prior O O
to O O
the O O
female O O
patient O O
receiving O O
each O O
prescription O O

The O O
interaction O O
of O O
Exjade B-brand B-brand
with O O
hydroxyurea B-drug B-drug
has O O
not O O
been O O
formally O O
studied O O
. O O

In O O
addition O O
to O O
bleeding O O
associated O O
with O O
heparin B-drug B-drug
and O O
vitamin B-group B-group
K I-group I-group
antagonists I-group I-group
, O O
drugs O O
that O O
alter O O
platelet O O
function O O
( O O
such O O
as O O
acetylsalicylic B-drug B-drug
acid I-drug I-drug
, O O
dipyridamole B-drug B-drug
and O O
Abciximab B-drug B-drug
) O O
may O O
increase O O
the O O
risk O O
of O O
bleeding O O
if O O
administered O O
prior O O
to O O
, O O
during O O
, O O
or O O
after O O
Activase B-brand B-brand
therapy O O
. O O

Although O O
the O O
pressor O O
activity O O
of O O
Desmopressin B-drug B-drug
is O O
very O O
low O O
compared O O
to O O
its O O
antidiuretic O O
activity O O
, O O
large O O
doses O O
of O O
Desmopressin B-drug B-drug
Tablets O O
should O O
be O O
used O O
with O O
other O O
pressor O B-group
agents O I-group
only O O
with O O
careful O O
patient O O
monitoring O O
. O O

No O O
formal O O
drug O O
interaction O O
studies O O
with O O
anti-neoplastic B-group B-group
agents I-group I-group
have O O
been O O
conducted O O
. O O

Digoxin B-drug B-drug
: O O
Coadministration O O
of O O
digoxin B-drug B-drug
, O O
a O O
P-glycoprotein O O
substrate O O
, O O
with O O
oral O O
conivaptan B-drug B-drug
resulted O O
in O O
a O O
reduction O O
in O O
clearance O O
and O O
an O O
increase O O
in O O
digoxin B-drug B-drug
Cmax O O
and O O
AUC O O
values O O
. O O

Cephalosporins-Cephalosporins B-group B-group
containing O O
side O O
chains O O
of O O
N-methylthiotetrazole O B-drug_n
( O O
cefmenoxime B-drug B-drug
, O O
cefoperazone B-drug B-drug
, O O
cefotetan B-drug B-drug
, O O
cefamandole B-drug B-drug
, O O
latamoxef B-drug B-drug
) O O
or O O
methylthiadiazole O B-drug
( O O
cefazolin B-drug B-drug
) O O
can O O
cause O O
vitamin O B-group
K O I-group
deficiency O O
and O O
hypoprothrombinemia O O
. O O

May O O
interact O O
with O O
the O O
following O O
: O O
cholestyramine B-drug B-drug
, O O
colestipol B-drug B-drug
( O O
use O O
with O O
thiazide B-group B-group
diuretics I-group I-group
may O O
prevent O O
the O O
diuretic B-group B-group
from O O
working O O
properly O O
; O O

although O O
combinations O O
are O O
sometimes O O
used O O
for O O
therapeutic O O
advantage O O
, O O
when O O
used O O
concurrently O O
, O O
patient O O
should O O
be O O
closely O O
monitored O O
. O O

It O O
is O O
concluded O O
that O O
neurotensin B-drug_n B-drug_n
modulates O O
in O O
an O O
opposite O O
way O O
the O O
function O O
of O O
the O O
enkephalinergic O O
neurons O O
and O O
the O O
central O O
action O O
of O O
tuftsin B-drug_n B-drug_n
. O O

Intensive O O
monitoring O O
of O O
renal O O
function O O
is O O
recommended O O
in O O
patients O O
requiring O O
any O O
combination O O
of O O
nephrotoxic O O
medications O O
. O O

Thus O O
cimetidine B-drug B-drug
appeared O O
to O O
alter O O
the O O
renal O O
excretion O O
of O O
both O O
gabapentin B-drug B-drug
and O O
creatinine O O
, O O
an O O
endogenous O O
marker O O
of O O
renal O O
function O O
. O O

May O O
interact O O
with O O
other O O
creams O O
, O O
lotions O O
, O O
or O O
skin O O
medicines O O
when O O
placed O O
on O O
the O O
same O O
areas O O
of O O
your O O
skin O O
that O O
you O O
are O O
using O O
bentoquatam B-drug_n B-drug
. O O

Neuroleptic B-group B-group
Drugs I-group I-group
- O O
L-phenylalanine B-drug B-drug
may O O
potentiate O O
the O O
tardive O O
dyskinesia O O
side O O
reactions O O
of O O
neuroleptic B-group B-group
drugs I-group I-group
if O O
used O O
concomitantly O O
with O O
them O O
. O O

Beta B-group B-group
blockers I-group I-group
may O O
exacerbate O O
the O O
rebound O O
hypertension O O
which O O
can O O
follow O O
the O O
withdrawal O O
of O O
clonidine B-drug B-drug
. O O

MAO B-group B-group
inhibitors I-group I-group
prolong O O
and O O
intensify O O
the O O
effects O O
of O O
antihistamines B-group B-group
. O O

Other O O
5-HT1B/1D B-group O
Agonists I-group O
Concomitant O O
use O O
of O O
other O O
5-HT1B/1D B-group B-group
agonists I-group I-group
within O O
24 O O
hours O O
of O O
treatment O O
with O O
AXERT B-brand B-brand
is O O
contraindicated O O
. O O

The O O
following O O
agents O O
may O O
increase O O
certain O O
actions O O
or O O
side O O
effects O O
of O O
anticholinergic B-group B-group
drugs I-group I-group
. O O
amantadine B-drug B-group
antiarrhythmic B-group I-group
agents I-group I-group
of O I-group
class O I-group
( O O
e.g O O
. O O
quinidine B-drug B-drug
) O O
, O O
antihistamines B-group B-group
antipsychotic I-group I-group
agents I-group I-group
( O O
e.g O O
. O O
phenothiazines B-group B-group
) O O
, O O
benzodiazepines B-group B-group
. O O

Effect O O

The O O
utilization O O
of O O
digitoxin B-drug B-drug
for O O
such O O
patients O O
may O O
be O O
considered O O
as O O
an O O
alternative O O
. O O

Type O O
2 O O
diabetes O O
mellitus O O
is O O
a O O
growing O O
problem O O
not O O
only O O
in O O
the O O
United O O
States O O
but O O
also O O
across O O
the O O
world O O
. O O

No O O
pharmacodynamic O O
effects O O
of O O
either O O
histamine B-group B-group
H2 I-group I-group
receptor I-group I-group
antagonist I-group I-group
were O O
observed O O
. O O

BACKGROUND O O
. O O

Neuroleptic B-group O
: O O
pimozide B-drug B-drug

These O O
results O O
indicate O O
that O O
dosage O O
adjustment O O
of O O
quetiapine B-drug B-drug
may O O
be O O
necessary O O
when O O
the O O
two O O
drugs O O
are O O
given O O
concurrently O O
and O O
that O O
caution O O
may O O
be O O
required O O
when O O
administering O O
other O O
drugs O O
that O O
inhibit O O
or O O
induce O O
cytochromes O O
, O O
particularly O O
P450 O O
3A4 O O
. O O

Therefore O O
, O O
if O O
concomitant O O
use O O
of O O
these O O
agents O O
is O O
indicated O O
because O O
of O O
demonstrated O O
hypokalemia O O
, O O
they O O
should O O
be O O
used O O
with O O
caution O O
and O O
with O O
frequent O O
monitoring O O
of O O
serum O O
potassium O O
. O O

Aspirin B-brand B-brand
: O O
Ketoprofen B-drug B-drug
does O O
not O O
alter O O
aspirin B-brand B-brand
absorption O O
; O O

Other O O
strong O O
inhibitors O O
of O O
CYP3A4 O O
( O O
e.g. O O
, O O
itraconazole B-drug B-drug
, O O
clarithromycin B-drug B-drug
, O O
nefazodone B-drug B-drug
, O O
troleandomycin B-drug B-drug
, O O
ritonavir B-drug B-drug
, O O
nelfinavir B-drug B-drug
) O O
would O O
be O O
expected O O
to O O
behave O O
similarly O O
. O O

Effect O O
of O O
other O O
drugs O O
on O O
Vardenafil B-drug B-drug

No O O
specific O O
drug O O
interaction O O
studies O O
have O O
been O O
conducted O O
. O O

Because O O
of O O
possible O O
clinical O O
significance O O
, O O
the O O
two O O
drugs O O
should O O
not O O
be O O
administered O O
concurrently O O
. O O

These O O
agents O O
may O O
also O O
prolong O O
the O O
clinically O O
effective O O
duration O O
of O O
action O O
by O O
up O O
to O O
25 O O
% O O
. O O

Since O O
this O O
could O O
be O O
explained O O
either O O
by O O
enhanced O O
absorption O O
or O O
by O O
an O O
alteration O O
of O O
hepatic O O
metabolism O O
of O O
labetalol B-drug B-drug
HCl I-drug I-drug
, O O
special O O
care O O
should O O
be O O
used O O
in O O
establishing O O
the O O
dose O O
required O O
for O O
blood O O
pressure O O
control O O
in O O
such O O
patients O O
. O O

Rifampin B-drug B-drug
may O O
decrease O O
serum O O
digoxin B-drug B-drug
concentration O O
, O O
especially O O
in O O
patients O O
with O O
renal O O
dysfunction O O
, O O
by O O
increasing O O
the O O
non-renal O O
clearance O O
of O O
digoxin B-drug B-drug
. O O

Drug O O
interaction O O
studies O O
have O O
shown O O
that O O
esomeprazole B-drug B-drug
does O O
not O O
have O O
any O O
clinically O O
significant O O
interactions O O
with O O
phenytoin B-drug B-drug
, O O
warfarin B-drug B-drug
, O O
quinidine B-drug B-drug
, O O
clarithromycin B-drug B-drug
or O O
amoxicillin B-drug B-drug
. O O

In O O
patients O O
receiving O O
concurrent O O
therapy O O
with O O
clonidine B-drug B-drug
, O O
if O O
therapy O O
is O O
to O O
be O O
discontinued O O
, O O
it O O
is O O
suggested O O
that O O
ZEBETA B-brand B-brand
be O O
discontinued O O
for O O
several O O
days O O
before O O
the O O
withdrawal O O
of O O
clonidine B-drug B-drug
. O O

Both O O
groups O O
of O O
agents O O
lower O O
blood O O
levels O O
and O O
efficacy O O
of O O
amphetamines B-group B-group
. O O

METHODS O O
: O O
Clinical O O
studies O O
, O O
case O O
reports O O
, O O
and O O
commentaries O O
and O O
editorials O O
concerning O O
sildenafil B-drug B-drug
published O O
in O O
the O O
international O O
literature O O
between O O
January O O
1999 O O
and O O
August O O
2000 O O
were O O
identified O O
through O O
searches O O
of O O
MEDLINE O B-brand
, O O
PREMEDLINE O B-brand
, O O
and O O
International O O
Pharmaceutical O O
Abstracts O O
, O O
using O O
the O O
terms O O
sildenafil B-drug B-drug
, O O
Viagra B-brand B-brand
, O O
and O O
erectile O O
dysfunction O O
. O O

Therefore O O
, O O
if O O
digoxin B-drug B-drug
is O O
administered O O
with O O
VAPRISOL B-brand B-brand
, O O
the O O
clinician O O
should O O
be O O
alert O O
to O O
the O O
possibility O O
of O O
increases O O
in O O
digoxin B-drug B-drug
levels O O
. O O

While O O
no O O
in O O
vivo O O
drug-drug O O
interaction O O
studies O O
were O O
conducted O O
between O O
estazolam B-drug B-drug
and O O
inducers O O
of O O
CYP3A O O
, O O
compounds O O
that O O
are O O
potent O O
CYP3A O O
inducers O O
( O O
such O O
as O O
carbamazepine B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
rifampin B-drug B-drug
, O O
and O O
barbiturates B-group B-group
) O O
would O O
be O O
expected O O
to O O
decrease O O
estazolam B-drug B-drug
concentrations O O
. O O

Compounds O O
in O O
these O O
categories O O
result O O
in O O
a O O
decreased O O
efficacy O O
of O O
bromocriptine B-drug B-drug
mesylate I-drug I-drug
: O O
phenothiazines B-group B-group
, O O
haloperidol B-drug B-drug
, O O
metoclopramide B-drug B-drug
, O O
pimozide B-drug B-drug
. O O

Both O O
the O O
sedative O O
and O O
anticholinergic O O
effects O O
of O O
the O O
major B-group O
tranquilizers I-group B-group
are O O
also O O
additive O O
to O O
those O O
of O O
desipramine B-drug B-drug
. O O

The O O
intravenous O O
application O O
of O O
perchlorate B-drug_n B-drug
offers O O
advantages O O
in O O
clinical O O
use O O
. O O

therefore O O
, O O
the O O
disposition O O
of O O
eszopiclone B-drug B-drug
is O O
not O O
expected O O
to O O
be O O
sensitive O O
to O O
alterations O O
in O O
protein O O
binding O O
. O O

Three O O
patients O O
met O O
ACR O O
criteria O O
for O O
liver O O
biopsy O O
( O O
1 O O
: O O
Roegnik O B-brand
Grade O O
I O O
, O O
2 O O
: O O
Roegnik O B-brand
Grade O O
IIIa O O
) O O
. O O

Nervous O O
System O O
: O O
Although O O
the O O
occurrence O O
of O O
peripheral O O
neuropathy O O
is O O
frequent O O
, O O
the O O
development O O
of O O
severe O O
symptomatology O O
is O O
unusual O O
and O O
requires O O
a O O
dose O O
reduction O O
of O O
20 O O
% O O
for O O
all O O
subsequentcourses O O
of O O
TAXOL B-brand B-brand
. O O

Effect O O
of O O
ginsenosides B-drug_n B-drug_n
on O O
voltage-dependent O O
Ca O O
( O O
2+ O O
) O O
channel O O
subtypes O O
in O O
bovine O O
chromaffin O O
cells O O
. O O

antiarrhythmic B-group B-group
agents I-group I-group
concentration O O

Agents O O
that O O
induce O O
CYP3A4 O O
( O O
eg O O
, O O
carbamazepine B-drug B-drug
) O O
could O O
cause O O
an O O
increase O O
in O O
aripiprazole B-drug B-drug
clearance O O
and O O
lower O O
blood O O
levels O O
. O O

Do O O
not O O
take O O
this O O
medicine O O
with O O
thioridizine O B-drug
, O O
or O O
within O O
5 O O
weeks O O
of O O
taking O O
fluoxetine B-drug B-drug
. O O

The O O
magnitude O O
of O O
interaction O O
at O O
other O O
doses O O
is O O
not O O
known O O
. O O

However O O
, O O
the O O
peak O O
plasma O O
level O O
of O O
metformin B-drug B-drug
was O O
reduced O O
by O O
approximately O O
20 O O
% O O
when O O
taking O O
Acarbose B-drug B-drug
due O O
to O O
a O O
slight O O
delay O O
in O O
the O O
absorption O O
of O O
metformin B-drug B-drug
. O O

However O O
, O O
the O O
concomitant O O
use O O
of O O
Argatroban B-drug B-drug
and O O
warfarin B-drug B-drug
( O O
5-7.5 O O
mg O O
initial O O
oral O O
dose O O
followed O O
by O O
2.5-6 O O
mg/day O O
orally O O
for O O
6-10 O O
days O O
) O O
results O O
in O O
prolongation O O
of O O
the O O
prothrombin O O
time O O
( O O
PT O O
) O O
and O O
International O O
Normalized O O
Ratio O O
( O O
INR O O
) O O
. O O

Little O O
has O O
been O O
studied O O
of O O
the O O
adverse O O
effects O O
of O O
the O O
exposure O O
of O O
the O O
liver O O
to O O
the O O
interaction O O
of O O
ethanol B-drug B-drug
with O O
its O O
congeners O O
and O O
acetaldehyde B-drug_n B-drug_n
, O O
coexisting O O
in O O
the O O
contents O O
of O O
alcoholic O O
beverages O O
. O O

Other O O
Drugs O O
: O O
In O O
healthy O O
volunteers O O
, O O
amlodipine B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
glyburide B-drug B-drug
, O O
ranitidine B-drug B-drug
, O O
omeprazole B-drug B-drug
, O O
hormone B-drug O
replacement O O
therapy O O
( O O
a O O
combination O O
of O O
conjugated O B-group
estrogens B-group I-group
and O O
medroxyprogesterone B-drug B-drug
) O O
, O O
antacid B-group B-group
( O O
aluminum O B-drug
and O O
magnesium B-drug B-drug
hydroxides O I-drug
) O O
and O O
theophylline B-drug B-drug
did O O
not O O
affect O O
the O O
pharmacokinetics O O
of O O
TIKOSYN B-brand B-brand
. O O

Anticoagulants B-group B-group
, O O
oral O O

Although O O
there O O
are O O
no O O
study O O
data O O
to O O
evaluate O O
the O O
possibility O O
, O O
nitric B-group B-group
oxide I-group I-group
donor I-group I-group
compounds I-group I-group
, O O
including O O
sodium B-drug B-drug
nitroprusside I-drug I-drug
and O O
nitroglycerin B-drug B-drug
, O O
may O O
have O O
an O O
additive O O
effect O O
with O O
INOmax B-brand B-brand
on O O
the O O
risk O O
of O O
developing O O
methemoglobinemia O O
. O O

n-dodecyl B-drug O
gallate I-drug O
showed O O
the O O
most O O
potent O O
inhibition O O
( O O
66 O O
% O O
inhibition O O
at O O
10 O O
microM O O
) O O
, O O
which O O
was O O
far O O
more O O
potent O O
than O O
that O O
of O O
crude O O
tannic B-drug O
acid I-drug O
. O O

Inhibitors O O
of O O
this O O
isoenzyme O O
( O O
e.g. O O
, O O
macrolide B-group B-group
antibiotics I-group I-group
, O O
azole B-group B-group
antifungal I-group I-group
agents I-group I-group
, O O
protease B-group B-group
inhibitors I-group I-group
, O O
serotonin B-group B-group
reuptake I-group I-group
inhibitors I-group I-group
, O O
amiodarone B-drug B-drug
, O O
cannabinoids B-group B-group
, O O
diltiazem B-drug B-drug
, O O
grapefruit O O
juice O O
, O O
nefazadone B-drug B-drug
, O O
norfloxacin B-drug B-drug
, O O
quinine B-drug B-drug
, O O
zafirlukast B-drug B-drug
) O O
should O O
be O O
cautiously O O
coadministered O O
with O O
TIKOSYN B-brand B-brand
as O O
they O O
can O O
potentially O O
increase O O
dofetilide B-drug B-drug
levels O O
. O O

Electroconvulsive O O
Therapy O O
( O O
ECT O O
) O O
- O O
There O O
are O O
no O O
clinical O O
studies O O
of O O
the O O
combined O O
use O O
of O O
ECT O O
and O O
escitalopram B-drug B-drug
. O O

Midazolam B-drug B-drug
: O O
Aprepitant B-drug B-drug
increased O O
the O O
AUC O O
of O O
midazolam B-drug B-drug
, O O
a O O
sensitive O O
CYP3A4 O O
substrate O O
, O O
by O O
2.3-fold O O
on O O
Day O O
1 O O
and O O
3.3-fold O O
on O O
Day O O
5 O O
, O O
when O O
a O O
single O O
oral O O
dose O O
of O O
midazolam B-drug B-drug
2 O O
mg O O
was O O
coadministered O O
on O O
Day O O
1 O O
and O O
Day O O
5 O O
of O O
a O O
regimen O O
of O O
Aprepitant B-drug B-drug
125 O O
mg O O
on O O
Day O O
1 O O
and O O
80 O O
mg/day O O
on O O
Days O O
2 O O
through O O
5 O O
. O O

NNRTI-based B-group B-group
regimens O O
may O O
have O O
several O O
advantages O O
over O O
PI-based B-group O
therapy O O
for O O
initial O O
or O O
prolonged O O
therapy O O
, O O
including O O
more O O
convenient O O
administration O O
regimens O O
, O O
lower O O
tablet O O
volume O O
, O O
fewer O O
drug O O
interactions O O
, O O
and O O
central O O
nervous O O
system O O
penetration O O
. O O

The O O
clearance O O
of O O
salicylates B-group B-group
may O O
be O O
increased O O
with O O
concurrent O O
use O O
of O O
corticosteroids B-group B-group
. O O

As O O
with O O
all O O
drugs O O
, O O
care O O
should O O
be O O
exercised O O
when O O
treating O O
patients O O
with O O
multiple O O
medications O O
. O O

Caution O O
should O O
be O O
exercised O O
when O O
considering O O
the O O
use O O
of O O
BREVIBLOC B-brand B-brand
and O O
verapamil B-drug B-drug
in O O
patients O O
with O O
depressed O O
myocardial O O
function O O
. O O

For O O
a O O
4-fold O O
range O O
of O O
everolimus B-drug B-drug
doses O O
there O O
were O O
no O O
differential O O
effects O O
on O O
cyclosporine B-drug B-drug
dosing O O
or O O
pharmacokinetics O O
. O O

An O O
increase O O
in O O
serum O O
lithium B-drug B-drug
concentration O O
has O O
been O O
reported O O
during O O
concomitant O O
administration O O
of O O
lithium B-drug B-drug
with O O
ATACAND B-brand B-brand
, O O
so O O
careful O O
monitoring O O
of O O
serum O O
lithium B-drug B-drug
levels O O
is O O
recommended O O
during O O
concomitant O O
use O O
. O O

Neuropathy O O
has O O
occurred O O
more O O
frequently O O
in O O
patients O O
with O O
a O O
history O O
of O O
neuropathy O O
or O O
neurotoxic O O
drug O O
therapy O O
, O O
including O O
stavudine B-drug B-drug
, O O
and O O
these O O
patients O O
may O O
be O O
at O O
increased O O
risk O O
of O O
neuropathy O O
during O O
VIDEX B-brand B-brand
therapy O O
( O O
see O O
ADVERSE O O
REACTIONS O O
) O O
. O O

This O O
interference O O
may O O
result O O
in O O
an O O
apparent O O
factor O O
concentration O O
that O O
is O O
lower O O
than O O
the O O
true O O
concentration O O
. O O

oral O O
clearance O O
was O O
reduced O O
by O O
about O O
50 O O
% O O
. O O

Antacids B-group B-group
containing O O
magnesium B-drug B-drug
trisilicate I-drug I-drug
, O O
when O O
administered O O
concomitantly O O
with O O
nitrofurantoin B-drug B-drug
, O O
reduce O O
both O O
the O O
rate O O
and O O
extent O O
of O O
absorption O O
. O O

An O O
initial O O
dose O O
of O O
5 O O
mg O O
should O O
be O O
given O O
to O O
patients O O
who O O
are O O
concomitantly O O
being O O
treated O O
with O O
cimetidine B-drug B-drug
. O O

there O O
was O O
no O O
significant O O
change O O
in O O
prothrombin O O
test O O
results O O
during O O
the O O
trials O O
of O O
chloral B-drug B-drug
hydrate I-drug I-drug
and O O
methaqualone B-drug B-drug
. O O

Patients O O
treated O O
with O O
a O O
beta-adrenergic B-group B-group
receptor I-group I-group
blocking I-group I-group
agent I-group I-group
plus O O
a O O
catecholamine O B-group
depletor O I-group
should O O
therefore O O
be O O
closely O O
observed O O
for O O
evidence O O
of O O
hypotension O O
or O O
marked O O
bradycardia O O
, O O
which O O
may O O
produce O O
vertigo O O
, O O
syncope O O
, O O
or O O
postural O O
hypotension O O
. O O

Diuretics B-group B-group
: O O
Studies O O
in O O
normal O O
volunteers O O
have O O
shown O O
that O O
flurbiprofen B-drug B-drug
like O O
other O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
drugs I-group I-group
, O O
can O O
interfere O O
with O O
the O O
effects O O
of O O
furosemide B-drug B-drug
. O O

Usually O O
, O O
the O O
dosage O O
of O O
the O O
anticoagulant B-group B-group
should O O
be O O
reduced O O
by O O
one-half O O
( O O
depending O O
on O O
the O O
individual O O
case O O
) O O
to O O
maintain O O
the O O
prothrombin O O
time O O
at O O
the O O
desired O O
level O O
to O O
prevent O O
bleeding O O
complications O O
. O O

This O O
response O O
has O O
been O O
attributed O O
to O O
inhibition O O
of O O
renal O O
prostaglandin O O
synthesis O O
. O O

A O O
1-month O O
washout O O
period O O
was O O
inserted O O
between O O
the O O
treatment O O
periods O O
. O O

The O O
pharmacokinetics O O
of O O
naltrexone B-drug B-drug
and O O
its O O
major O O
metabolite O O
6-beta-naltrexol B-drug_n O
were O O
unaffected O O
following O O
co-administration O O
with O O
Acamprosate B-drug B-drug
. O O

cimetidine B-drug B-drug
; O O

they O O
also O O
suggest O O
that O O
alcoholic O O
beverages O O
are O O
not O O
equivalent O O
in O O
their O O
potential O O
to O O
cause O O
liver O O
damage O O
. O O

Results O O
of O O
preliminary O O
studies O O
in O O
humans O O
and O O
rats O O
suggest O O
that O O
nonabsorbable O O
antacids B-group B-group
given O O
concurrently O O
with O O
lactulose B-drug B-drug
may O O
inhibit O O
the O O
desired O O
lactulose-induced B-drug B-drug
drop O O
in O O
colonic O O
pH O O
. O O

Histamine B-group B-group
H2 I-group I-group
antagonists I-group I-group
: O O
Cimetidine B-drug B-drug
inhibits O O
CYP3A4 O O
and O O
can O O
increase O O
serum O O
amiodarone B-drug B-drug
levels O O
. O O

Cyclosporine B-drug B-drug
: O O
Modest O O
increases O O
in O O
mean O O
trough O O
cyclosporine B-drug B-drug
concentrations O O
were O O
observed O O
following O O
initiation O O
of O O
carvedilol B-drug B-drug
treatment O O
in O O
21 O O
renal O O
transplant O O
patients O O
suffering O O
from O O
chronic O O
vascular O O
rejection O O
. O O

. O O

These O O
reactions O O
have O O
been O O
observed O O
more O O
frequently O O
with O O
the O O
24-hour O O
infusion O O
than O O
with O O
the O O
3-hour O O
infusion O O
. O O

Altered O O
responsiveness O O
to O O
alcohol B-drug B-drug
after O O
exposure O O
to O O
organic O O
lead O O
. O O

At O O
37 O O
degrees O O
C O O
the O O
non-myelinated O O
axons O O
contained O O
28.4 O O
plus O O
or O O
minus O O
0.8 O O
S.E.M O O
. O O

Drugs O O
that O O
may O O
alter O O
imatinib B-drug B-drug
plasma O O
concentrations O O
Drugs O O
that O O
may O O
increase O O
imatinib B-drug B-drug
plasma O O
concentrations O O
: O O
Caution O O
is O O
recommended O O
when O O
administering O O
Gleevec B-brand B-brand
with O O
inhibitors O O
of O O
the O O
CYP3A4 O O
family O O
( O O
e.g. O O
, O O
ketoconazole B-drug B-drug
, O O
itraconazole B-drug B-drug
, O O
erythromycin B-drug B-drug
, O O
clarithromycin B-drug B-drug
) O O
. O O

Indinavir B-drug B-drug
concentrations O O
may O O
be O O
decreased O O
in O O
the O O
presence O O
of O O
nevirapine B-drug B-drug
. O O

Trileptal B-brand B-brand
dose O O
( O O
mg/day O O
) O O

It O O
is O O
recommended O O
that O O
these O O
tests O O
be O O
performed O O
at O O
weekly O O
or O O
biweekly O O
intervals O O
until O O
the O O
lipid O O
response O O
to O O
Accutane B-brand B-brand
is O O
established O O
. O O

Untreated O O
hypothyroidism O O
may O O
interfere O O
with O O
the O O
growth O O
response O O
to O O
somatrem B-drug O
or O O
somatropin B-drug B-drug
. O O

In O O
patients O O
receiving O O
a O O
potent O O
CYP3A4 O O
inducer O O
such O O
as O O
rifampicin B-drug B-drug
or O O
phenytoin B-drug B-drug
, O O
a O O
dose O O
increase O O
to O O
500 O O
mg O O
daily O O
should O O
be O O
considered O O
in O O
the O O
absence O O
of O O
severe O O
adverse O O
drug O O
reaction O O
, O O
and O O
clinical O O
response O O
and O O
adverse O O
events O O
should O O
be O O
carefully O O
monitored O O
( O O
see O O
CLINICAL O O
PHARMACOLOGY-Pharmacokinetics-Drug-Drug O O
Interactions O O
and O O
DOSAGE O O
AND O O
ADMINISTRATION-Dosage O O
Adjustment O O
sections O O
) O O
. O O

These O O
pharmacokinetic O O
effects O O
did O O
not O O
result O O
in O O
clinically O O
meaningful O O
changes O O
in O O
ECG O O
, O O
heart O O
rate O O
or O O
blood O O
pressure O O
beyond O O
those O O
changes O O
induced O O
by O O
diltiazem B-drug B-drug
alone O O
. O O

Agents O O
that O O
Inhibit O O
Cytochrome O O
P450 O O
Isoenzymes O O
and/or O O
Epoxide O O
Hydrolase O O
Carbamazepine B-drug B-drug
is O O
metabolized O O
mainly O O
by O O
cytochrome O O
P450 O O
( O O
CYP O O
) O O
3A4 O O
to O O
the O O
active O O
carbamazepine B-drug B-drug
10,11-epoxide I-drug I-drug
, O O
which O O
is O O
further O O
metabolized O O
to O O
the O O
trans-diol O O
by O O
epoxide O O
hydrolase O O
. O O

leukopenia O O

Drugs O O
That O O
Alter O O
Renal O O
Excretion O O
Ibuprofen B-drug B-drug
: O O
Ibuprofen B-drug B-drug
is O O
known O O
to O O
affect O O
renal O O
function O O
and O O
, O O
consequently O O
, O O
alter O O
the O O
renal O O
excretion O O
of O O
other O O
drugs O O
. O O

Misonidazole B-drug_n B-drug_n
also O O
reduced O O
the O O
" O O
early O O
" O O

. O O

There O O
was O O
no O O
evidence O O
of O O
any O O
pharmacokinetic O O
interactions O O
between O O
ERBITUX B-brand B-brand
and O O
irinotecan B-drug B-drug
. O O

Drug-Drug O O
Interactions O O
Cimetidine B-drug B-drug
: O O
Concomitant O O
use O O
of O O
cimetidine B-drug B-drug
is O O
contraindicated O O
. O O

. O O

The O O
possibility O O
of O O
hypotensive O O
effects O O
with O O
captopril B-drug B-drug
can O O
be O O
minimized O O
by O O
either O O
discontinuing O O
the O O
diuretic B-group B-group
or O O
increasing O O
the O O
salt O O
intake O O
approximately O O
one O O
week O O
prior O O
to O O
initiation O O
of O O
treatment O O
with O O
captopril B-drug B-drug
( O O
captopril B-drug B-drug
tablets O O
, O O
USP O O
) O O
or O O
initiating O O
therapy O O
with O O
small O O
doses O O
( O O
6.25 O O
or O O
12.5 O O
mg O O
) O O
. O O

Two O O
percent O O
of O O
patients O O
treated O O
concurrently O O
with O O
Kineret B-brand B-brand
and O O
etanercept B-drug B-drug
developed O O
neutropenia O O
( O O
ANC O O
1 O O
x O O
109/L O O
) O O
. O O

COPAXONE B-brand B-brand
has O O
not O O
been O O
formally O O
evaluated O O
in O O
combination O O
with O O
Interferon B-drug B-drug
beta I-drug I-drug
. O O

Estrogens B-group B-group
, O O
including O O
oral O O
contraceptives B-group B-group
: O O
Estrogens B-group B-group
may O O
decrease O O
the O O
hepatic O O
metabolism O O
of O O
certain O O
corticosteroids B-group B-group
, O O
thereby O O
increasing O O
their O O
effect O O
. O O

Potential O O
differences O O
in O O
cyclosporine B-drug B-drug
dosing O O
and O O
pharmacokinetics O O
at O O
different O O
levels O O
of O O
everolimus B-drug B-drug
exposure O O
were O O
assessed O O
in O O
the O O
context O O
of O O
ANOVA O O
. O O

Monitoring O O
of O O
anticoagulation O O
levels O O
is O O
recommended O O
. O O

These O O
data O O
emphasize O O
that O O
apoptosis O O
can O O
be O O
induced O O
in O O
MCF-7 O O
cells O O
either O O
by O O
activation O O
of O O
vitamin-D-mediated B-group O
signalling O O
or O O
disruption O O
of O O
estrogen-dependent B-group O
signalling O O
. O O

Antithyroid B-group B-group
agents I-group I-group
may O O
decrease O O
thyroidal O O
uptake O O
of O O
sodium B-drug B-drug
iodide I-drug I-drug
I131 I-drug O
, O O
a O O
rebound O O
in O O
uptake O O
may O O
occur O O
up O O
to O O
5 O O
days O O
after O O
sudden O O
withdrawal O O
of O O
Carbimazole B-drug B-drug
. O O

5HT3 B-group B-group
Antagonists I-group I-group
: O O
Based O O
on O O
reports O O
of O O
profound O O
hypotension O O
and O O
loss O O
of O O
consciousness O O
when O O
apomorphine B-drug B-drug
was O O
administered O O
with O O
ondansetron B-drug B-drug
, O O
the O O
concomitant O O
use O O
of O O
apomorphine B-drug B-drug
with O O
drugs O O
of O O
the O O
5HT3 B-group B-group
antagonist I-group I-group
class I-group I-group
( O O
including O O
, O O
for O O
example O O
, O O
ondansetron B-drug B-drug
, O O
granisetron B-drug B-drug
, O O
dolasetron B-drug B-drug
, O O
palonosetron B-drug B-drug
, O O
and O O
alosetron B-drug B-drug
) O O
is O O
contraindicated O O
. O O

Severe O O
anemia O O
( O O
Grade O O
3-4 O O
according O O
to O O
the O O
World O O
Health O O
Organization O O
criteria O O
) O O
was O O
significantly O O
greater O O
in O O
the O O
patients O O
who O O
received O O
CHOP-HAART O O
compared O O
with O O
the O O
patients O O
who O O
received O O
CHOP O O
alone O O
( O O
33 O O
% O O
vs. O O
7 O O
% O O
, O O
respectively O O
; O O
P O O
= O O
0.001 O O
) O O
. O O

atazanavir I-drug B-drug

Magnesium B-drug B-drug
infusions O O
can O O
only O O
be O O
envisaged O O
in O O
intensive O O
care O O
units O O
with O O
careful O O
monitoring O O
of O O
pulse O O
, O O
arterial O O
pressure O O
, O O
deep O O
tendon O O
reflexes O O
, O O
hourly O O
diuresis O O
, O O
electrocardiogram O O
and O O
respiratory O O
recordings O O
. O O

As O O
MHD B-drug_n B-drug_n
, O O
the O O
predominant O O
plasma O O
substrate O O
, O O
is O O
only O O
a O O
weak O O
inducer O O
of O O
UDP-glucuronyl O O
transferase O O
, O O
it O O
is O O
unlikely O O
to O O
have O O
an O O
effect O O
on O O
drugs O O
that O O
are O O
mainly O O
eliminated O O
by O O
conjugation O O
through O O
UDP-glucuronyl O O
transferase O O
( O O
e.g. O O
, O O
valproic B-drug B-drug
acid I-drug I-drug
, O O
lamotrigine B-drug B-drug
) O O
. O O

Other O O
concomitant O O
therapy O O
Although O O
specific O O
interaction O O
studies O O
were O O
not O O
performed O O
, O O
finasteride B-drug B-drug
doses O O
of O O
1 O O
mg O O
or O O
more O O
were O O
concomitantly O O
used O O
in O O
clinical O O
studies O O
with O O
acetaminophen B-drug B-drug
, O O
acetylsalicylic B-drug B-drug
acid I-drug I-drug
, O O
a-blockers O B-group
, O O
analgesics B-group B-group
, O O
angiotensin-converting B-group B-group
enzyme I-group I-group
( I-group O
ACE I-group B-group
) I-group I-group
inhibitors I-group I-group
, O O
anticonvulsants B-group B-group
, O O
benzodiazepines B-group B-group
, O O
beta B-group B-group
blockers I-group I-group
, O O
calcium-channel B-group B-group
blockers I-group I-group
, O O
cardiac O B-group
nitrates B-group I-group
, O O
diuretics B-group B-group
, O O
H2 B-group B-group
antagonists I-group I-group
, O O
HMG-CoA B-group B-group
reductase I-group I-group
inhibitors I-group I-group
, O O
prostaglandin B-group B-group
synthetase I-group I-group
inhibitors I-group I-group
( O O
also O O
referred O O
to O O
as O O
NSAIDs B-group B-group
) O O
, O O
and O O
quinolone B-group B-group
anti-infectives I-group I-group
without O O
evidence O O
of O O
clinically O O
significant O O
adverse O O
interactions O O
. O O

however O O
, O O
it O O
is O O
not O O
known O O
if O O
other O O
phenothiazines B-group B-group
produce O O
a O O
similar O O
response O O
. O O

Inhibition O O
of O O
CYP3A4 O O
metabolic O O
reactions O O
was O O
not O O
detected O O
in O O
in O O
vitro O O
experiments O O
. O O

Patients O O
should O O
take O O
other O O
drugs O O
at O O
least O O
one O O
hour O O
before O O
or O O
four O O
hours O O
after O O
COLESTID B-brand B-brand
Tablets O O
to O O
avoid O O
impeding O O
their O O
absorption O O
. O O

Nevertheless O O
, O O
there O O
may O O
be O O
the O O
potential O O
for O O
clinically O O
important O O
alterations O O
of O O
blood O O
levels O O
of O O
coadministered O O
drugs O O
. O O

Injection O O
There O O
is O O
inadequate O O
systematic O O
experience O O
with O O
the O O
use O O
of O O
baclofen B-drug B-drug
injection O O
in O O
combination O O
with O O
other O O
medications O O
to O O
predict O O
specific O O
drug-drug O O
interactions O O
. O O

N=17 O O
) O O
were O O
not O O
different O O
and O O
neither O O
were O O
gabapentin B-drug B-drug
pharmacokinetic O O
parameters O O
affected O O
by O O
valproic B-drug B-drug
acid I-drug I-drug
. O O

Other O O
depressasnts O B-group
such O O
as O O
alcohol B-drug B-drug
, O O
barbiturates B-group B-group
, O O
and O O
MAOIs B-group B-group
may O O
enhance O O
CNS O O
depression O O
when O O
administered O O
with O O
ethchlorvynol B-drug B-drug
. O O

Ketoconazole B-drug B-drug
: O O
Concomitant O O
use O O
of O O
ketoconazole B-drug B-drug
is O O
contraindicated O O
. O O

reduced O O
serum O O
folate O O
concentration O O
; O O

One O O
animal O O
in O O
the O O
high O O
dose O O
group O O
developed O O
a O O
B-cell O O
lymphoma O O
that O O
was O O
detected O O
after O O
28 O O
weeks O O
of O O
dosing O O
. O O

Clozapine B-drug B-drug
may O O
potentiate O O
the O O
hypotensive O O
effects O O
of O O
antihypertensive B-group B-group
drugs I-group I-group
and O O
the O O
anticholinergic O O
effects O O
of O O
atropine-type B-drug B-group
drugs O I-group
. O O

Drug O O
Laboratory O O
Test O O
Interactions O O
Interactions O O
between O O
darifenacin B-drug B-drug
and O O
laboratory O O
tests O O
have O O
not O O
been O O
studied O O
. O O

Ketoconazole B-drug B-drug

Increases O O
in O O
serum O O
creatinine O O
have O O
occurred O O
when O O
CEFOTAN B-brand B-brand
was O O
given O O
alone O O
. O O

Therefore O O
, O O
when O O
chlorothiazide B-drug B-drug
and O O
non-steroidal B-group B-group
anti-inflammatory I-group I-group
agents I-group I-group
are O O
used O O
concomitantly O O
, O O
the O O
patient O O
should O O
be O O
observed O O
closely O O
to O O
determine O O
if O O
the O O
desired O O
effect O O
of O O
the O O
diuretic B-group B-group
is O O
obtained O O

Although O O
the O O
proposed O O
methodology O O
for O O
deriving O O
experimental O O
designs O O
can O O
be O O
applied O O
to O O
any O O
nonlinear O O
regression O O
model O O
, O O
primary O O
focus O O
is O O
given O O
to O O
the O O
additive O O
and O O
nonadditive O O
independent O O
joint O O
action O O
( O O
IJA O O
) O O
models O O
for O O
individual O O
and O O
combined O O
exposures O O
proposed O O
by O O
Barton O B-brand
, O O
Braunberg O O
, O O
and O O
Friedman O B-drug
( O O
1 O O
) O O
. O O

diflunisal B-drug B-drug
; O O

Potassium B-drug B-drug
Supplements O O
and O O
Potassium-Sparing B-group B-group
Diuretics I-group I-group
: O O
Fosinopril B-drug B-drug
sodium I-drug I-drug
can O O
attenuate O O
potassium O O
loss O O
caused O O
by O O
thiazide B-group B-group
diuretics I-group I-group
. O O

a O O
reduction O O
in O O
the O O
usual O O
anticoagulant B-group B-group
dosage O O
may O O
be O O
required O O
in O O
patients O O
receiving O O
both O O
drugs O O
. O O

Delayed O O
Adverse O O
Reactions O O
to O O
Iodinated B-group O
Contrast I-group O
Media I-group O
: O O
A O O
review O O
of O O
the O O
literature O O
revealed O O
that O O
12.6 O O
% O O
( O O
range O O
11-28 O O
% O O
) O O
of O O
501 O O
patients O O
treated O O
with O O
various O O
interleukin-2 B-drug B-drug
containing O O
regimens O O
who O O
were O O
subsequently O O
administered O O
radiographic B-group O
iodinated I-group B-drug
contrast I-group O
media I-group O
experienced O O
acute O O
, O O
atypical O O
adverse O O
reactions O O
. O O

Ketoconazole B-drug B-drug
: O O
When O O
a O O
single O O
125-mg O O
dose O O
of O O
Aprepitant B-drug B-drug
was O O
administered O O
on O O
Day5 O O
of O O
a O O
10-day O O
regimen O O
of O O
400 O O
mg/day O O
of O O
ketoconazole B-drug B-drug
, O O
a O O
strong O O
CYP3A4 O O
inhibitor O O
, O O
the O O
AUC O O
of O O
aprepitant B-drug B-drug
increased O O
approximately O O
5-fold O O
and O O
the O O
mean O O
terminal O O
half-life O O
of O O
aprepitant B-drug B-drug
increased O O
approximately O O
3-fold O O
. O O

At O O
a O O
low O O
cocaine B-drug B-drug
dose O O
and O O
long O O
withdrawal O O
period O O
( O O
10 O O
mg/kg O O
, O O
twice O O
a O O
day O O
for O O
5 O O
days O O
followed O O
by O O
a O O
14-day O O
withdrawal O O
) O O
, O O
the O O
LST O O
mice O O
showed O O
tolerance O O
development O O
. O O

CONCLUSION O O
: O O
These O O
findings O O
indicate O O
that O O
verapamil B-drug B-drug
inhibits O O
cancer O O
metastasis O O
through O O
actions O O
that O O
do O O
not O O
affect O O
the O O
growth O O
of O O
intestinal O O
cancers O O
. O O

It O O
is O O
recommended O O
that O O
serum O O
lithium B-drug B-drug
levels O O
be O O
monitored O O
frequently O O
if O O
PRINIVIL B-brand B-brand
is O O
administered O O
concomitantly O O
with O O
lithium B-drug B-drug
. O O

Similarly O O
, O O
the O O
effects O O
of O O
phenytoin B-drug B-drug
on O O
phenobarbital B-drug B-drug
, O O
valproic B-drug B-drug
acid I-drug I-drug
and O O
sodium O B-drug
plasma O O
valproate B-drug B-drug
concentrations O O
are O O
unpredictable O O

Potential O O
for O O
Other O O
Drugs O O
to O O
Affect O O
Duloxetine B-drug B-drug
: O O
Both O O
CYP1A2 O O
and O O
CYP2D6 O O
are O O
responsible O O
for O O
duloxetine B-drug B-drug
metabolism O O
. O O

This O O
medication O O
should O O
not O O
be O O
taken O O
with O O
MAO B-group B-group
inhibitors I-group I-group
. O O

Substances O O
that O O
are O O
inducers O O
of O O
CYP3A4 O O
activity O O
increase O O
the O O
metabolism O O
of O O
gefitinib B-drug B-drug
and O O
decrease O O
its O O
plasma O O
concentrations O O
. O O

In O O
addition O O
, O O
patients O O
taking O O
drugs O O
that O O
inhibit O O
the O O
cytochrome O O
P450 O O
3A4 O O
isozyme O O
, O O
which O O
metabolizes O O
sildenafil B-drug B-drug
, O O
may O O
experience O O
increased O O
drug O O
concentrations O O
and O O
possible O O
toxicity O O
from O O
normal O O
doses O O
of O O
sildenafil B-drug B-drug
. O O

Alpha-blockers B-group B-group
: O O
When O O
Vardenafil B-drug B-drug
10 O O
or O O
20 O O
mg O O
was O O
given O O
to O O
healthy O O
volunteers O O
either O O
simultaneously O O
or O O
6 O O
hours O O
after O O
a O O
10 O O
mg O O
dose O O
of O O
terazosin B-drug B-drug
, O O
significant O O
hypotension O O
developed O O
in O O
a O O
substantial O O
number O O
of O O
subjects O O
. O O

Drug O O
Interactions O O
: O O
Flupenthixol B-drug B-drug
may O O
interact O O
with O O
some O O
drugs O O
, O O
like O O
Monoamine B-group B-group
oxidase I-group I-group
inhibitors I-group I-group
( O O
MAOI B-group B-group
) O O
: O O
MAOI B-group B-group
could O O
theoretically O O
affect O O
flupenthixol B-drug B-drug
pharmacodynamics O O
- O O
Arecoline B-drug_n B-brand
- O O
Eproxindine O B-drug
- O O
Ethanol B-drug B-drug
: O O
Flupenthixol B-drug B-drug
and O O
Ethanol B-drug B-drug
cause O O
additive O O
CNS O O
depression O O
- O O
Tricyclic B-group B-group
antidepressants I-group I-group
: O O
Flupenthixol B-drug B-drug
increases O O
the O O
effect O O
of O O
Tricyclic B-group B-group
antidepressants I-group I-group

Hepatic O O
Enzyme O O
Inducers O O
, O O
Inhibitors O O
and O O
Substrates O O
: O O
Drugs O O
which O O
induce O O
cytochrome O O
P450 O O
3A4 O O
( O O
CYP O O
3A4 O O
) O O
enzyme O O
activity O O
( O O
e.g. O O
, O O
barbiturates B-group B-group
, O O
phenytoin B-drug B-drug
, O O
carbamazepine B-drug B-drug
, O O
rifampin B-drug B-drug
) O O
may O O
enhance O O
the O O
metabolism O O
of O O
corticosteroids B-group B-group
and O O
require O O
that O O
the O O
dosage O O
of O O
the O O
corticosteroid B-group B-group
be O O
increased O O
. O O

In O O
addition O O
, O O
the O O
transfusion O O
practices O O
for O O
such O O
patients O O
may O O
need O O
to O O
be O O
modified O O
given O O
the O O
increased O O
risk O O
of O O
bleeding O O
. O O

600-1800 O O

See O O

If O O
this O O
is O O
not O O
possible O O
, O O
the O O
starting O O
dose O O
should O O
be O O
reduced O O
. O O

Until O O
data O O
on O O
possible O O
interactions O O
between O O
verapamil B-drug B-drug
and O O
disopyramide B-drug B-drug
phosphate I-drug I-drug
are O O
obtained O O
, O O
disopyramide B-drug B-drug
should O O
not O O
be O O
administered O O
within O O
48 O O
hours O O
before O O
or O O
24 O O
hours O O
after O O
verapamil B-drug B-drug
administration O O
. O O

Interaction O O
on O O
the O O
antinociceptive O O
effect O O
between O O
neurotensin B-drug_n B-drug
and O O
enkephalins B-drug_n B-group
or O O
tuftsin B-drug_n B-drug_n
. O O

It O O
is O O
recommended O O
that O O
these O O
tests O O
be O O
performed O O
weekly O O
or O O
every O O
other O O
week O O
until O O
the O O
lipid O O
response O O
to O O
Soriatane B-brand B-brand
has O O
stabilized O O
. O O

Decreased O O
core O O
temperature O O
in O O
female O O
rats O O
was O O
investigated O O
as O O
one O O
possible O O
index O O
of O O
the O O
disulfiram-ethanol B-drug B-drug
reaction O O
( O O
DER O O
) O O
. O O

There O O
were O O
transient O O
increases O O
in O O
liver O O
ALT O O
and O O
AST O O
when O O
CANCIDAS B-brand B-brand
and O O
cyclosporine B-drug B-drug
were O O
co-administered O O
. O O

Analyses O O
of O O
this O O
sequence O O
, O O
however O O
, O O
usually O O
give O O
little O O
consideration O O
to O O
the O O
nature O O
of O O
the O O
target O O
cell O O
or O O
to O O
the O O
characteristics O O
of O O
the O O
resultant O O
tumors O O
. O O

To O O
evaluate O O
the O O
impact O O
of O O
chemotherapy O O
plus O O
HAART O O
on O O
the O O
clinical O O
course O O
of O O
patients O O
with O O
HIV-related O O
, O O
systemic O O
, O O
non-Hodgkin O O
lymphoma O O
( O O
HIV-NHL O O
) O O
, O O
the O O
authors O O
compared O O
retrospectively O O
a O O
group O O
of O O
24 O O
patients O O
with O O
HIV-NHL O B-drug
who O O
were O O
treated O O
with O O
the O O
cyclophosphamide B-drug B-drug
, O O
doxorubicin B-drug B-drug
, O O
vincristine B-drug B-drug
, O O
and O O
prednisone B-drug B-drug
( O O
CHOP O O
) O O
chemotherapy O O
regimen O O
plus O O
HAART O O
with O O
a O O
group O O
of O O
80 O O
patients O O
who O O
were O O
treated O O
with O O
CHOP O O
chemotherapy O O
or O O
a O O
CHOP-like O O
regimen O O
( O O
i.e. O O
, O O
cyclophosphamide B-drug B-drug
, O O
doxorubicin B-drug B-drug
, O O
teniposide B-drug B-drug
, O O
and O O
prednisone B-drug B-drug
with O O
vincristine B-drug B-drug
plus O O
bleomycin B-drug B-drug
) O O
without O O
receiving O O
antiretroviral B-group B-group
therapy O O
. O O

indinavir I-drug B-drug
concentration O O

DRUG O O
INTERACTIONS O O

Changes O O
in O O
omeprazole B-drug B-drug
pharmacokinetics O O
were O O
not O O
studied O O
. O O

In O O
general O O
, O O
these O O
are O O
drugs O O
that O O
have O O
one O O
or O O
more O O
pharmacologic O O
activities O O
similar O O
to O O
bepridil B-drug B-drug
hydrochloride I-drug I-drug
, O O
including O O
anti-arrhythmic B-group B-group
agents I-group I-group
such O O
as O O
quinidine B-drug B-drug
and O O
procainamide B-drug B-drug
, O O
cardiac B-group B-group
glycosides I-group I-group
and O O
tricyclic B-group B-group
anti-depressants I-group I-group
. O O

Ranitidine B-drug B-drug
produced O O
smaller O O
, O O
nonsignificant O O
increases O O
. O O

Anesthetics/Sedatives/Hypnotics/Opioids B-group B-group
: O O
Co-administration O O
of O O
PRECEDEX B-brand B-brand
with O O
anesthetics B-group B-group
, O O
sedatives B-group B-group
, O O
hypnotics B-group B-group
, O O
and O O
opioids B-group B-group
is O O
likely O O
to O O
lead O O
to O O
an O O
enhancement O O
of O O
effects O O
. O O

Drug-Drug O O
Interactions O O
Given O O
the O O
primary O O
CNS O O
effects O O
of O O
aripiprazole B-drug B-drug
, O O
caution O O
should O O
be O O
used O O
when O O
ABILIFY B-brand B-brand
is O O
taken O O
in O O
combination O O
with O O
other O O
centrally B-group O
acting I-group O
drugs I-group O
and O O
alcohol B-drug B-drug
. O O

Rhabdomyolysis O O
secondary O O
to O O
a O O
drug O O
interaction O O
between O O
simvastatin B-drug B-drug
and O O
clarithromycin B-drug B-drug
. O O

Phenytoin B-drug B-drug
: O O
If O O
acitretin B-drug B-drug
is O O
given O O
concurrently O O
with O O
phenytoin B-drug B-drug
, O O
the O O
protein O O
binding O O
of O O
phenytoin B-drug B-drug
may O O
be O O
reduced O O
. O O

A O O
patient O O
had O O
phenytoin O B-drug
intoxication O O
after O O
administration O O
of O O
fluvoxamine B-drug B-drug
, O O
a O O
selective O B-group
serotonin O I-group
reuptake O I-group
inhibitor O I-group
. O O

There O O
were O O
no O O
differences O O
between O O
cecectomized O O
and O O
control O O
rats O O
in O O
basal O O
small O O
intestinal O O
transits O O
or O O
in O O
dmPGE2 B-drug_n B-drug_n
( O O
0.3 O O
mg/kg O O
, O O
p.o O O
. O O
) O O
-induced O O
enhancements O O
. O O

MAO B-group B-group
inhibitors I-group I-group
prolong O O
and O O
intensify O O
the O O
anticholinergic O O
effects O O
of O O
antihistamines B-group B-group
. O O

Agents O O
Affecting O O
Sympathetic O O
Activity O O
The O O
sympathetic O O
nervous O O
system O O
may O O
be O O
especially O O
important O O
in O O
supporting O O
blood O O
pressure O O
in O O
patients O O
receiving O O
captopril B-drug B-drug
alone O O
or O O
with O O
diuretics B-group B-group
. O O

Concurrent O O
use O O
of O O
flurbiprofen B-drug B-drug
and O O
aspirin B-brand B-brand
is O O
therefore O O
not O O
recommended O O
. O O

Coadministration O O
of O O
VIRACEPT B-brand B-brand
and O O
drugs O O
primarily O O
metabolized O O
by O O
CYP3A O O
( O O
e.g. O O
, O O
dihydropyridine B-group B-group
calcium I-group I-group
channel I-group I-group
blockers I-group I-group
) O O
may O O
result O O
in O O
increased O O
plasma O O
concentrations O O
of O O
the O O
other O O
drug O O
that O O
could O O
increase O O
or O O
prolong O O
both O O
its O O
therapeutic O O
and O O
adverse O O
effects O O
. O O

( O O
Note O O
: O O
All O O
patients O O
receiving O O
theophylline B-drug B-drug
should O O
be O O
monitored O O
appropriately O O
, O O
regardless O O
of O O
concomitant O O
drug O O
therapy O O
. O O
) O O

valproate B-drug B-drug
and O O
gabapentin B-drug B-drug
are O O
not O O
. O O

Therefore O O
, O O
when O O
meclofenamate B-drug B-drug
sodium I-drug I-drug
is O O
given O O
to O O
a O O
patient O O
receiving O O
warfarin B-drug B-drug
, O O
the O O
dosage O O
of O O
warfarin B-drug B-drug
should O O
be O O
reduced O O
to O O
prevent O O
excessive O O
prolongation O O
of O O
the O O
prothrombin O O
time O O
. O O

Lithium B-drug B-drug
: O O
NSAIDs B-group B-group
have O O
produced O O
an O O
elevation O O
of O O
plasma O O
lithium B-drug B-drug
levels O O
and O O
a O O
reduction O O
in O O
renal O O
lithium B-drug B-drug
clearance O O
. O O

65 O O
years O O
of O O
age O O
and O O
13 O O
patients O O
were O O

The O O
minimal O O
inhibitory O O
concentrations O O
of O O
clindamycin B-drug B-drug
and O O
gentamicin B-drug B-drug
alone O O
and O O
in O O
combinations O O
were O O
determined O O
by O O
a O O
microdilution O O
method O O
for O O
163 O O
aerobic O O
, O O
facultative O O
, O O
and O O
anaerobic O O
clinical O O
isolates O O
. O O

As O O
with O O
other O O
dialysis B-group O
solutions I-group O
, O O
blood O O
concentrations O O
of O O
dialyzable O O
drugs O O
may O O
be O O
reduced O O
by O O
dialysis O O
. O O

therefore O O
concomitant O O
administration O O
of O O
Itraconazole B-drug B-drug
with O O
cisapride B-drug B-drug
is O O
contraindicated O O
. O O

Particular O O
caution O O
is O O
recommended O O
when O O
administering O O
Gleevec B-brand B-brand
with O O
CYP3A4 O O
substrates O O
that O O
have O O
a O O
narrow O O
therapeutic O O
window O O
( O O
e.g. O O
, O O
cyclosporine B-drug B-drug
or O O
pimozide B-drug B-drug
) O O
. O O

Potassium O B-group
sparing O I-group
agents O I-group
should O O
generally O O
not O O
be O O
used O O
in O O
patients O O
with O O
heart O O
failure O O
receiving O O
enalapril B-drug B-drug
. O O

clinically O O
significant O O
interactions O O
with O O
other O O
drugs O O
through O O
competition O O
for O O
protein O O
binding O O
sites O O
are O O
therefore O O
unlikely O O
. O O

This O O
was O O
expected O O
because O O
zaleplon B-drug B-drug
is O O
primarily O O
metabolized O O
and O O
renal O O
excretion O O
of O O
unchanged O O
zaleplon B-drug B-drug
accounts O O
for O O
less O O
than O O
1 O O
% O O
of O O
the O O
administered O O
dose O O
. O O

A O O
muscle O O
biopsy O O
revealed O O
necrotizing O O
myopathy O O
secondary O O
to O O
a O O
toxin O O
. O O

Cyclosporine B-drug B-drug
: O O
Elevated O O
serum O O
levels O O
of O O
cyclosporine B-drug B-drug
have O O
been O O
reported O O
with O O
concomitant O O
use O O
of O O
cyclosporine B-drug B-drug
with O O
other O O
members O O
of O O
the O O
quinolone B-group B-group
class I-group I-group
. O O

The O O
gastrointestinal O O
absorption O O
of O O
cimetidine B-drug B-drug
and O O
ranitidine B-drug B-drug
is O O
accelerated O O
when O O
they O O
are O O
coadministered O O
with O O
cisapride B-drug B-drug
. O O

Amprenavir B-drug B-drug
significantly O O
decreases O O
clearance O O
of O O
rifabutin B-drug B-drug
and O O
25-O-desacetylrifabutin B-drug_n B-drug_n
, O O
and O O
the O O
combination O O
is O O
poorly O O
tolerated O O
. O O

ACE-inhibitors B-group B-group
: O O
Reports O O
suggest O O
that O O
NSAIDs B-group B-group
may O O
diminish O O
the O O
antihypertensive O O
effect O O
of O O
ACE-inhibitors B-group B-group
. O O

Therefore O O
, O O
CYP3A4 O O
substrates O O
known O O
to O O
have O O
a O O
narrow O O
therapeutic O O
index O O
such O O
as O O
alfentanil B-drug B-drug
, O O
astemizole B-drug B-drug
, O O
terfenadine B-drug B-drug
, O O
cisapride B-drug B-drug
, O O
cyclosporine B-drug B-drug
, O O
fentanyl B-drug B-drug
, O O
pimozide B-drug B-drug
, O O
quinidine B-drug B-drug
, O O
sirolimus B-drug B-drug
, O O
tacrolimus B-drug B-drug
, O O
or O O
ergot B-group B-group
alkaloids I-group I-group
( O O
ergotamine B-drug B-drug
, O O
dihydroergotamine B-drug B-drug
) O O
should O O
be O O
administered O O
with O O
caution O O
in O O
patients O O
receiving O O
SPRYCEL B-brand B-brand
. O O

Thus O O
, O O
when O O
VIOXX B-brand B-brand
and O O
lithium B-drug B-drug
are O O
administered O O
concurrently O O
, O O
subjects O O
should O O
be O O
observed O O
carefully O O
for O O
signs O O
of O O
lithium B-drug B-drug
toxicity O O
. O O

aminosalicylic B-drug B-drug
acid I-drug I-drug
; O O

Drug/Laboratory O O
Test O O
Interactions O O
Positive O O
direct O O
Coombs O O
tests O O
have O O
been O O
reported O O
during O O
treatment O O
with O O
the O O
cephalosporin B-group B-group
antibiotics I-group I-group
. O O

Cimetidine B-drug B-drug
: O O
In O O
a O O
study O O
in O O
healthy O O
volunteers O O
, O O
a O O
one-week O O
course O O
of O O
cimetidine B-drug B-drug
at O O
400 O O
mg O O
b.i.d O O
. O O
with O O
a O O
single O O
5 O O
mg O O
dose O O
of O O
isradipine B-drug B-drug
on O O
the O O
sixth O O
day O O
showed O O
an O O
increase O O
in O O
isradipine B-drug B-drug
mean O O
peak O O
plasma O O
concentrations O O
( O O
36 O O
% O O
) O O
and O O
significant O O
increase O O
in O O
area O O
under O O
the O O
curve O O
( O O
50 O O
% O O
) O O
. O O

Synergism O O
has O O
been O O
shown O O
between O O
halothane B-drug B-drug
anesthesia O O
and O O
intravenously O O
administered O O
labetalol B-drug B-drug
HCl I-drug I-drug
. O O

Methotrexate B-drug B-drug
: O O
In O O
an O O
interaction O O
study O O
of O O
rheumatoid O O
arthritis O O
patients O O
taking O O
methotrexate B-drug B-drug
, O O
CELEBREX B-brand B-brand
did O O
not O O
have O O
a O O
significant O O
effect O O
on O O
the O O
pharmacokinetics O O
of O O
methotrexate B-drug B-drug
. O O

Even O O
though O O
such O O
interactions O O
have O O
not O O
been O O
seen O O
in O O
clinical O O
studies O O
with O O
DynaCirc B-brand B-brand
( O O
isradipine B-drug B-drug
) O O
, O O
an O O
increased O O
volume O O
of O O
circulating O O
fluids O O
might O O
be O O
required O O
if O O
such O O
an O O
interaction O O
were O O
to O O
occur O O
. O O

Methadone B-drug B-drug
levels O O
may O O
be O O
decreased O O
; O O
increased O O
dosages O O
may O O
be O O
required O O
to O O
prevent O O
symptoms O O
of O O
opiate B-group B-group
withdrawal O O
. O O
Methadone B-drug B-drug
maintained O O
patients O O
beginning O O
nevirapine B-drug B-drug
therapy O O
should O O
be O O
monitored O O
forevidence O O
of O O
withdrawal O O
and O O
methadone B-drug B-drug
dose O O
should O O
be O O
adjusted O O
accordingly O O
. O O

Diazoxide I-drug B-drug
Hypotension O O

However O O
, O O
prudent O O
medical O O
practice O O
dictates O O
careful O O
monitoring O O
of O O
prothrombin O O
time O O
in O O
all O O
patients O O
treated O O
with O O
azithromycin B-drug B-drug
and O O
warfarin B-drug B-drug
concomitantly O O
. O O

The O O
preceding O O
lists O O
of O O
drugs O O
are O O
not O O
comprehensive O O
. O O

In O O
an O O
in O O
vitro O O
study O O
in O O
human O O
liver O O
microsomes O O
, O O
inhibition O O
of O O
CYP2A6 O O
hydroxylation O O
of O O
coumarin B-group B-drug_n
by O O
fondaparinux B-drug B-drug
( O O
200 O O
m O O
m O O
M O O
i.e. O O
, O O
350 O O
mg/L O O
) O O
was O O
17-28 O O
% O O
. O O

Chlorpromazine B-drug B-drug
: O O
Chlorpromazine B-drug B-drug
blocks O O
dopamine O B-drug
and O O
norepinephrine O B-drug
reuptake O O
, O O
thus O O
inhibiting O O
the O O
central O O
stimulant O O
effects O O
of O O
amphetamines B-group B-group
, O O
and O O
can O O
be O O
used O O
to O O
treat O O
amphetamine B-group B-drug
poisoning O O
. O O

In O O
this O O
study O O
, O O
the O O
effects O O
of O O
etofibrate B-drug B-drug
upon O O
chylomicron O B-drug
metabolism O O
was O O
tested O O
by O O
determination O O
of O O
the O O
plasma O O
kinetics O O
of O O
a O O
chylomicron-like O O
emulsion O O
model O O
in O O
12 O O
patients O O
with O O
coronary O O
artery O O
disease O O
, O O
aged O O
59+/-11 O O
years O O
, O O
( O O
total O O
cholesterol O O
: O O
240+/-41 O O
mg/dl O O
; O O
triglycerides O O
: O O
188+/-42 O O
mg/dl O O
) O O
submitted O O
to O O
a O O
randomized O O
, O O
crossover O O
, O O
double-blind O O
, O O
placebo-controlled O O
study O O
with O O
administration O O
of O O
1 O O
g O O
per O O
day O O
etofibrate B-drug B-drug
or O O
placebo O O
for O O
1-month O O
. O O

When O O
indinavir B-drug B-drug
at O O
an O O
increased O O
dose O O
( O O
1000 O O
mg O O
every O O
8 O O
hours O O
) O O
was O O
given O O
with O O
SUSTIVA B-brand B-brand
( O O
600 O O
mg O O
once O O
daily O O
) O O
, O O
the O O
indinavir B-drug B-drug
AUC O O
and O O
Cmin O O
were O O
decreased O O
on O O
average O O
by O O
33-46 O O
% O O
and O O
39-57 O O
% O O
, O O
respectively O O
, O O
compared O O
to O O
when O O
indinavir B-drug B-drug
( O O
800 O O
mg O O
every O O
8 O O
hours O O
) O O
was O O
given O O
alone O O
. O O

Onset O O
of O O
action O O
of O O
tricyclics B-group B-group
may O O
be O O
accelerated O O
. O O

Fatal O O
cardiac O O
arrests O O
have O O
occurred O O
in O O
patients O O
receiving O O
both O O
drugs O O
. O O

Drug-Laboratory O O
Test O O
Interactions O O
: O O
There O O
are O O
no O O
reported O O
drug-laboratory O O
test O O
interactions O O
. O O

HEMABATE B-brand B-brand
may O O
augment O O
the O O
activity O O
of O O
other O O
oxytocic B-group B-group
agents I-group I-group
. O O

Dexrazoxane B-drug B-drug
was O O
not O O
mutagenic O O
in O O
the O O
Ames O O
test O O
but O O
was O O
found O O
to O O
be O O
clastogenic O O
to O O
human O O
lymphocytes O O
in O O
vitro O O
and O O
to O O
mouse O O
bone O O
marrow O O
erythrocytes O O
in O O
vivo O O
( O O
micronucleus O O
test O O
) O O
. O O

Special O O
attention O O
should O O
be O O
given O O
to O O
electrolyte O O
and O O
acid-base O O
balance O O
in O O
patients O O
experiencing O O
severe O O
or O O
prolonged O O
diarrhea O O
or O O
in O O
patients O O
receiving O O
concomitant O O
diuretics B-drug B-group
. O O

Many O O
other O O
medicines O O
may O O
increase O O
or O O
decrease O O
the O O
effects O O
of O O
glimepiride B-drug B-drug
or O O
affect O O
your O O
condition O O
. O O

- O O
Drugs O O
that O O
may O O
either O O
increase O O
or O O
decrease O O
plasma O O
phenytoin B-drug B-drug
concentrations O O
include O O
: O O
phenobarbital B-drug B-drug
, O O
vaiproic O B-drug
acid O I-drug
, O O
and O O
sodium B-drug B-drug
valproate I-drug I-drug
. O O

We O O
reviewed O O
the O O
clinical O O
data O O
relating O O
to O O
the O O
efficacy O O
and O O
safety O O
of O O
pharmacologic O O
doses O O
of O O
ascorbic B-drug B-drug
acid I-drug I-drug
in O O
the O O
prevention O O
and O O
treatment O O
of O O
the O O
common O O
cold O O
. O O

Concomitant O O
administration O O
of O O
naproxen B-drug B-drug
and O O
aspirin B-brand B-brand
is O O
not O O
recommended O O
because O O
naproxen B-drug B-drug
is O O
displaced O O
from O O
its O O
binding O O
sites O O
during O O
the O O
concomitant O O
administration O O
of O O
aspirin B-brand B-brand
, O O
resulting O O
in O O
lower O O
plasma O O
concentrations O O
and O O
peak O O
plasma O O
levels O O
. O O

Although O O
it O O
has O O
not O O
been O O
established O O
that O O
there O O
is O O
an O O
interaction O O
between O O
Clozapine B-drug B-drug
and O O
benzodiazepines B-group B-group
or O O
other O O
psychotropics B-group B-group
, O O
caution O O
is O O
advised O O
when O O
clozapine B-drug B-drug
is O O
initiated O O
in O O
patients O O
taking O O
a O O
benzodiazepine B-group B-group
or O O
any O O
other O O
psychotropic B-group B-group
drug I-group I-group
. O O

In O O
addition O O
, O O
certain O O
drugs O O
inhibit O O
the O O
activity O O
of O O
this O O
isozyme O O
and O O
make O O
normal O O
metabolizers O O
resemble O O
poor O O
metabolizers O O
. O O

Aprepitant B-drug B-drug
is O O
a O O
substrate O O
for O O
CYP3A4 O O
; O O

This O O
interaction O O
should O O
be O O
given O O
consideration O O
in O O
patients O O
taking O O
NSAIDs B-group B-group
concomitantly O O
with O O
ACE-inhibitors B-group B-group
. O O

No O O
formal O O
assessments O O
of O O
pharmacokinetic O O
drug-drug O O
interactions O O
between O O
TRISENOX B-brand B-brand
and O O
other O O
agents O O
have O O
been O O
conducted O O
. O O

Studies O O
on O O
two O O
strains O O
of O O
pointer O O
dogs O O
have O O
demonstrated O O
that O O
administration O O
of O O
a O O
benzodiazepine B-group B-group
( O O
chlordiazepoxide B-drug B-drug
) O O
facilitates O O
acquisition O O
of O O
goal-directed O O
behavior O O
in O O
" O O
genetically O O
nervous O O
" O O

+24 O O
% O O
+14 O O
% O O
+43 O O
% O O
+40 O O
% O O

Non-steroidal B-group B-group
anti-inflammatory I-group I-group
agents I-group I-group
: O O
Seizures O O
have O O
been O O
reported O O
in O O
patients O O
taking O O
enoxacin B-drug B-drug
concomitantly O O
with O O
the O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
drug I-group I-group
fenbufen B-drug B-drug
. O O

In O O
humans O O
, O O
two O O
inhibitors O O
of O O
P450 O O
3A4 O O
have O O
been O O
studied O O
. O O

However O O
, O O
it O O
may O O
be O O
important O O
also O O
in O O
case O O
of O O
medical O O
examinations O O
for O O
insurances O O
and O O
job O O
appointments O O
, O O
since O O
some O O
patients O O
may O O
turn O O
out O O
to O O
need O O
expensive O O
drugs O O
or O O
to O O
be O O
susceptible O O
to O O
a O O
certain O O
disease O O
. O O

Tricyclic B-group B-group
antidepressants I-group I-group
may O O
antagonize O O
the O O
hypotensive O O
effects O O
of O O
clonidine B-drug B-drug
. O O

Flurbiprofen B-drug B-drug
did O O
not O O
affect O O
the O O
pharmacokinetic O O
profile O O
of O O
either O O
drug O O
, O O
and O O
the O O
mechanism O O
under O O
lying O O
the O O
interference O O
with O O
propranolols B-drug B-drug
hypotensive O O
effect O O
is O O
unknown O O
. O O

MEASUREMENTS O O
AND O O
MAIN O O
RESULTS O O
: O O
In O O
December O O
1998 O O
, O O
the O O
following O O
was O O
gathered O O
for O O
every O O
MAC O O
with O O
more O O
than O O
one O O
drug O O
treatment O O
: O O
age O O
, O O
sex O O
, O O
number O O
of O O
drugs O O
, O O
intrinsic O O
value O O
, O O
drugs O O
prescribed O O
, O O
daily O O
dose O O
and O O
pharmacological O O
interactions O O
( O O
PI O O
) O O
, O O
classified O O
( O O
using O O
the O O
scale O O
of O O
Hansten O B-brand
1996 O O
) O O
into O O
light O O
and O O
clinically O O
relevant O O
. O O

Drugs O O
Metabolized O O
by O O
P450IID6 O O
A O O
subset O O
( O O
3 O O
% O O
to O O
10 O O
% O O
) O O
of O O
the O O
population O O
has O O
reduced O O
activity O O
of O O
certain O O
drug O O
metabolizing O O
enzymes O O
such O O
as O O
the O O
cytochrome O O
P450 O O
isoenzyme O O
P450IID6 O O
. O O

( O O
Concurrent O O
use O O
with O O
thiazide B-group B-group
diuretics I-group I-group
may O O
enhance O O
the O O
possibility O O
of O O
digitalis B-group B-group
toxicity O O
associated O O
with O O
hypokalemia O O
. O O
) O O

14 O O
% O O
increase O O
[ O O
CI O O
: O O
2 O O
% O O
increase O O
, O O
24 O O
% O O
increase O O
] O O
25 O O
% O O
decrease O O
[ O O
CI O O
: O O
12 O O
% O O
decrease O O
, O O
51 O O
% O O
decrease O O
] O O

Thus O O
, O O
results O O
of O O
the O O
DST O O
should O O
be O O
interpreted O O
with O O
caution O O
in O O
these O O
patients O O
. O O

Furosemide B-drug B-drug
: O O
Clinical O O
studies O O
, O O
as O O
well O O
as O O
post-marketing O O
observations O O
, O O
have O O
shown O O
that O O
NSAIDs B-group B-group
can O O
reduce O O
the O O
natriuretic O O
effect O O
of O O
furosemide B-drug B-drug
and O O
thiazides B-group B-group
in O O
some O O
patients O O
. O O

Folic B-drug B-drug
acid I-drug I-drug
in O O
large O O
amounts O O
may O O
counteract O O
the O O
antiepileptic O O
effect O O
of O O
phenobarbital B-drug B-drug
, O O
phenytoin B-drug B-drug
and O O
primidone B-drug B-drug
, O O
and O O
increase O O
the O O
frequency O O
of O O
seizures O O
in O O
susceptible O O
pediatric O O
patients O O
. O O

It O O
is O O
important O O
that O O
health O O
care O O
professionals O O
be O O
aware O O
of O O
the O O
potential O O
for O O
medications O O
to O O
interfere O O
with O O
clinical O O
laboratory O O
tests O O
. O O

Antidiabetic B-group B-group
Agents I-group I-group
( O O
Insulin B-drug B-drug
, O O
Sulfonylureas B-group B-group
) O O
: O O
Requirements O O
for O O
insulin B-drug B-drug
or O O
oral O O
antidiabetic B-group B-group
agents I-group I-group
may O O
be O O
reduced O O
in O O
hypothyroid O O
patients O O
with O O
diabetes O O
mellitus O O
and O O
may O O
subsequently O O
increase O O
with O O
the O O
initiation O O
of O O
thyroid O B-group
hormone O I-group
replacement O O
therapy O O
. O O

Antihypertensives B-drug B-group
: O O
Amiodarone B-drug B-drug
should O O
be O O
used O O
with O O
caution O O
in O O
patients O O
receiving O O
-receptor B-drug B-group
blocking O I-group
agents O I-group
( O O
e.g. O O
, O O
propranolol B-drug B-drug
, O O
a O O
CYP3A4 B-drug O
inhibitor O O
) O O
or O O
calcium B-drug B-group
channel I-drug I-group
antagonists O I-group
( O O
e.g. O O
, O O
verapamil B-drug B-drug
, O O
a O O
CYP3A4 B-drug O
substrate O O
, O O
and O O
diltiazem B-drug B-drug
, O O
a O O
CYP3A4 B-drug O
inhibitor O O
) O O
because O O
of O O
the O O
possible O O
potentiation O O
of O O
bradycardia O O
, O O
sinus O O
arrest O O
, O O
and O O
AV O O
block O O
; O O

Carcinogenesis O O
, O O
Mutagenesis O O
, O O
Impairment O O
of O O
Fertility O O
No O O
long-term O O
carcinogenicity O O
studies O O
have O O
been O O
carried O O
out O O
with O O
dexrazoxane B-drug B-drug
in O O
animals O O
. O O

No O O
formal O O
drug O O
interaction O O
studies O O
have O O
been O O
conducted O O
with O O
Rebif B-brand B-brand
. O O

Recurrence O O
of O O
skin O O
reactions O O
at O O
a O O
site O O
of O O
previous O O
extravasation O O
following O O
administration O O
of O O
TAXOL B-brand B-brand
at O O
a O O
different O O
site O O
, O O
ie O O
, O O
recall O O
, O O
has O O
been O O
reported O O
rarely O O
. O O

Pharmacokinetic O O
studies O O
document O O
no O O
clinically O O
relevant O O
interactions O O
with O O
other O O
agents O O
given O O
concomitantly O O
, O O
including O O
thiazide B-group B-group
diuretics I-group I-group
, O O
digoxin B-drug B-drug
, O O
and O O
cimetidine B-drug B-drug
. O O

When O O
therapeutic O O
concentrations O O
of O O
furosemide B-drug B-drug
, O O
propranolol B-drug B-drug
, O O
dipyridamole B-drug B-drug
, O O
warfarin B-drug B-drug
, O O
quinidine B-drug B-drug
, O O
or O O
naproxen B-drug B-drug
were O O
added O O
to O O
human O O
plasma O O
( O O
in O O
vitro O O
) O O
, O O
the O O
plasma O O
protein O O
binding O O
of O O
nicardipine B-drug B-drug
HCl I-drug I-drug
was O O
not O O
altered O O
. O O

Drugs O O
which O O
inhibit O O
CYP O O
3A4 O O
( O O
e.g. O O
, O O
ketoconazole B-drug B-drug
, O O
macrolide B-group B-group
antibiotics I-group I-group
such O O
as O O
erythromycin B-drug B-drug
) O O
have O O
the O O
potential O O
to O O
result O O
in O O
increased O O
plasma O O
concentrations O O
of O O
corticosteroids B-group B-group
. O O

No O O
dosage O O
adjustment O O
is O O
required O O
for O O
Fluvoxamine B-drug B-drug
Tablets O O
. O O

Antimycobacterial B-group B-group
Agents I-group I-group
: O O
rifampin B-drug B-drug
CONTRAINDICATED O O
since O O
the O O
coadministration O O
of O O
this O O
product O O
with O O
saquinavir B-drug B-drug
in O O
an O O
antiretroviral B-group B-group
regimen O O
reduces O O
the O O
plasma O O
concentrations O O
of O O
saquinavir B-drug B-drug
. O O

Ethyl B-drug B-drug
alcohol I-drug I-drug
is O O
known O O
to O O
effect O O
the O O
functional O O
integrity O O
of O O
the O O
limbic O O
system O O
, O O
particularly O O
the O O
hippocampus O O
, O O
and O O
to O O
alter O O
behaviors O O
which O O
are O O
thought O O
to O O
be O O
mediated O O
through O O
limbic O O
function O O
. O O

Prothrombin O O
times O O
were O O
not O O
affected O O
by O O
tiagabine B-drug B-drug
. O O

The O O
specific O O
pharmacokinetic O O
changes O O
that O O
occur O O
with O O
co-administration O O
of O O
nevirapine B-drug B-drug
and O O
other O O
drugs O O
are O O
listed O O
in O O
CLINICAL O O
PHARMACOLOGY O O
, O O
Table O O
1 O O
. O O

No O O
formal O O
drug O O
interaction O O
studies O O
have O O
been O O
performed O O
with O O
RAPTIVA B-brand B-brand
. O O

The O O
disposition O O
of O O
theophylline B-drug B-drug
was O O
not O O
altered O O
by O O
concomitant O O
cetirizine B-drug B-drug
administration O O
. O O

. O O

Toxicodynamic O O
interference O O
between O O
solvents O B-group
can O O
give O O
rise O O
to O O
additive O O
, O O
potentiation O O
, O O
synergistic O O
, O O
antagonistic O O
effects O O
. O O

Similarly O O
, O O
nateglinide B-drug B-drug
had O O
no O O
influence O O
on O O
the O O
serum O O
protein O O
binding O O
of O O
propranolol B-drug B-drug
, O O
glyburide B-drug B-drug
, O O
nicardipine B-drug B-drug
, O O
warfarin B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
acetylsalicylic B-drug B-drug
acid I-drug I-drug
, O O
and O O
tolbutamide B-drug B-drug
in O O
vitro O O
. O O

Dantrium B-brand B-drug
is O O
metabolized O O
by O O
the O O
liver O O
, O O
and O O
it O O
is O O
theoretically O O
possible O O
that O O
its O O
metabolism O O
may O O
be O O
enhanced O O
by O O
drugs O O
known O O
to O O
induce O O
hepatic O O
microsomal O O
enzymes O O
. O O

Oral O O
neomycin B-drug B-drug
inhibits O O
the O O
gastrointestinal O O
absorption O O
of O O
penicillin B-drug B-drug
V I-drug I-drug
, O O
oral O O
vitamin B-drug B-group
B-12 I-drug I-group
, O O
methotrexate B-drug B-drug
and O O
5-fluorouracil B-drug B-drug
. O O

If O O
concomitant O O
treatment O O
with O O
sumatriptan B-drug B-drug
and O O
an O O
SSRI B-group B-group
( O O
e.g. O O
, O O
fluoxetine B-drug B-drug
, O O
fluvoxamine B-drug B-drug
, O O
paroxetine B-drug B-drug
, O O
sertraline B-drug B-drug
, O O
citalopram B-drug B-drug
, O O
escitalopram B-drug B-drug
) O O
is O O
clinically O O
warranted O O
, O O
appropriate O O
observation O O
of O O
the O O
patient O O
is O O
advised O O
. O O

however O O
, O O
the O O
second O O
contraction O O
was O O
potentiated O O
. O O

Nevertheless O O
, O O
caution O O
is O O
indicated O O
in O O
the O O
co-administration O O
of O O
TCA5 O B-group
with O O
any O O
of O O
the O O
SSRIs B-group B-group
and O O
also O O
in O O
switching O O
from O O
one O O
class O O
to O O
the O O
other O O
. O O

- O O
a O O
beta-blocker B-group B-group
such O O
as O O
propranolol B-drug B-drug
( O O
Inderal B-brand B-brand
) O O
, O O
atenolol B-drug B-drug
( O O
Tenormin B-brand B-brand
) O O
, O O
acebutolol B-drug B-drug
( O O
Sectral B-brand B-brand
) O O
, O O
metoprolol B-drug B-drug
( O O
Lopressor B-brand B-brand
) O O
, O O
and O O
others O O
; O O

Caution O O
is O O
recommended O O
in O O
patients O O
with O O
hepatic O O
impairment O O
. O O

transaminases O O
( O O
AST O O

In O O
this O O
study O O
there O O
was O O
no O O
evidence O O
of O O
a O O
blunting O O
of O O
the O O
antihypertensive O O
action O O
of O O
VASOTEC B-brand B-brand
. O O

The O O
effects O O
of O O
DCG-IV B-drug_n B-drug_n
were O O
very O O
strong O O
and O O
completely O O
depressed O O
the O O
PCP-induced B-drug_n B-drug_n
hyperlocomotion O O
. O O

Carbamazepine B-drug B-drug

It O O
is O O
recommended O O
that O O
glucose O O
tests O O
based O O
on O O
enzymatic O O
glucose O O
oxidase O O
reactions O O
( O O
such O O
as O O
Clinistix O O
** O O
or O O
Tes-Tape O O
** O O
) O O
be O O
used O O
. O O

Therefore O O
, O O
concomitant O O
use O O
of O O
ribavirin B-drug B-drug
with O O
either O O
of O O
these O O
drugs O O
should O O
be O O
avoided O O
. O O

No O O
trials O O
specifically O O
examining O O
potential O O
drug O O
interactions O O
with O O
Natrecor B-brand B-brand
were O O
conducted O O
, O O
although O O
many O O
concomitant O O
drugs O O
were O O
used O O
in O O
clinical O O
trials O O
. O O

Theophylline B-drug B-drug
: O O
A O O
single O O
10 O O
mg O O
dose O O
of O O
tiagabine B-drug B-drug
did O O
not O O
affect O O
the O O
pharmacokinetics O O
of O O
theophylline B-drug B-drug
at O O
steady O O
state O O
. O O

Valproic B-drug B-drug
acid I-drug I-drug
diminished O O
binding O O
of O O
phenobarbital B-drug B-drug
by O O
a O O
net O O
change O O
of O O
9.9 O O
% O O
( O O
percentage O O
increase O O
in O O
FDF O O
, O O
21.2 O O
% O O
) O O
at O O
1732 O O
micromol/L O O
. O O

Ibogaine B-drug_n B-drug_n
produces O O
whole O O
body O O
tremors O O
and O O
, O O
at O O
high O O
doses O O
( O O
> O O
or O O
= O O
100 O O
mg/kg O O
) O O
, O O
cerebellar O O
damage O O
; O O

The O O
use O O
of O O
NIMBEX B-brand B-brand
before O O
succinylcholine B-drug B-drug
to O O
attenuate O O
some O O
of O O
the O O
side O O
effects O O
of O O
succinylcholine B-drug B-drug
has O O
not O O
been O O
studied O O
. O O

Additionally O O
, O O
saquinavir B-drug B-drug
is O O
a O O
substrate O O
for O O
P-Glycoprotein O O
( O O
Pgp O O
) O O
. O O

[ O O
The O O
GABA-ergic O O
system O O
and O O
brain O O
edema O O
] O O
It O O
has O O
been O O
shown O O
in O O
rats O O
with O O
experimental O O
toxic O O
and O O
traumatic O O
edemas O O
that O O
picrotoxin B-drug_n B-drug_n
( O O
1 O O
mg/kg O O
) O O
removes O O
the O O
antiedematous O O
action O O
of O O
diazepam B-drug B-drug
, O O
phenazepam B-drug_n B-drug
, O O
phenibut B-drug_n B-drug_n
and O O
amizyl B-drug_n O
and O O
reduces O O
the O O
action O O
of O O
phentolamine B-drug B-drug
. O O

Patients O O
on O O
warfarin-type B-group B-group
anticoagulant I-group I-group
therapy O O
may O O
require O O
dosage O O
adjustment O O
of O O
the O O
anticoagulant O B-group
during O O
and O O
after O O
griseofulvin B-drug B-drug
therapy O O
. O O

Concomitant O O
administration O O
of O O
rifampin B-drug B-drug
with O O
ketoconazole B-drug B-drug
tablets O O
reduces O O
the O O
blood O O
levels O O
of O O
the O O
latter O O
. O O

No O O
data O O
are O O
available O O
regarding O O
interactions O O
with O O
other O O
drugs O O
that O O
have O O
renal O O
clearance O O
mechanisms O O
similar O O
to O O
that O O
of O O
lamivudine B-drug B-drug
. O O

In O O
13-day-old O O
embryos O O
, O O
glycine B-drug B-drug
was O O
ineffective O O
in O O
both O O
doses O O
. O O

Triazolam B-drug B-drug
: O O
Erythromycin B-drug B-drug
has O O
been O O
reported O O
to O O
decrease O O
the O O
clearance O O
of O O
triazolam B-drug B-drug
and O O
, O O
thus O O
, O O
may O O
increase O O
the O O
pharmacologic O O
effect O O
of O O
triazolam B-drug B-drug
. O O

( O O
Thiazide B-group B-group
diuretics I-group I-group
may O O
raise O O
blood O O
glucose O O
levels O O
; O O

Consequently O O
, O O
the O O
combination O O
of O O
methotrexate B-drug B-drug
with O O
acitretin B-drug B-drug
is O O
also O O
contraindicated O O
. O O

The O O
role O O
of O O
norepinephrine B-drug B-drug
uptake-1 O O
was O O
studied O O
in O O
electrically O O
stimulated O O
( O O
1 O O
Hz O O
, O O
37 O O
degrees O O
C O O
) O O
human O O
ventricular O O
cardiac O O
preparations O O
and O O
isolated O O
myocardial O O
membranes O O
. O O

Drugs O O
that O O
induce O O
CYP3A4 O O
activity O O
would O O
be O O
expected O O
to O O
increase O O
the O O
clearance O O
of O O
indinavir B-drug B-drug
, O O
resulting O O
in O O
lowered O O
plasma O O
concentrations O O
of O O
indinavir B-drug B-drug
. O O

Fluconazole B-drug B-drug
: O O
Concomitant O O
administration O O
of O O
fluconazole B-drug B-drug
at O O
200 O O
mg O O
QD O O
resulted O O
in O O
a O O
two-fold O O
increase O O
in O O
celecoxib B-drug B-drug
plasma O O
concentration O O
. O O

Starlix B-brand B-brand
is O O
a O O
potential O O
inhibitor O O
of O O
the O O
CYP2C9 O O
isoenzyme O O
in O O
vivo O O
as O O
indicated O O
by O O
its O O
ability O O
to O O
inhibit O O
the O O
in O O
vitro O O
metabolism O O
of O O
tolbutamide B-drug B-drug
. O O

Healthcare O O
prescribers O O
are O O
advised O O
to O O
consult O O
the O O
package O O
inserts O O
of O O
medication O O
administered O O
concomitantly O O
with O O
oral O O
contraceptives B-group B-group
. O O

Catecholamine-depleting O B-group
Agents O I-group
: O O
Patients O O
taking O O
both O O
agents B-group O
with I-group O
b-blocking I-group B-group
properties I-group I-group
and O O
a O O
drug O O
that O O
can O O
deplete O O
catecholamines O O
( O O
e.g. O O
, O O
reserpine B-drug B-drug
and O O
monoamine B-group B-group
oxidase I-group I-group
inhibitors I-group I-group
) O O
should O O
be O O
observed O O
closely O O
for O O
signs O O
of O O
hypotension O O
and/or O O
severe O O
bradycardia O O
. O O

Drugs O O
Metabolized O O
by O O
CYP3A O O
: O O
Results O O
of O O
in O O
vitro O O
studies O O
demonstrate O O
that O O
duloxetine B-drug B-drug
does O O
not O O
inhibit O O
or O O
induce O O
CYP3A O O
activity O O
. O O

astemizole B-drug B-drug
, O O
bepridil B-drug B-drug
, O O
sparfloxacin B-drug B-drug
, O O
and O O
terodiline B-drug B-drug
. O O

for O O
adult-onset O O
diabetics O O
, O O
dosage O O
adjustment O O
of O O
hypoglycemic B-group B-group
medications I-group I-group
may O O
be O O
necessary O O
during O O
and O O
after O O
thiazide B-group B-group
diuretic I-group I-group
therapy O O
; O O

Beta B-group B-group
Blockers I-group I-group
: O O
Although O O
the O O
results O O
of O O
a O O
clinical O O
study O O
did O O
not O O
indicate O O
a O O
safe O O
problem O O
associated O O
with O O
the O O
administration O O
of O O
D.H.E B-brand B-brand
. I-brand O
45 I-brand B-brand
( O O
dihydroergotamine B-drug B-drug
mesylate I-drug I-drug
) O O
Injection O O
, O O
USP O O
to O O
subjects O O
already O O
receiving O O
propranolol B-drug B-drug
, O O
there O O
have O O
been O O
reports O O
that O O
propranolol B-drug B-drug
may O O
potentiate O O
the O O
vasoconstrictive O O
action O O
of O O
ergotamine B-drug B-drug
by O O
blocking O O
the O O
vasodilating O O
property O O
of O O
epinephrine O B-drug
. O O

May O O
interact O O
with O O
skin O O
products O O
or O O
shampoos O O
for O O
dandruff O O
or O O
psoriasis O O
. O O

No O O
data O O
are O O
available O O
for O O
the O O
coadministration O O
of O O
INVIRASE/ritonavir B-brand B-brand
or O O
FORTOVASE/ritonavir B-brand B-brand
and O O
garlic O O
capsules O O
. O O

There O O
was O O
no O O
evidence O O
of O O
toxicity O O
. O O

BROVANA B-brand B-brand
, O O
as O O
with O O
other O O
beta2-agonists B-group B-group
, O O
should O O
be O O
administered O O
with O O
extreme O O
caution O O
to O O
patients O O
being O O
treated O O
with O O
monoamine B-group B-group
oxidase I-group I-group
inhibitors I-group I-group
, O O
tricyclic B-group B-group
antidepressants I-group I-group
, O O
or O O
drugs O O
known O O
to O O
prolong O O
the O O
QTc O O
interval O O
because O O
the O O
action O O
of O O
adrenergic B-group B-group
agonists I-group I-group
on O O
the O O
cardiovascular O O
system O O
may O O
be O O
potentiated O O
by O O
these O O
agents O O
. O O

Drug O O
laboratory O O
Test O O
Interactions O O
Serum O O
Salicylate O B-group
Assays O O
: O O
Caution O O
should O O
be O O
used O O
in O O
interpreting O O
the O O
results O O
of O O
serum O O
salicylate O O
assays O O
when O O
diflunisal B-drug B-drug
is O O
present O O
. O O

CANCIDAS B-brand B-brand
did O O
not O O
increase O O
the O O
plasma O O
levels O O
of O O
cyclosporine B-drug B-drug
. O O

Levetiracetam B-drug B-drug
and O O
its O O
major O O
metabolite O O
, O O
at O O
concentrations O O
well O O
above O O
cmax O O
levels O O
achieved O O
within O O
the O O
therapeutic O O
dose O O
range O O
, O O
are O O
neither O O
inhibitors O O
of O O
nor O O
high O O
affinity O O
substrates O O
for O O
human O O
liver O O
cytochrome O O
P450 O O
isoforms O O
, O O
epoxide O O
hydrolase O O
or O O
UDP-glucuronidation O O
enzymes O O
. O O

Beta-adrenergic B-group B-group
blocking I-group I-group
agents I-group I-group
: O O
Coadministration O O
of O O
beta-adrenergic B-group B-group
blocking I-group I-group
agents I-group I-group
did O O
not O O
have O O
any O O
effect O O
on O O
either O O
the O O
safety O O
or O O
efficacy O O
of O O
ibutilide B-drug B-drug
in O O
the O O
clinical O O
trials O O
. O O

co-administration O O
of O O
phenytoin B-drug B-drug
may O O
produce O O
a O O
synergistic O O
anticonvulsant O O
action O O
. O O

whereas O O
urinary O O
excretion O O
was O O
decreased O O
in O O
both O O
cases O O
. O O

A O O
drug-drug O O
interaction O O
study O O
evaluated O O
the O O
effect O O
of O O
the O O
use O O
of O O
ACZONE B-brand B-brand
Gel O O
, O O
5 O O
% O O
, O O
in O O
combination O O
with O O
double O O
strength O O
( O O
160 O O
mg/800 O O
mg O O
) O O
trimethoprim/sulfamethoxazole B-drug B-drug
( O O
TMP/SMX B-drug B-drug
) O O
. O O

An O O
intravenous O O
dose O O
of O O
50 O O
mg O O
perchlorate B-drug_n B-drug
was O O
in O O
respect O O
of O O
competitive O O
suppression O O
of O O
organs O O
actively O O
concentrating O O
pertechnetate B-drug B-drug
as O O
effective O O
as O O
intravenous O O
1000 O O
mg O O
ClO-4- O O
simultaneously O O
or O O
1000 O O
mg O O
orally O O
30 O O
min O O
before O O
the O O
injection O O
of O O
radiopertechnetate B-drug B-drug
. O O

The O O
glucocorticoid-induced O O
gene O O
transcription O O
was O O
strongly O O
suppressed O O
by O O
synthetic O B-group
alkyl O I-group
esters O I-group
; O O

Administration O O
of O O
diltiazem B-drug B-drug
hydrochloride I-drug I-drug
concomitantly O O
with O O
propranolol B-drug B-drug
in O O
five O O
normal O O
volunteers O O
resulted O O
in O O
increased O O
propranolol B-drug B-drug
levels O O
in O O
all O O
subjects O O
and O O
bioavailability O O
of O O
propranolol B-drug B-drug
was O O
increased O O
approximately O O
50 O O
% O O
. O O

In O O
patients O O
in O O
whom O O
CYP3A4 O O
inducers O O
( O O
eg O O
, O O
dexamethasone B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
carbamazepine B-drug B-drug
, O O
rifampicin B-drug B-drug
, O O
phenobarbital B-drug B-drug
) O O
are O O
indicated O O
, O O
alternative O O
agents O O
with O O
less O O
enzyme O O
induction O O
potential O O
should O O
be O O
used O O
. O O

There O O
is O O
no O O
evidence O O
that O O
EPA B-drug B-drug
supplements O O
have O O
detrimental O O
effects O O
on O O
glucose O B-drug
tolerance O O
, O O
insulin O B-drug
secretion O O
or O O
insulin O B-drug
resistance O O
in O O
non-diabetic O O
subjects O O
. O O

The O O
behavioral O O
effects O O
of O O
the O O
stereoisomers O O
of O O
N-allylnormetazocine B-drug_n B-drug_n
( O O
NANM B-drug_n B-drug_n
) O O
were O O
compared O O
with O O
those O O
of O O
phencyclidine B-drug_n B-drug_n
( O O
PCP B-drug_n B-drug_n
) O O
in O O
pigeons O O
and O O
squirrel O O
monkeys O O
responding O O
under O O
a O O
multiple O O
fixed-interval O O
fixed-ratio O O
( O O
FI O O
FR O O
) O O
schedule O O
of O O
food O O
presentation O O
. O O

The O O
pharmacokinetics O O
and O O
protein O O
binding O O
of O O
fosphenytoin B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
and O O
diazepam B-drug B-drug
were O O
not O O
altered O O
when O O
diazepam B-drug B-drug
and O O
Cerebyx B-brand B-brand
were O O
concurrently O O
administered O O
in O O
single O O
submaximal O O
doses O O
. O O

Since O O
higher O O
doses O O
of O O
ketoconazole B-drug B-drug
( O O
400 O O
mg O O
daily O O
) O O
may O O
result O O
in O O
higher O O
increases O O
in O O
Cmax O O
and O O
AUC O O
, O O
a O O
single O O
2.5 O O
mg O O
dose O O
of O O
Vardenafil B-drug B-drug
should O O
not O O
be O O
exceeded O O
in O O
a O O
24-hour O O
period O O
when O O
used O O
in O O
combination O O
with O O
ketoconazole B-drug B-drug
400 O O
mg O O
daily O O
. O O

Also O O
, O O
concomitant O O
administration O O
of O O
quinolones B-group B-group
with O O
products O O
containing O O
iron B-drug B-drug
, O O
multivitamins B-group B-group
containing O O
zinc B-drug B-drug
, O O
or O O
Videx B-brand B-brand
( O O
didanosine B-drug B-drug
) O O
chewable/buffered O O
tablets O O
or O O
the O O
pediatric O O
powder O O
for O O
oral O O
solution O O
may O O
result O O
in O O
low O O
urine O O
levels O O
. O O

The O O
risk O O
of O O
this O O
interaction O O
may O O
be O O
reduced O O
if O O
digoxin B-drug B-drug
is O O
given O O
as O O
capsules O O
. O O

CHOLESTYRAMINE B-drug B-drug
: O O
The O O
influence O O
of O O
the O O
bile-acidsequestering O O
agent O O
cholestyramine B-drug B-drug
on O O
the O O
pharmacokinetits O O
of O O
cerivastatin B-drug B-drug
sodium I-drug I-drug
was O O
evaluated O O
in O O
12 O O
healthy O O
males O O
in O O
2 O O
separate O O
randomized O O
crossover O O
studies O O
. O O

Cimetidine B-drug B-drug
: O O
Cimetidine B-drug B-drug
increases O O
nicardipine B-drug B-drug
HCl I-drug I-drug
plasma O O
levels O O
. O O

Catecholamine-depleting O O
drugs O O
, O O
e.g. O O
, O O
reserpine B-drug B-drug
, O O
may O O
have O O
an O O
additive O O
effect O O
when O O
given O O
with O O
beta B-group B-group
blocking I-group I-group
agents I-group I-group
. O O

Higher O O
dosage O O
of O O
oral O O
hypoglycemic B-group B-group
agents I-group I-group
may O O
be O O
required O O
. O O

( O O
In O O
some O O
patients O O
, O O
the O O
steroidal B-group B-group
anti-inflammatory I-group I-group
agent I-group I-group
can O O
reduce O O
the O O
diuretic O B-group
, O O
natriuretic O O
, O O
and O O
antihypertensive O O
effects O O
of O O
loop O O
, O O
potassium O B-drug
sparing O O
, O O
and O O
thiazide B-group B-group
diuretics I-group I-group
. O O

Care O O
should O O
be O O
taken O O
if O O
labetalol B-drug B-drug
is O O
used O O
concomitantly O O
with O O
calcium B-group B-group
antagonists O I-group
of O O
the O O
verapamil B-drug B-drug
type O O
. O O

There O O
are O O
reports O O
of O O
enhanced O O
as O O
well O O
as O O
diminished O O
effects O O
of O O
anticoagulants B-group B-group
when O O
given O O
concurrently O O
with O O
corticosteroids B-group B-group
. O O

Effect O O
of O O
probenecid B-drug B-drug
on O O
the O O
apparent O O
volume O O
of O O
distribution O O
and O O
elimination O O
of O O
cloxacillin B-drug B-drug
. O O

They O O
may O O
be O O
administered O O
alternately O O
when O O
the O O
preceding O O
effect O O
of O O
other O O
such O O
drug O O
has O O
subsided O O
. O O

The O O
role O O
of O O
AMEVIVE B-brand B-brand
in O O
the O O
development O O
of O O
the O O
lymphoid O O
malignancy O O
and O O
the O O
hyperplasia O O
observed O O
in O O
non-human O O
primates O O
and O O
the O O
relevance O O
to O O
humans O O
is O O
unknown O O
. O O

Impaired O O
glucose O O
tolerance O O
. O O

ethinyl I-drug B-drug
estradiol I-drug I-drug
concentration O O

There O O
was O O
a O O
small O O
decrease O O
in O O
the O O
clearance O O
of O O
cetirizine B-drug B-drug
caused O O
by O O
a O O
400-mg O O
dose O O
of O O
theophylline B-drug B-drug
; O O

These O O
drugs O O
should O O
be O O
coadministered O O
with O O
caution O O
, O O
and O O
frequent O O
monitoring O O
of O O
serum O O
lithium B-drug B-drug
levels O O
is O O
recommended O O
. O O

Alcohol B-drug B-drug
( O O
increases O O
bioavailability O O
by O O
50 O O
% O O
) O O
, O O
cimetidine B-drug B-drug
, O O
and O O
valproates O B-group
. O O

Other O O
: O O
Instances O O
of O O
rash O O
, O O
pruritus O O
, O O
ankle O O
edema O O
, O O
excessive O O
perspiration O O
, O O
weight O O
gain O O
, O O
nasal O O
congestion O O
. O O

Therefore O O
, O O
MAO B-group B-group
inhibitors I-group I-group
should O O
be O O
discontinued O O
at O O
least O O
two O O
weeks O O
prior O O
to O O
the O O
cautious O O
initiation O O
of O O
therapy O O
with O O
SINEQUAN B-brand B-brand
. O O

Cimetidine B-drug B-drug

ADL B-drug B-drug
8-2698 I-drug I-drug
, O O
a O O
trans-3,4-dimethyl-4- O O
( O O
3-hydroxyphenyl O B-drug
) O O
piperidine O B-drug
, O O
prevents O O
gastrointestinal O O
effects O O
of O O
intravenous O O
morphine B-drug B-drug
without O O
affecting O O
analgesia O O
. O O

The O O
change O O
in O O
furosemide B-drug B-drug
clearance O O
value O O
is O O
not O O
likely O O
to O O
be O O
clinically O O
significant O O
. O O

Methotrexate B-drug B-drug
- O O
There O O
is O O
one O O
report O O
that O O
methotrexate B-drug B-drug
may O O
decrease O O
the O O
possible O O
effectiveness O O
of O O
supplemental O O
L-glutamine B-drug B-drug
for O O
chemotherapy-induced O O
mucositis O O
. O O

Methadone B-drug B-drug

Plasma O O
concentrations O O
and O O
effects O O
potentially O O
increased O O
or O O
decreased O O
by O O
SUSTIVA B-brand B-brand
. O O

The O O
clearance O O
by O O
means O O
of O O
4-hydroxytolbutamide B-drug_n B-drug_n
and O O
carboxytolbutamide B-drug_n B-drug_n
was O O
significantly O O
reduced O O
in O O
both O O
groups O O
( O O
ie O O
, O O
from O O
901 O O
mL/h O O
to O O
318 O O
mL/h O O
in O O
the O O
group O O
that O O
received O O
150 O O
mg O O
of O O
tolbutamide B-drug B-drug
per O O
day O O
and O O
from O O
723 O O
mL/h O O
to O O
457 O O
mL/h O O
in O O
the O O
group O O
that O O
received O O
75 O O
mg O O
of O O
tolbutamide B-drug B-drug
per O O
day O O
) O O
. O O

Aspirin B-brand B-brand
: O O
Concurrent O O
administration O O
of O O
aspirin B-brand B-brand
and O O
flurbiprofen B-drug B-drug
resulted O O
in O O
50 O O
% O O
lower O O
serum O O
flurbiprofen B-drug B-drug
concentrations O O
. O O

Therefore O O
, O O
simultaneous O O
use O O
of O O
creams O O
, O O
ointments O B-group
or O O
oils O O
should O O
be O O
avoided O O
. O O

Aspirin B-brand B-brand
, O O
warfarin B-drug B-drug
, O O
heparin B-drug B-drug
, O O
NSAIDs B-group B-group

Approximately O O
2/3 O O
of O O
the O O
patients O O
in O O
the O O
Phase O O
3 O O
study O O
received O O
either O O
prophylactic O O
low O O
dose O O
heparin B-drug B-drug
( O O
unfractionated B-drug B-drug
heparin I-drug I-drug
up O O
to O O
15,000 O O
units/day O O
) O O
or O O
prophylactic O O
doses O O
of O O
low B-group O
molecular I-group O
weight I-group O
heparins I-group O
as O O
indicated O O
in O O
the O O
prescribing O O
information O O
for O O
the O O
specific O O
products O O
. O O

Patients O O
receiving O O
SPRYCEL B-brand B-brand
should O O
not O O
take O O
St. O O
Johns O O
wort O O
. O O

Alternatively O O
, O O
provide O O
medical O O
supervision O O
for O O
at O O
least O O
one O O
hour O O
after O O
the O O
initial O O
dose O O
. O O

The O O
effects O O
of O O
HMG-CoA B-group B-group
reductase I-group I-group
inhibitors I-group I-group
on O O
male O O
fertility O O
have O O
not O O
been O O
studied O O
in O O
adequate O O
numbers O O
of O O
patients O O
. O O

No O O
drug O O
, O O
nutritional O O
supplement O O
, O O
food O O
or O O
herb O O
interactions O O
are O O
known O O
. O O

In O O
long O O
surgical O O
procedures O O
during O O
enflurane B-drug B-drug
or O O
isoflurane B-drug B-drug
anesthesia O O
, O O
less O O
frequent O O
maintenance O O
dosing O O
, O O
lower O O
maintenance O O
doses O O
, O O
or O O
reduced O O
infusion O O
rates O O
of O O
NIMBEX B-brand B-brand
may O O
be O O
necessary O O
. O O

Other O O
substances O O
: O O
Grapefruit O O
juice O O
given O O
to O O
healthy O O
volunteers O O
increased O O
amiodarone B-drug B-drug
AUC O O
by O O
50 O O
% O O
and O O
Cmax O O
by O O
84 O O
% O O
, O O
resulting O O
in O O
increased O O
plasma O O
levels O O
of O O
amiodarone B-drug B-drug
. O O

With O O
simultaneous O O
dosing O O
of O O
Vardenafil B-drug B-drug
20 O O
mg O O
and O O
terazosin B-drug B-drug
10 O O
mg O O
, O O
2 O O
of O O
9 O O
subjects O O
experienced O O
a O O
standing O O
systolic O O
blood O O
pressure O O
of O O
less O O
than O O
85 O O
mm O O
Hg O O
. O O

Auranofin B-drug B-drug
should O O
not O O
be O O
used O O
together O O
with O O
penicillamine B-drug B-drug
( O O
Depen B-brand B-brand
, O O
Cuprimine B-brand B-brand
) O O
, O O
another O O
arthritis O O
medication O O
. O O

This O O
practice O O
resulted O O
in O O
no O O
apparent O O
increase O O
in O O
local O O
breast O O
cancer O O
recurrence O O
relative O O
to O O
published O O
accounts O O
in O O
the O O
literature O O
. O O

Continuous O O
cardiac O O
monitoring O O
is O O
not O O
required O O
except O O
for O O
patients O O
with O O
serious O O
conduction O O
abnormalities O O
. O O

Agents O O
Affecting O O
Cytochrome O O
P450 O O
3A4 O O
Isoenzyme O O
System O O
Fentanyl B-drug B-drug
is O O
metabolized O O
mainly O O
via O O
the O O
human O O
cytochrome O O
P450 O O
3A4 O O
isoenzyme O O
system O O
( O O
CYP3A4 O O
) O O
, O O
therefore O O
potential O O
interactions O O
may O O
occur O O
when O O
DURAGESIC B-brand B-brand
is O O
given O O
concurrently O O
with O O
agents O O
that O O
affect O O
CYP3A4 O O
activity O O
. O O

Thiolated B-drug_n B-drug_n
carboxymethylcellulose I-drug_n I-drug_n
: O O
in O O
vitro O O
evaluation O O
of O O
its O O
permeation O O
enhancing O O
effect O O
on O O
peptide O B-group
drugs O I-group
. O O

Ethoxzolamide B-drug B-drug
may O O
increase O O
the O O
action O O
of O O
tricyclics B-group B-group
, O O
amphetamines B-group B-group
, O O
procainamide B-drug B-drug
, O O
and O O
quinidine B-drug B-drug
. O O

General O O
: O O
Significant O O
interactions O O
may O O
occur O O
when O O
celecoxib B-drug B-drug
is O O
administered O O
together O O
with O O
drugs O O
that O O
inhibit O O
P450 O O
2C9 O O
. O O

Commonly O O
used O O
drugs O O
such O O
as O O
phenylpropanolamine B-drug B-drug
and O O
pseudoephedrine B-drug B-drug
have O O
been O O
specifically O O
studied O O
. O O

May O O
interact O O
with O O
the O O
following O O
: O O
beta-adrenergic B-group B-group
blocking I-group I-group
agents I-group I-group
( O O
these O O
medicines O O
may O O
make O O
your O O
condition O O
worse O O
and O O
prevent O O
the O O
adrenergic B-group B-group
bronchodilators I-group I-group
from O O
working O O
properly O O
) O O
and O O
disopyramide B-drug B-drug
, O O
quinidine B-drug B-drug
, O O
phenothiazines B-group B-group
, O O
and O O
procainamide B-drug B-drug
( O O
these O O
medicines O O
may O O
increase O O
the O O
risk O O
of O O
heart O O
problems O O
) O O
. O O

However O O
, O O
in O O
another O O
study O O
in O O
healthy O O
volunteers O O
, O O
the O O
pharmacokinetics O O
of O O
butorphanol B-drug B-drug
were O O
significantly O O
altered O O
( O O
29 O O
% O O
decrease O O
in O O
AUC O O
and O O
38 O O
% O O
decrease O O
in O O
Cmax O O
) O O
when O O
a O O
1-mg O O
dose O O
of O O
STADOL B-brand B-brand
NS I-brand I-brand
was O O
administered O O
1 O O
minute O O
after O O
a O O
20-mg O O
dose O O
of O O
sumatriptan B-drug B-drug
nasal O I-drug
spray O O
. O O

( O O
The O O
two O O
drugs O O
were O O
administered O O
in O O
opposite O O
nostrils O O
. O O
) O O

Limited O O
data O O
in O O
patients O O
receiving O O
known O O
enzyme O O
inducers O O
( O O
phenytoin B-drug B-drug
, O O
phenobarbital B-drug B-drug
, O O
carbamazepine B-drug B-drug
) O O
indicate O O
only O O
a O O
30 O O
% O O
increase O O
in O O
the O O
rate O O
of O O
flecainide B-drug B-drug
elimination O O
. O O

Dosage O O
of O O
the O O
drugs O O
mentioned O O
above O O
and O O
other O O
similarly O O
metabolized O O
drugs O O
, O O
particularly O O
those O O
of O O
low O O
therapeutic O O
ratio O O
or O O
in O O
patients O O
with O O
renal O O
and/or O O
hepatic O O
impairment O O
, O O
may O O
require O O
adjustment O O
when O O
starting O O
or O O
stopping O O
concomitantly O O
administered O O
Tagamet B-brand B-brand
to O O
maintain O O
optimum O O
therapeutic O O
blood O O
levels O O
. O O

However O O
, O O
because O O
some O O
quinolones B-group B-group
have O O
been O O
reported O O
to O O
enhance O O
the O O
effects O O
of O O
warfarin B-drug B-drug
or O O
its O O
derivatives O O
, O O
prothrombin O O
time O O
or O O
other O O
suitable O O
anticoagulation O O
test O O
should O O
be O O
monitored O O
closely O O
if O O
a O O
quinolone B-group B-group
antimicrobial I-group I-group
is O O
administered O O
with O O
warfarin B-drug B-drug
or O O
its O O
derivatives O O
. O O

In O O
five O O
men O O
, O O
terfenadine B-drug B-drug
levels O O
were O O
undetectable O O
( O O
5 O O
ng/mL O O
) O O
throughout O O
the O O
study O O
; O O

Therefore O O
, O O
chloroprocaine B-drug B-drug
should O O
not O O
be O O
used O O
in O O
any O O
condition O O
in O O
which O O
a O O
sulfonamide B-group B-group
drug I-group I-group
is O O
being O O
employed O O
. O O

Pletal B-brand B-brand
does O O
not O O
, O O
however O O
, O O
appear O O
to O O
cause O O
increased O O
blood O O
levels O O
of O O
drugs O O
metabolized O O
by O O
CYP3A4 O O
, O O
as O O
it O O
had O O
no O O
effect O O
on O O
lovastatin B-drug B-drug
, O O
a O O
drug O O
with O O
metabolism O O
very O O
sensitive O O
to O O
C.P.A O O
. O O
inhibition O O
. O O

When O O
administering O O
other O O
drugs O O
for O O
which O O
alterations O O
in O O
blood O O
levels O O
could O O
have O O
a O O
clinically O O
significant O O
effect O O
on O O
safety O O
or O O
efficacy O O
, O O
physicians O O
should O O
consider O O
monitoring O O
drug O O
levels O O
or O O
effects O O
. O O

Tacrolimus O B-drug
Felodipine B-drug I-drug
may O O
increase O O
the O O
blood O O
concentration O O
of O O
tacrolimus B-drug B-drug
. O O

Drugs O O
That O O
Inhibit O O
Alprazolam B-drug B-drug
Metabolism O O
Via O O
Cytochrome O O
P450 O O
3A O O
: O O
The O O
initial O O
step O O
in O O
alprazolam B-drug B-drug
metabolism O O
is O O
hydroxylation O O
catalyzed O O
by O O
cytochrome O O
P450 O O
3A O O
( O O
CYP O O
3A O O
) O O
. O O

In O O
patients O O
who O O
have O O
received O O
muscle B-group B-group
relaxants I-group I-group
, O O
doxapram B-drug B-drug
may O O
temporarily O O
mask O O
the O O
residual O O
effects O O
of O O
muscle B-group B-group
relaxant I-group I-group
drugs I-group I-group
. O O

Co-administration O O
of O O
probenecid B-drug B-drug
with O O
acyclovir B-drug B-drug
has O O
been O O
shown O O
to O O
increase O O
the O O
mean O O
half-life O O
and O O
the O O
area O O
under O O
the O O
concentration-time O O
curve O O
. O O

Pressor O O
agents O O
- O O
Because O O
of O O
possible O O
effects O O
on O O
blood O O
pressure O O
, O O
STRATTERA B-brand B-brand
should O O
be O O
used O O
cautiously O O
with O O
pressor O O
agents O O
. O O

Increased O O
plasma O O
HDL O O
and O O
HDL2 O O
cholesterol O O
subfraction O O
concentrations O O
, O O
reduced O O
LDL O O
cholesterol O O
concentration O O
, O O
increased O O
triglyceride O O
levels O O
. O O

Iron B-group B-drug
Supplements I-group O
and O O
Foods O O
Fortified O O
With O O
Iron B-drug B-drug
Concomitant O O
administration O O
of O O
cefdinir B-drug B-drug
with O O
a O O
therapeutic O O
iron B-group B-drug
supplement I-group O
containing O O
60 O O
mg O O
of O O
elemental O O
iron B-drug B-drug
( O O
as O O
FeSO4 O B-brand
) O O
or O O
vitamins B-group B-group
supplemented O O
with O O
10 O O
mg O O
of O O
elemental O O
iron B-drug B-drug
reduced O O
extent O O
of O O
absorption O O
by O O
80 O O
% O O
and O O
31 O O
% O O
, O O
respectively O O
. O O

Use O O
in O O
Conjunction O O
with O O
Other O O
Antiepileptic B-group B-group
Drugs I-group I-group
: O O
The O O
addition O O
of O O
Felbatol B-brand B-brand
to O O
antiepileptic B-group B-group
drugs I-group I-group
( O O
AEDs B-group B-group
) O O
affects O O
the O O
steady-state O O
plasma O O
concentrations O O
of O O
AEDs B-group B-group
. O O

- O O
isoniazid B-drug B-drug
( O O
Nydrazid B-brand B-brand
) O O
; O O

Specific O O
Effects O O
of O O
Felbatol B-brand B-brand
on O O
Other O O
Antiepileptic B-group B-group
Drugs I-group I-group
Phenytoin B-drug B-drug
: O O
Felbatol B-brand B-brand
causes O O
an O O
increase O O
in O O
steady-state O O
phenytoin B-drug B-drug
plasma O O
concentrations O O
. O O

There O O
were O O
no O O
significant O O
effects O O
on O O
QTc O O
intervals O O
, O O
and O O
no O O
reports O O
of O O
sedation O O
or O O
syncope O O
. O O

monitor O O
closely O O
for O O
evidence O O
of O O
hypotension O O
and/or O O
excessive O O
bradycardia O O
( O O
e.g. O O
, O O
vertigo O O
, O O
syncope O O
, O O
postural O O
hypotension O O
) O O
. O O

Unmodified O O
NaCMC B-drug_n B-drug_n
( O O
1 O O
% O O
m/v O O
) O O
significantly O O
improved O O
the O O
transport O O
ratio O O
( O O
R= O O
P O O
( O O
app O O
) O O
polymer/ O O
P O O
( O O
app O O
) O O
control O O
) O O
of O O
NaFlu B-drug B-drug
to O O
1.3 O O
and O O
1 O O
% O O
( O O
m/v O O
) O O
NaCMC B-drug_n O
conjugated O O
with O O
cysteine B-drug B-drug
further O O
enhanced O O
the O O
permeation O O
. O O

To O O
each O O
preparation O O
was O O
added O O
one O O
additional O O
drug O O
at O O
three O O
concentrations O O
ranging O O
from O O
therapeutic O O
to O O
toxic O O
. O O

To O O
investigate O O
the O O
effect O O
of O O
disease O O
states O O
or O O
concomitant O O
drug O O
administration O O
on O O
a O O
patient O O
's O O
response O O
to O O
etodolac B-drug B-drug
, O O
additional O O
pharmacokinetic O O
studies O O
were O O
carried O O
out O O
in O O
special O O
populations O O
. O O

No O O
clinical O O
drug O O
interaction O O
studies O O
have O O
been O O
conducted O O
. O O

Ergotamine B-drug B-drug
: O O
Concurrent O O
use O O
of O O
erythromycin B-drug B-drug
and O O
ergotamine B-drug B-drug
or O O
dihydroergotamine B-drug B-drug
has O O
been O O
associated O O
in O O
some O O
patients O O
with O O
acute O O
ergot O O
toxicity O O
characterized O O
by O O
severe O O
peripheral O O
vasospasm O O
and O O
dysesthesia O O
. O O

Herbal O O
remedies O O
, O O
nephropathies O O
, O O
and O O
renal O O
disease O O
. O O

Diclofenac B-drug B-drug
is O O
a O O
prostaglandin O B-group
synthetase O I-group
inhibitor O I-group
, O O
however O O
, O O
and O O
all O O
drugs O O
that O O
inhibit O O
prostaglandin O O
synthesis O O
interfere O O
with O O
platelet O O
function O O
to O O
some O O
degree O O
; O O

nonetheless O O
, O O
the O O
possibility O O
that O O
causative O O
factors O O
may O O
interact O O
synergistically O O
to O O
increase O O
the O O
risk O O
and/or O O
severity O O
of O O
bone O O
marrow O O
suppression O O
warrants O O
consideration O O
. O O

In O O
studies O O
in O O
female O O
rats O O
at O O
doses O O
0.01 O O
mg/kg/day O O
( O O
IM O O
; O O

Mean O O
T O O
max O O
and O O
mean O O
plasma O O
elimination O O
half-life O O
of O O
albendazole B-drug B-drug
sulfoxide I-drug I-drug
were O O
unchanged O O
. O O

Sildenafil B-drug B-drug
dose O O
should O O
not O O
exceed O O
a O O
maximum O O
of O O
25 O O
mg O O
in O O
a O O
48- O O
hour O O
period O O
in O O
patients O O
receiving O O
concomitant O O
indinavir B-drug B-drug
therapy O O
. O O

Herb/Nutraceutical O O
: O O
St O O
Johns O O
wort O O
may O O
decrease O O
the O O
effectiveness O O
of O O
combination B-group B-group
hormonal I-group I-group
contraceptives I-group I-group
by O O
inducing O O
hepatic O O
enzymes O O
. O O

urticaria O O

Caverject B-brand O
: O O
The O O
potential O O
for O O
pharmacokinetic O O
drug-drug O O
interactions O O
between O O
alprostadil B-drug B-drug
and O O
other O O
agents O O
has O O
not O O
been O O
formally O O
studied O O
. O O

therefore O O
, O O
it O O
should O O
be O O
recognized O O
that O O
a O O
positive O O
Coombs O O
test O O
may O O
be O O
due O O
to O O
the O O
drug O O
. O O

Although O O
no O O
drug-drug O O
interaction O O
studies O O
have O O
been O O
conducted O O
in O O
vivo O O
, O O
it O O
is O O
expected O O
that O O
no O O
significant O O
interaction O O
would O O
occur O O
when O O
nitazoxanide B-drug B-drug
is O O
co-administered O O
with O O
drugs O O
that O O
either O O
are O O
metabolized O O
by O O
or O O
inhibit O O
cytochrome O O
P450 O O
enzymes O O
. O O

There O O
are O O
no O O
clinical O O
data O O
on O O
concomitant O O
use O O
of O O
NUROMAX B-brand B-brand
and O O
other O O
nondepolarizing O B-group
neuromuscular B-group I-group
blocking I-group I-group
agents I-group I-group
. O O

Administration O O
of O O
thiazide B-group B-group
diuretics I-group I-group
to O O
hypoparathyroid O O
patients O O
who O O
are O O
concurrently O O
being O O
treated O O
with O O
dihydrotachysterol B-drug B-drug
may O O
cause O O
hypercalcemia O O
. O O

antibiotics B-group B-group
; O O

These O O
agents O O
should O O
not O O
be O O
used O O
in O O
patients O O
treated O O
with O O
NIZORAL B-brand B-brand
Tablets O O
. O O

Amiodarone B-drug B-drug
, O O
disopyramide B-drug B-drug
, O O
lidocaine B-drug B-drug

The O O
pharmacokinetics O O
of O O
ethanol B-drug B-drug
were O O
not O O
affected O O
by O O
multiple-dose O O
administration O O
of O O
tiagabine B-drug B-drug
. O O

The O O
CNS O O
effects O O
of O O
butalbital B-drug B-drug
may O O
be O O
enhanced O O
by O O
monoamine B-group B-group
oxidase I-group I-group
( I-group I-group
MAO I-group I-group
) I-group I-group
inhibitors I-group I-group
. O O

Indinavir B-drug B-drug
may O O
be O O
taken O O
with O O
a O O
light O O
meal O O
1 O O
h O O
following O O
the O O
administration O O
of O O
400 O O
mg O O
of O O
didanosine B-drug B-drug
. O O

Nitrates B-group B-group
: O O
The O O
concomitant O O
use O O
of O O
Bepridil B-drug B-drug
with O O
long- O B-group
and O O
short-acting O B-group
nitrates B-group I-group
has O O
been O O
safely O O
tolerated O O
in O O
patients O O
with O O
stable O O
angina O O
pectoris O O
. O O

The O O
results O O
we O O
present O O
clearly O O
show O O
that O O
the O O
drug O O
alters O O
the O O
cellular O O
permeability O O
, O O
and O O
thus O O
the O O
exogenous O O
respiration O O
becomes O O
sensitive O O
to O O
the O O
drug O O
. O O

Vardenafil B-drug B-drug
( O O
20 O O
mg O O
) O O
did O O
not O O
potentiate O O
the O O
hypotensive O O
effects O O
of O O
alcohol B-drug B-drug
during O O
the O O
4-hour O O
observation O O
period O O
in O O
healthy O O
volunteers O O
when O O
administered O O
with O O
alcohol B-drug B-drug
( O O
0.5 O O
g/kg O O
body O O
weight O O
) O O
. O O

In O O
addition O O
to O O
this O O
pharmacological O O
interaction O O
, O O
this O O
report O O
describes O O
a O O
novel O O
chemical O O
reaction O O
between O O
temazepam B-drug B-drug
( O O
a O O
benzodiazepine B-group B-group
) O O
and O O
ethanol B-drug B-drug
under O O
acidic O O
conditions O O
similar O O
to O O
those O O
found O O
in O O
vivo O O
, O O
resulting O O
in O O
a O O
3-ethoxylated O O
product O O
. O O

MEASUREMENTS O O
and O O
MAIN O O
RESULTS O O
: O O
Blood O O
samples O O
were O O
drawn O O
and O O
12-lead O O
electrocardiograms O O
performed O O
at O O
specified O O
time O O
points O O
after O O
the O O
last O O
morning O O
dose O O
of O O
cisapride B-drug B-drug
in O O
phases O O
1 O O
and O O
3 O O
. O O

increased O O
liver O O

Still O O
other O O
pathways O O
have O O
been O O
proposed O O
. O O

Sympathomimetic B-group B-group
Agents I-group I-group
: O O
Possible O O
increased O O
risk O O
of O O
coronary O O
insufficiency O O
in O O
patients O O
with O O
coronary O O
artery O O
disease O O
. O O

In O O
addition O O
, O O
new O O
cases O O
of O O
diabetes O O
have O O
been O O
diagnosed O O
during O O
Accutane B-brand B-brand
therapy O O
, O O
although O O
no O O
causal O O
relationship O O
has O O
been O O
established O O

This O O
may O O
potentiate O O
and O O
prolong O O
hypnotic O O
and O O
sedative O O
effects O O
, O O
especially O O
with O O
repeated O O
dosing O O
or O O
chronic O O
administration O O
of O O
these O O
agents O O
. O O

Several O O
of O O
the O O
tricyclic B-group B-group
antidepressants I-group I-group
have O O
been O O
cited O O
in O O
these O O
reports O O
. O O

Bleeding O O
from O O
a O O
number O O
of O O
sites O O
may O O
be O O
a O O
complication O O
of O O
warfarin B-drug B-drug
treatment O O
and O O
GI O O
bleeding O O
a O O
complication O O
of O O
ketoprofen B-drug B-drug
treatment O O
. O O

. O O

Between O O
1988 O O
and O O
1993 O O
, O O
more O O
than O O
7,000 O O
patients O O
were O O
diagnosed O O
and O O
treated O O
. O O

Therefore O O
, O O
monitoring O O
of O O
theophylline B-drug B-drug
plasma O O
levels O O
should O O
be O O
considered O O
and O O
dosage O O
of O O
theophylline B-drug B-drug
adjusted O O
, O O
as O O
required O O
. O O

Both O O
CYP3A4 O O
and O O
CYP2D6 O O
are O O
responsible O O
for O O
aripiprazole B-drug B-drug
metabolism O O
. O O

Separating O O
the O O
doses O O
of O O
antacid B-group B-group
and O O
lomefloxacin B-drug B-drug
minimizes O O
this O O
decrease O O
in O O
bioavailability O O
; O O

TCAs B-group B-group
decrease O O
the O O
hypotensive O O
effect O O
of O O
guanfacine B-drug B-drug
. O O

Poor O O
metabolizers O O
have O O
higher O O
than O O
expected O O
plasma O O
concentrations O O
of O O
tricyclic B-group B-group
antidepressants I-group I-group
( O O
TCAs B-group B-group
) O O
when O O
given O O
usual O O
doses O O
. O O

Non-selective B-group B-group
monoamine I-group I-group
oxidase I-group I-group
( I-group I-group
MAO I-group I-group
) I-group I-group
inhibitors I-group I-group
- O O
including O O
phenelzine B-drug B-drug
sulfate I-drug I-drug
, O O
tranylcypromine B-drug B-drug
sulfate I-drug I-drug
and O O
pargyline B-drug B-drug
HC1 O O
. O O

However O O
, O O
this O O
sample O O
size O O
is O O
too O O
small O O
to O O
allow O O
for O O
any O O
conclusions O O
to O O
be O O
drawn O O
regarding O O
the O O
risk O O
of O O
rashes O O
with O O
concomitant O O
AUGMENTIN B-brand B-brand
XR I-brand I-brand
and O O
allopurinol B-drug B-drug
use O O
. O O

The O O
introductory O O
chapter O O
discusses O O
the O O
advantages O O
and O O
disadvantages O O
of O O
POCs B-group B-group
and O O
the O O
magnitude O O
and O O
prevalence O O
of O O
their O O
use O O
. O O

Theophylline B-drug B-drug
: O O
The O O
effect O O
of O O
steady-state O O
fluvoxamine B-drug B-drug
l50 O O
mg O O
bid O O
on O O
the O O
pharmacokinetics O O
of O O
a O O
single O O
dose O O
of O O
Theophylline B-drug B-drug
( O O
375 O O
mg O O
) O O
as O O
442 O O
mg O O
aminophylline B-drug B-drug
was O O
evaluated O O
in O O
12 O O
healthy O O
non-smoking O O
, O O
male O O
volunteers O O
. O O

The O O
effects O O
of O O
supplementary O O
oral O O
cobalt B-drug B-drug
and O O
iron B-drug B-drug
, O O
as O O
well O O
as O O
the O O
interaction O O
between O O
both O O
at O O
the O O
absorption O O
site O O
, O O
fecal O O
and O O
urinary O O
excretion O O
as O O
well O O
as O O
the O O
retention O O
of O O
these O O
trace O O
elements O O
were O O
determined O O
by O O
using O O
four O O
diets O O
containing O O
either O O
9 O O
or O O
63 O O
micrograms/kg O O
of O O
Co B-drug O
and O O
48 O O
or O O
446 O O
mg/kg O O
of O O
Fe B-drug B-drug
over O O
a O O
period O O
of O O
19 O O
days O O
in O O
a O O
total O O
of O O
24 O O
rats O O
. O O

These O O
fulvestrant B-drug B-drug
doses O O
correspond O O
to O O
approximately O O
2- O O
, O O
3- O O
, O O
and O O
3-fold O O
the O O
systemic O O
exposure O O
[ O O
AUC0-30 O O
days O O
] O O
achieved O O
in O O
women O O
. O O

This O O
review O O
discusses O O
the O O
actions O O
of O O
the O O
two O O
drugs O O
on O O
certain O O
brain O O
chemical O O
( O O
i.e. O O
, O O
neurotransmitter O O
) O O
systems O O
and O O
the O O
extent O O
to O O
which O O
the O O
effects O O
of O O
the O O
two O O
drugs O O
may O O
interact O O
. O O

Cholestyramine B-drug B-drug
: O O
Cholestyramine B-drug B-drug
binds O O
both O O
T4 B-drug O
and O O
T3 B-drug O
in O O
the O O
intestine O O
, O O
thus O O
impairing O O
absorption O O
of O O
these O O
thyroid B-group B-group
hormones I-group I-group
. O O

The O O
use O O
of O O
Adenocard B-brand B-brand
in O O
patients O O
receiving O O
digitalis B-group B-group
may O O
be O O
rarely O O
associated O O
with O O
ventricular O O
fibrillation O O
. O O

Cisapride B-drug B-drug

The O O
patient O O
was O O
also O O
chronically O O
receiving O O
phenytoin B-drug B-drug
, O O
phenobarbital B-drug B-drug
, O O
digoxin B-drug B-drug
, O O
and O O
levothyroxine B-drug B-drug
sodium I-drug I-drug
. O O

Pregnancy O O
: O O
Category O O
X O O
: O O
Use O O
With O O
Ribavirin B-drug B-drug
( O O
see O O
CONTRAINDICATIONS O O
) O O
Significant O O
teratogenic O O
and/or O O
embryocidal O O
effects O O
have O O
been O O
demonstrated O O
in O O
all O O
animal O O
species O O
exposed O O
to O O
ribavirin B-drug B-drug
. O O

When O O
Itraconazole B-drug B-drug
was O O
coadministered O O
with O O
phenytoin B-drug B-drug
, O O
rifampin B-drug B-drug
, O O
or O O
H2antagonists O B-group
, O O
reduced O O
plasma O O
concentrations O O
of O O
itraconazole B-drug B-drug
were O O
reported O O
. O O

. O O

phenytoin B-drug B-drug
; O O

Azithromycin B-drug B-drug
had O O
no O O
significant O O
impact O O
on O O
the O O
Cmax O O
and O O
AUC O O
of O O
zidovudine B-drug B-drug
, O O
although O O
it O O
significantly O O
decreased O O
the O O
zidovudine B-drug B-drug
tmax O O
by O O
44 O O
% O O
and O O
increased O O
the O O
intracellular O O
exposure O O
to O O
phosphorylated O O
zidovudine B-drug B-drug
by O O
110 O O
% O O
. O O

At O O
similar O O
median O O
follow-up O O
, O O
opportunistic O O
infection O O
( O O
OI O O
) O O
rates O O
and O O
mortality O O
were O O
significantly O O
lower O O
in O O
the O O
CHOP-HAART O O
patients O O
than O O
in O O
the O O
CHOP O O
patients O O
( O O
18 O O
% O O
vs. O O
52 O O
% O O
, O O
respectively O O
; O O
P O O
= O O
0.05 O O
; O O
and O O
38 O O
% O O
vs. O O
85 O O
% O O
, O O
respectively O O
; O O
P O O
= O O
0.001 O O
) O O
. O O

If O O
ProSom B-brand B-brand
is O O
given O O
concomitantly O O
with O O
other O O
drugs O O
acting O O
on O O
the O O
central O O
nervous O O
system O O
, O O
careful O O
consideration O O
should O O
be O O
given O O
to O O
the O O
pharmacology O O
of O O
all O O
agents O O
. O O

Patients O O
taking O O
Acamprosate B-drug B-drug
concomitantly O O
with O O
antidepressants B-group B-group
more O O
commonly O O
reported O O
both O O
weight O O
gain O O
and O O
weight O O
loss O O
, O O
compared O O
with O O
patients O O
taking O O
either O O
medication O O
alone O O
. O O

however O O
, O O
no O O
specific O O
drug O O
interaction O O
studies O O
have O O
been O O
performed O O
to O O
evaluate O O
potential O O
drug-drug O O
interaction O O
. O O

No O O
well-known O O
drug O O
interactions O O
with O O
glutamic B-drug B-drug
acid I-drug I-drug

It O O
was O O
established O O
that O O
both O O
angiotensins O B-group
inhibited O O
gastric O O
acid O O
secretion O O
stimulated O O
by O O
pentagastrin B-drug B-drug
but O O
not O O
by O O
histamine B-drug B-drug
. O O

As O O
with O O
other O O
agents O O
which O O
prolong O O
ECG O O
intervals O O
, O O
caution O O
should O O
be O O
exercised O O
in O O
patients O O
taking O O
drugs O O
which O O
prolong O O
ECG O O
intervals O O
, O O
particularly O O
QTc O O
. O O

Other O O
interactions O O
: O O
Vardenafil B-drug B-drug
had O O
no O O
effect O O
on O O
the O O
pharmacodynamics O O
of O O
glyburide B-drug B-drug
( O O
glucose O B-drug
and O O
insulin O B-drug
concentrations O O
) O O
and O O
warfarin B-drug B-drug
( O O
prothrombin O O
time O O
or O O
other O O
pharmacodynamic O O
parameters O O
) O O
. O O

Patients O O
treated O O
with O O
TENORMIN B-brand B-brand
plus O O
a O O
catecholamine O B-group
depletor O I-group
should O O
therefore O O
be O O
closely O O
observed O O
for O O
evidence O O
of O O
hypotension O O
and/or O O
marked O O
bradycardia O O
which O O
may O O
produce O O
vertigo O O
, O O
syncope O O
, O O
or O O
postural O O
hypotension O O
. O O

diazoxide B-drug B-drug
; O O

Aspirin B-brand B-brand
: O O
Concurrent O O
administration O O
of O O
aspirin B-brand B-brand
may O O
lower O O
meclofenamate B-drug B-drug
sodium I-drug I-drug
plasma O O
levels O O
, O O
possibly O O
by O O
competing O O
for O O
protein-binding O O
sites O O
. O O

Gentamicin B-drug B-drug
is O O
an O O
aminoglycoside B-group B-group
antibiotic I-group I-group
used O O
to O O
treat O O
a O O
wide O O
variety O O
of O O
infections O O
caused O O
by O O
gram-negative O O
organisms O O
, O O
but O O
it O O
is O O
potentially O O
toxic O O
to O O
the O O
kidneys O O
. O O

Drug/Laboratory O O
Test O O
Interactions O O
None O O
known O O
. O O

Interactions O O
attributed O O
to O O
the O O
combined O O
use O O
of O O
baclofen B-drug B-drug
injection O O
and O O
epidural O O
morphine B-drug B-drug
include O O
hypotension O O
and O O
dyspnea O O
. O O

Antiarrhythmics B-group B-group

Isocarboxazid B-drug B-drug
should O O
be O O
administered O O
with O O
caution O O
to O O
patients O O
receiving O O
Antabuse B-brand B-brand
( O O
disulfiram B-drug B-drug
, O O
Wyeth-Ayerst O O
Laboratories O O
) O O
. O O

Since O O
acetaminophen B-drug B-drug
in O O
high O O
doses O O
has O O
been O O
associated O O
with O O
hepatotoxicity O O
, O O
concomitant O O
administration O O
of O O
diflunisal B-drug B-drug
and O O
acetaminophen B-drug B-drug
should O O
be O O
used O O
cautiously O O
, O O
with O O
careful O O
monitoring O O
of O O
patients O O
. O O

The O O
appropriate O O
doses O O
for O O
this O O
combination O O
, O O
with O O
respect O O
to O O
efficacy O O
and O O
safety O O
, O O
have O O
not O O
been O O
established O O
. O O

These O O
observations O O
are O O
discussed O O
in O O
reference O O
to O O
possible O O
deleterious O O
effects O O
following O O
the O O
administration O O
of O O
pargyline B-drug B-drug
to O O
patients O O
with O O
Parkinson O O
's O O
Disease O O
. O O

There O O
was O O
evidence O O
for O O
longitudinal O O
stability O O
in O O
AUC O O
of O O
everolimus B-drug B-drug
during O O
the O O
course O O
of O O
the O O
study O O
. O O

It O O
is O O
recommended O O
that O O
the O O
combination O O
of O O
intravenous O O
dantrolene B-drug B-drug
sodium I-drug I-drug
and O O
calcium B-group B-group
channel I-group I-group
blockers I-group I-group
, O O
such O O
as O O
verapamil B-drug B-drug
, O O
not O O
be O O
used O O
together O O
during O O
the O O
management O O
of O O
malignant O O
hyperthermia O O
crisis O O
until O O
the O O
relevance O O
of O O
these O O
findings O O
to O O
humans O O
is O O
established O O
. O O

L-glutamine B-drug B-drug
has O O
orphan O O
drug O O
status O O
for O O
this O O
indication O O
. O O

BACKGROUND O O
: O O
The O O
feasibility O O
and O O
efficacy O O
of O O
concomitant O O
chemotherapy O O
and O O
highly B-group B-group
active I-group I-group
antiretroviral I-group I-group
therapy O O
( O O
HAART O O
) O O
is O O
still O O
unknown O O
in O O
patients O O
with O O
human O O
immunodeficiency O O
virus O O
( O O
HIV O O
) O O
-related O O
malignancies O O
. O O

Coadministration O O
of O O
SULAR B-brand B-brand
with O O
phenytoin B-drug B-drug
or O O
any O O
known O O
CYP3A4 O O
inducer O O
should O O
be O O
avoided O O
and O O
alternative O O
antihypertensive B-group B-group
therapy O O
should O O
be O O
considered O O
. O O

The O O
concomitant O O
use O O
of O O
other O O
CYP3A4 O O
inhibitors O O
such O O
as O O
diltiazem B-drug B-drug
and O O
erythromycin B-drug B-drug
with O O
transdermal O O
fentanyl B-drug B-drug
may O O
also O O
result O O
in O O
an O O
increase O O
in O O
fentanyl B-drug B-drug
plasma O O
concentrations O O
, O O
which O O
could O O
increase O O
or O O
prolong O O
adverse O O
drug O O
effects O O
and O O
may O O
cause O O
serious O O
respiratory O O
depression O O
. O O

This O O
information O O
should O O
be O O
considered O O
when O O
changing O O
from O O
intravenous O O
amiodarone B-drug B-drug
to O O
oral O O
amiodarone B-drug B-drug
. O O

Alcohol B-drug B-drug
: O O
Alcohol B-drug B-drug
( O O
0.5 O O
g/kg O O
body O O
weight O O
: O O
approximately O O
40 O O
mL O O
of O O
absolute O O
alcohol O B-drug
in O O
a O O
70 O O
kg O O
person O O
) O O
and O O
vardenafil B-drug B-drug
plasma O O
levels O O
were O O
not O O
altered O O
when O O
dosed O O
simultaneously O O
. O O

Ketoconazole B-drug B-drug
: O O
Ketoconazole B-drug B-drug
may O O
inhibit O O
both O O
synthetic O O
and O O
catabolic O O
enzymes O O
of O O
vitamin B-group B-group
D I-group I-group
. O O

Although O O
the O O
mechanism O O
of O O
interaction O O
between O O
fenoprofen B-drug B-drug
and O O
aspirin B-brand B-brand
is O O
not O O
totally O O
known O O
, O O
enzyme O O
induction O O
and O O
displacement O O
of O O
fenoprofen B-drug B-drug
from O O
plasma O O
albumin O O
binding O O
sites O O
are O O
possibilities O O
. O O

In O O
evaluating O O
the O O
potential O O
for O O
interactions O O
among O O
co-administered O O
antiepilepsy O O
drugs O O
( O O
AEDs B-group B-group
) O O
, O O
whether O O
or O O
not O O
an O O
AED B-group B-group
induces O O
or O O
does O O
not O O
induce O O
metabolic O O
enzymes O O
is O O
an O O
important O O
consideration O O
. O O

Other O O
drugs O O
that O O
increase O O
gastrointestinal O O
motility O O
may O O
produce O O
similar O O
effects O O
. O O

Bromocriptine B-drug B-drug
mesylate I-drug I-drug
may O O
interact O O
with O O
dopamine B-group B-group
antagonists I-group I-group
, O O
butyrophenones B-group B-group
, O O
and O O
certain O O
other O O
agents O O
. O O

Inhibition O O
and O O
stimulation O O
of O O
the O O
effect O O
of O O
oxytocin B-drug B-drug
on O O
milk O O
ejection O O
by O O
vasopressin O B-drug
was O O
demonstrated O O
. O O

Accelerated O O
prothrombin O O
time O O
, O O
partial O O
thromboplastin O O
time O O
, O O
and O O
platelet O O
aggregation O O
time O O
; O O

Care O O
should O O
be O O
taken O O
when O O
using O O
immunoanalytical O O
methods O O
to O O
measure O O
plasma O O
phenytoin B-drug B-drug
concentrations O O
following O O
Cerebyx B-brand B-brand
administration O O
. O O

Organometals O O
also O O
compromise O O
the O O
limbic O O
system O O
and O O
result O O
in O O
deficits O O
in O O
learning O O
and O O
memory O O
. O O

Furthermore O O
it O O
has O O
been O O
proposed O O
that O O
isoniazid B-drug B-drug
resulted O O
In O O
induction O O
of O O
P-450IIE1 O O
in O O
the O O
patients O O
liver O O
which O O
, O O
in O O
turn O O
, O O
resulted O O
in O O
a O O
greater O O
proportion O O
of O O
the O O
ingested O O
acetaminophen B-drug B-drug
being O O
converted O O
to O O
the O O
toxic O O
metabolites O O
. O O

Based O O
on O O
the O O
above O O
data O O
from O O
in O O
vitro O O
and O O
in O O
vivo O O
studies O O
, O O
it O O
is O O
unlikely O O
that O O
alosetron B-drug B-drug
will O O
inhibit O O
the O O
hepatic O O
metabolic O O
clearance O O
of O O
drugs O O
metabolized O O
by O O
the O O
major O O
CYP O O
enzyme O O
3A4 O O
, O O
as O O
well O O
as O O
the O O
CYP O O
enzymes O O
2D6 O O
, O O
2C9 O O
, O O
2C19 O O
, O O
2E1 O O
, O O
or O O
1A2 O O
. O O

This O O
may O O
lead O O
to O O
reduced O O
clearance O O
of O O
caffeine B-drug B-drug
and O O
the O O
prolongation O O
of O O
its O O
plasma O O
half-life O O
. O O

Cimetidine B-drug B-drug
- O O
In O O
subjects O O
who O O
had O O
received O O
21 O O
days O O
of O O
40 O O
mg/day O O
racemic O O
citalopram B-drug B-drug
, O O
combined O O
administration O O
of O O
400 O O
mg/day O O
cimetidine B-drug B-drug
for O O
8 O O
days O O
resulted O O
in O O
an O O
increase O O
in O O
citalopram B-drug B-drug
AUC O O
and O O
Cmax O O
of O O
43 O O
% O O
and O O
39 O O
% O O
, O O
respectively O O
. O O

- O O
Methotrexate B-drug B-drug
( O O
e.g. O O
, O O
Mexate B-brand B-brand
) O O
Use O O
of O O
methotrexate B-drug B-drug
with O O
sulfapyridine B-drug B-drug
may O O
increase O O
the O O
chance O O
of O O
side O O
effects O O
affecting O O
the O O
liver O O
and/or O O
the O O
side O O
effects O O
of O O
methotrexate B-drug B-drug

Norepinephrine B-drug B-drug
: O O
Amphetamines B-group B-group
enhance O O
the O O
adrenergic O O
effect O O
of O O
norepinephrine B-drug B-drug
. O O

A O O
possible O O
interaction O O
has O O
been O O
suggested O O
with O O
hormonal B-group B-group
contraceptives I-group I-group
and O O
the O O
herbal O O
supplement O O
St. O O
Johns O O
Wort O O
based O O
on O O
some O O
reports O O
of O O
oral O O
contraceptive B-group B-group
users O O
experiencing O O
breakthrough O O
bleeding O O
shortly O O
after O O
starting O O
St. O O
Johns O O
Wort O O
. O O

In O O
an O O
emergency O O
situation O O
when O O
opioid O B-group
analgesia O I-group
must O O
be O O
administered O O
to O O
a O O
patient O O
receiving O O
REVIA B-brand B-brand
, O O
the O O
amount O O
of O O
opioid B-group B-group
required O O
may O O
be O O
greater O O
than O O
usual O O
, O O
and O O
the O O
resulting O O
respiratory O O
depression O O
may O O
be O O
deeper O O
and O O
more O O
prolonged O O
. O O

The O O
net O O
effect O O
of O O
these O O
interactions O O
is O O
summarized O O
in O O
the O O
following O O
table O O
: O O
AED B-group B-group
AED I-group I-group
Felbatol B-brand B-brand

In O O
these O O
patients O O
, O O
approximately O O
half O O
of O O
the O O
CPK O O
elevations O O
returned O O
to O O
normal O O
within O O
2 O O
weeks O O
and O O
half O O
returned O O
to O O
normal O O
within O O
4 O O
weeks O O
. O O

Studies O O
on O O
the O O
mechanism O O
of O O
action O O
of O O
miconazole B-drug B-drug
: O O
effect O O
of O O
miconazole B-drug B-drug
on O O
respiration O O
and O O
cell O O
permeability O O
of O O
Candida O O
albicans O O
. O O

Concurrent O O
use O O
of O O
these O O
agents O O
should O O
generally O O
be O O
avoided O O
. O O

- O O
Mephenytoin B-drug B-drug
( O O
e.g. O O
, O O
Mesantoin B-brand B-brand
) O O
Use O O
of O O
sulfapyridine B-drug B-drug
with O O
these O O
medicines O O
may O O
increase O O
the O O
chance O O
of O O
side O O
effects O O
of O O
these O O
medicines O O

Such O O
patients O O
may O O
be O O
unresponsive O O
to O O
the O O
usual O O
doses O O
of O O
epinephrine B-drug B-drug
used O O
to O O
treat O O
allergic O O
reaction O O
. O O

1- O O
adrenergic O O
receptor O O
antagonism O O
, O O
aripiprazole B-drug B-drug
has O O
the O O
potential O O
to O O
enhance O O
the O O
effect O O
of O O
certain O O
antihypertensive B-group B-group
agents I-group I-group
. O O

Nephrotoxicity O O
and O O
ototoxicity O O
were O O
not O O
noted O O
when O O
ceftazidime B-drug B-drug
was O O
given O O
alone O O
in O O
clinical O O
trials O O
. O O

Median O O
gastric O O
pH O O
was O O
significantly O O
higher O O
when O O
indinavir B-drug B-drug
was O O
taken O O
after O O
didanosine B-drug B-drug
administration O O
; O O

carbamazepine B-drug B-drug
; O O

Patients O O
taking O O
other O O
drugs O O
that O O
are O O
substrates O O
of O O
CYP450 O O
3A4 O O
, O O
especially O O
patients O O
with O O
renal O O
and/or O O
hepatic O O
impairment O O
, O O
may O O
require O O
dosage O O
adjustment O O
when O O
starting O O
or O O
stopping O O
concomitantly O O
administered O O
diltiazem B-drug B-drug
in O O
order O O
to O O
maintain O O
optimum O O
therapeutic O O
blood O O
levels O O
. O O

The O O
initiated O O
cells O O
that O O
result O O
from O O
this O O
hit O O
may O O
vary O O
from O O
those O O
that O O
demonstrate O O
very O O
little O O
progression O O
in O O
cell O O
type O O
and O O
may O O
or O O
may O O
not O O
require O O
exogenous O O
enhancement O O
of O O
growth O O
to O O
those O O
that O O
can O O
progress O O
very O O
rapidly O O
to O O
fully O O
malignant O O
behavior O O
. O O

Exert O O
particular O O
caution O O
in O O
combining O O
chlorprothixene B-drug B-drug
with O O
other O O
anticholinergic B-group B-group
drugs I-group I-group
( O O
tricyclic B-group B-group
antidepressants I-group I-group
and O O
antiparkinsonian B-group B-group
agents I-group I-group
) O O
: O O
Particularly O O
the O O
elderly O O
may O O
develop O O
delirium O O
, O O
high O O
fever O O
, O O
severe O O
obstipation O O
, O O
even O O
ileus O O
and O O
glaucoma O O
. O O

Poor O O
metabolizers O O
have O O
higher O O
than O O
expected O O
plasma O O
concentrations O O
of O O
tricyclic B-group B-group
antidepressants I-group I-group
( O O
TCAs B-group B-group
) O O
when O O
given O O
usual O O
doses O O
. O O

14C-cholesterol O O
ester O O
fractional O O
clearance O O
rate O O
was O O
260 O O
% O O
greater O O
after O O
etofibrate B-drug B-drug
than O O
after O O
placebo O O
. O O

The O O
mean O O
( O O
SD O O
) O O
cumulative O O
urinary O O
excretion O O
of O O
immunoreactive O O
digoxin B-drug B-drug
after O O
concurrent O O
treatment O O
with O O
rofecoxib B-drug B-drug
or O O
placebo O O
was O O
228.2 O O
( O O
+/- O O
30.8 O O
) O O
and O O
235.1 O O
( O O
+/- O O
39.1 O O
) O O
micrograms/120 O O
hours O O
, O O
respectively O O
. O O

Therefore O O
, O O
ketoconazole B-drug B-drug
should O O
be O O
administered O O
with O O
caution O O
with O O
intranasal O O
ciclesonide B-drug B-drug
. O O

Since O O
the O O
renal O O
excretion O O
of O O
unchanged O O
dasatinib B-drug B-drug
and O O
its O O
metabolites O O
is O O
4 O O
% O O
, O O
a O O
decrease O O
in O O
total O O
body O O
clearance O O
is O O
not O O
expected O O
in O O
patients O O
with O O
renal O O
insufficiency O O
. O O

Estrogen B-group B-group
, O O
Oral O O
Contraceptives B-group B-group
: O O
Estrogens B-group B-group
tend O O
to O O
increase O O
serum O O
thyroxine-binding O O
globulin O O
( O O
TBg O O
) O O
. O O

Although O O
acid-base O O
and O O
electrolyte O O
disturbances O O
were O O
not O O
reported O O
in O O
the O O
clinical O O
trials O O
with O O
dorzolamide B-drug B-drug
, O O
these O O
disturbances O O
have O O
been O O
reported O O
with O O
oral O O
carbonic B-group B-group
anhydrase I-group I-group
inhibitors I-group I-group
and O O
have O O
, O O
in O O
some O O
instances O O
, O O
resulted O O
in O O
drug O O
interactions O O
( O O
e.g. O O
, O O
toxicity O O
associated O O
with O O
high-dose O O
salicylate B-group B-group
therapy O O
) O O
. O O

This O O
is O O
also O O
to O O
be O O
considered O O
when O O
leflunomide B-drug B-drug
treatment O O
is O O
followed O O
by O O
such O O
drugs O O
without O O
a O O
drug O O
elimination O O
procedure O O
. O O

Consequently O O
, O O
plasma O O
concentrations O O
of O O
drugs O O
metabolized O O
by O O
these O O
two O O
isoenzymes O O
will O O
be O O
decreased O O
when O O
TRACLEER B-brand B-brand
is O O
co-administered O O
. O O

Heparin B-drug B-drug
: O O
No O O
human O O
drug O O
interaction O O
studies O O
with O O
heparin B-drug B-drug
were O O
conducted O O
. O O

The O O
effects O O
of O O
mixing O O
NovoLog B-brand B-brand
with O O
insulins B-group O
of O O
animal O O
source O O
or O O
insulin B-drug B-drug
preparations O O
produced O O
by O O
other O O
manufacturers O O
have O O
not O O
been O O
studied O O
. O O

astemizole B-drug B-drug
midazolam I-drug I-drug
, O O
triazolam B-drug B-drug
cisapride I-drug I-drug
ergot O I-drug
derivatives O I-drug
voriconazole B-drug I-drug

In O O
a O O
study O O
in O O
normal O O
volunteers O O
, O O
concomitant O O
administration O O
of O O
buspirone B-drug B-drug
HCl I-drug I-drug
and O O
haloperidol B-drug B-drug
resulted O O
in O O
increased O O
serum O O
haloperidol B-drug B-drug
concentrations O O
. O O

The O O
inhibitory O O
potential O O
of O O
ciclesonide B-drug B-drug
on O O
CYP450 O O
isoenzymes O O
has O O
not O O
been O O
studied O O
. O O

prolonged O O
hot O O
weather O O
; O O

Thus O O
, O O
smaller O O
doses O O
of O O
adenosine B-drug B-drug
may O O
be O O
effective O O
in O O
the O O
presence O O
of O O
dipyridamole B-drug B-drug
. O O

Drugs O O
Prolonging O O
the O O
QT/QTc O O
Interval O O
Caution O O
should O O
be O O
exercised O O
when O O
prescribing O O
apomorphine B-drug B-drug
concomitantly O O
with O O
drugs O O
that O O
prolong O O
the O O
QT/QTc O O
interval O O
. O O

In O O
healthy O O
subjects O O
receiving O O
cimetidine B-drug B-drug
( O O
1 O O
gm O O
daily O O
) O O
for O O
one O O
week O O
, O O
plasma O O
flecainide B-drug B-drug
levels O O
increased O O
by O O
about O O
30 O O
% O O
and O O
half-life O O
increased O O
by O O
about O O
10 O O
% O O
. O O

The O O
effects O O
celecoxib B-drug B-drug
on O O
the O O
pharmacokinetics O O
and/or O O
pharmacodynamics O O
of O O
glyburide B-drug B-drug
, O O
ketoconazole B-drug B-drug
, O O
methotrexate B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
tolbutamide B-drug B-drug
, O O
and O O
warfarin B-drug B-drug
have O O
been O O
studied O O
in O O
vivo O O
and O O
clinically O O
important O O
interactions O O
have O O
not O O
been O O
found O O
. O O

Albuterol B-drug B-drug
, O O
Antihistamines B-group B-group
, O O
antidiabetic B-group B-group
drugs I-group I-group
, O O
diuretics B-group B-group
, O O
digitalis B-group B-group
. O O

Animal O O
data O O
indicated O O
that O O
bupropion B-drug B-drug
may O O
be O O
an O O
inducer O O
of O O
drug-metabolizing O O
enzymes O O
in O O
humans O O
. O O

600-1800 O O

Age O O
( O O
range O O
, O O
17-69 O O
years O O
) O O
, O O
weight O O
( O O
range O O
, O O
49-106 O O
kg O O
) O O
, O O
and O O
sex O O
( O O
65 O O
men O O
and O O
36 O O
women O O
) O O
were O O
not O O
significant O O
contributors O O
to O O
variability O O
. O O

Therefore O O
, O O
if O O
concomitant O O
administration O O
of O O
these O O
agents O O
is O O
indicated O O
, O O
dosing O O
should O O
be O O
separated O O
by O O
2 O O
hours O O
. O O

No O O
separate O O
information O O
available O O

Therefore O O
the O O
, O O
combination O O
of O O
anakinra B-drug B-drug
with O O
other O O
TNF-blocking B-group B-group
agents I-group I-group
, O O
including O O
HUMIRA B-brand B-brand
, O O
may O O
also O O
result O O
i O O
n O O
similar O O
toxicities O O
. O O

Co-administration O O
of O O
aliskiren B-drug B-drug
did O O
not O O
significantly O O
affect O O
the O O
pharmacokinetics O O
of O O
lovastatin B-drug B-drug
, O O
digoxin B-drug B-drug
, O O
valsartan B-drug B-drug
, O O
amlodipine B-drug B-drug
, O O
metformin B-drug B-drug
, O O
celecoxib B-drug B-drug
, O O
atenolol B-drug B-drug
, O O
atorvastatin B-drug B-drug
, O O
ramipril B-drug B-drug
or O O
hydrochlorothiazide B-drug B-drug
. O O

The O O
onset O O
of O O
neuromuscular O O
blockade O O
by O O
succinylcholine B-drug B-drug
was O O
unaffected O O
by O O
BREVIBLOC B-brand B-brand
, O O
but O O
the O O
duration O O
of O O
neuromuscular O O
blockade O O
was O O
prolonged O O
from O O
5 O O
minutes O O
to O O
8 O O
minutes O O
. O O

Therefore O O
, O O
patients O O
concurrently O O
taking O O
antiseizure O B-group
medication O I-group
and O O
Mefloquine B-drug B-drug
should O O
have O O
the O O
blood O O
level O O
of O O
their O O
antiseizure O B-group
medication O I-group
monitored O O
and O O
the O O
dosage O O
adjusted O O
appropriately O O
. O O

Therefore O O
, O O
drugs O O
that O O
affect O O
CYP3A4 O O
and/or O O
Pgp O O
, O O
may O O
modify O O
the O O
pharmacokinetics O O
of O O
saquinavir B-drug B-drug
. O O

There O O
is O O
no O O
clinical O O
experience O O
to O O
date O O
on O O
the O O
use O O
of O O
Femara B-brand B-brand
in O O
combination O O
with O O
other O O
anticancer O B-group
agents O I-group
. O O

Due O O
to O O
wide O O
interindividual O O
variability O O
in O O
the O O
dose O O
adjustment O O
required O O
, O O
it O O
is O O
recommended O O
that O O
cyclosporine B-drug B-drug
concentrations O O
be O O
monitored O O
closely O O
after O O
initiation O O
of O O
carvedilol B-drug B-drug
therapy O O
and O O
that O O
the O O
dose O O
of O O
cyclosporine B-drug B-drug
be O O
adjusted O O
as O O
appropriate O O
. O O

Patients O O
who O O
are O O
treated O O
with O O
ZYVOX B-brand B-brand
and O O
concomitant O O
serotonergic B-group B-group
agents I-group I-group
should O O
be O O
closely O O
observed O O
for O O
signs O O
and O O
symptoms O O
of O O
serotonin O O
syndrome O O
( O O
e.g. O O
, O O
cognitive O O
dysfunction O O
, O O
hyperpyrexia O O
, O O
hyperreflexia O O
, O O
incoordination O O
) O O
. O O

Misonidazole B-drug_n B-drug_n
protects O O
mouse O O
tumour O O
and O O
normal O O
tissues O O
from O O
the O O
toxicity O O
of O O
oral O O
CCNU B-drug B-drug
. O O

Serial O O
pharmacokinetic O O
dosing O O
has O O
been O O
proposed O O
as O O
a O O
method O O
to O O
accomplish O O
this O O
goal O O
. O O

clarithromycin I-drug B-drug
concentration O O

Among O O
494 O O
subjects O O
who O O
received O O
Angiomax B-brand B-brand
in O O
clinical O O
trials O O
and O O
were O O
tested O O
for O O
antibodies O O
, O O
2 O O
subjects O O
had O O
treatment-emergent O O
positive O O
bivalirudin B-drug O
antibody O O
tests O O
. O O

The O O
effect O O
of O O
theophylline B-drug B-drug
on O O
the O O
pharmacokinetics O O
of O O
citalopram B-drug B-drug
was O O
not O O
evaluated O O
. O O

Safety O O
and O O
effectiveness O O
in O O
children O O
has O O
not O O
been O O
established O O
. O O

Except O O
in O O
life-threatening O O
situations O O
, O O
avoid O O
this O O
combination O O
. O O

Evoked O O
hind O O
limb O O
digital O O
extensor O O
tension O O
( O O
hoof O O
twitch O O
) O O
was O O
maintained O O
at O O
40 O O
% O O
of O O
baseline O O
for O O
1 O O
h O O
by O O
atracurium B-drug B-drug
infusion O O
in O O
7 O O
horses O O
anaesthetised O O
with O O
halothane B-drug B-drug
. O O

Ritonavir B-drug B-drug
- O O
Combined O O
administration O O
of O O
a O O
single O O
dose O O
of O O
ritonavir B-drug B-drug
( O O
600 O O
mg O O
) O O
, O O
both O O
a O O
CYP3A4 O O
substrate O O
and O O
a O O
potent O O
inhibitor O O
of O O
CYP3A4 O O
, O O
and O O
escitalopram B-drug B-drug
( O O
20 O O
mg O O
) O O
did O O
not O O
affect O O
the O O
pharmacokinetics O O
of O O
either O O
ritonavir B-drug B-drug
or O O
escitalopram B-drug B-drug
. O O

We O O
investigated O O
the O O
effects O O
of O O
adenosine O B-group
receptor O I-group
antagonists O I-group
, O O
caffeine B-drug B-drug
, O O
theophylline B-drug B-drug
, O O
8-phenyltheophylline B-drug_n B-drug
, O O
and O O
8-cyclopentyl-1,3-dipropylxanthine B-drug_n B-drug
( O O
DPCPX B-drug_n B-brand
) O O
, O O
in O O
a O O
light/dark O O
test O O
in O O
mice O O
. O O

b-Adrenergic B-group B-group
Blocking I-group I-group
Agents I-group I-group
: O O
Actions O O
of O O
some O O
of O O
beta-blocking B-group B-group
agents I-group I-group
may O O
be O O
impaired O O
when O O
hypothyroid O O
patients O O
become O O
euthyroid O O
. O O

In O O
these O O
trials O O
, O O
heart O O
rate O O
and O O
systolic O O
blood O O
pressure O O
were O O
approximately O O
2-3 O O
bpm O O
and O O
6-8 O O
mm O O
Hg O O
higher O O
, O O
respectively O O
, O O
in O O
subjects O O
on O O
concomitant O O
theophylline B-drug B-drug
compared O O
with O O
the O O
overall O O
population O O
. O O

( O O
Both O O
drugs O O
were O O
thus O O
dosed O O
to O O
steady O O
state O O
. O O
) O O

Efavirenz B-drug B-drug

Concomitant O O
treatment O O
with O O
thrombolytics B-group B-group
( O O
eg O O
, O O
rt-PA O O
or O O
streptokinase B-drug O
) O O
may O O
: O O
- O O
increase O O
the O O
risk O O
of O O
bleeding O O
complications O O
- O O
considerably O O
enhance O O
the O O
effect O O
of O O
REFLUDAN B-brand B-brand
on O O
aPTT O O
prolongation O O

When O O
duloxetine B-drug B-drug
was O O
administered O O
( O O
at O O
a O O
dose O O
of O O
60 O O
mg O O
BID O O
) O O
in O O
conjunction O O
with O O
a O O
single O O
50-mg O O
dose O O
of O O
desipramine B-drug B-drug
, O O
a O O
CYP2D6 O O
substrate O O
, O O
the O O
AUC O O
of O O
desipramine B-drug B-drug
increased O O
3-fold O O
. O O

WARFARIN B-drug B-brand
: O O
Co- O O
administration O O
of O O
warfarin B-drug B-drug
and O O
cerivastatin B-drug B-drug
to O O
healthy O O
volunteers O O
did O O
not O O
result O O
in O O
any O O
changes O O
in O O
prothrombin O O
time O O
or O O
clotting O O
factor O O
VII O O
when O O
compared O O
to O O
co-administration O O
of O O
warfarin B-drug B-drug
and O O
placebo O O
. O O

It O O
would O O
be O O
expected O O
that O O
laxative B-group O
use O O
during O O
therapy O O
with O O
CAMPTOSAR B-brand B-brand
would O O
worsen O O
the O O
incidence O O
or O O
severity O O
of O O
diarrhea O O
, O O
but O O
this O O
has O O
not O O
been O O
studied O O
. O O

Pharmacokinetic O O
evaluation O O
of O O
the O O
digoxin-amiodarone B-drug B-drug
interaction O O
. O O

Increasing O O
the O O
indinavir B-drug B-drug
dose O O
to O O
1000 O O
mg O O
every O O
8 O O
hours O O
does O O
not O O
compensate O O
for O O
the O O
increased O O
indinavir B-drug B-drug
metabolism O O
due O O
to O O
SUSTIVA B-brand B-brand
. O O

Convulsions O O
have O O
been O O
reported O O
with O O
this O O
concurrent O O
use O O
. O O

The O O
effect O O
of O O
desflurane B-drug B-drug
on O O
the O O
disposition O O
of O O
other O O
drugs O O
has O O
not O O
been O O
determined O O
. O O

Hormonal O B-group
contraceptives B-group I-group
Co-administration O O
of O O
Trileptal B-brand B-brand
with O O
an O O
oral O O
contraceptive B-group B-group
has O O
been O O
shown O O
to O O
influence O O
the O O
plasma O O
concentrations O O
of O O
the O O
two O O
hormonal O O
components O O
, O O
ethinylestradiol B-drug B-drug
( O O
EE O O
) O O
and O O
levonorgestrel B-drug B-drug
( O O
LNG O O
) O O
. O O

RAPTIVA B-brand B-brand
should O O
not O O
be O O
used O O
with O O
other O O
immunosuppressive B-group B-group
drugs I-group I-group
. O O

In O O
5 O O
other O O
schizophrenic O O
patients O O
treated O O
with O O
oral O O
haloperidol B-drug B-drug
and O O
rifampin B-drug B-drug
, O O
discontinuation O O
of O O
rifampin B-drug B-drug
produced O O
a O O
mean O O
3.3-fold O O
increase O O
in O O
haloperidol B-drug B-drug
concentrations O O
. O O

When O O
such O O
drugs O O
are O O
withdrawn O O
from O O
a O O
patient O O
receiving O O
glipizide B-drug B-drug
, O O
the O O
patient O O
should O O
be O O
observed O O
closely O O
for O O
loss O O
of O O
control O O
. O O

This O O
may O O
be O O
due O O
to O O
an O O
improved O O
glucose O O
utilization O O
with O O
simultaneous O O
reduction O O
in O O
insulin B-drug B-drug
requirement O O

Cyclopropane B-drug B-drug
or O O
halogenated B-group B-group
hydrocarbon I-group I-group
anesthetics I-group I-group
increase O O
cardiac O O
autonomic O O
irritability O O
and O O
may O O
sensitize O O
the O O
myocardium O O
to O O
the O O
action O O
of O O
certain O O
intravenously O O
administered O O
catecholamines B-group B-group
, O O
such O O
as O O
dopamine B-drug B-drug
. O O

Esomeprazole B-drug B-drug
may O O
potentially O O
interfere O O
with O O
CYP2C19 O O
, O O
the O O
major O O
esomeprazole B-drug B-drug
metabolizing O O
enzyme O O
. O O

Ketoconazole B-drug B-drug
: O O
Ketoconazole B-drug B-drug
may O O
inhibit O O
both O O
synthetic O O
and O O
catabolic O O
enzymes O O
of O O
vitamin B-group B-group
D I-group I-group
. O O

* O O
This O O
table O O
is O O
not O O
all O O
inclusive O O
** O O
VIRACEPT B-brand B-brand
may O O
not O O
be O O
effective O O
due O O
to O O
decreased O O
nelfinavir B-drug B-drug
plasma O O
concentrations O O
in O O
patients O O
taking O O
these O O
agents O O
concomitantly O O

The O O
effects O O
of O O
allopurinol B-drug B-drug
on O O
didanosine B-drug B-drug
pharmacokinetics O O
in O O
subjects O O
with O O
normal O O
renal O O
function O O
are O O
not O O
known O O
. O O

Therefore O O
, O O
diphenoxylate B-drug B-drug
has O O
the O O
potential O O
to O O
prolong O O
the O O
biological O O
half-lives O O
of O O
drugs O O
for O O
which O O
the O O
rate O O
of O O
elimination O O
is O O
dependent O O
on O O
the O O
microsomal O O
drug O O
metabolizing O O
enzyme O O
system O O
. O O

Digoxin B-drug B-drug
- O O
In O O
subjects O O
who O O
had O O
received O O
21 O O
days O O
of O O
40 O O
mg/day O O
racemic O O
citalopram B-drug B-drug
, O O
combined O O
administration O O
of O O
citalopram B-drug B-drug
and O O
digoxin B-drug B-drug
( O O
single O O
dose O O
of O O
1 O O
mg O O
) O O
did O O
not O O
significantly O O
affect O O
the O O
pharmacokinetics O O
of O O
either O O
citalopram B-drug B-drug
or O O
digoxin B-drug B-drug
. O O

Valproic B-drug B-drug
Acid I-drug I-drug
: O O
The O O
mean O O
steady-state O O
trough O O
serum O O
valproic B-drug B-drug
acid I-drug I-drug
concentrations O O
prior O O
to O O
and O O
during O O
concomitant O O
gabapentin B-drug B-drug
administration O O
( O O
400 O O
mg O O
TID O O
; O O

Tricyclic B-group B-group
antidepressants I-group I-group
have O O
been O O
reported O O
to O O
blunt O O
the O O
hypotensive O O
effect O O
of O O
systemic O O
clonidine.It B-drug O
is O O
not O O
known O O
whether O O
the O O
concurrent O O
use O O
of O O
these O O
agents O O
with O O
ALPHAGAN B-brand B-brand
P I-brand O
in O O
humans O O
can O O
lead O O
to O O
resulting O O
interference O O
with O O
the O O
IOP O O
lowering O O
effect O O
. O O

DIAGNOSTIC O O
INTERFERENCE O O
With O O
expected O O
physiologic O O
effects O O
: O O
Blood O O
and O O
urine O O
glucose O O
levels O O
( O O
usually O O
only O O
in O O
patients O O
with O O
a O O
predisposition O O
for O O
glucose O O
intolerance O O
) O O
and O O
Serum O O
bilirubin O O
levels O O
( O O
by O O
displacement O O
from O O
albumin O O
binding O O
) O O
and O O
Serum O O
calcium O O
levels O O
( O O
thiazide B-group B-group
diuretics I-group I-group
should O O
be O O
discontinued O O
before O O
parathyroid-function O O
tests O O
are O O
carried O O
out O O
) O O
and O O
Serum O O
uric O O
acid O O
levels O O
( O O
may O O
be O O
increased O O
) O O
Serum O O
magnesium O B-drug
, O O
potassium O O
, O O
and O O
sodium O O
levels O O
( O O
may O O
be O O
decreased O O
; O O

Anastrozole B-drug B-drug
did O O
not O O
inhibit O O
P450 O O
2A6 O O
or O O
the O O
polymorphic O O
P450 O O
2D6 O O
in O O
human O O
liver O O
microsomes O O
. O O

In O O
addition O O
, O O
oxcarbazepine B-drug B-drug
and O O
MHD B-drug_n B-drug_n
induce O O
a O O
subgroup O O
of O O
the O O
cytochrome O O
P450 O O
3A O O
family O O
( O O
CYP3A4 O O
and O O
CYP3A5 O O
) O O
responsible O O
for O O
the O O
metabolism O O
of O O
dihydropyridine B-group B-group
calcium I-group I-group
antagonists I-group I-group
and O O
oral O O
contraceptives B-group B-group
, O O
resulting O O
in O O
a O O
lower O O
plasma O O
concentration O O
of O O
these O O
drugs O O
. O O

Gentamicin B-drug B-drug
did O O
not O O
interfere O O
with O O
the O O
activity O O
of O O
clindamycin B-drug B-drug
within O O
the O O
range O O
of O O
concentrations O O
tested O O
( O O
0.1 O O
to O O
100 O O
mug/ml O O
) O O
; O O

Plasma O O
concentrations O O
may O O
be O O
increased O O
by O O
CRIXIVAN B-brand B-brand
. O O

Intraventricular O O
injection O O
of O O
beta-endorphin B-drug_n B-drug_n
and O O
morphine B-drug B-drug
produced O O
an O O
inhibition O O
of O O
the O O
tail-flick O O
response O O
to O O
the O O
heat O O
stimulus O O
in O O
rats O O
. O O

Interaction O O
of O O
GABITRIL B-brand B-brand
with O O
Other O O
Drugs O O
: O O
Cimetidine B-drug B-drug
: O O
Co-administration O O
of O O
cimetidine B-drug B-drug
( O O
800 O O
mg/day O O
) O O
to O O
patients O O
taking O O
tiagabine B-drug B-drug
chronically O O
had O O
no O O
effect O O
on O O
tiagabine B-drug B-drug
pharmacokinetics O O
. O O

The O O
following O O
are O O
examples O O
of O O
substances O O
that O O
may O O
increase O O
the O O
blood-glucose-lowering O O
effect O O
and O O
susceptibility O O
to O O
hypoglycemia O O
: O O
oral O O
antidiabetic B-group B-group
products I-group I-group
, O O
ACE B-group B-group
inhibitors I-group I-group
, O O
disopyramide B-drug B-drug
, O O
fibrates B-group B-group
, O O
fluoxetine B-drug B-drug
, O O
monoamine B-group B-group
oxidase I-group I-group
( I-group I-group
MAO I-group I-group
) I-group I-group
inhibitors I-group I-group
, O O
propoxyphene B-drug B-drug
, O O
salicylates B-group B-group
, O O
somatostatin B-group B-group
analog I-group I-group
( O O
e.g. O O
, O O
octreotide B-drug B-drug
) O O
, O O
sulfonamide B-group B-group
antibiotics I-group I-group
. O O

However O O
, O O
the O O
pharmacodynamic O O
effect O O
increased O O
by O O
190 O O
% O O
( O O
QTc O O
increase O O
over O O
time O O
) O O
and O O
by O O
84 O O
% O O
( O O
Maximum O O
QTc O O
increase O O
) O O
. O O

Mutagenesis O O
PEGASYS B-brand B-brand
did O O
not O O
cause O O
DNA O O
damage O O
when O O
tested O O
in O O
the O O
Ames O O
bacterial O O
mutagenicity O O
assay O O
and O O
in O O
the O O
in O O
vitro O O
chromosomal O O
aberration O O
assay O O
in O O
human O O
lymphocytes O O
, O O
either O O
in O O
the O O
presence O O
or O O
absence O O
of O O
metabolic O O
activation O O
. O O

Ganciclovir B-drug B-drug
: O O
Administration O O
of O O
VIDEX B-brand B-brand
2 O O
hours O O
prior O O
to O O
or O O
concurrent O O
with O O
oral O O
ganciclovir B-drug B-drug
was O O
associated O O
with O O
a O O
111 O O
( O O
114 O O
) O O
% O O
increase O O
in O O
the O O
steady-state O O
AUC O O
of O O
didanosine B-drug B-drug
( O O
n O O
= O O
12 O O
) O O
. O O

In O O
addition O O
, O O
certain O O
drugs O O
that O O
are O O
metabolized O O
by O O
this O O
isoenzyme O O
, O O
including O O
many O O
antidepressants B-group B-group
( O O
tricyclic B-group B-group
antidepressants I-group I-group
, O O
selective B-group B-group
serotonin I-group I-group
reuptake I-group I-group
inhibitors I-group I-group
, O O
and O O
others O O
) O O
, O O
may O O
inhibit O O
the O O
activity O O
of O O
this O O
isoenzyme O O
, O O
and O O
thus O O
may O O
make O O
normal O O
metab-olizers O O
resemble O O
poor O O
metabolizers O O
with O O
regard O O
to O O
concomitant O O
therapy O O
with O O
other O O
drugs O O
metabolized O O
by O O
this O O
enzyme O O
system O O
, O O
leading O O
to O O
drug O O
interactions O O
. O O

in O O
one O O
man O O
, O O
the O O
C O O
max O O
of O O
terfenadine B-drug B-drug
was O O
8.1 O O
ng/mL O O
with O O
terfenadine B-drug B-drug
alone O O
and O O
7.2 O O
ng/mL O O
with O O
terfenadine B-drug B-drug
plus O O
dirithromycin B-drug B-drug
. O O

The O O
mechanism O O
( O O
s O O
) O O
of O O
altered O O
topo O O
I O O
expression O O
in O O
certain O O
tumor O O
types O O
is O O
unknown O O
, O O
but O O
may O O
be O O
related O O
to O O
the O O
central O O
importance O O
of O O
topoisomerases O O
in O O
proliferating O O
cell O O
functions O O
( O O
transcription O O
, O O
replication O O
, O O
etc O O
. O O
) O O
, O O
and O O
the O O
aberrant O O
and O O
chronic O O
activation O O
of O O
these O O
functions O O
as O O
a O O
result O O
of O O
specific O O
tumorigenic O O
alterations O O
. O O

All O O
subjects O O
received O O
amprenavir B-drug B-drug
( O O
1,200 O O
mg O O
twice O O
a O O
day O O
) O O
for O O
4 O O
days O O
, O O
followed O O
by O O
a O O
7-day O O
washout O O
period O O
, O O
followed O O
by O O
either O O
rifabutin B-drug B-drug
( O O
300 O O
mg O O
once O O
a O O
day O O
[ O O
QD O O
] O O
) O O
( O O
cohort O O
1 O O
) O O
or O O
rifampin B-drug B-drug
( O O
600 O O
mg O O
QD O O
) O O
( O O
cohort O O
2 O O
) O O
for O O
14 O O
days O O
. O O

Prospective O O
, O O
long-term O O
studies O O
on O O
concomitant O O
administration O O
of O O
VIOXX B-brand B-brand
and O O
aspirin B-brand B-brand
have O O
not O O
been O O
conducted O O
. O O

therefore O O
, O O
it O O
is O O
theoretically O O
possible O O
that O O
lansoprazole B-drug B-drug
may O O
interfere O O
with O O
the O O
absorption O O
of O O
drugs O O
where O O
gastric O O
pH O O
is O O
an O O
important O O
determinant O O
of O O
bioavailability O O
( O O
e.g O O
. O O
ketoconazole B-drug B-drug
, O O
ampicillin B-drug B-drug
esters O I-drug
, O O
iron B-drug B-drug
salts O O
, O O
digoxin B-drug B-drug
) O O
. O O

Use O O
of O O
MAO B-group B-group
inhibitors I-group I-group
may O O
cause O O
an O O
excessive O O
increase O O
in O O
blood O O
pressure O O
and O O
heart O O
stimulation O O
. O O

Dosage O O
adjustment O O
of O O
STRATTERA B-brand B-brand
may O O
be O O
necessary O O
when O O
coadministered O O
with O O
CYP2D6 O O
inhibitors O O
, O O
e.g. O O
, O O
paroxetine B-drug B-drug
, O O
fluoxetine B-drug B-drug
, O O
and O O
quinidine B-drug B-drug
. O O

Data O O
from O O
a O O
randomized O O
trial O O
of O O
HEXALEN B-brand B-brand
and O O
cisplatin B-drug B-drug
plus O O
or O O
minus O O
pyridoxine B-drug B-drug
in O O
ovarian O O
cancer O O
indicated O O
that O O
pyridoxine B-drug B-drug
significantly O O
reduced O O
neurotoxicity O O
; O O

May O O
lead O O
to O O
loss O O
of O O
virologic O O
response O O
and O O
possible O O
resistance O O
to O O
CRIXIVAN B-brand B-brand
or O O
to O O
the O O
class O O
of O O
protease B-group B-group
inhibitors I-group I-group
. O O

Antineoplastic B-group B-group
agents I-group I-group
( O O
e. O O
g. O O
, O O
nitrogen B-drug B-drug
mustard I-drug I-drug
, O O
etc O O
. O O
) O O
should O O
be O O
given O O
concomitantly O O
only O O
with O O
great O O
caution O O
. O O

These O O
observations O O
suggest O O
that O O
exogenous O O
co-factors O O
could O O
be O O
involved O O
in O O
the O O
occurrence O O
of O O
ARE O O
. O O

bromelains B-drug B-group
; O O

Anticholinesterases B-group B-group
( O O
neostgmine O B-drug
, O O
physostigmine B-drug B-drug
) O O
, O O
lignocaine B-drug B-drug
, O O
quinine B-drug B-drug
, O O
procainamide B-drug B-drug
can O O
enhance O O
toxicity O O
and O O
cause O O
cardio O O
respiratory O O
depression O O
. O O

increased O O
norepinephrine-induced O O
platel O O
et O O
aggregation O O
; O O

Vardenafil B-drug B-drug

Binding O O
to O O
Serum O O
Proteins O O
: O O
The O O
following O O
agents O O
may O O
either O O
inhibit O O
levothyroxine B-drug B-drug
sodium I-drug I-drug
binding O O
to O O
serum O O
proteins O O
or O O
alter O O
the O O
concentrations O O
of O O
serum O O
binding O O
proteins O O
: O O
androgens B-group B-group
and O O
related O O
anabolic B-group B-group
hormones I-group I-group
, O O
asparaginase B-drug O
, O O
clofibrate B-drug B-drug
, O O
estrogens B-group B-group
and O O
estrogen-containing B-group B-group
compounds I-group I-group
, O O
5-fluorouracil B-drug B-drug
, O O
furosemide B-drug B-drug
, O O
glucocorticoids B-group B-group
, O O
meclofenamic B-drug B-drug
acid I-drug I-drug
, O O
mefenamic B-drug B-drug
acid I-drug I-drug
, O O
methadone B-drug B-drug
, O O
perphenazine B-drug B-drug
, O O
phenylbutazone B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
salicylates B-group B-group
, O O
tamoxifen B-drug B-drug
. O O

Paroxetine B-drug B-drug
: O O
Coadministration O O
of O O
once O O
daily O O
doses O O
of O O
aprepitant B-drug B-drug
, O O
as O O
a O O
tablet O O
formulation O O
comparable O O
to O O
85 O O
mg O O
or O O
170 O O
mg O O
of O O
the O O
capsule O O
formulation O O
, O O
with O O
paroxetine B-drug B-drug
20 O O
mg O O
once O O
daily O O
, O O
resulted O O
in O O
a O O
decrease O O
in O O
AUC O O
by O O
approximately O O
25 O O
% O O
and O O
Cmax O O
, O O
by O O
approximately O O
20 O O
% O O
of O O
both O O
aprepitant B-drug B-drug
and O O
paroxetine B-drug B-drug
. O O

Sumatriptan B-drug B-drug
: O O
Sumatriptan B-drug B-drug
has O O
been O O
reported O O
to O O
cause O O
coronary O O
artery O O
vasospasm O O
, O O
and O O
its O O
effect O O
could O O
be O O
additive O O
with O O
D.H.E B-brand B-brand
. I-brand O
45 I-brand B-brand
( O O
dihydroergotamine B-drug B-drug
mesylate I-drug I-drug
) O O
Injection O O
, O O
USP O O
. O O

It O O
was O O
shown O O
that O O
neurotensin B-drug_n B-drug_n
antagonized O O
evidently O O
the O O
antinociceptive O O
effect O O
of O O
enkephalins B-drug_n B-group
and O O
their O O
analogue O O
. O O

If O O
signs O O
and O O
symptoms O O
suggestive O O
of O O
digoxin B-drug B-drug
toxicity O O
occur O O
when O O
enoxacin B-drug B-drug
and O O
digoxin B-drug B-drug
are O O
given O O
concomitantly O O
, O O
physicians O O
are O O
advised O O
to O O
obtain O O
serum O O
digoxin B-drug B-drug
levels O O
and O O
adjust O O
digoxin B-drug B-drug
doses O O
appropriately O O
. O O

Antidiabetic B-group B-group
drugs I-group I-group
( O O
oral O O
agents O O
and O O
insulin B-drug B-drug
) O O
: O O
hypoglycemia O O
or O O
hyperglycemia O O
; O O

The O O
effect O O
of O O
rifampin B-drug B-drug
on O O
the O O
warfarin B-drug B-drug
requirement O O
of O O
our O O
patient O O
appeared O O
to O O
be O O
maximal O O
5 O O
to O O
7 O O
days O O
after O O
the O O
initiation O O
of O O
rifampin B-drug B-drug
and O O
extended O O
a O O
similar O O
length O O
of O O
time O O
after O O
rifampin B-drug B-drug
withdrawal O O
. O O

The O O
ratio O O
between O O
the O O
liver O O
weight O O
and O O
body O O
weight O O
was O O
found O O
to O O
be O O
lower O O
in O O
the O O
treated O O
animals O O
than O O
in O O
the O O
control O O
group O O
. O O

Other O O
Potentially O O
Clinically O O
Significant O O
Drug O O
or O O
Herbal O O
Product O O
Interactions O O
With O O
SUSTIVAb O B-brand

With O O
oral O O
dapsone B-drug B-drug
treatment O O
, O O
folic B-group B-group
acid I-group I-group
antagonists I-group I-group
such O O
as O O
pyrimethamine B-drug B-drug
have O O
been O O
noted O O
to O O
possibly O O
increase O O
the O O
likelihood O O
of O O
hematologic O O
reactions O O

Ketoconazole B-drug B-drug
increased O O
mean O O
alosetron B-drug B-drug
plasma O O
concentrations O O
( O O
AUC O O
) O O
by O O
29 O O
% O O
. O O

Although O O
the O O
specific O O
drug O O
interaction O O
was O O
not O O
studied O O
in O O
a O O
clinical O O
trial O O
, O O
there O O
have O O
been O O
more O O
than O O
50 O O
episodes O O
of O O
concomitant O O
use O O
of O O
antifibrinolytic O B-group
therapies O I-group
( O O
i.e. O O
, O O
tranexamic B-drug B-drug
acid I-drug I-drug
, O O
aminocaproic B-drug B-drug
acid I-drug I-drug
) O O
and O O
NovoSeven B-brand B-brand
. O O

Urinary O O
excretion O O
and O O
renal O O
clearance O O
were O O
correspondingly O O
reduced O O
. O O

During O O
transfer O O
to O O
oral O O
amiodarone B-drug B-drug
, O O
the O O
dose O O
levels O O
of O O
previously O O
administered O O
agents O O
should O O
be O O
reduced O O
by O O
30 O O
to O O
50 O O
% O O
several O O
days O O
after O O
the O O
addition O O
of O O
oral O O
amiodarone B-drug B-drug
. O O

Ketoconazole B-drug B-drug
: O O
Coadministration O O
of O O
ketoconazole B-drug B-drug
( O O
200 O O
mg/day O O
for O O
14 O O
days O O
) O O
with O O
a O O
15-mg O O
single O O
dose O O
of O O
aripiprazole B-drug B-drug
increased O O
the O O
AUC O O
of O O
aripiprazole B-drug B-drug
and O O
its O O
active O O
metabolite O O
by O O
63 O O
% O O
and O O
77 O O
% O O
, O O
respectively O O
. O O

Survanta B-brand B-brand
also O O
increased O O
rate O O
of O O
dissolution O O
, O O
in O O
a O O
manner O O
similar O O
to O O
sodium B-drug_n B-drug
dodecyl I-drug_n I-drug
sulfate I-drug_n I-drug
. O O

Since O O
drowsiness O O
may O O
occur O O
with O O
use O O
of O O
this O O
drug O O
, O O
patients O O
should O O
be O O
warned O O
of O O
this O O
possibility O O
and O O
cautioned O O
against O O
driving O O
a O O
car O O
or O O
operating O O
dangerous O O
machinery O O
while O O
taking O O
Atarax B-brand B-brand
. O O

Dolasetron B-drug B-drug
mesylate I-drug I-drug
did O O
not O O
inhibit O O
the O O
antitumor O O
activity O O
of O O
four O O
chemotherapeutic B-group B-group
agents I-group I-group
( O O
cisplatin B-drug B-drug
, O O
5-fluorouracil B-drug B-drug
, O O
doxorubicin B-drug B-drug
, O O
cyclophosphamide B-drug B-drug
) O O
in O O
four O O
murine O O
models O O
. O O

Bisphosphonates B-group B-group
are O O
known O O
to O O
interfere O O
with O O
the O O
use O O
of O O
bone-imaging O B-group
agents O I-group
. O O

An O O
additive O O
hypotensive O O
effect O O
has O O
been O O
reported O O
with O O
the O O
combination O O
of O O
systemic O O
clonidine B-drug B-drug
and O O
neuroleptic B-group O
therapy O O
. O O

Nizatidine B-drug B-drug
does O O
not O O
inhibit O O
the O O
cytochrome O O
P-450-linked O O
drug-metabolizing O O
enzyme O O
system O O
; O O

Aspirin B-brand B-brand
should O O
be O O
used O O
cautiously O O
in O O
conjunction O O
with O O
cortico-steroids B-group B-group
in O O
patients O O
suffering O O
from O O
hypopro-thrombinemia O O
. O O

RATIONALE O O
: O O
Stress O O
and O O
glucocorticoids B-group B-group
facilitate O O
and O O
reinstate O O
psychostimulant O B-drug
self-administration O O
in O O
rodents O O
. O O

Methotrexate B-drug B-drug
: O O
NSAIDs B-group B-group
have O O
been O O
reported O O
to O O
competitively O O
inhibit O O
methotrexate B-drug B-drug
accumulation O O
in O O
rabbit O O
kidney O O
slices O O
. O O

However O O
, O O
co-administration O O
of O O
Duloxetine B-drug B-drug
with O O
aluminum- B-drug B-drug
and O O
magnesium-containing B-drug B-drug
antacids B-group B-group
( O O
51 O O
mEq O O
) O O
or O O
Duloxetine B-drug B-drug
with O O
famotidine B-drug B-drug
, O O
had O O
no O O
significant O O
effect O O
on O O
the O O
rate O O
or O O
extent O O
of O O
duloxetine B-drug B-drug
absorption O O
after O O
administration O O
of O O
a O O
40-mg O O
oral O O
dose O O
. O O

It O O
is O O
indicated O O
that O O
the O O
first O O
and O O
second O O
contractile O O
responses O O
to O O
PTX B-drug_n B-drug_n
have O O
entirely O O
different O O
properties O O
. O O

Dopamine O B-drug
( O O
DA O O
) O O
levels O O
did O O
not O O
differ O O
significantly O O
in O O
either O O
striatum O O
( O O
STR O O
) O O
or O O
nucleus O O
accumbens O O
( O O
NAC O O
) O O
for O O
the O O
cocaine-treated B-drug B-drug
animals O O
to O O
their O O
corresponding O O
saline-treated O O
controls O O
. O O

Other O O
: O O
Coadministration O O
of O O
grapefruit O O
juice O O
with O O
cisapride B-drug B-drug
increases O O
the O O
bioavailability O O
of O O
cisapride B-drug B-drug
and O O
concomitant O O
use O O
should O O
be O O
avoided O O
. O O

ACE B-group B-group
inhibitors I-group I-group
: O O
Reports O O
suggest O O
that O O
NSAIDs B-group B-group
may O O
diminish O O
the O O
antihypertensive O O
effect O O
of O O
Angiotensin B-group B-group
Converting I-group I-group
Enzyme I-group I-group
( I-group I-group
ACE I-group I-group
) I-group I-group
inhibitors I-group I-group
. O O

Similarly O O
, O O
the O O
acute O O
toxicity O O
was O O
also O O
diminished O O
by O O
a O O
DMF O O
of O O
0.74 O O
. O O

Therefore O O
, O O
careful O O
monitoring O O
of O O
blood O O
glucose O O
is O O
recommended O O
when O O
these O O
agents O O
are O O
coadministered O O
. O O

Drug-drug O O
interactions O O
In O O
vitro O O
studies O O
using O O
human O O
liver O O
microsomes O O
indicate O O
that O O
fenofibrate B-drug B-drug
and O O
fenofibric B-drug_n B-drug
acid I-drug_n I-drug
are O O
not O O
inhibitors O O
of O O
cytochrome O O
( O O
CYP O O
) O O
P450 O O
isoforms O O
CYP3A4 O O
, O O
CYP2D6 O O
, O O
CYP2E1 O O
, O O
or O O
CYP1A2 O O
. O O

Drugs O O
that O O
may O O
have O O
their O O
plasma O O
concentration O O
altered O O
by O O
dasatinib B-drug B-drug
CYP3A4 O O
Substrates O O
: O O
Dasatinib B-drug B-drug
is O O
a O O
time-dependent O O
inhibitor O O
of O O
CYP3A4 O O
. O O

Evidence O O
for O O
reduction O O
of O O
norepinephrine B-drug B-drug
uptake O O
sites O O
in O O
the O O
failing O O
human O O
heart O O
. O O

metabolizers O O
. O O

The O O
effects O O
of O O
tricyclic B-group B-group
antidepressants I-group I-group
on O O
clonidines B-drug B-group
analgesic O I-group
actions O O
are O O
not O O
known O O
. O O

All O O
subjects O O
received O O
glipizide B-drug B-drug
alone O O
and O O
following O O
treatment O O
with O O
100 O O
mg O O
of O O
fluconazole B-drug B-drug
as O O
a O O
single O O
daily O O
oral O O
dose O O
for O O
seven O O
days O O
. O O

Therefore O O
FORADIL B-brand B-brand
should O O
not O O
be O O
given O O
together O O
with O O
-adrenergic O B-group
blockers O I-group
( O O
including O O
eye O O
drops O O
) O O
unless O O
there O O
are O O
compelling O O
reasons O O
for O O
their O O
use O O
. O O

In O O
addition O O
, O O
deaths O O
have O O
been O O
reported O O
rarely O O
with O O
concomitant O O
administration O O
of O O
terfenadine B-drug B-drug
and O O
erythromycin B-drug B-drug
. O O

It O O
reduced O O
the O O
number O O
of O O
deaths O O
induced O O
by O O
nonlethal O O
( O O
2 O O
mg/kg O O
) O O
dose O O
of O O
endotoxin B-drug_n B-drug_n
but O O
increased O O
the O O
number O O
of O O
deaths O O
induced O O
by O O
a O O
highly O O
lethal O O
dose O O
( O O
8 O O
mg/kg O O
) O O
. O O

and O O
phase O O
3 O O
( O O
days O O
45-52 O O
) O O
: O O
cisapride B-drug B-drug
10 O O
mg O O
4 O O
times/day O O
( O O
days O O
45-51 O O
) O O
plus O O
fluoxetine B-drug B-drug
20 O O
mg/day O O
( O O
days O O
45-52 O O
) O O
. O O

Digoxin B-drug B-drug
: O O
Concomitant O O
administration O O
of O O
tiagabine B-drug B-drug
did O O
not O O
affect O O
the O O
steady-state O O
pharmacokinetics O O
of O O
digoxin B-drug B-drug
or O O
the O O
mean O O
daily O O
trough O O
serum O O
level O O
of O O
digoxin B-drug B-drug
. O O

No O O
dose O O
relationship O O
has O O
been O O
observed O O
. O O

Acetazolamide B-drug B-drug
may O O
prevent O O
the O O
urinary O O
antiseptic O O
effect O O
of O O
methenamine B-drug B-drug
. O O

When O O
administered O O
concurrently O O
, O O
the O O
following O O
drugs O O
may O O
interact O O
with O O
amphotericin B-drug B-drug
B I-drug I-drug
: O O
Antineoplastic B-group B-group
agents I-group I-group
: O O
may O O
enhance O O
the O O
potential O O
for O O
renal O O
toxicity O O
, O O
bronchospasm O O
and O O
hypotension O O
. O O

The O O
last O O
4 O O
chapters O O
cover O O
interactions O O
with O O
drugs O O
and O O
laboratory O O
tests O O
, O O
common O O
side O O
effects O O
, O O
breast O O
feeding O O
, O O
and O O
effective O O
use O O
of O O
POCs B-group B-group
. O O

Patients O O
who O O
have O O
previously O O
received O O
pelvic/ O O
abdominal O O
irradiation O O
are O O
at O O
increased O O
risk O O
of O O
severe O O
myelosuppression O O
following O O
the O O
administration O O
of O O
CAMPTOSAR B-brand B-brand
. O O

Five O O
days O O
of O O
dofetilide B-drug B-drug
treatment O O
did O O
not O O
significantly O O
affect O O
steady-state O O
pharmacokinetic O O
variables O O
of O O
digoxin B-drug B-drug
compared O O
with O O
placebo O O
; O O

For O O
patients O O
with O O
advanced O O
HIV O O
disease O O
and O O
poor-risk O O
AIDS-related O O
Kaposi O O
s O O
sarcoma O O
, O O
TAXOL B-brand B-brand
, O O
at O O
the O O
recommended O O
dose O O
for O O
this O O
disease O O
, O O
can O O
be O O
initiated O O
and O O
repeated O O
if O O
the O O
neutrophil O O
count O O
is O O
at O O
least O O
1000 O O
cells/mm3 O O
. O O

If O O
co-administration O O
is O O
essential O O
, O O
close O O
monitoring O O
may O O
be O O
appropriate O O
. O O

These O O
results O O
suggest O O
that O O
the O O
analgesic O O
effect O O
of O O
STADOL B-brand B-brand
NS I-brand I-brand
may O O
be O O
diminished O O
when O O
it O O
is O O
administered O O
shortly O O
after O O
sumatriptan B-drug B-drug
nasal O I-drug
spray O O
, O O
but O O
by O O
30 O O
minutes O O
any O O
such O O
reduction O O
in O O
effect O O
should O O
be O O
minimal O O
. O O

Clinical O O
significance O O
of O O
reduced O O
efavirenz B-drug B-drug
concentrations O O
unknown O O
. O O

Acetylsalicylic B-drug B-drug
acid I-drug I-drug
did O O
not O O
alter O O
the O O
clearance O O
( O O
pharmacokinetics O O
) O O
of O O
iloprost B-drug B-drug
. O O

Anticoagulants B-group B-group
predispose O O
a O O
patient O O
to O O
bleeding O O
problems O O
. O O

Review O O
of O O
these O O
case O O
reports O O
indicates O O
that O O
the O O
patients O O
were O O
mainly O O
receiving O O
thiazide B-group B-group
diuretics I-group I-group
for O O
hypertension O O
and O O
that O O
tests O O
to O O
rule O O
out O O
decreased O O
renal O O
function O O
secondary O O
to O O
hypertensive O O
nephropathy O O
were O O
not O O
often O O
performed O O
. O O

Inhibitors O O
of O O
CYP1A2 O O
: O O
Concomitant O O
use O O
of O O
duloxetine B-drug B-drug
with O O
fluvoxamine B-drug B-drug
, O O
an O O
inhibitor O O
of O O
CYP1A2 O O
, O O
results O O
in O O
approximately O O
a O O
6-fold O O
increase O O
in O O
AUC O O
and O O
about O O
a O O
2.5-fold O O
increase O O
in O O
Cmax O O
of O O
duloxetine B-drug B-drug
. O O

Benzodiazepines B-group B-group
were O O
administered O O
to O O
mice O O
30 O O
min O O
before O O
applying O O
the O O
analgesic B-group B-group
drugs I-group I-group
. O O

We O O
previously O O
reported O O
that O O
seeds O O
of O O
Artocarpus O O
integrifolia O O
( O O
jackfruit O O
) O O
contain O O
a O O
lectin O O
, O O
which O O
we O O
call O O
jacalin B-drug_n B-drug_n
, O O
that O O
is O O
both O O
a O O
potent O O
T O O
cell O O
mitogen O O
and O O
an O O
apparently O O
T O O
cell-independent O O
activator O O
of O O
human O O
B O O
cells O O
for O O
the O O
secretion O O
of O O
immunoglobulins O B-group
. O O

Thus O O
in O O
order O O
to O O
avoid O O
bleeding O O
, O O
reduced O O
dosage O O
of O O
heparin B-drug B-drug
is O O
recommended O O
during O O
treatment O O
with O O
antithrombin B-drug B-drug
III I-drug I-drug
( O O
human O O
) O O
. O O

Phosphate-Binding O O
Agents O O
: O O
Since O O
vitamin B-group B-group
D I-group I-group
also O O
has O O
an O O
effect O O
on O O
phosphate O O
transport O O
in O O
the O O
intestine O O
, O O
kidneys O O
and O O
bones O O
, O O
the O O
dosage O O
of O O
phosphate-binding O O
agents O O
must O O
be O O
adjusted O O
in O O
accordance O O
with O O
the O O
serum O O
phosphate O O
concentration O O
. O O

Limited O O
clinical O O
experience O O
indicates O O
that O O
requirements O O
for O O
volatile B-group O
inhalation I-group O
anesthetics I-group B-group
are O O
reduced O O
by O O
30 O O
to O O
50 O O
% O O
for O O
the O O
first O O
sixty O O
( O O
60 O O
) O O
minutes O O
following O O
ALFENTA B-brand B-brand
induction O O
The O O
concomitant O O
use O O
of O O
erythromycin B-drug B-drug
with O O
ALFENTA B-brand B-brand
can O O
significantly O O
inhibit O O
ALFENTA B-brand B-brand
clearance O O
and O O
may O O
increase O O
the O O
risk O O
of O O
prolonged O O
or O O
delayed O O
respiratory O O
depression O O
. O O

The O O
clinical O O
significance O O
of O O
this O O
finding O O
is O O
unknown O O
. O O

When O O
paroxetine B-drug B-drug
, O O
a O O
potent O O
inhibitor O O
of O O
CYP2D6 O O
, O O
was O O
co-administered O O
with O O
BROVANA B-brand B-brand
at O O
steady-state O O
, O O
exposure O O
to O O
either O O
drug O O
was O O
not O O
altered O O
. O O

This O O
effect O O
has O O
been O O
attributed O O
to O O
inhibition O O
of O O
renal O O
prostaglandin O O
synthesis O O
by O O
ibuprofen B-drug B-drug
. O O

While O O
additional O O
research O O
is O O
needed O O
, O O
the O O
initial O O
clinical O O
data O O
in O O
kidney O O
recipients O O
suggest O O
that O O
sirolimus B-drug B-drug
, O O
in O O
combination O O
with O O
cyclosporine B-drug B-drug
or O O
tacrolimus B-drug B-drug
, O O
might O O
have O O
the O O
potential O O
to O O
reduce O O
the O O
frequency O O
of O O
rejection O O
episodes O O
, O O
permit O O
reductions O O
in O O
cyclosporine B-drug B-drug
or O O
tacrolimus B-drug B-drug
dosage O O
, O O
and O O
permit O O
steroid O B-group
withdrawal O O
( O O
Kelly O O
, O O
1999 O O
) O O
. O O

The O O
findings O O
of O O
these O O
studies O O
are O O
summarized O O
in O O
the O O
following O O
table O O
: O O
Effects O O
on O O
steady-state O O
fexofenadine B-drug B-drug
pharmacokinetics O O
after O O
7 O O
days O O
of O O
co-administration O O
with O O
fexofenadine B-drug B-drug
hydrochloride I-drug I-drug
120 O O
mg O O
every O O
12 O O
hours O O
( O O
two O O
times O O
the O O
recommended O O
twice O O
daily O O
dose O O
) O O
in O O
healthy O O
volunteers O O
( O O
n=24 O O
) O O

Apraclonidine B-drug B-drug
should O O
not O O
be O O
used O O
in O O
patients O O
receiving O O
MAO B-group B-group
inhibitors.. O I-group

Corticosteroids B-group B-group
: O O
A O O
relationship O O
of O O
functional O O
antagonism O O
exists O O
between O O
vitamin B-group B-group
D I-group I-group
analogues O I-group
, O O
which O O
promote O O
calcium O O
absorption O O
, O O
and O O
corticosteroids B-group B-group
, O O
which O O
inhibit O O
calcium O O
absorption O O
. O O

No O O
formal O O
drug O O
interaction O O
studies O O
have O O
been O O
performed O O
with O O
ZEVALIN B-brand B-brand
. O O

In O O
patients O O
receiving O O
nonselective O B-group
monoamine B-group I-group
oxidase I-group I-group
inhibitors I-group I-group
( O O
MAOIs B-group B-group
) O O
( O O
e.g. O O
, O O
selegiline B-drug B-drug
hydrochloride I-drug I-drug
) O O
in O O
combination O O
with O O
serotoninergic B-group B-group
agents I-group I-group
( O O
e.g. O O
, O O
fluoxetine B-drug B-drug
, O O
fluvoxamine B-drug B-drug
, O O
paroxetine B-drug B-drug
, O O
sertraline B-drug B-drug
, O O
venlafaxine B-drug B-drug
) O O
, O O
there O O
have O O
been O O
reports O O
of O O
serious O O
, O O
sometimes O O
fatal O O
, O O
reactions O O
. O O

In O O
a O O
first O O
experiment O O
, O O
male O O
adult O O
Wistar O O
rats O O
were O O
fasted O O
for O O
12 O O
h O O
. O O

In O O
a O O
study O O
with O O
concomitant O O
administration O O
of O O
aspirin B-brand B-brand
and O O
fosinopril B-drug B-drug
sodium I-drug I-drug
, O O
the O O
bioavailability O O
of O O
unbound O O
fosinoprilat B-drug_n B-drug
was O O
not O O
altered O O
. O O

The O O
toxicity O O
of O O
cadmium O O
, O O
zinc B-drug B-drug
and O O
cadmium/zinc O O
mixtures O O
at O O
concentrations O O
ranging O O
from O O
1000 O O
to O O
50000 O O
microg/l O O
were O O
investigated O O
against O O
cercariae O O
and O O
metacercariae O O
of O O
Parorchis O O
acanthus O O
obtained O O
from O O
the O O
dog O O
whelk O O
Nucella O O
lapillus O O
. O O

The O O
emerging O O
roles O O
of O O
non-nucleoside B-group B-group
reverse I-group I-group
transcriptase I-group I-group
inhibitors I-group I-group
in O O
antiretroviral B-group B-group
therapy O O
. O O

The O O
safety O O
and O O
efficacy O O
of O O
anakinra B-drug B-drug
used O O
in O O
combination O O
with O O
HUMIRA B-brand B-brand
has O O
not O O
been O O
studied O O
. O O

Both O O
ibogaine B-drug_n B-drug_n
and O O
18-MC B-drug_n B-drug_n
ameliorate O O
opioid B-group O
withdrawal O O
signs O O
. O O

Rofecoxib B-drug B-drug
did O O
not O O
influence O O
the O O
plasma O O
pharmacokinetics O O
or O O
renal O O
elimination O O
of O O
a O O
single O O
oral O O
dose O O
of O O
digoxin B-drug B-drug
. O O

Resting O O
membrane O O
potential O O
, O O
input O O
impedance O O
and O O
the O O
proportion O O
of O O
neurons O O
displaying O O
transient O O
outward O O
rectification O O
were O O
each O O
significantly O O
altered O O
for O O
neurons O O
recorded O O
with O O
1 O O
% O O
but O O
not O O
0.05-0.2 O O
% O O
biocytin O O
. O O

Anticholinergic B-group B-group
drugs I-group I-group
may O O
antagonize O O
the O O
effects O O
of O O
the O O
drugs O O
that O O
alter O O
gastrointestinal O O
motility O O
, O O
such O O
as O O
metoclopramide B-drug B-drug
. O O

In O O
clinical O O
trials O O
, O O
FLOLAN B-brand B-brand
was O O
used O O
with O O
digoxin B-drug B-drug
, O O
diuretics B-group B-group
, O O
anticoagulants B-group B-group
, O O
oral O O
vasodilators B-group B-group
, O O
and O O
supplemental O O
oxygen.In B-drug B-drug
a O O
pharmacokinetic O O
substudy O O
in O O
patients O O
with O O
congestive O O
heart O O
failure O O
receiving O O
furosemide B-drug B-drug
or O O
digoxin B-drug B-drug
in O O
whom O O
therapy O O
with O O
FLOLAN B-brand B-brand
was O O
initiated O O
, O O
apparent O O
oral O O
clearance O O
values O O
for O O
furosemide B-drug B-drug
( O O
n O O
= O O
23 O O
) O O
and O O
digoxin B-drug B-drug
( O O
n O O
= O O
30 O O
) O O
were O O
decreased O O
by O O
13 O O
% O O
and O O
15 O O
% O O
, O O
respectively O O
, O O
on O O
the O O
second O O
day O O
of O O
therapy O O
and O O
had O O
returned O O
to O O
baseline O O
values O O
by O O
day O O
87 O O
. O O

The O O
changes O O
in O O
plasma O O
levels O O
were O O
within O O
the O O
range O O
of O O
plasma O O
levels O O
achieved O O
in O O
adequate O O
and O O
well-controlled O O
clinical O O
trials O O
. O O

. O O

In O O
an O O
uncontrolled O O
study O O
of O O
over O O
200 O O
patients O O
with O O
congestive O O
heart O O
failure O O
during O O
which O O
digoxin B-drug B-drug
blood O O
levels O O
were O O
not O O
measured O O
, O O
digitalis O B-group
toxicity O O
was O O
not O O
observed O O
. O O

Cyclophosphamide B-drug B-drug
used O O
concurrently O O
with O O
Cerubidine B-brand B-brand
may O O
also O O
result O O
in O O
increased O O
cardiotoxicity O O
. O O

Naproxen B-drug B-drug
: O O
The O O
concomitant O O
administration O O
of O O
diflunisal B-drug B-drug
and O O
naproxen B-drug B-drug
in O O
normal O O
volunteers O O
had O O
no O O
effect O O
on O O
the O O
plasma O O
levels O O
of O O
naproxen B-drug B-drug
, O O
but O O
significantly O O
decreased O O
the O O
urinary O O
excretion O O
of O O
naproxen B-drug B-drug
and O O
its O O
glucuronide O B-drug
metabolite O O
. O O

Drug O O
Class O O
: O O
Drug O O
Name O O
Clinical O O
Comment O O

phenobarbital B-drug B-drug
reduced O O
it O O
by O O
a O O
net O O
change O O
of O O
6.6 O O
% O O
( O O
percentage O O
increase O O
in O O
FDF O O
, O O
8.5 O O
% O O
) O O
at O O
431 O O
micromol/L O O
. O O

No O O
clinically O O
important O O
pharmacokinetic O O
interactions O O
occurred O O
when O O
PRINIVIL B-brand B-brand
was O O
used O O
concomitantly O O
with O O
propranolol B-drug B-drug
or O O
hydrochlorothiazide B-drug B-drug
. O O

Experience O O
with O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
drugs I-group I-group
( O O
NSAIDs B-group B-group
) O O
suggests O O
the O O
potential O O
for O O
interactions O O
with O O
furosemide B-drug B-drug
and O O
ACE B-group B-group
inhibitors I-group I-group
. O O

Drug/Laboratory O O
Test O O
Interactions O O
The O O
administration O O
of O O
cefepime B-drug B-drug
may O O
result O O
in O O
a O O
false-positive O O
reaction O O
for O O
glucose O O
in O O
the O O
urine O O
when O O
using O O
Clinitest O O
tablets O O
. O O

Furosemide B-drug B-drug
: O O
Clinical O O
studies O O
, O O
as O O
well O O
as O O
random O O
observations O O
, O O
have O O
shown O O
that O O
ibuprofen B-drug B-drug
can O O
reduce O O
the O O
natriuretic O O
effect O O
of O O
furosemide B-drug B-drug
and O O
thiazides B-group B-group
in O O
some O O
patients O O
. O O

Aminoglutethimide B-drug B-drug
diminishes O O
the O O
effect O O
of O O
coumarin B-group B-group
and O O
warfarin B-drug B-drug
. O O

There O O
was O O
no O O
effect O O
of O O
ZEBETA B-brand B-brand
on O O
prothrombin O O
time O O
in O O
patients O O
on O O
stable O O
doses O O
of O O
warfarin B-drug B-drug
. O O

To O O
avoid O O
potentiation O O
, O O
the O O
physician O O
wishing O O
to O O
terminate O O
treatment O O
with O O
Isocarboxazid B-drug B-drug
and O O
begin O O
therapy O O
with O O
another O O
agent O O
should O O
allow O O
for O O
an O O
interval O O
of O O
10 O O
days O O
. O O

Studies O O
in O O
healthy O O
volunteers O O
have O O
shown O O
that O O
Acarbose B-drug B-drug
has O O
no O O
effect O O
on O O
either O O
the O O
pharmacokinetics O O
or O O
pharmacodynamics O O
of O O
digoxin B-drug B-drug
, O O
nifedipine B-drug B-drug
, O O
propranolol B-drug B-drug
, O O
or O O
ranitidine B-drug B-drug
. O O

CONCLUSIONS O O
: O O
Sildenafil B-drug B-drug
is O O
an O O
effective O O
first-line O O
therapy O O
for O O
erectile O O
dysfunction O O
in O O
men O O
. O O

Monoamine B-group B-group
oxidase I-group I-group
( I-group I-group
MAO I-group I-group
) I-group I-group
inhibitors I-group I-group
such O O
as O O
isocarboxazid B-drug B-drug
( O O
e.g. O O
, O O
Marplan B-brand B-brand
) O O
, O O
phenelzine B-drug B-drug
( O O
e.g. O O
, O O
Nardil B-brand B-brand
) O O
, O O
procarbazine B-drug B-drug
( O O
e.g. O O
, O O
Matulane B-brand B-brand
) O O
, O O
selegiline B-drug B-drug
( O O
e.g. O O
, O O
Eldepryl B-brand B-brand
) O O
, O O
and O O
tranylcypromine B-drug B-drug
( O O
e.g. O O
, O O
Parnate B-brand B-brand
) O O
: O O
Using O O
these O O
medicines O O
with O O
L-tryptophan B-drug B-drug
may O O
increase O O
the O O
chance O O
of O O
side O O
effects O O
. O O

Furthermore O O
, O O
whenever O O
one O O
of O O
these O O
other O O
drugs O O
is O O
withdrawn O O
from O O
co-therapy O O
, O O
an O O
increased O O
dose O O
of O O
tricyclic B-drug B-group
antidepressant I-drug I-group
may O O
be O O
required O O
. O O

These O O
in O O
vitro O O
studies O O
suggest O O
that O O
concomitant O O
administration O O
of O O
zalcitabine B-drug B-drug
and O O
lamivudine B-drug B-drug
in O O
humans O O
may O O
result O O
in O O
sub-therapeutic O O
concentrations O O
of O O
active O O
phosphorylated O O
zalcitabine B-drug B-drug
, O O
which O O
may O O
lead O O
to O O
a O O
decreased O O
antiretroviral B-group O
effect O O
of O O
zalcitabine B-drug B-drug
. O O

CONTRAINDICATED O O
due O O
to O O
potential O O
for O O
serious O O
and/or O O
life-threatening O O
reactions O O
such O O
as O O
prolonged O O
or O O
increased O O
sedation O O
or O O
respiratory O O
depression O O
. O O

Pancreatic O O
content O O
after O O
perfusion O O
did O O
not O O
correlate O O
with O O
release O O
during O O
perfusion O O
. O O

Patients/Guardians O O
should O O
be O O
given O O
the O O
following O O
information O O
: O O
i O O
. O O

Epidemiological O O
studies O O
of O O
the O O
case-control O O
and O O
cohort O O
design O O
that O O
have O O
demonstrated O O
an O O
association O O
between O O
use O O
of O O
psychotropic B-group B-group
drugs I-group I-group
that O O
interfere O O
with O O
serotonin O O
reuptake O O
and O O
the O O
occurrence O O
of O O
upper O O
gastrointestinal O O
bleeding O O
have O O
also O O
shown O O
that O O
concurrent O O
use O O
of O O
an O O
NSAID B-group B-group
or O O
aspirin B-brand B-brand
potentiated O O
the O O
risk O O
of O O
bleeding O O
. O O

Carbamazepine B-drug B-drug

Plasma O O
concentrations O O
( O O
AUC O O
0-24 O O
hrs O O
) O O
of O O
erythromycin B-drug B-drug
decreased O O
15 O O
% O O
with O O
coadministration O O
of O O
loratadine B-drug B-drug
relative O O
to O O
that O O
observed O O
with O O
erythromycin B-drug B-drug
alone O O
. O O

Relative O O
to O O
the O O
general O O
population O O
, O O
plasma O O
concentrations O O
of O O
fluvastatin B-drug B-drug
do O O
not O O
vary O O
as O O
a O O
function O O
of O O
either O O
age O O
or O O
gender O O
. O O

Patients O O
who O O
are O O
applying O O
Panretin B-brand B-brand
gel O O
should O O
not O O
concurrently O O
use O O
products O O
that O O
contain O O
DEET B-drug B-drug
( O O
N O O
, O O
N-diethyl-m-toluamide B-drug B-drug_n
) O O
, O O
a O O
common O O
component O O
of O O
insect O O
repellent O O
products O O
. O O

- O O
Alcohol B-drug B-drug
, O O
barbiturates B-group B-group
, O O
or O O
narcotics B-group B-group
: O O
Potentiation O O
of O O
otthostatic O O
hypotension O O
may O O
occur O O

The O O
concomitant O O
use O O
of O O
alcohol B-drug B-drug
or O O
other O O
central B-group B-group
nervous I-group I-group
system I-group I-group
depressants I-group I-group
may O O
have O O
an O O
additive O O
effect O O
. O O

Fluconazole B-drug B-drug

Therefore O O
, O O
serum O O
levels O O
of O O
methotrexate B-drug B-drug
should O O
be O O
monitored O O
in O O
patients O O
to O O
avoid O O
drug O O
toxicity O O
. O O

Therefore O O
, O O
if O O
concomitant O O
use O O
of O O
such O O
agents O O
is O O
indicated O O
, O O
they O O
should O O
be O O
given O O
with O O
caution O O
, O O
and O O
the O O
patients O O
serum O O
potassium O O
should O O
be O O
monitored O O
frequently O O
. O O

Nelfinavir B-drug B-drug

The O O
results O O
generated O O
to O O
date O O
in O O
clinical O O
pharmacokinetic O O
studies O O
with O O
fluvastatin B-drug B-drug
thus O O
support O O
its O O
use O O
in O O
a O O
broad O O
population O O
of O O
hypercholesterolaemic O O
patients O O
. O O

Ritonavir B-drug B-drug
significantly O O
prolonged O O
the O O
half-life O O
of O O
vardenafil B-drug B-drug
to O O
26 O O
hours O O
. O O

In O O
separate O O
studies O O
of O O
patients O O
receiving O O
maintenance O O
doses O O
of O O
warfarin B-drug B-drug
, O O
hydrochlorothiazide B-drug B-drug
, O O
or O O
digoxin B-drug B-drug
, O O
irbesartan B-drug B-drug
administration O O
for O O
7 O O
days O O
had O O
no O O
effect O O
on O O
the O O
pharmacodynamics O O
of O O
warfarin B-drug B-drug
( O O
prothrombin O O
time O O
) O O
or O O
pharmacokinetics O O
of O O
digoxin B-drug B-drug
. O O

Concurrent O O
administration O O
of O O
oxyphenbutazone B-drug B-drug
and O O
androgens B-group B-group
may O O
result O O
in O O
elevated O O
serum O O
levels O O
of O O
oxyphenbutazone B-drug B-drug
. O O

Potentiation O O
occurs O O
with O O
ganglionic O B-drug
or O O
peripheral B-group B-group
adrenergic I-group I-group
blocking I-group I-group
drugs I-group I-group
. O O

The O O
metabolism O O
of O O
saquinavir B-drug B-drug
is O O
mediated O O
by O O
cytochrome O O
P450 O O
, O O
with O O
the O O
specific O O
isoenzyme O O
CYP3A4 O O
responsible O O
for O O
90 O O
% O O
of O O
the O O
hepatic O O
metabolism O O
. O O

Inhibitors O O
of O O
CYP3A4-Eplerenone B-drug B-drug
metabolism O O
is O O
predominantly O O
mediated O O
via O O
CYP3A4 O O
. O O

Like O O
isoflurane B-drug B-drug
, O O
desflurane B-drug B-drug
does O O
not O O
predispose O O
to O O
premature O O
ventricular O O
arrhythmias O O
in O O
the O O
presence O O
of O O
exogenously O O
infused O O
epinephrine B-drug B-drug
in O O
swine O O
. O O

( O O
May O O
inhibit O O
gastrointestinal O O
absorption O O
of O O
the O O
thiazide B-group B-group
diuretics I-group I-group
; O O

No O O
dose O O
adjustment O O
of O O
SUSTIVA B-brand B-brand
is O O
recommended O O
when O O
given O O
with O O
clarithromycin B-drug B-drug
. O O

By O O
contrast O O
, O O
spermidine B-drug_n B-drug
( O O
1 O O
mM O O
) O O
and O O
putrescine B-drug_n B-drug
( O O
1 O O
mM O O
) O O
had O O
no O O
significant O O
effect O O
on O O
the O O
translocation O O
when O O
added O O
alone O O
. O O

Antidepressants B-group B-group
: O O
In O O
vitro O O
data O O
indicate O O
that O O
nefazodone B-drug O
inhibits O O
the O O
metabolism O O
of O O
cisapride B-drug B-drug
, O O
which O O
can O O
result O O
in O O
an O O
increase O O
in O O
plasma O O
cisapride B-drug B-drug
levels O O
and O O
prolongation O O
of O O
the O O
QT O O
interval O O
on O O
the O O
ECG O O
. O O

In O O
this O O
study O O
we O O
investigated O O
whether O O
also O O
glycine B-drug B-drug
fulfils O O
the O O
function O O
as O O
co-activator O O
in O O
glutamatergic O O
activation O O
of O O
NMDA O O
receptors O O
in O O
the O O
neuronal O O
apparatus O O
of O O
spontaneous O O
motility O O
in O O
chick O O
embryos O O
. O O

Treatment O O
of O O
RAS-3T3 O O
cells O O
with O O
nucleophosmin/B23 O O
antisense O O
oligomer O O
significantly O O
potentiated O O
the O O
apoptosis O O
induced O O
by O O
serum O O
deprivation O O
. O O

However O O
, O O
when O O
addiction O O
is O O
defined O O
as O O
compulsion O O
, O O
loss O O
of O O
control O O
and O O
continued O O
use O O
in O O
spite O O
of O O
adverse O O
consequences O O
, O O
cocaine B-drug B-drug
drug O O
hunger O O
can O O
be O O
seen O O
as O O
an O O
agent O O
of O O
addictive O O
disease O O
. O O

Micro-dosed O O
Progesterone B-drug B-drug
Preparations O O
: O O
Micro-dosed O O
progesterone B-drug B-drug
preparations O O
( O O
minipills O O
that O O
do O O
not O O
contain O O
an O O
estrogen B-group B-group
) O O
may O O
be O O
an O O
inadequate O O
method O O
of O O
contraception O O
during O O
Accutane B-brand B-brand
therapy O O
. O O

. O O

The O O
use O O
of O O
NUROMAX B-brand B-brand
before O O
succinylcholine B-drug B-drug
to O O
attenuate O O
some O O
of O O
the O O
side O O
effects O O
of O O
succinylcholine B-drug B-drug
has O O
not O O
been O O
studied O O
. O O

Drug-drug O O
interactions O O
with O O
Mefloquine B-drug B-drug
have O O
not O O
been O O
explored O O
in O O
detail O O
. O O

indinavir I-drug B-drug
concentration O O

Dopamine-induced B-drug B-drug
renal O O
and O O
mesenteric O O
vasodilation O O
is O O
not O O
antagonized O O
by O O
either O O
alpha- O B-drug
or O O
beta-adrenergic B-group B-group
blocking B-drug I-group
agents I-drug I-group
. O O

These O O
results O O
suggest O O
that O O
acute O O
dosing O O
with O O
clozapine B-drug B-drug
would O O
not O O
affect O O
behaviors O O
most O O
closely O O
associated O O
with O O
PCP B-drug_n B-drug_n
intoxication O O
. O O

In O O
clinical O O
trials O O
, O O
similar O O
changes O O
in O O
carbamazepine B-drug B-drug
and O O
carbamazepine B-drug_n B-drug
epoxide I-drug_n I-drug
were O O
seen O O
. O O

However O O
, O O
it O O
has O O
been O O
established O O
that O O
acitretin B-drug B-drug
interferes O O
with O O
the O O
contraceptive O O
effect O O
of O O
microdosed O B-drug
progestin B-drug I-drug
minipill O O
preparations O O
. O O

quinidine B-drug B-drug
; O O

Statistically O O
significant O O
changes O O
in O O
prothrombin O O
and O O
partial O O
thromboplastin O O
times O O
have O O
been O O
reported O O
in O O
normal O O
volunteers O O
. O O

Persons O O
taking O O
most O O
antibiotics B-group B-group
, O O
methotrexate B-drug B-drug
and O O
pyrimethamine B-drug B-drug
invalidate O O
folic B-drug B-drug
acid I-drug I-drug
and O O
vitamin B-drug B-drug
B12 I-drug I-drug
diagnostic O O
blood O O
assays O O
. O O

Other O O
plasma O O
proteins O O
may O O
be O O
increased O O
( O O
angiotensinogen/renin O O
substrate O O
, O O
alpha-1-antitrypsin O B-drug_n
, O O
ceruloplasmin O B-drug
) O O
. O O

use O O
caution O O
. O O

DRUG/LABORATORY O O
TEST O O
INTERACTIONS O O
: O O
EFFECT O O
ON O O
BLOOD O O
COAGULATION O O
Ketoprofen B-drug B-drug
decreases O O
platelet O O
adhesion O O
and O O
aggregation O O
. O O

Even O O
when O O
an O O
aminoglycoside B-group B-group
and O O
a O O
penicillin-type B-group B-group
drug O I-group
are O O
administered O O
separately O O
by O O
different O O
routes O O
, O O
a O O
reduction O O
in O O
aminoglycoside B-group B-group
serum O O
half-life O O
or O O
serum O O
levels O O
has O O
been O O
reported O O
in O O
patients O O
with O O
impaired O O
renal O O
function O O
and O O
in O O
some O O
patients O O
with O O
normal O O
renal O O
function O O
. O O

Therefore O O
, O O
administration O O
of O O
quinolones B-group B-group
with O O
antacids B-group B-group
containing O O
calcium B-drug B-drug
, O O
magnesium B-drug B-drug
, O O
or O O
aluminum B-drug B-drug
; O O

Substances O O
that O O
are O O
potent O O
inhibitors O O
of O O
CYP3A4 O O
activity O O
( O O
eg O O
, O O
ketoconazole B-drug B-drug
and O O
itraconazole B-drug B-drug
) O O
decrease O O
gefitinib B-drug B-drug
metabolism O O
and O O
increase O O
gefitinib B-drug B-drug
plasma O O
concentrations O O
. O O

Beta-adrenergic B-group B-group
blocking I-group I-group
agents I-group I-group
: O O
concurrent O O
use O O
may O O
blunt O O
the O O
response O O
to O O
arbutamine B-drug B-drug
. O O

2 O O
. O O

Rifampin B-drug B-drug
: O O
Co-administration O O
of O O
VIOXX B-brand B-brand
with O O
rifampin B-drug B-drug
600 O O
mg O O
daily O O
, O O
a O O
potent O O
inducer O O
of O O
hepatic O O
metabolism O O
, O O
produced O O
an O O
approximate O O
50 O O
% O O
decrease O O
in O O
rofecoxib B-drug B-drug
plasma O O
concentrations O O
. O O

Certain O O
endocrine O O
and O O
liver O O
function O O
tests O O
may O O
be O O
affected O O
by O O
estrogen-containing B-group B-group
oral O I-group
contraceptives B-group I-group
. O O

Caution O O
should O O
be O O
exercised O O
with O O
simultaneous O O
use O O
of O O
clonidine B-drug B-drug
and O O
other O O
similar O O
pharmacologic O O
agents O O

Aspirin B-brand B-brand
: O O
Concomitant O O
administration O O
of O O
low-dose O O
aspirin B-brand B-brand
with O O
VIOXX B-brand B-brand
may O O
result O O
in O O
an O O
increased O O
rate O O
of O O
GI O O
ulceration O O
or O O
other O O
complications O O
, O O
compared O O
to O O
use O O
of O O
VIOXX B-brand B-brand
alone O O
. O O

Although O O
additional O O
drug O O
interaction O O
studies O O
have O O
not O O
been O O
conducted O O
, O O
the O O
most O O
common O O
medications O O
used O O
concomitantly O O
with O O
anagrelide B-drug B-drug
in O O
clinical O O
trials O O
were O O
aspirin B-brand B-brand
, O O
acetaminophen B-drug B-drug
, O O
furosemide B-drug B-drug
, O O
iron B-drug B-drug
, O O
ranitidine B-drug B-drug
, O O
hydroxyurea B-drug B-drug
, O O
and O O
allopurinol B-drug B-drug
. O O

Drug O O
Class O O
: O O
Drug O O
Name O O
Clinical O O
Comment O O

VIRACEPT B-brand B-brand
and O O
rifampin B-drug B-drug
should O O
not O O
be O O
coadministered O O
. O O

Potential O O
Terfenadine B-drug B-drug
, O O
Astemizole B-drug B-drug
, O O
and O O
Cisapride B-drug B-drug
Interactions O O

The O O
pharmacokinetics O O
of O O
praziquantel B-drug B-drug
were O O
unchanged O O
following O O
coadministration O O
with O O
albendazole B-drug B-drug
( O O
400 O O
mg O O
) O O
. O O

- O O
Reduced O O
serum O O
folate O O
concentration O O

Concurrent O O
administration O O
of O O
dyphylline B-drug B-drug
and O O
probenecid B-drug B-drug
, O O
which O O
competes O O
for O O
tubular O O
secretion O O
, O O
has O O
been O O
shown O O
to O O
increase O O
the O O
plasma O O
half-life O O
of O O
dyphylline B-drug B-drug
. O O

H-2 O B-group
Antagonists O I-group
: O O
In O O
studies O O
with O O
human O O
volunteers O O
, O O
co-administration O O
of O O
cimetidine B-drug B-drug
or O O
ranitidine B-drug B-drug
with O O
ibuprofen B-drug B-drug
had O O
no O O
substantive O O
effect O O
on O O
ibuprofen B-drug B-drug
serum O O
concentrations O O
. O O

dextran B-drug B-drug
; O O

Caution O O
should O O
be O O
exercised O O
when O O
administering O O
nabumetone B-drug B-drug
with O O
warfarin B-drug B-drug
since O O
interactions O O
have O O
been O O
seen O O
with O O
other O O
NSAIDs B-group B-group
. O O

Drugs O O
that O O
reportedly O O
may O O
increase O O
oral O O
anticoagulant B-group B-group
response O O
, O O
ie O O
, O O
increased O O
prothrombin O O
response O O
, O O
in O O
man O O
include O O
: O O
alcohol* B-drug B-drug
; O O
allopurinol B-drug B-drug
; O O
aminosalicylic B-drug B-drug
acid I-drug I-drug
; O O
amiodarone B-drug B-drug
; O O
anabolic B-group B-group
steroids I-group I-group
; O O
antibiotics B-group B-group
; O O
bromelains B-drug B-group
; O O
chloral B-drug B-drug
hydrate* O O
; O O
chlorpropamide B-drug B-drug
; O O
chymotrypsin B-drug B-drug
; O O
cimetidine B-drug B-drug
; O O
cinchophen B-drug B-drug
; O O
clofibrate B-drug B-drug
; O O
dextran B-drug B-drug
; O O
dextrothyroxine B-drug B-drug
; O O
diazoxide B-drug B-drug
; O O
dietary O O
deficiencies O O
; O O
diflunisal B-drug B-drug
; O O
disulfiram B-drug B-drug
; O O
drugs O O
affecting O O
blood O O
elements O O
; O O
ethacrynic B-drug B-drug
acid I-drug I-drug
; O O
fenoprofen B-drug B-drug
; O O
glucagon B-drug B-drug
; O O
hepatotoxic O O
drugs O O
; O O
ibuprofen B-drug B-drug
; O O
indomethacin B-drug B-drug
; O O
influenza B-group B-group
virus I-group I-group
vaccine I-group I-group
; O O
inhalation O O
anesthetics B-group B-group
; O O
mefenamic B-drug B-drug
acid I-drug I-drug
; O O
methyldopa B-drug B-drug
; O O
methylphenidate B-drug B-drug
; O O
metronidazole B-drug B-drug
; O O
miconazole B-drug B-drug
; O O
monoamine B-group B-group
oxidase I-group I-group
inhibitors I-group I-group
; O O
nalidixic B-drug B-drug
acid I-drug I-drug
; O O
naproxen B-drug B-drug
; O O
oxolinic B-drug B-drug
acid I-drug I-drug
; O O
oxyphenbutazone B-drug B-drug
; O O
pentoxifylline B-drug B-drug
; O O
phenylbutazone B-drug B-drug
; O O
phenyramidol B-drug_n B-drug
; O O
phenytoin B-drug B-drug
; O O
prolonged O O
hot O O
weather O O
; O O
prolonged B-group B-group
narcotics I-group I-group
; O O
pyrazolones B-group B-group
; O O
quinidine B-drug B-drug
; O O
quinine B-drug B-drug
; O O
ranitidine* B-drug B-drug
; O O
salicylates B-group B-group
; O O
sulfinpyrazone B-drug B-drug
; O O
sulfonamides B-group B-group
, O O
long O O
acting O O
; O O
sulindac B-drug B-drug
; O O
thyroid B-group B-group
drugs I-group I-group
; O O
tolbutamide B-drug B-drug
; O O
triclofos B-drug B-drug
sodium I-drug I-drug
; O O
trimethoprim/sulfamethoxazole B-drug B-drug
; O O
unreliable O O
prothrombin O O
time O O
determinations O O
; O O
warfarin B-drug B-drug
sodium I-drug I-drug
overdosage O O
. O O

Nephrotoxicity O O
frequently O O
limits O O
the O O
dose O O
of O O
cisplatin B-drug B-drug
to O O
less O O
than O O
120 O O
mg/m2 O O
per O O
injection O O
. O O

If O O
isradipine B-drug B-drug
therapy O O
is O O
initiated O O
in O O
a O O
patient O O
currently O O
receiving O O
cimetidine B-drug B-drug
careful O O
monitoring O O
for O O
adverse O O
reactions O O
is O O
advised O O
and O O
downward O O
dose O O
adjustment O O
may O O
be O O
required O O
. O O

Long O O
Acting O O
Nitrates B-group B-group
: O O
Nifedipine B-drug B-drug
may O O
be O O
safely O O
co-administered O O
with O O
nitrates B-group B-group
, O O
but O O
there O O
have O O
been O O
no O O
controlled O O
studies O O
to O O
evaluate O O
the O O
antianginal O O
effectiveness O O
of O O
this O O
combination O O
. O O

These O O
steps O O
include O O
regular O O
reevaluations O O
of O O
dosages O O
and O O
plasma O O
drug O O
concentrations O O
, O O
recognition O O
and O O
understanding O O
of O O
drug O O
side O O
effects O O
, O O
and O O
avoidance O O
of O O
certain O O
agents O O
. O O

This O O
interaction O O
should O O
be O O
given O O
consideration O O
in O O
patients O O
taking O O
NSAIDs B-group B-group
concomitantly O O
with O O
ACE B-group B-group
inhibitors I-group I-group
. O O

In O O
addition O O
, O O
based O O
on O O
the O O
population O O
pharmacokinetics O O
analysis O O
of O O
the O O
combined O O
data O O
from O O
grapefruit O O
and O O
orange O O
juices O O
studies O O
with O O
the O O
data O O
from O O
a O O
bioequivalence O O
study O O
, O O
the O O
bioavailability O O
of O O
fexofenadine B-drug B-drug
was O O
reduced O O
by O O
36 O O
% O O
. O O

Agents O O
that O O
Induce O O
Cytochrome O O
P450 O O
Isoenzymes O O
Carbamazepine B-drug B-drug
is O O
metabolized O O
by O O
CYP3A4 O O
. O O

All O O
77 O O
strains O O
of O O
Staphylococcus O O
aureus O O
, O O
Diplococcus O O
pneumoniae O O
, O O
Streptococcus O O
pyogenes O O
, O O
and O O
anaerobic O O
bacteria O O
( O O
except O O
for O O
three O O
strains O O
of O O
Clostridium O B-drug_n
) O O
were O O
inhibited O O
by O O
1.6 O O
mug O O
or O O
less O O
of O O
clindamycin B-drug B-drug
per O O
ml O O
. O O

Several O O
tricyclic B-group B-group
antidepressants I-group I-group
have O O
been O O
reported O O
to O O
block O O
the O O
pharmacologic O O
effects O O
of O O
guanethidine B-drug B-drug
, O O
clonidine B-drug B-drug
, O O
or O O
similar O O
agents O O
, O O
and O O
such O O
an O O
effect O O
may O O
be O O
anticipated O O
with O O
CMI B-drug B-drug
because O O
of O O
its O O
structural O O
similarity O O
to O O
other O O
tricyclic B-group B-group
antidepressants I-group I-group
. O O

The O O
consumption O O
of O O
alcohol B-drug B-drug
during O O
treatment O O
with O O
WELLBUTRIN B-brand B-brand
should O O
be O O
minimized O O
or O O
avoided O O
( O O
also O O
see O O
a O O
href= O O
bupropz_od.htm O O
# O O
CI O O
CONTRAINDICATIONS O O
) O O

Intravenous O O
infusion O O
of O O
iloprost B-drug B-drug
had O O
no O O
effect O O
on O O
the O O
pharmacokinetics O O
of O O
digoxin B-drug B-drug
. O O

Zalcitabine B-drug B-drug
also O O
has O O
no O O
significant O O
effect O O
on O O
the O O
intracellular O O
phosphorylation O O
of O O
ZDV B-drug B-drug_n
, O O
as O O
shown O O
in O O
vitro O O
in O O
peripheral O O
blood O O
mononuclear O O
cells O O
or O O
in O O
two O O
other O O
cell O O
lines O O
( O O
U937 O O
and O O
Molt-4 O O
) O O
. O O

- O O
Mercaptopurine B-drug B-drug
( O O
e.g. O O
, O O
Purinethol B-brand B-brand
) O O
or O O

Therefore O O
, O O
patients O O
under O O
methotrexate B-drug B-drug
therapy O O
should O O
be O O
carefully O O
monitored O O
when O O
concomitant O O
ciprofloxacin B-drug B-drug
therapy O O
is O O
indicated O O
. O O

Additionally O O
, O O
aripiprazole B-drug B-drug
and O O
dehydroaripiprazole B-drug_n B-drug
did O O
not O O
show O O
potential O O
for O O
altering O O
CYP1A2-mediated O O
metabolism O O
in O O
vitro O O
. O O

75 O O
years O O
of O O
age O O
. O O

The O O
use O O
of O O
FLUDARA B-brand B-brand
FOR O O
INJECTION O O
in O O
combination O O
with O O
pentostatin B-drug B-drug
is O O
not O O
recommended O O
due O O
to O O
the O O
risk O O
of O O
severe O O
pulmonary O O
toxicity O O
. O O

The O O
homodimeric O O
disintegrin O O
contortrostatin B-drug_n B-drug_n
was O O
compared O O
directly O O
to O O
the O O
monomeric O O
disintegrins O O
echistatin B-drug_n B-drug_n
and O O
flavoridin B-drug_n B-drug_n
for O O
the O O
ability O O
to O O
affect O O
protein O O
tyrosine O O
phosphorylation O O
in O O
tumor O O
cells O O
. O O

Extreme O O
caution O O
should O O
be O O
exercised O O
when O O
administering O O
TAXOL B-brand B-brand
to O O
such O O
patients O O
, O O
with O O
dose O O
reduction O O
as O O
recommended O O
in O O
DOSAGE O O
AND O O
ADMINISTRATION O O
, O O
Table O O
17 O O
. O O

The O O
carcinogenic O O
potential O O
of O O
ribavirin B-drug B-drug
has O O
not O O
been O O
fully O O
determined O O
. O O

Warfarin B-drug B-drug
: O O
Quinolones B-group B-group
may O O
enhance O O
the O O
effects O O
of O O
the O O
oral O O
anticoagulant B-group B-group
, O O
warfarin B-drug B-drug
, O O
or O O
its O O
derivatives O O
. O O

however O O
, O O
it O O
is O O
considered O O
to O O
be O O
unlikely O O
that O O
this O O
decrease O O
of O O
phosphorylated O O
lamivudine B-drug B-drug
concentration O O
is O O
of O O
clinical O O
significance O O
, O O
as O O
lamivudine B-drug B-drug
is O O
a O O
more O O
efficient O O
substrate O O
for O O
deoxycytidine O O
kinase O O
than O O
zalcitabine B-drug B-drug
. O O

Therefore O O
, O O
when O O
EDECRIN B-brand B-brand
and O O
non- B-group B-group
steroidal I-group I-group
anti- I-group I-group
inflammatory I-group I-group
agents I-group I-group
are O O
used O O
concomitantly O O
, O O
the O O
patient O O
should O O
be O O
observed O O
closely O O
to O O
determine O O
if O O
the O O
desired O O
effect O O
of O O
the O O
diuretic B-group B-group
is O O
obtained O O
. O O

Cardiovascular O O
disease O O
is O O
considered O O
in O O
the O O
next O O
chapter O O
, O O
and O O
chapter O O
7 O O
presents O O
findings O O
on O O
endometrial O O
, O O
ovarian O O
, O O
cervical O O
, O O
breast O O
, O O
and O O
other O O
cancers O O
. O O

aeruginosa O O
as O O
common O O
pathogens O O
of O O
drug O O
addicts O O
in O O
areas O O
where O O
abuse O O
of O O
this O O
combination O O
of O O
drugs O O
has O O
increased O O
. O O

Antihypertensive B-group B-group
Medications O I-group
and O O
Vasodilators B-group B-group
: O O
The O O
following O O
adverse O O
events O O
were O O
experienced O O
more O O
commonly O O
in O O
patients O O
receiving O O
concomitant O O
antihypertensive B-group B-group
medications I-group I-group
or O O
vasodilators B-group B-group
( O O
n O O
= O O
94 O O
) O O
compared O O
to O O
patients O O
not O O
receiving O O
these O O
concomitant O O
drugs O O
( O O
n O O
= O O
456 O O
) O O
: O O
hypotension O O
10 O O
% O O
vs O O
4 O O
% O O
, O O
myocardial O O
infarction O O
3 O O
% O O
vs O O
1 O O
% O O
, O O
serious O O
pneumonia O O
5 O O
% O O
vs O O
3 O O
% O O
, O O
serious O O
falls O O
9 O O
% O O
vs O O
3 O O
% O O
, O O
and O O
bone O O
and O O
joint O O
injuries O O
6 O O
% O O
vs O O
2 O O
% O O
. O O

Antacids B-group B-group
( O O
aluminum- B-drug B-drug
or O O
magnesium-containing B-drug B-drug
) O O
: O O
Concomitant O O
administration O O
of O O
300-mg O O
cefdinir B-drug B-drug
capsules O O
with O O
30 O O
mL O O
Maalox B-brand B-brand
TC I-brand I-brand
suspension O O
reduces O O
the O O
rate O O
( O O
Cmax O O
) O O
and O O
extent O O
( O O
AUC O O
) O O
of O O
absorption O O
by O O
approximately O O
40 O O
% O O
. O O

Acetazolamide B-drug B-drug
may O O
increase O O
or O O
decrease O O
blood O O
glucose O O
levels O O
. O O

Etodolac B-drug B-drug
is O O
characterised O O
by O O
a O O
high O O
oral O O
bioavailability O O
, O O
low O O
clearance O O
, O O
a O O
small O O
volume O O
of O O
distribution O O
, O O
and O O
a O O
7-hour O O
half-life O O
. O O

Antacids B-group B-group
or O O
sucralfate B-drug B-drug
substantially O O
interfere O O
with O O
the O O
absorption O O
of O O
some O O
quinolones B-group B-group
, O O
resulting O O
in O O
low O O
urine O O
levels O O
. O O

amiodarone B-drug B-drug
; O O

Effects O O
of O O
GABITRIL B-brand B-brand
on O O
other O O
Antiepilepsy O B-group
Drugs O I-group
( O O
AEDs B-group B-group
) O O
: O O
Phenytoin B-drug B-drug
: O O
Tiagabine B-drug B-drug
had O O
no O O
effect O O
on O O
the O O
steady-state O O
plasma O O
concentrations O O
of O O
phenytoin B-drug B-drug
in O O
patients O O
with O O
epilepsy O O
. O O

It O O
is O O
not O O
known O O
whether O O
AMEVIVE B-brand B-brand
is O O
excreted O O
in O O
human O O
milk O O
. O O

When O O
prescribing O O
for O O
older O O
patients O O
, O O
some O O
physicians O O
are O O
overly O O
cautious O O
, O O
and O O
this O O
strategy O O
can O O
result O O
in O O
a O O
less O O
than O O
optimal O O
treatment O O
outcome O O
. O O

Long-term O O
studies O O
are O O
needed O O
to O O
determine O O
whether O O
the O O
insulin-sensitizing O O
effects O O
of O O
the O O
glitazones B-group B-group
can O O
prevent O O
or O O
delay O O
premature O O
atherosclerotic O O
cardiovascular O O
disease O O
, O O
morbidity O O
, O O
and O O
death O O
. O O

. O O

Low O O
initial O O
dosing O O
and O O
small O O
gradual O O
dose O O
increases O O
should O O
be O O
employed O O
. O O

Etodolac B-drug B-drug
is O O
highly O O
protein O O
bound O O
. O O

Caution O O
should O O
be O O
used O O
when O O
coadministering O O
medications O O
that O O
are O O
substrates O O
, O O
inhibitors O O
, O O
or O O
inducers O O
of O O
CYP3A4 O O
, O O
or O O
potentially O O
toxic O O
medications O O
that O O
are O O
metabolized O O
by O O
CYP3A4 O O
. O O

Of O O
particular O O
importance O O
, O O
sufficient O O
time O O
must O O
elapse O O
before O O
initiating O O
TCAtreatment B-group B-brand
in O O
a O O
patient O O
being O O
withdrawn O O
from O O
fluoxetine B-drug B-drug
, O O
given O O
the O O
long O O
half-life O O
of O O
the O O
parent O O
and O O
active O O
metabolite O O
( O O
at O O
least O O
5 O O
weeks O O
may O O
be O O
necessary O O
) O O
. O O

In O O
some O O
cases O O
where O O
serious O O
ventricular O O
arrhythmias O O
, O O
QT O O
prolongation O O
, O O
and O O
torsades O O
de O O
pointes O O
have O O
occurred O O
when O O
cisapride B-drug B-drug
was O O
taken O O
in O O
conjunction O O
with O O
one O O
of O O
the O O
cytochrome O O
P450 O O
3A4 O O
inhibitors O O
, O O
elevated O O
blood O O
cisapride B-drug B-drug
levels O O
were O O
noted O O
at O O
the O O
time O O
of O O
the O O
QT O O
prolongation O O
. O O

After O O
stopping O O
Fluvoxamine B-drug B-drug
Tablets O O
, O O
at O O
least O O
2 O O
weeks O O
should O O
be O O
allowed O O
before O O
starting O O
a O O
MAOI B-group B-group
. O O

cardiovascular O O
effects O O
can O O
be O O
potentiated O O
. O O

When O O
these O O
products O O
are O O
administered O O
concomitantly O O
, O O
prothrombin O O
time O O
or O O
other O O
suitable O O
coagulation O O
tests O O
should O O
be O O
closely O O
monitored O O
. O O

These O O
results O O
, O O
together O O
with O O
the O O
known O O
relationships O O
between O O
estrogen B-group B-group
and O O
the O O
immune O O
response O O
, O O
suggest O O
that O O
estrogens B-group B-group
affect O O
the O O
course O O
of O O
septic O O
shock O O
in O O
a O O
complex O O
fashion O O
and O O
may O O
have O O
either O O
protective O O
or O O
deleterious O O
effect O O
. O O

Warfarin B-drug B-drug
: O O
When O O
fluvoxamine B-drug B-drug
maleate I-drug I-drug
( O O
50 O O
mg O O
tid O O
) O O
was O O
administered O O
concomitantly O O
with O O
warfarin B-drug B-drug
for O O
two O O
weeks O O
, O O
warfarin B-drug B-drug
plasma O O
concentrations O O
increased O O
by O O
98 O O
% O O
and O O
prothrombin O O
times O O
were O O
prolonged O O
. O O

Nonketotic O B-group
, O O
genetically O O
diabetic O O
Cinese O O
hamsters O O
show O O
subnormal O O
pancreatic O O
insulin O O
release O O
and O O
impaired O O
suppression O O
of O O
glucagon O O
in O O
response O O
to O O
glucose O B-drug
. O O

If O O
a O O
patient O O
requires O O
TIKOSYN B-brand B-brand
and O O
anti-ulcer B-group O
therapy O O
, O O
it O O
is O O
suggested O O
that O O
omeprazole B-drug B-drug
, O O
ranitidine B-drug B-drug
, O O
or B-drug O
antacids B-group B-group
( O O
aluminum O B-drug
and O O
magnesium B-drug B-drug
hydroxides O I-drug
) O O
be O O
used O O
as O O
alternatives O O
to O O
cimetidine B-drug B-drug
, O O
as O O
these O O
agents O O
have O O
no O O
effect O O
on O O
the O O
pharmacokinetic O O
profile O O
of O O
TIKOSYN B-brand B-brand
. O O

Altered O O
mental O O
status O O
in O O
an O O
adolescent O O
presents O O
a O O
diagnostic O O
challenge O O
, O O
and O O
the O O
clinician O O
depends O O
on O O
clinical O O
evaluation O O
and O O
laboratory O O
studies O O
to O O
determine O O
therapy O O
and O O
prognosis O O
. O O

This O O
increased O O
incidence O O
of O O
atherosclerotic O O
disease O O
is O O
intricately O O
associated O O
with O O
insulin O B-drug
resistance O O
, O O
which O O
is O O
a O O
major O O
pathophysiologic O O
abnormality O O
in O O
type O O
2 O O
diabetes O O
. O O

Twenty-four O O
h O O
exposures O O
of O O
fully O O
formed O O
cysts O O
had O O
no O O
effect O O
on O O
excystment O O
in O O
vitro O O
. O O

Co-administration O O
of O O
atorvastatin B-drug B-drug
resulted O O
in O O
about O O
a O O
50 O O
% O O
increase O O
in O O
aliskiren B-drug B-drug
Cmax O O
and O O
AUC O O
after O O
multiple O O
dosing O O
. O O

The O O
clinical O O
relevance O O
of O O
this O O
in O O
vitro O O
finding O O
is O O
unknown O O
. O O

As O O
with O O
other O O
antipsychotic B-group B-group
agents I-group I-group
, O O
it O O
should O O
be O O
noted O O
that O O
HALDOL B-brand B-brand
may O O
be O O
capable O O
of O O
potentiating O B-group
CNS B-group I-group
depressants I-group I-group
such O O
as O O
anesthetics B-group B-group
, O O
opiates B-group B-group
, O O
and O O
alcohol B-drug B-drug
. O O

Clinical O O
trials O O
of O O
such O O
combinations O O
should O O
be O O
accompanied O O
by O O
detailed O O
pharmacokinetic O O
evaluation O O
. O O

Beta-adrenergic B-group B-group
blocking I-group I-group
agents I-group I-group
should O O
be O O
withdrawn O O
at O O
least O O
48 O O
hours O O
before O O
conducting O O
an O O
arbutamine-mediated B-drug O
stress O O
test O O
. O O

Of O O
the O O
remaining O O
cases O O
, O O
two O O
were O O
cardiac O O
, O O
two O O
hepatic O O
and O O
the O O
rest O O
were O O
mixed O O
drug O O
overdose O O
. O O

Loop B-group B-group
Diuretics I-group I-group
: O O
Furosemide B-drug B-drug
administered O O
concurrently O O
with O O
captopril B-drug B-drug
does O O
not O O
alter O O
the O O
pharmacokinetics O O
of O O
captopril B-drug B-drug
in O O
renally O O
impaired O O
hypertensive O O
patients O O
. O O

Preliminary O O
data O O
which O O
suggest O O
that O O
dapsone B-drug B-drug
may O O
inhibit O O
the O O
anti-inflammatory O O
activity O O
of O O
Lamprene B-brand B-brand
have O O
not O O
been O O
confirmed O O
. O O

Other O O
drugs O O
which O O
may O O
enhance O O
the O O
neuromuscular O O
blocking O O
action O O
of O O
nondepolarizing O B-group
agents O I-group
such O O
as O O
NUROMAX B-brand B-brand
include O O
certain O O
antibiotics B-group B-group
( O O
e. O O
g. O O
, O O
aminoglycosides B-group B-group
, O O
tetracyclines B-group B-group
, O O
bacitracin B-group B-drug
, O O
polymyxins B-group B-group
, O O
lincomycin B-drug B-drug
, O O
clindamycin B-drug B-drug
, O O
colistin B-drug B-drug
, O O
and O O
sodium B-drug B-drug
colistimethate I-drug I-drug
) O O
, O O
magnesium B-drug B-drug
salts O O
, O O
lithium B-drug B-drug
, O O
local O O
anesthetics B-group B-group
, O O
procainamide B-drug B-drug
, O O
and O O
quinidine B-drug B-drug
. O O

No O O
differences O O
in O O
adverse O O
events O O
or O O
QTc O O
interval O O
were O O
observed O O
when O O
subjects O O
were O O
administered O O
fexofenadine B-drug B-drug
hydrochloride I-drug I-drug
alone O O
or O O
in O O
combination O O
with O O
either O O
erythromycin B-drug B-drug
or O O
ketoconazole B-drug B-drug
. O O

Ergotamine B-drug B-drug

Aminosalicylic B-drug B-drug
acid I-drug I-drug
may O O
also O O
decrease O O
the O O
absorption O O
of O O
vitamin B-drug B-drug
B12 I-drug I-drug
, O O
which O O
can O O
lead O O
to O O
a O O
deficiency O O
. O O

Increasing O O
the O O
felbamate B-drug B-drug
dose O O
to O O
2400 O O
mg/day O O
increased O O
the O O
steadystate O O
valproate B-drug B-drug
Cmin O O
to O O
96 O O
25 O O
micrograms/mL O O
. O O

St. O O
John O O
s O O
Wort O O
should O O
be O O
avoided O O
while O O
taking O O
this O O
medicine O O
due O O
to O O
the O O
additive O O
effects O O
of O O
serotonin O O
. O O

Accordingly O O
, O O
careful O O
patient O O
monitoring O O
and O O
dose O O
adjustment O O
of O O
metformin B-drug B-drug
is O O
recommended O O
in O O
patients O O
concomitantly O O
taking O O
cephalexin B-drug B-drug
and O O
metformin B-drug B-drug
. O O

Read O O
circulars O O
for O O
lithium B-drug B-drug
preparations O O
before O O
use O O
of O O
such O O
concomitant O O
therapy O O
. O O

In O O
two O O
controlled O O
crossover O O
clinical O O
pharmacology O O
studies O O
in O O
healthy O O
male O O
( O O
n=12 O O
in O O
each O O
study O O
) O O
a O O
nd O O
female O O
( O O
n=12 O O
in O O
each O O
study O O
) O O
volunteers O O
, O O
desloratadine B-drug B-drug
7.5 O O
mg O O
( O O
1.5 O O
times O O
the O O
daily O O
dose O O
) O O
once O O
daily O O
was O O
coadministered O O
with O O
erythromycin B-drug B-drug
500 O O
mg O O
every O O
8 O O
hours O O
or O O
ketoconazole B-drug B-drug
200 O O
mg O O
every O O
12 O O
hours O O
for O O
10 O O
days O O
. O O

reproductive O O
tract O O
infections O O
; O O

If O O
iron B-group B-drug
supplements I-group O
are O O
required O O
during O O
OMNICEF B-brand B-brand
therapy O O
, O O
OMNICEF B-brand B-brand
should O O
be O O
taken O O
at O O
least O O
2 O O
hours O O
before O O
or O O
after O O
the O O
supplement O O
. O O

Women O O
of O O
childbearing O O
potential O O
make O O
up O O
a O O
considerable O O
segment O O
of O O
the O O
patient O O
population O O
affected O O
by O O
psoriasis O O
. O O

Generally O O
, O O
this O O
phenomenon O O
has O O
not O O
been O O
associated O O
with O O
other O O
clinically O O
significant O O
events O O
. O O

. O O

Methotrexate B-drug B-drug
: O O
Concomitant O O
administration O O
of O O
methotrexate B-drug B-drug
and O O
some O O
NSAIDs B-group B-group
has O O
been O O
reported O O
to O O
reduce O O
the O O
clearance O O
of O O
methotrexate B-drug B-drug
, O O
enhancing O O
the O O
toxicity O O
of O O
methotrexate B-drug B-drug
. O O

Digitalis B-group B-group
: O O
Vitamin B-group B-group
D I-group I-group
dosage O O
must O O
be O O
determined O O
with O O
care O O
in O O
patients O O
undergoing O O
treatment O O
with O O
digitalis B-group B-group
, O O
as O O
hypercalcemia O O
in O O
such O O
patients O O
may O O
precipitate O O
cardiac O O
arrhythmias O O
. O O

include O O
terfenadine B-drug B-drug
, O O
astemizole B-drug B-drug
, O O
cisapride B-drug B-drug
, O O
midazolam B-drug B-drug
, O O
and O O
triazolam B-drug B-drug
. O O

Stimulation O O
of O O
the O O
glands O O
with O O
carbachol B-drug B-drug
synergistically O O
augmented O O
the O O
response O O
to O O
dibutyryl O O
cAMP O O
. O O

There O O
were O O
no O O
clinically O O
significant O O
drug O O
interactions O O
for O O
any O O
of O O
these O O
drugs O O

Caution O O
should O O
be O O
observed O O
when O O
anileridine B-drug B-drug
is O O
coadministered O O
with O O
other O O
opioids B-group B-group
, O O
sedatives B-group B-group
, O O
phenothiazines B-group B-group
, O O
or O O
anesthetics B-group B-group
, O O
as O O
these O O
agents O O
may O O
increase O O
respiratory O O
and O O
circulatory O O
depression O O
. O O

However O O
, O O
no O O
adverse O O
effects O O
on O O
fertility O O
were O O
observed O O
in O O
male O O
Rhesus O O
monkeys O O
treated O O
with O O
non-pegylated B-drug O
interferon I-drug B-drug
alfa-2a I-drug I-drug
for O O
5 O O
months O O
at O O
doses O O
up O O
to O O
25 O O
x O O
106 O O
IU/kg/day O O
. O O

The O O
most O O
potent O O
inhibitory O O
activity O O
was O O
observed O O
for O O
vardenafil O B-drug
metabolite O O
M1 O O
, O O
which O O
had O O
a O O
Ki O O
of O O
1.4 O O
uM O O
toward O O
CYP3A4 O O
, O O
which O O
is O O
about O O
20 O O
times O O
higher O O
than O O
the O O
M1 O O
Cmax O O
values O O
after O O
an O O
80 O O
mg O O
Vardenafil B-drug B-drug
dose O O
. O O

This O O
effect O O
did O O
not O O
depend O O
on O O
the O O
order O O
of O O
application O O
of O O
the O O
drugs O O
. O O

Tizoxanide B-drug B-drug
is O O
highly O O
bound O O
to O O
plasma O O
protein O O
( O O
99.9 O O
% O O
) O O
. O O

combination O O
therapy O O
is O O
contemplated O O
, O O
the O O
dosage O O
of O O
one O O
or O O
both O O
agents O O
should O O
be O O
reduced O O
. O O

There O O
was O O
no O O
significant O O
difference O O
in O O
the O O
pharmacodynamic O O
effect O O
of O O
warfarin B-drug B-drug
administered O O
alone O O
and O O
warfarin B-drug B-drug
administered O O
with O O
Lodine B-brand B-brand
as O O
measured O O
by O O
prothrombin O O
time O O
. O O

Since O O
the O O
concomitant O O
administration O O
of O O
warfarin B-drug B-drug
with O O
amiodarone B-drug B-drug
increases O O
the O O
prothrombin O O
time O O
by O O
100 O O
% O O
after O O
3 O O
to O O
4 O O
days O O
, O O
the O O
dose O O
of O O
the O O
anticoagulant B-drug B-group
should O O
be O O
reduced O O
by O O
one-third O O
to O O
one-half O O
, O O
and O O
prothrombin O O
times O O
should O O
be O O
monitored O O
closely O O
. O O

The O O
clinical O O
presentation O O
and O O
natural O O
history O O
of O O
neoplasia O O
are O O
also O O
affected O O
by O O
aging O O
. O O

In O O
period O O
A O O
, O O
all O O
volunteers O O
took O O
500 O O
mg O O
of O O
tolbutamide B-drug B-drug
orally O O
. O O

Warfarin B-drug B-drug
: O O
Concomitant O O
administration O O
of O O
daptomycin B-drug B-drug
( O O
6 O O
mg/kg O O
once O O
every O O
24 O O
hours O O
for O O
5 O O
days O O
) O O
and O O
warfarin B-drug B-drug
( O O
25 O O
mg O O
single O O
oral O O
dose O O
) O O
had O O
no O O
significant O O
effect O O
on O O
the O O
pharmacokinetics O O
of O O
either O O
drug O O
, O O
and O O
the O O
INR O O
was O O
not O O
significantly O O
altered O O
. O O

ACE-inhibitors B-group B-group
Reports O O
suggest O O
that O O
NSAIDs B-group B-group
may O O
diminish O O
the O O
antihypertensive O O
effect O O
of O O
ACE-inhibitors B-group B-group
. O O

Caution O O
is O O
recommended O O
during O O
the O O
coadministration O O
of O O
any O O
of O O
these O O
with O O
alprazolam B-drug B-drug
. O O

Metformin B-drug B-drug
: O O
When O O
Starlix B-brand B-brand
120 O O
mg O O
three O O
times O O
daily O O
before O O
meals O O
was O O
administered O O
in O O
combination O O
with O O
metformin B-drug B-drug
500 O O
mg O O
three O O
times O O
daily O O
to O O
patients O O
with O O
Type O O
2 O O
diabetes O O
, O O
there O O
were O O
no O O
clinically O O
relevant O O
changes O O
in O O
the O O
pharmacokinetics O O
of O O
either O O
agent O O
. O O

. O O

Drugs O O
Metabolized O O
by O O
P450 O O
2D6 O O
: O O
The O O
biochemical O O
activity O O
of O O
the O O
drug O O
metabolizing O O
isozyme O O
cytochrome O O
P450 O O
2D6 O O
( O O
debrisoquin O O
hydroxylase O O
) O O
is O O
reduced O O
in O O
a O O
subset O O
of O O
the O O
aucasian O O
population O O
( O O
about O O
7 O O
% O O
-10 O O
% O O
of O O
Caucasians O O
are O O
so-called O O
poor O O
metabolizers O O
) O O
; O O

The O O
clinical O O
significance O O
of O O
these O O
findings O O
has O O
not O O
been O O
established O O
. O O

Administration O O
of O O
1,3-difluoroacetone B-drug_n B-drug_n
( O O
100 O O
mg O O
kg O O
( O O
-1 O O
) O O
body O O
weight O O
) O O
to O O
rats O O
in O O
vivo O O
resulted O O
in O O
( B-drug_n B-drug_n
- I-drug_n I-drug_n
) I-drug_n I-drug_n
-erythro-fluorocitrate I-drug_n I-drug_n
synthesis O O
in O O
the O O
kidney O O
, O O
which O O
was O O
preceded O O
by O O
an O O
elevation O O
in O O
fluoride O O
levels O O
and O O
followed O O
by O O
citrate O O
accumulation O O
. O O

The O O
following O O
are O O
examples O O
of O O
substances O O
that O O
may O O
reduce O O
the O O
blood-glucose-lowering O O
effect O O
: O O
corticosteroids B-group B-group
, O O
niacin B-drug B-drug
, O O
danazol B-drug B-drug
, O O
diuretics B-group B-group
, O O
sympathomimetic B-group B-group
agents I-group I-group
( O O
e.g. O O
, O O
epinephrine B-drug B-drug
, O O
salbutamol B-drug B-drug
, O O
terbutaline B-drug B-drug
) O O
, O O
isoniazid B-drug B-drug
, O O
phenothiazine B-group B-group
derivatives I-group I-group
, O O
somatropin B-drug B-drug
, O O
thyroid B-group B-group
hormones I-group I-group
, O O
estrogens B-group B-group
, O O
progestogens B-group B-group
( O O
e.g. O O
, O O
in O O
oral O O
contraceptives B-group B-group
) O O
. O O

In O O
EMs O O
, O O
selective O O
inhibitors O O
of O O
CYP2D6 O O
increase O O
atomoxetine B-drug B-drug
steady-state O O
plasma O O
concentrations O O
to O O
exposures O O
similar O O
to O O
those O O
observed O O
in O O
PMs O O
. O O

If O O
these O O
preparations O O
have O O
been O O
used O O
it O O
is O O
advisable O O
not O O
to O O
start O O
therapy O O
with O O
DIFFERIN B-brand B-brand
Gel O O
until O O
the O O
effects O O
of O O
such O O
preparations O O
in O O
the O O
skin O O
have O O
subsided O O
. O O

Based O O
on O O
clinical O O
and O O
pharmacokinetic O O
results O O
from O O
the O O
ATAC O O
trial O O
, O O
tamoxifen B-drug B-drug
should O O
not O O
be O O
administered O O
with O O
anastrozole B-drug B-drug
( O O
see O O
CLINICAL O O
PHARMACOLOGY O O
Drug O O
Interactions O O
and O O
CLINICAL O O
PHARMACOLOGY O O
- O O
Clinical O O
Studies O O
- O O
Adjuvant O O
Treatment O O
of O O
Breast O O
Cancer O O
in O O
Postmenopausal O O
Women O O
subsections O O
) O O
. O O

Naproxen B-drug B-drug
may O O
interfere O O
with O O
some O O
urinary O O
assays O O
of O O
5-hydroxy O O
indoleacetic O O
acid O O
( O O
5HIAA O O
) O O
. O O

Chlorpromazine B-drug B-drug
: O O
Chlorpromazine B-drug B-drug
blocks O O
dopamine O B-drug
and O O
norepinephrine O B-drug
receptors O O
, O O
thus O O
inhibiting O O
the O O
central O O
stimulant O O
effects O O
of O O
amphetamines B-group B-group
and O O
can O O
be O O
used O O
to O O
treat O O
amphetamine B-group B-drug
poisoning O O
. O O

The O O
pharmacokinetic O O
interactions O O
listed O O
below O O
are O O
potentially O O
clinically O O
important O O
. O O

Quinidine B-drug B-drug
: O O
Coadministration O O
of O O
a O O
10-mg O O
single O O
dose O O
of O O
aripiprazole B-drug B-drug
with O O
quinidine B-drug B-drug
( O O
166 O O
mg/day O O
for O O
13 O O
days O O
) O O
, O O
a O O
potent O O
inhibitor O O
of O O
CYP2D6 O O
, O O
increased O O
the O O
AUC O O
of O O
aripiprazole B-drug B-drug
by O O
112 O O
% O O
but O O
decreased O O
the O O
AUC O O
of O O
its O O
active O O
metabolite O O
, O O
dehydroaripiprazole B-drug_n B-drug_n
, O O
by O O
35 O O
% O O
. O O

The O O
effect O O
of O O
clonazepam B-drug B-drug
on O O
the O O
metabolism O O
of O O
other O O
drugs O O
has O O
not O O
been O O
investigated O O
. O O

Patients O O
receiving O O
these O O
drugs O O
who O O
are O O
given O O
Lodine B-brand B-brand
, O O
or O O
any O O
other O O
NSAID B-group B-group
, O O
and O O
particularly O O
those O O
patients O O
with O O
altered O O
renal O O
function O O
, O O
should O O
be O O
observed O O
for O O
the O O
development O O
of O O
the O O
specific O O
toxicities O O
of O O
these O O
drugs O O
. O O

RESULTS O O
: O O
The O O
geometric O O
mean O O
( O O
90 O O
% O O
confidence O O
interval O O
) O O
whole O O
blood O O
sirolimus B-drug B-drug
area O O
under O O
the O O
plasma O O
concentration O O
time-curve O O
increased O O
60 O O
% O O
( O O
35 O O
% O O
-90 O O
% O O
) O O
, O O
from O O
736 O O
to O O
1178 O O
ng O O
x O O
h/mL O O
, O O
and O O
maximum O O
concentration O O
increased O O
43 O O
% O O
( O O
14 O O
% O O
-81 O O
% O O
) O O
, O O
from O O
67 O O
to O O
96 O O
ng/mL O O
, O O
with O O
diltiazem B-drug B-drug
coadministration O O
, O O
whereas O O
the O O
mean O O
elimination O O
half-life O O
of O O
sirolimus B-drug B-drug
decreased O O
slightly O O
, O O
from O O
79 O O
to O O
67 O O
hours O O
. O O

This O O
might O O
be O O
explained O O
by O O
a O O
blockade O O
by O O
probenecid B-drug B-drug
of O O
the O O
elimination O O
of O O
cloxacillin B-drug B-drug
by O O
the O O
liver O O
. O O

*CBZ O B-drug_n
epoxide O I-drug_n

Levothyroxine B-drug B-drug
Sodium I-drug I-drug
Absorption O O
: O O
The O O
following O O
agents O O
may O O
bind O O
and O O
decrease O O
absorption O O
of O O
levothyroxine B-drug B-drug
sodium I-drug I-drug
from O O
the O O
gastrointestinal O O
tract O O
: O O
aluminum B-drug B-drug
hydoxide I-drug I-drug
, O O
cholestyramine B-drug B-drug
resin O I-drug
, O O
colestipol B-drug B-drug
hydrochloride I-drug I-drug
, O O
ferrous B-drug B-drug
sulfate I-drug I-drug
, O O
sodium B-drug B-drug
polystyrene I-drug I-drug
sulfonate I-drug I-drug
, O O
soybean O O
flour O O
( O O
e.g. O O
, O O
infant O O
formula O O
) O O
, O O
sucralfate B-drug B-drug
. O O

Fulvestrant B-drug B-drug
was O O
associated O O
with O O
an O O
increased O O
incidence O O
of O O
fetal O O
variations O O
in O O
rabbits O O
( O O
backwards O O
displacement O O
of O O
the O O
pelvic O O
girdle O O
, O O
and O O
27 O O
pre-sacral O O
vertebrae O O
at O O
0.25 O O
mg/kg/day O O
IM O O
; O O

Didanosine B-drug B-drug
: O O
It O O
is O O
recommended O O
that O O
didanosine B-drug B-drug
be O O
administered O O
on O O
an O O
empty O O
stomach O O
; O O

While O O
not O O
systematically O O
studied O O
, O O
certain O O
drugs O O
may O O
induce O O
the O O
metabolism O O
of O O
bupropion B-drug B-drug
( O O
e.g. O O
, O O
carbamazepine B-drug B-drug
, O O
phenobarbital B-drug B-drug
, O O
phenytoin B-drug B-drug
) O O
. O O

Changes O O
in O O
the O O
testes O O
and O O
epididymides O O
had O O
not O O
recovered O O
20 O O
weeks O O
after O O
cessation O O
of O O
dosing O O
. O O

The O O
incidence O O
of O O
ARE O O
suddenly O O
exceeded O O
10 O O
% O O
of O O
the O O
patients O O
treated O O
by O O
melarsoprol B-drug B-drug
during O O
August O O
1992 O O
and O O
September O O
1993 O O
. O O

Monoamine B-group B-group
oxidase I-group I-group
( I-group I-group
MAO I-group I-group
) I-group I-group
inhibitors I-group I-group
prolong O O
and O O
intensify O O
the O O
anticholinergic O O
effects O O
of O O
antihistamines B-group B-group
. O O

Potential O O
for O O
Duloxetine B-drug B-drug
to O O
Affect O O
Other O O
Drugs O O
: O O
Drugs O O
Metabolized O O
by O O
CYP1A2 O O
: O O
In O O
vitro O O
drug O O
interaction O O
studies O O
demonstrate O O
that O O
duloxetine B-drug B-drug
does O O
not O O
induce O O
CYP1A2 O O
activity O O
, O O
and O O
it O O
is O O
unlikely O O
to O O
have O O
a O O
clinically O O
significant O O
effect O O
on O O
the O O
metabolism O O
of O O
CYP1A2 O O
substrates O O
. O O

In O O
a O O
comparison O O
of O O
digitalis B-group B-group
tolerance O O
in O O
dogs O O
anesthetized O O
with O O
ketamine B-drug B-drug
, O O
Innovar B-brand B-brand
Vet I-brand O
, O O
or O O
pentobarbital B-drug B-drug
, O O
the O O
dosage O O
of O O
ouabain B-drug B-drug
needed O O
to O O
cause O O
ventricular O O
tachycardia O O
was O O
significantly O O
higher O O
, O O
as O O
was O O
the O O
LD50 O O
of O O
ouabain B-drug B-drug
, O O
with O O
ketamine B-drug B-drug
or O O
Innovar B-brand B-brand
than O O
with O O
pentobarbital B-drug B-drug
. O O

Should O O
it O O
be O O
decided O O
to O O
discontinue O O
therapy O O
in O O
patients O O
receiving O O
beta-blockers B-group B-group
and O O
clonidine B-drug B-drug
concurrently O O
, O O
the O O
beta-blocker B-group B-group
should O O
be O O
discontinued O O
slowly O O
over O O
several O O
days O O
before O O
the O O
gradual O O
withdrawal O O
of O O
clonidine B-drug B-drug
. O O

Therefore O O
, O O
prothrombin O O
time O O
should O O
be O O
carefully O O
monitored O O
in O O
patients O O
receiving O O
Itraconazole B-drug B-drug
and O O
coumarin-like B-group B-group
drugs O I-group
simultaneously O O
. O O

Few O O
data O O
exist O O
on O O
drug O O
interactions O O
with O O
caffeine B-drug B-drug
in O O
preterm O O
neonates O O
. O O

Ethosuximide B-drug B-drug
: O O
Amphetamines B-group B-group
may O O
delay O O
intestinal O O
absorption O O
of O O
ethosuximide B-drug B-drug
. O O

Selective O O
survival O O
in O O
pentazocine B-drug B-drug
and O O
tripelennamine B-drug B-drug
of O O
Pseudomonas O O
aeruginosa O O
serotype O O
O11 O O
from O O
drug O O
addicts O O
. O O

A O O
reduced O O
Clozapine B-drug B-drug
dose O O
should O O
be O O
considered O O
. O O

Nevertheless O O
, O O
caution O O
is O O
indicated O O
in O O
the O O
coadministration O O
of O O
TCAs B-group B-group
with O O
any O O
of O O
the O O
SSRIs B-group B-group
and O O
also O O
in O O
switching O O
from O O
one O O
class O O
to O O
the O O
other O O
. O O

Ergot-Containing B-group O
Drugs I-group O
: O O
These O O
drugs O O
have O O
been O O
reported O O
to O O
cause O O
prolonged O O
vasospastic O O
reactions O O
. O O

Observations O O
from O O
drug O O
interaction O O
studies O O
with O O
FORTOVASE B-brand B-brand
may O O
not O O
be O O
predictive O O
for O O
INVIRASE B-brand B-brand
. O O

Antihistamines B-drug B-group
: O O
astemizole* B-drug B-drug
, O O
terfenadine* B-drug B-drug
CONTRAINDICATED O O
due O O
to O O
potential O O
for O O
serious O O
and/or O O
life-threatening O O
cardiac O O
arrhythmias O O
. O O

indinavir I-drug B-drug
concentration O O
ritonavir B-drug B-drug
concentration O O

No O O
data O O
on O O
the O O
level O O
of O O
circulating O O
catecholamines O O
after O O
apraclonidine B-drug B-drug
withdrawal O O
are O O
available O O
. O O

Amiodarone B-drug B-drug
inhibits O O
CYP2D6 B-drug O
. O O

No O O
CNS O O
lesions O O
have O O
been O O
observed O O
in O O
mice O O
after O O
chronic O O
treatment O O
for O O
up O O
to O O
2 O O
years O O
at O O
doses O O
up O O
to O O
400 O O
mg/kg/day O O
or O O
in O O
rats O O
at O O
doses O O
up O O
to O O
100 O O
mg/kg/day O O
. O O

Coadministration O O
of O O
efavirenz B-drug B-drug
with O O
drugs O O
primarily O O
metabolized O O
by O O
these O O
isozymes O O
may O O
result O O
in O O
altered O O
plasma O O
concentrations O O
of O O
the O O
coadministered O O
drug O O
. O O

. O O

Coadministration O O
of O O
VIRACEPT B-brand B-brand
and O O
drugs O O
that O O
inhibit O O
CYP3A O O
may O O
increase O O
nelfinavir B-drug B-drug
plasma O O
concentrations O O
. O O

Changes O O
in O O
hepatic O O
function O O
induced O O
by O O
concomitant O O
therapies O O
may O O
affect O O
epirubicin B-drug B-drug
metabolism O O
, O O
pharmacokinetics O O
, O O
therapeutic O O
efficacy O O
, O O
and/or O O
toxicity O O
. O O

Twitch O O
gradually O O
returned O O
to O O
pre-gentamycin B-drug O
strength O O
over O O
the O O
course O O
of O O
the O O
next O O
hour O O
. O O

